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ABSTRACT 
Schizophrenia is a devastating mental disease affecting approximately 1 % of all 
populations. Recent studies have suggested that deficient uptake of free fatty acids or 
excessive breakdown of cell-membrane phospholipids, directly or indirectly triggered by 
lipid peroxidative damage, may be associated with schizophrenia and possibly other 
neurodegenerati ve disorders. 
This study provides more information on the influence of the presence of different fatty 
acids (FAs): stearic acid (SA), oleic acid (OA), arachidonic acid (AA), eicosapentaenoic 
acid (EPA), and docosahexaenoic acid (DHA) and dietary antioxidants (ascorbic acid, a-
tocopherol, f3-carotene and astaxanthin) as components of the culture-medium on the 
human monocytic cell line (U937) by the measurements of cell-viability, productions qf by-
products of lipid peroxidation (lipid hydroperoxides and volatile hydrocarbons), AA-
release/uptake and cPLA2 expression upon induced-oxidative stress with the radical-
mediating system oft-butyl hydroperoxide (t-BHP)/Fe2+. 
Of all FAs used, the PUFAs (AA, EPA and DHA) at 40 µM concentrations reduced cell-
membrane integrity significantly whereas SA and OA had no effect after 72 h of 
incubation, suggesting the cytotoxicity of the PUF As above certain concentrations. 
This study shows that U937 cells accumulate lipid hydroperoxides, generate ethane,·butane 
and pentane, release and incorporate AA at a greater rate in response to induced-oxidative 
stress by a mechanism probably involving cPLA2. In addition, AA is incorporated into 
cellular phospholipids at a greater rate post-oxidation. With oxidative-stress, the presence 
iii 
of EPA but not DHA in cellular phospholipids significantly increases the accumulation of. 
AA in the extracellular fluid. 
Studies revealed that under oxidative-stress a-tocopherol is a potent antioxidant markedly 
inhibiting AA-release but not its uptake. Whilst ascorbic acid appeared to promote AA-
release, f3-carotene and astaxanthin conferred no protective effect. Collectively, this study 
demonstrates the potency of a-tocopherol, ascorbic acid, f3-carotene and astaxanthin 
against oxidant-induced peroxidative damage, AA release/uptake and ultimately total loss 
of cell-viability. In EPA-pretreated cells, AA-release is enhanced with/without oxidant-
activation suggesting its action by stimulating the availability of AA possibly for 
prostaglandin production. 
iv 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
1.1 GENERAL INTRODUCTION 
Schizophrenia is a psychiatric disease found to be common in all known populations with a 
lifetime prevalence of somewhere between 0.5% and 1.5% (WHO, 1979). The disorder 
normally strikes in young adulthood with a combination of hallucinations, delusions and 
social withdrawal symptoms (Strauss, 1994), frequently resulting in the unemployment of 
the individual thus costing the society a productive citizen. Studies estimate the overall UK 
cost burden of schizophrenia, including both direct and indirect costs, at £2.6 billion 
pounds sterling per annum in 1997 (Knapp, 1997). For the past40 years, the dominant 
theme governing research into schizophrenia, the affective disorders such as tardive 
dyskinesia, and other central nervous system diseases, has related these conditions to 
neurotransmitter system abnormalities especially those affecting dopamine D2 receptors. 
As a result, therapeutics, largely developed in the 1950s, have been directed towards 
finding agents that will modulate the neurotransmitter system in some way (Horrobin 
1999a). However, recent studies using receptor labels in vivo, have failed to show any 
consistent abnormality of dopamine D2 receptors in drug naive schizophrenic patients 
(Parde 1997). Apart from that, the current antipsychotic drugs have only limited efficacy in 
many patients and possess numerous side effects such as tardive dyskinesia and obesity, 
which limit patient compliance (Kane 1994). There is, therefore, the need for 
improvements in the treatment of schizophrenia, which will have significant payoffs in both 
the human and financial costs of the disorder. Over the past two decades a large number of 
studies have examined a hypothesis with direct implications for the treatment of 
schizophrenia: "the membrane phospholipid hypothesis" (Horrobin et al., 1994). The 
hypothesis states that . a systemic abnormality in one or more aspects of membrane 
phospholipid metabolism is an etiological factor in the development and/or symptoms of 
schizophrenia. Interest in this area of research has steadily increased characterized by the 
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recent review by Fenton and colleagues (Fenton et al., 2000) who state that "Studies of 
fatty acid metabolism have proved fruitful for generating and testing novel etiologic 
hypotheses and new therapeutic agents for schizophrenia". Furthermore, treatment of 
schizophrenia with lipids and their derivatives, in particular the fatty acid eicosapentaenoic 
acid (EPA) but not docosahexaenoic acid (DHA), has produced promising preliminary 
results and is the subject of several ongoing clinical trials in the USA and Europe 
(Richardson et al., 1999; 2000; Joy et al., 2000; Puri et al., 2000). A key piece of evidence 
in support of a membrane abnormality in schizophrenia comes from experiments utilizing 
the B-vitamin niacin (nicotinic acid). That study demonstrated that vasodilatatory response 
to niacin is deficient in schizophrenia (Ward et al., 1998). The vasodilatatory response is 
dependent upon the mobilization of arachidonic acid in skin macrophages and its 
conversion to prostaglandins. It is also a marker of the availability of arachidonic acid for 
cell signaling. The phenomenon indicates that the availability of arachidonic acid is 
reduced in schizophrenia (Olney and Farber, 1995). 
1.2 NEURODEGENERA TIVE DISEASES 
The world now suffers from an increasing burden of mental illnesses with a rising need for 
improvements in treatments. At present, about 450 million people suffer from mental or 
behavioural disorders, with only a small proportion receiving even the most basic treatment 
(WHO 2001). In most developing countries, many individuals with severe neuronal 
disorders are left to cop~ as best as they can with their personal burdens. In all populations, 
many are victimized for their illness becoming targets of stigma and discrimination. 
Globally, neuro-psychiatric illnesses represent four of the ten leading causes of disability 
(WHO, 2001). This increasing burden results in high costs in terms of human and 
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economic loss. It is now known that most illnesses, both mental and physical, are 
influenced by a combination of biological, psychological and social factors. 
Mental and 
behavioural 
disorder 
Mental and behavioural disorders affect people of ajl ages, races, sexes, in all countries and 
they-cause sufferings to_families, communities and the individuals themselves. 
- Biological factors include age and sex. These are associated with mental and 
behavioural disorders. For example, depression has been shown to be sex-related 
probably due to hormonal changes, domestic and sexual violence more common to 
women (WHO, 2001). 
- Psychological factors: One of the main findings throughout the 20th century that has 
shaped current understanding is the importance of relationships with parents or 
guardians during childhood. Affectionate, attentive and stable caring allows infants 
and young children to normally develop such functions as language, intellect and 
emotional regulation. Children deprived of nurture from parents or guardians are 
more likely to develop mental and behavioural disorders, either during childhood or 
later in life irrespective of adequate nutrition and bodily care. Secondly, human 
behaviour is partly shaped through interactions with the natural or social 
environment, which can result in either desirable or undesirable consequences. 
Most individuals engage in rewarding activities while others engage in ones inviting 
punishment. Mental and behavioural disorders can be seen as maladaptive 
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behaviour that has been learned either directly or through observing others over 
time (WHO, 2001). Thirdly, mental and behavioural disorders such as anxiety and 
depression can occur from the failure of an individual to cope adaptively to stressful 
events of life. Generally, people who try to avoid thinking ·about or dealing with 
stressors are more susceptible to anxiety and depression. On the other hand, those 
who share their problems attempting to find ways of managing stressors, function 
better over time (WHO, 2001). 
Social factors: For example, urbanization, racism, poverty and technological change 
have been associated with the development of mental and behavioural disorders. 
Urbanization may contribute to this disorder through the influence of increased 
stressors and adverse life events such as overcrowding, polluted environments, 
poverty or dependence on a cash economy, high violence levels and reduced social 
support. Rural life also imposes problems on people. For example, isolation, lack 
of transport and communication, limited education and economic opportunities. 
Poverty is linked with economic deprivation, low education and unemployment. 
1.3 SCIDZOPHRENIA 
Schizophrenia is a severe mental disorder that typically begins in late adolescence or early 
adulthood. From the clinical perspective, signs and symptoms are many, varied and are 
often classified as "positive" and "negative" symptoms. The positive symptoms refer to the 
hallucinations, delusions (strong belief in ideas that are false and without basis in reality), 
thought alienation and disorder which typically occur early on in the course of the illness 
and which respond well to treatment. Negative Symptoms include emotional blunting, 
social withdrawal, cognitive deficits and poverty of speech and activity (Kuperberg and 
Heckers, 2000). Schizophrenia is found to exist approximately equally between males and 
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females though the onset tends to be later in females. The economic cost of schizophrenia 
to society is very high. In 1991 an estimate of the cost burden of schizophrenia in the 
United States was US$ 19 billion in direct expenditure and· US$. 46 billion in lost 
productivity (WHO, 2001). It is the third most costly illness to the Canadian economy, 
estimated to be $2.35 billion dollars in 1996 (Goeree et al., 1999). 
1.3.1 Treatment of schizophrenia 
The discovery and improvement of useful therapeutics for the management of 
schizophrenia occurred' largely in the second half of the 20th century. The first being 
chlorpromazine, was developed from compounds with anti-histaminic and sedative 
properties. It was originally used as part of a pre-anesthetic cocktail, which was found to 
induce a state of mind similar to that observed in schizophrenic patients after treatment by 
frontal lobotomy, a popular treatment for schizophrenia at that time (Horrobin, 1999a). 
Chlopromazine (an antipsychotic drug) was thought to act by blocking dopamine D2 
receptors (Zimmer et al, 1998) therefore, the development of drugs in the 1950s was 
directed at finding agents that will modulate these receptors in some wa.y. However recent 
studies have failed to show any consistent dysfunction in dopamine D2 receptors (Parde, 
1997). In addition, after the disappearance of the obvious symptoms of schizophrenia, 
some residual symptoms may remain. These include lack of interest and initiative in daily 
activities and work, social incompetence and inability to take interest in pleasurable 
activities possibly causing continued disability and poor life quality to the individual and 
placing considerable burden on families (Pai and Kapur, 1982). 
However, it has been repeatedly demonstrated that schizophrenia follows a less severe 
course in developing countries (Kulhara and Wig 1978; Thara and Eaton 1996). For 
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instance, the proportion of patients showing full remission at 2 years was 63% in 
developing countries compared to 37% in developed countries (Jablensky et al., 1992). 
· Possible explanations for this better outcome are based on stronger family support and 
fewer demands on the patients, although the exact reasons for these differences are unclear. 
Schizophrenia reduces an affected individual's life span by an average of 10 years 
worldwide. , 
Currently, the primary prevention of schizophrenia is impossible. Treatment of 
schizophrenia has 3 rriain components: medications to relieve symptoms and prevent 
relapse; education and psychosocial interventions to help patients and their families to cope 
with the illness and its complications and help prevent relapse; rehabilitation to help 
patients back into the community and regain educational and occupational functioning. 
The ultimate goals of treatment are to identify the illness as soon as possible, treat 
symptoms, provide skills to patients and their families, maintain improvement over time, 
prevent relapse, re-integrate patients into the community, and to regain normal life. 
Presently, two groups of drugs are used in the treatment of schizophrenia. 
Standard antipsychotics (also referred to as neuroleptics): This group of drugs was 
introduced 50 years ago and have proved useful in decreasing, and sometimes eliminating, 
certain symptoms of schizophrenia such as hallucinations and delusions. These drugs 
function by blocking dopamine D2 receptors in the brain thus reducing the overactivity of 
dopamine. Dopamine is the chemical messenger in the brain mainly involved with 
thinking, emotions, behaviour and perception. However, recent studies using receptor 
labels in vivo showed no consistent abnormalities in dopamine D2 receptors in drug-naive 
schizophrenics (Parde, 1997). They are also known to reduce associated symptoms such as 
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agitation, impulsiveness and aggressiveness. This can be achieved in days or weeks in 
about 70% of patients. If these drugs are consistently used, they can also reduce the risk of 
relapse by up to 50% (WHO, 2001). Antipsychotic drugs address the symptoms of the 
disease and not the disease itself nor its cause. They are therefore not curative but rather 
drugs to reduce or control symptoms or to prevent relapse of the disease. Besides, these 
drugs have been shown to lose their potency in a significant number of patients over a 
period of time. Furthermore, after chronic treatments with these drugs, some patients 
develop side effects such as movement disorders, including drug-induced Parkinsonism, 
tardive dyskinesia (TD)~ akathsia (a subjective sense of restlessness) and cardiovascular and 
cognitive effects (American College of Neuropsychopharmacology, 1973; Kane and Smith, 
1982; Yassa et al., 1997) causing extreme discomfort to patients resulting in medication 
non-compliance and relapse of the disease (Kane, 1994 ). 
Novel antipsychotics (also known as "atypical" antipsychotics): These newer drugs have 
less side effects but there is no clear evidence that they differ significantly from the older 
drugs in their effectiveness. Most recent economic studies have focused on the cost-
effectiveness of active pharmacotherapies indicating that the newer drugs are not 
significantly more efficacious than the older ones though they posses fewer side-effects. 
There therefore, seems to be a knowledge gap in the cause of the disease and a loophole in 
the efficacy and effectiveness of the available pharmacotherapies, which is thought to be 
explained by the membrane phospholipid hypothesis of schizophrenia (Horrobin, 1999a) as 
will be discussed in this thesis. 
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1.4 NEURODEVELOPMENTAL APPROACH TO SCIDZOPHRENIA 
A neurodevelopmental approach to schizophrenia proposes that interaction between genetic 
and early environmental factors affects both the formation process and functions of nerve 
cells (Nasrallah, 1993; Falkai and Bogerts, 1995; Weinberger 1995). These factors start 
operating during the neurodevelopmental stages of the foetus, influenced by perinatal 
events. The factorial effects become fully expressed in early adulthood when the brain 
finally matures with completed myelination. 
Some key pieces of evidence for a neurodevelopmental approach are: 
- Abnormalities in brain morphology and an increased ventricular size in 
schizophrenic patients (Nasrallah, 1993; Falkai and Bogerts, 1995; Weinberger, 
1995). Some of these deviations from normal occur well before the development of 
overt schizophrenic symptoms (Horrobin, 1999b). 
- Behavioural and neuromotor abnormalities occur in childhood, which may be 
predictive to some degree of later schizophrenia. These abnormalities include low 
IQ. (David et al., 1997); poor motor skills (Marcus, 1974; Jones, 1994); poor 
language and word skill development (Crow 1995; 1996); lack of concentration 
(Rieder and Nichols 1979) and poor social development (Fish 1987). In many 
people who later develop schizophrenia, certain behavioural patterns are detectable 
in childhood and adolescence (Horrobin, 1999b). 
- During pregnancy and the perinatal period, events such as obstetric complications, 
low birth weight and perinatal hypoxia (McNeil and Kaij, 1978; O'Callaghan et al., 
1992; McGrath and Murray, 1995); starvation during pregnancy (Susser and Lin, 
1992); low head circumference in otherwise normal individuals (McNeil et al., 
1993); viral infections especially in the second trimester (O'Callaghan et al., 1991; 
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Sham et al., 1992), have been associated with an increased risk of later 
schizophrenia. On the other hand, prolonged breast-feeding appears to be protective 
against the later development of schizophrenia (Mccreadie, 1997; Peet, 1997). 
- There are sex differences at the onset and clinical course of the disease, with 
females usually affected later, and less severely than males but showing a second; 
late post-menopausal, peak in incidence (Iacano, 1992; Murray et al., 1992). 
In both hemispheres, the risk of schizophrenia appears to be higher in children born 
during winter months than those at other times (Dalen, 1975; Yakley and Murray, 
1995). 
These findings suggest that there may be a genetic and environmental basis for 
schizophrenia. However, none of these neurodevelopmental influences seems to 
individually account for more than a small percentage of the total number of schizophrenic 
. patients in the community at large. There is still a fundamental lack of biochemical 
explanation for the expression of the genetic and neurodevelopmental influences in 
schizophrenia. Hypofunction of glutamate receptors h~s been put forward as a biochemical 
substrate for developmental problems, but this does not fully explain all the known 
neurodevelopmental effects (Olney and Farber, 1995). The observations consistent with 
the neurodevelopmental hypothesis are thought to occur by a disturbed phospholipid 
metabolism (Horrobin et al., 1994; Mahadik and Evans, 1997; Horrobin 1998), which can 
be explained by the "membrane phospholipid hypothesis". 
1.5 MEMBRANE PHOSPHOLIPID HYPOTHESIS OF SCIIlZOPHRENIA 
Over the past two decades a large number of studies have examined a hypothesis with 
direct implications for the treatment of schizophrenia, "the membrane phospholipid 
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hypothesis" (Horrobin et al., 1994 ). This hypothesis states that "a systemic abnormality -in 
one or more aspects of membrane phospholipid metabolism is an etiological factor in the 
development and/or symptoms of schizophrenia". The phospholipid hypothesis proposes 
that "in schizophrenia, there are at least two primary faulty genetic abnormalities and that 
the effect of these may be attenuated or exacerbated by a third gene. The two primary 
abnormalities- are an increased rate of removal of polyunsaturated fatty acids (PUFAs), 
from membrane phospholipids, coupled with a reduced rate of incorporation of these same 
fatty acids into membrane phospholipids" (Horrobin, 1998). Each of these abnormalities 
may arise from changes· in the activity or regulation of one or more of a group of 
phospholipase enzymes. Horrobin et al. (1994) suggested that schizophrenia is a disorder 
with abnormal phospholipid structure and metabolism, not only in neuronal cells but also in 
other tissues. Several studies on schizophrenic patients have reported various findings 
supporting the membrane phospholipid hypothesis: 
- Reports have shown depleted levels of several polyunsaturated fatty acids, 
especially arachidonic acid (AA) in phospholipids from red blood cell 
membranes of schizophrenic patients (Ramchand, 1996). 
- Treatment of schizophrenia with essential fatty acids and their derivatives, in 
particular the polyunsaturated fatty acid EPA, has yielded positive preliminary 
results and is the subject of ongoing clinical trials in Europe and North America 
(Richardson et al., 1999; Fenton, 2000; Joy et al., 2000; Richardson et al, 2000; 
Puri et al., 2000). 
- Schizophrenics' show reduced flushing after oral or topical administration of the 
B-vitamin, niacin (Ramchand et al., 1996; Ward et al., 1998), suggesting that 
schizophrenics have reduced availability of AA as flushing after niacin 
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administration occurs upon the enhancement of the production of prostaglandins 
from AA. This response is a marker of AA available for cell signaling. 
- Glutamate receptor hypofunction proposed by Olney and Farber (1995), as a 
biochemical substrate for developmental problems can even be explained by the 
membrane phospholipid hypothesis, since normal functioning of glutamate 
receptors require normal AA levels in membrane phospholipids (Horrobin, 
1999b). 
- There is considerable evidence that schizophrenic cells show increased levels of 
lipid peroxidation. Studies have demonstrated increased hydrocarbon levels in 
expired air from sc.hizophrenics (Hinsberger et al., 1995), and increased 
thiobarbituric acid reactive substances (TBARS) in drug naive patients during 
their first psychotic episodes (Ramchand et al., 1996). Hydrocarbons and 
TBARS are biomarkers of lipid peroxidation. 
- Phospholipase A2 (PLA2) has been reported to be increased in platelets from 
schizophrenic patients (Ramchand et al., 1996). Also, 31P magnetic resonance 
imaging has shown evidence of an increase in phospholipid breakdown in 
schizophrenia (Yao et al., 2002), which might be as the result of an over-active 
PLA2 (Glen et al., 1994; Hinsberger et al., 1995). 
- Previous studies of antioxidant enzyme activity levels in schizophrenic patients 
have generated controversial results. Some studies have reported a significant 
increase in superoxide dismutase (SOD) activity levels (Abdalla et al., 1986; 
Reddy et al., 1991; Lohr, 1991; Kuloglu et al., 2002) and high GSHPx levels 
(Kuloglu et al., 2002). Others have shown reduced GSHPx levels (Abdalla et 
al., 1986; Stoklasova et al., 1986) and low catalase (CAT) activity in 
schizophrenic patients compared to controls (Reddy et al., 1991). However 
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many of these reports suggest a decrease in cellular protection against oxidative 
damage to membrane phospholipids. 
Clinical trials for three months with PUFA supplementation in schizophrenic 
patients showed significant improvements in schizophrenic symptoms with EPA 
treatments in comparison to patients treated with ORA-supplements (Peet et al., 
2001). 
1.6 BIOLOGICAL CELL MEMBRANES 
Biological membranes are organized sheet-like assemblies consisting mainly of lipids and 
proteins. These sheet-like structures are non-covalent assemblies, thermodynamically 
stable and metabolically active. Membrane functions are indispensable for life. Plasma 
membranes give cells their integrity by separating them from their environment. Cell 
membranes are highly selective permeability barriers rather than impervious walls since 
they contain specific molecular pumps and gates, used for the transport of essential 
molecules and ions. Eukaryotic cells also contain internal membranes forming the 
boundaries of organelles such as the mitochondria, chloroplast, lysosomes, peroxisomes 
- etc. 
Membranes control the flow of information between cells and their environment. They 
contain specific receptors for external stimuli. For example, the movement of bacteria 
towards food, the response of target cells to hormones such as adrenalin, and light 
perception are processes in which the primary event is the detection of a signal by a specific 
membrane receptor. In tum, some membranes generate signals, which can be chemical or 
electrical. Thus, cell membranes play a critical and central role in biological 
communication both hormonal- and neuro-transmission. 
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Far from being just a bag of soluble components, the cell is viewed as a highly organized 
entity with many functional compartments each limited by one or more membranes. 
Membranes are highly viscous yet plastic structures surrounding all living cells. Plasma 
membranes form closed compartments around cellular protoplasm separating one cell from 
another, permitting cellular individuality. The plasma membrane has selective differences 
in composition between the internal and external cellular environments. The selective 
permeability is provided by pumps and channels for ions and substrates by specific receptor 
signals. 
1.6.1 The importance of biological membranes 
Alterations of membrane structures can affect water balance, ion influx and outflux and 
therefore, all cellular processes. Specific deficiencies or alterations of certain membrane 
components lead to a variety of diseases. For example, lack of an iodide transporter, causes 
congenital goitre. The maintenance of a normal environment around and in a cell is a 
fundamental requirement. Water makes up about 56% of the lean body mass of the human 
body and is distributed in two large compartments namely the intracellular and extracellular 
fluids. The intracellular fluid (ICF) compartment constitutes two-thirds of total water and 
provides the environment for the cell to make, · store and utilize energy, repair itself, 
replicate and perform special functions. On the other hand, the extracellular fluid (ECF) 
contains a third of the total body water and is distributed between the plasma and interstitial 
compartments. The ECF is a delivery system. It provides to the cell nutrients such as 
glucose, fatty acids, amino acids, vitamins, various ions, trace minerals· and a variety of 
respiratory molecules (hormones) that coordinate the functions of widely separated cells. 
The ECF removes carbon-dioxide waste products, toxic and detoxified materials from the 
immediate cellular environment. Common features of biological membranes are: 
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- Membranes are sheet.;.like structures with a thickness between 60 and 100 A. 
- They consist mainly of proteins and lipids. In most biological membranes, the 
weight ratio of protein to lipids ranges from 1 :4 to 4: 1. They also contain 
carbohydrates linked to lipids and proteins. 
- Membrane lipids are relatively small molecules possessing both a hydrophilic and 
hydrophobic moiety. These lipids spontaneously form closed bimolecular sheets in 
aqueous media (Fig. 1.1). The lipid bi-layers form barriers to the flow of polar 
molecules. 
- Membrane proteins are specific in nature. They mediate distinctive functions of 
membranes. They function as pumps, gates or channels, receptors, energy 
transducers and enzymes. They are embedded in lipid bi-layers, which create 
suitable environments for their action. 
- Cell membranes are non-covalent assemblies i.e. the constituent lipid and protein 
molecules are held together by many non-covalent interactions, which are 
cooperative. 
- Membranes are asymmetric i.e. the two faces of a membrane are different. 
- Membranes are fluid structures. Lipid molecules diffuse rapidly in the plane of the 
membrane, as do proteins, unless they are anchored by specific interactions but they 
do not rotate across the membrane. Membranes can be regarded as two-
dimensional solutions of oriented proteins and lipids. 
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Table 1.1 The protein : lipid ratio of some purified membranes 
Percentage by Weight 
Membrane 
Myelin 
Plasma Membrane: 
HumanRBC 
Mouse Liver 
Amoeba 
Mitochondrial Liver 
Membrane 
Protein 
18 
49 · 
44 
54 
76 
Lipid 
79 
43 
52 
42 
24 
Source: Guidotti G. Ann. ReviewBiochem 1972; 41:731. 
1.7 MEMBRANE LIPIDS 
Carbohydrate 
3 
8 
4 
4 
0 
Membrane lipids are sheet like structures, only a few molecules thick, that form closed 
boundaries between compartments of different composition. Lipids are water in-soluble 
bio-molecules that are highly soluble in organic solvents such as chloroform. They have a 
wide variety of biological functions including serving as fuel molecules, highly 
concentrated energy stores, signal molecules and components of the membranes. There are 
different classes of lipids but all derive their distinctive properties from the hydrocarbon 
nature of a major portion of their structure. Lipids serve as protective coatings on the 
surface of many organisms and also play significant roles in cell recognition, species 
specificity and tissue immunity. 
Lipids have fundamental structural and functional roles in cell membranes generally and 
particularly in the central nervous system. They form the matrix within which membrane 
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proteins and carbohydrates interact. Membrane proteins include receptors, ion channels 
and second messenger binding proteins. Second messengers are intracellular mediators 
formed by the binding of an effector to a receptor in cell membranes. Membranes differ in 
their protein content depending on their functions. For example, myelin, a membrane 
serving as an insulator around certain nerve fibers, is low in protein (18%) with lipids being 
the major molecular species. A dysfunction in membrane lipids may therefore result in 
defective membrane protein activities, cellular ion transport and may even result in cell 
death. So far, lipids have been largely ignored and the neurochemical basis for most 
psychiatric disorders · concentrated on, with particular emphasis primarily on 
neurotransmitters and their receptor systems (Peet, et al., 1999). However, more recently, 
there has been increasing recognition that neurotransmitters and the receptor mechanisms 
are substantially influenced by the lipid environment without which there will be profound 
disorders in membrane activities (Witt and Nielson, 1994). 
Membrane lipids constitute about 50% of the mass of most animal cell plasma membranes. 
All are amphipathic molecules containing both hydrophilic and hydrophobic surfaces. They 
can take the shape of a bilayer (bimolecular sheets with the hydrophobic tails sandwiched 
between the hydrophilic head groups) or a micelle (a spherical shape with tails pointing 
inward) (Fig. 1.1). Membrane lipids have many functions including the control of cell 
permeability and fluidity. 
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A MICELLE 
Fig. 1.1 Phospholipid bilayer 
Unlike plasma membranes of non-neuronal cells, neuronal plasma membranes, contain as 
much as 69.5% of the total cell lipids, constituting over 50% of the dry weight in human 
brain, are enriched in respect of four major phospholipid classes: phosphatidylcholine, 
phosphatidylinositol, phosphatidylethanolamine and phosphatidylserine (Suzuki et al., 
1981 ). As much as 20% of the brain by weight consists of PUF As mostly AA and DHA 
(Horrobin, 1996) which are highly susceptible to oxidative damage. 
1.8 MEMBRANE LIPID CLASSES 
There are three major kinds of membrane lipids, namely: phospholipids, glycolipids and 
cholesterol. Phospholipids are the major class of membrane lipids. They are abundant in 
all biological membranes. 
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Table 1.2 Lipids in animal cells 
Lipid Class Hydrophilic Unit 
Phospholipids: 
Phosphoglycerides Phosphorylated alcohol 
Sphingomyelin Phosphoryl choline 
Glycolipid 
Cholesterol 
1.8.1 Phospholipids 
One or more sugar 
Residues. 
OH group at C-3 
Hydrophobic Unit 
Fatty Acid chains 
Fatty acid chain and 
hydrocarbon chain of 
sphingosine 
Fatty acid chain and 
hydrocarbon chain of 
sphingosine. 
Entire molecule excluding 
the hydroxyl group at C-3. 
The two major phospholipid groups are phosphoglycerides (also known as 
glycerophospholipids) and sphingolipids composed of sphingomyelins. 
1.8.1.1 Phosphoglycerides 
They are the more common group of phospholipids. They are made up of a glycerol 
backbone attached via an ester linkage to two fatty acid chains and a phosphorylated 
alcohol (Fig. 1.2). 
) 
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CH2O - Fatty acid chain at the sn-1 position 
I 
CHO-Fatty acid chain at the sn-2 position 
0 
II 
CH2O - P-O-
1 
o-
Choline CH2 (OH) - CH2 - N (CH3)/ or 
Ethanolamine CH2 (OH) - CH2 - NH3 + or 
Serine CH2 (OH) - CH(NH3 +)(COO-) or 
Inositol 
Fig. 1.2 Phospholipid structure. 
In glycerophospholipids, the hydrophilic unit is also known as the polar head group 
represented by a circle whereas, the hydrophobic unit containing the hydrocarbon tails are 
depicted by straight or wavy line (Fig. 1.1). In an aqueous medium, the polar head groups 
have the affinity for water whilst the hydrocarbon tails avoid water. These preferences are 
accommodated by the formation of a micelle, a globular structure in which polar head 
groups are on the surf~ce in contact with the aqueous environment with the hydrocarbon 
tails sequestered inside (Fig. 1.1 ). 
Another arrangement fulfilling both the hydrophilic and hydrophobic preferences of 
membrane lipids is a bimolecular sheet also known as the lipid bi-layer (Fig. 1.1). The 
favoured arrangement of phospholipids in an aqueous environment is the bi-layer form 
rather than a micelle as their two fatty acyl chains are too bulky to fit into the interior of a 
micelle. In contrast, salts of fatty acids containing only one fatty acyl chain readily form 
micelles. The formation of the bi-layer rather than the micelles by phospholipids is of 
critical importance in biological membranes. Whilst a micelle is a limited structure, usually 
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less than 200 A in diameter,. the lipid bi-layer can have macroscopic dimensions 
(millimeter, 107 A). Phospholipids and glycolipids are important membrane constituents 
because they readily form extensive bimolecular sheets. In addition, these sheets serve as 
permeability barriers and yet are fluid in nature. 
The formation of a lipid bi-layer is a self-assembly process, inherent in the structure of the 
lipid molecules in their amphipathic character. It is a rapid and spontaneous process in 
aqueous media driven predominantly by hydrophobic interactions. Water molecules are 
released from the hydrophobic tails of membrane lipids as these tails become sequestered in 
the non-polar interior of the bi-molecular sheet. van der Waals forces of attraction between 
the hydrophobic tails favour close packing. There are also electrostatic and hydrogen-
bonding attractions between the polar head groups and water molecules. The lipid bi-layers 
are stabilized by a full array of forces that mediate molecular interactions in biological 
systems. In eukaryotic cells, the fatty acid constituents are usually even numbered carbon 
molecules, mostly containing 12 to 24 carbons. They are unbranched in animal cells and 
can be saturated or unsaturated. The double bond configuration in unsaturated fatty acids is 
almost always cis. The length and the degree of unsaturation in fatty acid chains in 
membrane lipids have profound effects on membrane fluidity . 
. 1,YYYYYYYYYYYY ~0 
Hc-c-c-c-c-c-c-c-c-c-c-c-c-c-c-c 3 I I I I I I I I I I I I I I ''n-H H H H H H H H HH HHHH 
Palmitate (ionized form of palmitic acid) (C16:0). 
20 
ff rY Y Y Y Y Y f Y Y Y Y, Y -~0 
Hc-c-c-c-c-c-c-c-c=c-c-c-c-c-c-c-c-c 
3 I I I I I I I I I I I I I I 'o-
H H H H H H H HHHHHHH 
Oleate (ionized form of oleic acid) (C18:t) 
Under physiological conditions, · these fatty acids are ionized and so they may also be 
referred to as palmitate and oleate for emphasis on this. In phosphoglycerides, the hydroxyl 
groups at C-1 and C-2 of the glycerol backbone are esterified to the carboxyl groups of two 
fatty acid chains while the C-3 hydroxyl group is esterified to phosphoric acid. The 
resulting compound, called phosphatidate (or diacylglycerol-3-phosphate), is the simplest 
phosphoglyceride. Only small amounts of phosphatidate are present in membranes but it is 
a key intermediate in the biosyntheisis of the other phosphoglycerides. The absolute 
configuration of the glycerol-3-phosphate moiety of membrane lipids is shown in the Fig. 
1.3. 
1CH2OH 
~ 
HO r::::------- 2C __ __, HO-C-H 
~ 
(A) (B) 
Fig.1.3 Absolute configuration of the glycerol-3-phosphate moiety of membrane 
lipids: (A) H and OH, attached to C-2, are in front of the plane of the page, whereas C-1 
and C-3 are behind it; (B) Fischer representation of this structure. In a Fischer projection, 
horizontal bonds denote bonds in front, whereas vertical bonds denote bonds behind the 
plane of the page. 
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The major phosphoglycerides are derived from phosphatidate. The phosphate group of 
phosphatidate is esterified to the hydroxyl group of one of several alcohols. The five 
·common alcohol moieties of phosphoglycerides are ethanolamine, inositol, choline, serine 
and glycerol. 
Phosphatidyl ,choline (PC) (Fig. 1.4) is a phosphoglyceride found in most biological 
membranes of higher organisms. The word "phosphatidyl" specifically means diacyl 
glycerophosphoric acid. PC is the most widely distributed phospholipid. In many tissues, 
PC makes up about half of the total PL fraction. It is a neutral or zwitterionic phospholipid 
over a pH ranging from strongly acidjc to strongly alkaline. In animal tissues, stearic acid 
and arachidonic acid are commonly esterified to the sn-1 and sn-2 positions (respectively) 
of PC. 
CH200C-R1 
I 
R2COOCH 0 
I II 
CH2 - 0 - P - 0 - CH2CH2W(CH3)3 
I 
o-[H, OH] 
Fig. 1.4 Phosphatidylcholine (PC). 
The phospholipid molecule is therefore not one pure compound but a mixture of closely 
related molecules differing in fatty acid composition. This is a property of all known tissue 
phospholipids. Enzymatic evidence suggests that the sn-1 position of PC is esterified 
largely to saturated fatty acids, and the sn-2 position to unsaturated fatty acids (Sugimoto 
and Yamashita, 1999). 
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CH2-0-C-(CH2)14-CH3 
I 
H3C-(CH2)1-HC=CH-(CH2)1-C-O-CH O Cfu 
II I II / 
0 CH2-0-P-O-CH2-CH2-N+-Cfu 
I ~ 
o- CH3 
Fig.1.5 A phosphatidylcholine ( 1-palmitoyl-2-oleoyl-phosphatidylcholine ). 
Phosphatidylserine (PS) _is the only amino acid containing glycerophospholipid in animal 
cells. It is an acidic phospholipid usually occuring- in tissues as a salt with K+, Na+, Ca2+, 
Mg2+. Though PS is widely distributed, it is usually a minor PL component in most cell 
types. In animal brain cells, AA or DHA is commonly localized at the sn-2 position and 
stearic acid acylated at the sn-1 position of PS. 
Fig.1.6 
0 
II 
CH2-0-C-R1 
I 
R2-C-O-CH O 
II I II 
0 CH2-0-P-O-CH2-CH-NHt 
I I 
o- coo-
Phosphatidylserine. 
Phosphatidylethanolamine (PE) is a neutral or zwitterionic phospholipid (at least in the pH 
range 2-7). PE in animal tissues commonly has stearic acid at the sn-1 position and AA at 
the sn-2 position. 
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Fig.1.7 
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II 
R1-C-O-CH2 
I 
R2-C-O-CH O 
II I II 
0 CH2-0-P-O-CH2-CH2-NHt 
I o-
Phosphatidylethanolamine. 
Phosphatidylinositol (PI) is an acidic phospholipid. PI is especially abundant in brain 
tissues but present in all tissues and cell types. Stearic acid is most commonly acylated at 
the sn-1 position and AA at the sn-2 position of PI in animal tissues. 
H 
Fig.1.8 
0 
II 
CH2-0-C-R1 
I 
OH OH o CH-O-C-R2 
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Phosphatidylinositol. 
In general, all double bonds in fatty acids i.e. R1 and R2 positions of the glycerol backbone 
of phospholipids are of the cis configuration. A major difference among phospholipids is 
the charge carried by the polar head groups at neutral pH. Some phosphoglycerides (e.g. 
PC and PE) have no net electrical charge while others (e.g. PG, cardiolipin (DPG) and PS) 
have a net negative charge. A few rare phospholipids carry a net positive charge at neutral 
pH. Nonetheless, the polar head groups of all phospholipids can pack together into the 
characteristic bi-layer structure. 
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1.8.1.2 Sphingomyelin 
As the name implies, sphingomyelin is prominent in myelin sheaths. Sphingomyelin is the 
only phospholipid without a glycerol backbone. Instead, it has a sphingosine backbone. 
Sphingosine is an amine alcohol containing a long, unsaturated hydrocarbon chain. In 
sphingomyelin, the amino group of the sphingosine backbone is linked to a fatty acid by an 
amide bond. In addition, the primary hydroxyl group of sphingosine is esterified to 
phosphoryl choline. Thus, the conformation of sphingomyelin resembles that of 
phosphatidylcholine. 
H H 0 
I I II + 
H3C-(CH2)12-HC = CH-C-C-CH2-0-P- 0- CH2- CH2-N (CH3)3 
I I 
OH N-H 
I 
I . \ o- ) 
"--·· -----------------·-··---------. ___ ' /-------------- . 
\ 
C=O Phosphoryl choline unit 
Fatty acid unit I 
R1 
(A) 
H H 
I I 
H3C-(CH2)12-HC = CH-C-C-CH20H 
I I 
OH NH3+ 
(B) 
Fig. 1.9 (A) Sphingomyelin. (B) Sphingosine backbone. 
Sphingolipids are important membrane components present in large amounts in the brain 
and nerve tissues. All sphingolipids contain: one fatty acid molecule, a sphingosine 
backbone i.e. a sphingosine molecule or one of its derivatives and a polar head group. 
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1.8.2 Glycolipids 
As the name implies, glycolipids are sugar-containing lipids. In animal cells, glycolipids 
like sphingomyelins are derived from sphingosine. The amino group of the sphingosine 
backbone is acylated by a fatty acid, as in sphingomyelin. Glycolipids however differ from 
sphingomyelin in the nature of the unit that is linked to the primary hydroxyl group of the 
sphingosine backbone. In glycolipids, one or more sugars (instead of phosphoryl choline) 
are attached to this group. The simplest glycolipid is cerebroside, with a single hexose 
sugar moiety, either glucose or galactose (Fig. 1.10). 
Glycolipids are also called glycosphingolipids. Sphingomyelins and glycolipids are similar 
in shape to phosphoglycerides and can form mixed bi-layers with them. More complex 
glycolipids, such as gangliosides, contain a branched chain with three or more sugar 
residues of which at least one is sialic acid, attached to the primary alcohol of sphingosine. 
H H 
I I 
H3C - (CH2)12 - HC = CH - C - C - CH2 - 0 -
I I 
OH N-H 
I 
O=C 
I 
R1 
Fig. 1.10 Cerebroside (a glycolipid). 
1.8.3 Cholesterol 
Glucose or 
Galacfose 
Sugar Unit 
Cholesterol is an important· neutral lipid found in some membranes belonging to the group 
of sterols. It is the most common sterol in membranes, existing almost exclusively in the 
plasma membrane of mammalian cells. It can be found in lesser amounts in the membranes 
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of cellular organelles such as the mitochondria, golgi bodies and nucleus. Cholesterol is 
generally more abundant towards the outside of the· plasma membrane. It intercalates 
among the phospholipids of the membrane, with its hydroxyl group at the aqueous interface 
and the remainder of the molecule within the leaflet. This sterol is present in_ eukaryotes 
but not in most prokaryotes. 
CH3 H I . I 
H-C-CH -CH -CH -C-CH 
2 2 2 I 3 
HC 3 
· . CH 
Fig.1.11 A cholesterol molecule. 
1.8.4 Fatty acid metabolism 
Physiological functions of fatty acids 
3 
- Fatty acids are building blocks of phospholipids and glycolipids. They are · 
amphipathic molecules playing critical roles in biological membranes. 
- Many proteins are modified by the covalent attachment of fatty acids, which targets 
them to membrane locations. Soluble cytosolic proteins can be anchored by 
covalent bonds to a fatty acyl group via myristoylation at the N-terminus or 
palmitoylation of cysteine residues. 
- Fatty acids are fuel molecules stored as triacylglycerols, which are uncharged esters 
of glycerol (neutral fats). 
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- Fatty acid derivatives function as hormones and intracellular · messengers. For 
example, prostaglandins, leukotrienes and thromboxanes (local hormones called 
eicosanoids) derived from arachidonic acid (C20:4). 
. 1.8.5 Fatty acid Nomenclature 
The systemic names of fatty acids are derived from its parent hydrocarbon by the 
substitution of 'oic' for the last 'e'. For example, C18 (saturated fatty acid) is called 
octadecanoic acid as the parent hydrocarbon is octadecane. A C18 fatty acid with one 
double bond is called octadecenoic acid; with two double bonds, octadecadienoic acid; and 
with three double bonds called octadecatrienoic acid. The symbol 16:0 denotes a C16 fatty 
acid with no double bonds while 18:2 shows that there are two double bonds. Fatty acid 
carbon atoms are numbered starting from the carboxy terminus (Fig. 1.12). 
Fig.1.12 
0 
II 
H3C - (CH2)n - 3CH2 - 2CH2 - 1C 
co f3 a \ 
OH 
The numbering of fatty acid carbon atoms. 
The second and third carbon atoms are usually referred to as a and (3, respectively, whereas 
the methyl carbon atom at the distal end of the chain is called the ro-carbon. The position 
of a double bond is denoted by the symbol I:},, followed by a superscript number. For 
example, cis- /i9 represents a cis double bond between carbon atoms 9 and 10. Trans- !i3 
means that there is a trans double bond between carbon atoms 3 and 4. Alternatively, the 
position of a double bond can be denoted by counting from the distal end with the ro -
carbon atom (the methyl carbon) as number 1. 
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H H 
I I 
H3C-CH2-C = C-CH2-R-coo-
t ro-3 double bond 
ro-carbon atom 
Fig.1.13 Structure of an ro-3 fatty acid. 
Although the ,systemic naming of fatty acids has been described, the present study refers to 
them by their trivial names because these names are still more commonly used. 
1.8.6 Properties of fatty acids 
- ~n biological systems, fatty acids usually contain even numbers of carbon atoms, 
usually between 12 and 24. In animals, the hydrocarbon chain is almost invariably 
unbranched. The alkyl chain may be saturated or unsaturated ( containing one or 
more double bonds). The configuration of double bonds in most unsaturated fatty 
acids is cis. The double bonds in PUFAs are separated by at least one methylene 
group. 
- The properties of fatty acids and the lipids derived from them are largely dependent 
on their chain length and degree of saturation. Saturated fatty acids have a higher 
melting point than unsaturated fatty acids. For example, stearic acid has a melting 
point of 69 .6°C while oleic acid ( containing one cis double bond) has a melting 
point of 13.4°C. The melting point for PUFAs of the C18 series is even lower. 
Chain length also affects melting points of fatty acids. The melting point of 
palmitic acid (C16) is 6.5°C lower than that of stearic acid (C18) i.e. the shorter the 
chain length, the lower the melting point. Hence, short chain length and 
unsaturation enhances the fluidity of fatty acids and their derivatives. 
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- Triacylglycerols (TA Gs) are highly concentrated energy stores because they are 
reduced and anhydrous. The energy yield from the complete oxidation of fatty 
acids is about 9kcal/g, in contrast to about 4kcal/g for carbohydrates and proteins. 
In addition, TAGs are highly non-polar and so stored in nearly anhydrous forms, 
whereas proteins and carbohydrates are much more polar and as such largely 
hydrated. In actual fact, 1 g of dry glycogen binds about 2 g of water. 
Consequently, a gram of nearly anhydrous fat stores more than six times as much 
energy as a gram of hydrated glycogen. Thus TAGs, rather than glycogen, were 
selected in evolution as the major energy reservoir. 
- TA Gs are hydrolysed by Ii pases (Fig. 1.14 ). 
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0 CH2-0-C-R1 
II I 
R2-C-O-CH 0 
I II 
CH2-0-C-R3 
Triacylglycerol 
Lipases 
+ 3H20 ► 
Fig. 1.14 Hydrolysis of triacylglycerols (TAGs). 
CH20H 
I 
HO-CH + 
I 
CH20H 
Glycerol 
0 
II 
R1-C 
\ 
o-
0 
II 
R2-C 
\· 
o-
0 
II 
R3-C 
\ 
a-
Fatty acids 
The activity of adipose cell lipase is regulated by epinephrine, norepinephrine, glucagon 
and adenocorticotropic hormone. These hormones stimulate the adenylate cyclase enzyme 
of adipose cells, which raises the intracellular concentrations of cyclic adenosine 
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monophosphate (cAMP). Increased levels of cAMP trigger a protein kinase, which in turn 
activates the lipase enzyme by phosphorylating it. 
Glycerol formed by lipolysis is phosphorylated and oxidized to dihydroxyacetone 
phosphate, which is then isomerized to glyceraldehyde-3-phosphate (Fig. 1. 15). This 
intermediate is on both glycolytic and the gluconeogenic pathways. As such, glycerol can 
be converted into pyruvate or glucose in the liver, which contains the appropriate enzymes. 
The reverse process can occur by the reduction of dihydroxyacetone phosphate to glycerol-
3-phosphate, which is hydrolysed by a phosphatase to give glycerol. Thus glycerol and 
glycolytic intermediates are readily inter-convertible. 
CH20H 
I 
HO-C-H 
I 
CH20H 
Glycerol 
Fig.1.15 
ATP ADP+Pi 
Glycerol kinase 
CHzOH NAD+ NADH + H+ 
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HO-C-H \I 
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Phosphorylation of glycerol. 
1.8.7 Fatty acid breakdown 
CH20H 
I 
0= C 
I 
CH2-0PO/-
Dihydroxyacetone 
Phosphate 
Fatty acids are degraded by oxidation at the f3 - carbon. Oxidation of fatty acids takes place 
in the mitochondria. Fatty acid activation occurs in two steps. First, the fatty acid reacts 
with ATP forming an acyl adenylate: 
0 0 
II \ II 
R-C + ATP __ __.. R-C-AMP 
\ " 
+ PPi (pyrophosphate). 
o-
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The sulthydryl group of CoA then attacks the acyl adenylate, which is tightly bound to the 
enzyme, to form acyl CoA and AMP: 
0 
II 
R-C-AMP + 
Giving: 
0 
HS-CoA \ 
0 
0 
II 
R-C-S-CoA + AMP 
II 
R-C + 
\ 
--'- II AMP + CoA \ R-C-S-CoA + AMP + PPi 
o-
PPi is then rapidly hydrolysed by a pyrophosphatase, making the overall reaction: 
R-Coo- + CoA + ATP + H20 ---~ Acyl CoA + AMP + 2Pi + 2H+ 
The above reaction is irreversible because 2 high-energy bonds are consumed whereas, 
only one is formed. 
Fatty acids are activated on the outer mitochondrial membrane and oxidized in the 
mitochondrial matrix. Long chain acyl CoA molecules do not readily traverse the inner 
mitochondrial membrane, hence, a special transport mechanism is required. Activated long 
chain fatty acids are transported across the inner mitochondrial membrane by carnitine, a 
zwitterionic compound formed from lysine. The acyl group is transferred from the sulfur 
atom of CoA to the hydroxyl group of carnitine to form acyl carnitine. This reaction (Fig. 
1.16) is catalyzed by carnitine acyl transferase I, located on the cytosolic face of the inner 
mitochondrial membrane. 
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Fig. 1.16 The transport of long chain acyl CoA molecules across the inner 
mitochondrial membrane. 
Acyl carnitine is then shuttled across the inner mitochondrial membrane by a translocase. 
The acyl group is transferred back to CoA on the matrix side of the membrane. This 
reaction is catalyzed by carnitine acyl transferase II. Finally, carnitine is returned to the 
cytosolic side by the translocase, in exchange for an incoming acyl carnitine. A defect in 
the transferase or translocase, or a deficiency of carnitine, might impair the oxidation of 
long-chain fatty acids. Fatty acid oxidation is the major energy yielding process in the 
following three states: fasting, exercise or a high fat diet. Carnitine is not required for the 
transfer of medium chain (Cs and C10) acyl CoAs into the mitochondrial matrix. 
1.8.8 fl-Oxidation pathway of fatty acids 
In the {)-oxidation pathway of fatty acids, the first reaction is the oxidation of acyl CoA by 
an acyl CoA dehydrogenase to give an enoyl CoA with a trans double bond between C-2 
and C-3 (Fig. 1.17). 
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FAD FADH2 
R-CH2-CH2-CH~O-S-CoA ~ L_ ~ R-CH~H=CH-C~-CoA 
Oxidation 2 y H20 Acyl CoA Trans-Li -enoyl CoA 
Hydration 
Fig. 1.17 
R-CH2-CHOH-CH2-CO-S-CoA 
L-3-hydroxyacyl CoA 
First reaction of the ~-oxidation pathway. 
The second reaction is the hydration of the double bonds between C-2 and C-3 by enoyl 
CoA hydratase. 
Trans-Li2-enoyl CoA + H20 _"-::: ___ L-3 - hydroxyacyl CoA 
This is followed by the second oxidation reaction, which converts the hydroxyl group at C- . 
3 into a keto group, generating NADH. It is a reversible reaction. 
L-3-hydroxyacyl CoA RCH2-CO-CH2-CO-S-CoA 
Oxidation. 
The final step is the cleavage of 3-ketoacyl CoA by the thiol group of a second molecule of 
CoA, yielding acetyl CoA and an acyl CoA shortened by 2 carbon atoms. This thiolytic 
cleavage is catalyzed by ~-ketothiolase. 
SH-CoA 
3-Ketoacyl CoA >. ► CH3-CO-S-CoA + R-CH2-CO-S-CoA 
Thiolysis Acetyl Co A Acyl Co A (Cn-2) 
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The shortened acyl CoA then undergoes another cycle of oxidation, starting with the 
reaction catalyzed by acyl CoA dehydrogenase. 
- fatty acyl chains with 12 to 18 carbons are oxidized by the long chain acyl CoA 
dehydrogenase. 
- The medium-chain acyl CoA dehydrogenase oxidizes fatty acyl chains with 14 to 4 
carbons whereas, 
- The short-chain acyl CoA dehydrogenase acts on 4- and 6- carbon acyl chains. 
In the first three rounds of degradation of palmitate for instance, two carbon units are 
sequentially removed form the carboxyl end of the fatty acid. 
H3C-(CH2)rCH2-CHi-CH2-CHi-CH2-CHi-CH2-CO-S-CoA 
~ H3C-CO-S---CoA 
H3C-(CH2)1- CHi-CH2-CH2-CHi-CH2-CO-S-CoA 
~ H3C-CO-S---CoA 
H3C-(CH2)rCH2-CH2-CH2-CO-S-CoA 
~ H3C-CO-S---CoA 
H3C-(CH2)1-CHi-CO-S-CoA 
1.8.9 Oxidation of unsaturated fatty acids 
Many of the reactions are similar to those for saturated fatty acids with only two additional 
enzymes: an isomerase and a reductase needed to degrade a wide range of unsaturated fatty 
acids. Take the oxidation of palmitoleate for example, this C16 unsaturated fatty acid with 
35 
one double bond between C9 and C10, is activated and- transported across the inner 
mitochondrial membrane in a similar manner as saturated fatty acids. 
Palmitoleoyl CoA then undergoes three cycles of degradation, which are carried out by the 
same enzymes as in the oxidation of saturated fatty acids. Three stages of degradation of 
palmitoleoyl CoA are as follows: 
Palmitoleate 
Palmitoleoyl CoA 
H3C-(CH2)sCH=CH(CH2)z-CH2-CO-S-CoA 
~ H3C--CO-S--CoA 
cis-L~.3-enoyl CoA. 
However, the cis-.tl3 -enoyl CoA formed in the third round is not a substrate for acyl CoA 
dehydrogenase. The presence of a double bond between C-3 and C-4 inhibits the formation 
of another double bond between C-2 and C-3. This problem is resolved by a new reaction 
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that shifts the position and configuration of the cis-A3-enoyl bond. An isomerase converts 
this double bond into a trans-A2 -double bond. The subsequent reactions are those of the 
saturated fatty acid oxidation pathway, in which the trans-A2-enoyl CoA is a regular 
substrate. 
HH 
H3C-(CH2)s-C=C-CH2-CO-S-CoA 
cis-A3 -enoyl CoA 
isomerase H 
-->~ H3C-(CH2)s-CH2-C=C-CO-S-CoA 
"- H 
trans-A2-enoyl CoA 
1.8.10 Oxidation of polyunsaturated fatty acids . 
Consider linoleate, a C1s PUPA with cis-A9 and cis-A12 double bonds, after 3 rounds of (3 -
oxidation: 
CH3(CH2)4(CH=CHCH2)2(CH2)6-Coo-
Linoleate l 
CH3(CH2)4(CH=CHCH2)2CH2- CH2- CH2- CH2- CH2- CH2-CO-S-CoA 
Linoleoyl CoA l ~ H3C-CO-S-CoA 
CH3(CH2)4(CH=CHCH2)2CH2- CH2- CH2- CH2-CO-S-CoA 
k H3C--CO-S---CoA 
CH3(CH2)4(CH=CHCH2)zCH2- CH2-CO-S-CoA 
k H3C--CO-S--CoA 
CH3(CH2)4CH=CHCH2-CH=CH-CH2-CO-S-CoA 
with a cis-A3 -double bond 
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The cis-A3 double bond formed after 3 rounds of f3 - oxidation is converted by the 
isomerase into a trans-A 2 double bond. However, the cis-A 12 double bond of linoleate 
poses a new problem. After 3 rounds of f3 - oxidation of linoleate, the following reaction 
takes place: 
CH3(CH2)4CH=CHCH2-CH=CH-CH2-CO-S-CoA 
cis, cis-A3, A6-dienoyl CoA l · 
1somerase 
2, 6-dienoyl CoA. 
NAD+ ;! 
· Oxidation 
H++NADH 
CoA--SH i Thiolysis 
Acyl CoA Acetyl CoA 
The acyl CoA above is produced by 4 rounds of f3 - oxidation. It contains a cis-A 4 double 
bond. Dehydrogenation of this species by acyl CoA dehydrogenase yields a 2, 4 - .dienoyl 
intermediate, which is not a substrate for the next enzyme in the f3 - oxidation pathway. 
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AcylCoA FAD ~ 
dehydrogenase 
FADH2 
CH3(CH2)4CH=CH-CH=CH-CO-S-CoA 
Trans A 2, cis A 4-dienoyl CoA (2, 4-dienoyl CoA) 
The cis A 4problem from the above product is overcome by 2, 4-dienoyl CoA reductase, an 
enzyme utilizing NADPH to reduce the 2, 4-dienoyl intermediate to cis A3 -enoyl CoA. 
2, 4-dienoyl CoA 
NADPH+H+ ~ 2, 4-dienoyl CoA 
· reductase 
NADP+ . 
cis A3-enoyl CoA 
trans A2-enoyl CoA 
Only two extra enzymes are required for the f3-oxidation of any PUFA. Odd numbered 
double bonds. are handled by the isomerase, and even-numbered ones by the reductase and 
the isomerase. A round of f3 - oxidation of saturated fatty acids includes: oxidation by FAD 
(flavin adenine dinucleotide ); hydration; oxidation by NAD+ and thiolysis by CoA. Odd-
numbered fatty acids are minor spe~ies, oxidized in the same fashion as even-numbered 
ones except that propionyl CoA and acetyl CoA, rather than two molecules of acetyl CoA, 
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are produced in the final round of degradation. The activated 3-C unit of propionyl CoA 
enters the Krebs cycle after conversion into succinyl CoA. 
H3C-CH2 -CO-S -CoA 
Propionyl CoA 
The acetyl CoA formed from fatty acid oxidation enters the Krebs cycle only if fat and 
carbohydrate degradation are appropriately balanced. The reason being that the entry of· 
acetyl CoA into the Krebs cycle is dependent on the availability of oxaloacetate for the 
formation of citrate, but the concentration of oxaloacetate is lowered if carbohydrate is 
unavailable or improperly used. Oxaloacetate is normally produced from pyruvate, 
generated from glycolysis. In fasting or diabetes, oxaloacetate is converted to glucose by 
the gluconeogenic pathway making it unavailable for condensation with acetyl CoA. 
Under such conditions, acetyl CoA is converted to acetoacetate and D-3-hydroxybutyrate. 
Acetoacetate, D-3-hydroxybutyrate and acetone are sometimes referred to as ketone bodies. 
The major-site for the production of acetoac;etate and 3-hydroxybutyrate is the liver. They 
are· both normal fuels of respiration and are quantitatively important as sources of energy. 
Glucose is the major fuel for the brain and red blood cells in well-nourished people on a 
balanced diet. However, the brain utilizes acetoacetate during starvation and diabetes. In 
prolonged starvation, 75% of the fuel needs of the brain are met by acetoacetate (a water-
soluble, transportable form of acetyl units). Acetoacetate can be activated by the transfer of 
CoA from succinyl CoA in a reaction catalyzed by a specific CoA transferase~ Acetoacetyl 
CoA is then cleaved by thiolase to yield 2 molecules of acetyl CoA (Fig. 1.18), which can 
then enter the Krebs cycle. Animals cannot convert fatty acids into glucose but plants can. 
40 
Succinyl CoA Succinate 
Acetoacetate >,, ~ ► Acetoacetyl CoA 
CoA 
transferase 
COi 
__ \, ____ ► .2 Acetyl CoA 
Thiolase 
AcetylCoA 
+H20 CoA 
OH 
2-Acetyl Co A ~ CH3-CO--CHz-CO-S-CoA\lOOCCH2J-CHz-CO-S-CoA 
(1) Acetoacetyl Co A (2) I 3-hydroxy-3-
CH3 methyl glutaryl 
NADH 
-ooc-CH2-CHOH-CH3 
D-3-hydroxy butyrate 
~L 
(4) 
CoA 
(3)~ 
AcetylCoA 
-ooc-CH2-CO-CH3 
Acetoacetate 
Acetone 
Fig.1.18 Activation of acetoacetate where (1): 3-ketothiolase; (2): hyroxymethyl 
glutaryl CoA synthase; (3): hydroxymethyl glutaryl CoA cleavage enzyme and (4): D-3 
hydroxybutyrate dehydrogenase. 
1.8.11 Biosynthesis of fatty acids 
Fatty acids are synthesized and broken down by different pathways and the synthesis is not 
simply the reversal of the degradative process. Fatty acid synthesis starts by the 
carboxylation of acetyl CoA to malonyl CoA. This is an irreversible reaction. 
Acetyl Co A 
carboxylase 
H3C-CO-S-CoA +ATP+ HC03----► -ooC-CHi-CO-S-CoA +ADP+ Pi+ H+ 
Acetyl Co A Malonyl Co A 
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The enzyme system catalyzing the synthesis of saturated long-chain fatty acids form acetyl 
CoA, malonyl CoA, and NADPH is called fatty acid synthase. The elongation process 
starts with the formation of acetyl-ACP and malonyl-ACP (acyl carrier protein). 
Acetyl transacylase 
Acetyl CoA Acetyl-ACP + CoA 
Malonyl transacylase 
\ 
Malonyl CoA \ Malonyl-ACP + CoA 
Odd numbered fatty ac'ids are synthesized starting with propionyl-ACP, which is formed 
from propionyl CoA by acetyl transacylase. Malonyl transacylase is highly specific for its 
substrate while acetyl transacylase is not. 
Acetyl-ACP and malonyl-ACP react to form acetoacetyl-ACP. 
CH3-CO-S-ACP 
Acetvl-ACP 
+ 
ACP J1 
+COi ,,..!. 
-00C-CH2-CO-S-ACP 
Malonvl-c-ACP 
Condensation by acyl-
rnalonyl -ACP 
Condensing enzyme. 
H3C-CO-CH2-CO-S-ACP 
Acetoacetyl- ACP 
The next three steps reduce the keto group at C-3 to a methylene group. 
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Acetoacetyl-ACP 
NADPH 
, "'1 Reduction 
NADp+ ~ 
D - 3 hydroxybutyryl-ACP 
H3C-CH=CH-CO-S-ACP 
Crotonyl-ACP (A trans-Ll 2 -enoyl-ACP) 
NADPH ~ 
, Reduction 
NADp+ 
H3C-CH2-CH2-CO-S-ACP 
Butyryl-ACP 
This completes the first elongation cycle. In the second round of fatty acid synthesis, 
butyryl-ACP condenses with malonyl-ACP to form a C6-f3-ketoacyl-ACP. 
H3C-CH2-CH2-CO-S-ACP + -00C-CH2-CO-S-ACP 
Butyryl-ACP Malonyl CoA 
Condensation 
ACP+CoA 
H3C-CH2-CH2-CO-CH2-CO-S-ACP 
C6-j3-ketoacyl-A~!PH ~ Reduction 
NADp+ ✓i 
H3C-CH2-CH2-CHOH-CH2-CO-S-ACP 
D - 3 hydroxyhexyryl-ACP 
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H3C-CH2-CH2-CH=CH-CO-S~ACP 
A trans-~ 2 -enoyl-ACP 
NADPH ~ 
NADr+¥ i Reduction 
H3C-CH2-CHi-CHi-CH2-CO-S-ACP 
C6-Acyl-ACP 
The C-6 acyl ACP, is ready for a third round of elongation. This elongation cycle 
continues until the formation of C16-acyl-ACP, an intermediate that is not a substrate for the 
condensing enzyme. Instead, it is hydrolyzed to give palmitate and ACP. For the synthesis 
of palmitate: 
Acetyl CoA + 7 Malonyl CoA + 14 NADPH + 20 H+ 
Palmitate + 7 CO2 + 14 NADP+ + 8 CoA + 6 H2O. 
For the synthesis of malonyl CoA used in the above equation: 
7 Acetyl CoA + 7 CO2 + 7 ADP ~ 7 Malonyl CoA + 7 ADP + 7 Pi + 14 H+ 
Hence the overall stoichiometric reaction for the synthesis of palmitate is: 
8 Acetyl CoA + 7 ATP+ 14 NADPH + 6 H+ 
Palmitate + 14 NADP+ + 8 CoA + 6 H2O + 7 ADP+ 7 Pi. 
Fatty acids are synthesized in the cytosol whereas, acetyl CoA is formed from pyruvate in 
mitochondria by oxidative decarboxylation: 
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-OOC-CO-CH3 + NAD+ + CoA --t acetyl CoA + CO2 + NADH. 
Acetyl CoA produced in the mitochondria must be transferred to the cytosol for fatty acid 
synthesis (Fig. 1.19). Mitochondrial membranes are not readily permeable to acetyl CoA, 
so carnitine carries long-chain fatty acids. The membrane barrier to acetyl CoA is bypassed 
by citrate, which carries acetyl groups across the inner mitochondrial membrane. Citrate is 
formed in the mitochondrial matrix by the condensation of acetyl CoA with oxaloacetate. 
Mitochondrion 
Acetyl CoA 
Citrate 
Cytosol 
------------ Citrate 
ATP 
CoA+H20 
xaloacetate 
Ox 
Reduction )6-; NADH 
Carboxylation 
Fig.1.19 
NADp+ Mal ate 
NADPH ~ \/(3) 
Pyruvate---------Pyruvate ~ · 
COz 
Transport of acetyl CoA into the cytosol, where (1): Cleavage by citrate 
lyase; (2): Malate dehydrogenase; (3): Oxidative decarboxylation and (4): Pyruvate 
carboxylase. 
Oxaloacetate formed in the transfer of acetyl groups to the cytosol must now be returned to 
the mitochondria. Fatty acid metabolism is stringently controlled so that synthetic and 
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breakdown processes are highly responsive to physiological needs. Fatty acid synthesis 
and degradation are reciprocally regulated so that both are not simultaneously active. 
The major product of fatty acid synthase is palmitate. In eukaryotes, longer fatty acids are 
formed by elongation reactions catalyzed by enzymes on the cytosolic side of the 
membranes of the endoplasmic reticulum. To study these reactions, the membrane is 
fragmented into closed vesicles called microsomes. Microsomal enzymes add 2-carbon 
units sequentially to the carboxyl end of both saturated and unsaturated fatty acids. 
Malonyl CoA is the 2-C donor in the elongation of fatty acyl CoAs. Again, condensation is 
driven by the decarboxylation of malonyl CoA. Microsomal systems also introduce 
double bonds into long-chain acyl CoAs. For example, in the conversion of stearoyl CoA 
into oleoyl CoA, a cis ll.9 double bond is inserted by an oxidase that employs molecular 
oxygen and NADH (or NADPH). 
Stearoyl CoA + NADH + H+ + 02---+ Oleoyl CoA + NAD+ + 2H20. 
This reaction is catalyzed by a complex of 3-membrane-bound enzymes: NADH-
cytochrome b5 reductase; cytochrome b5 and a ti9 desaturase. A variety of unsaturated fatty 
acids can be formed from oleate by a combination of elongation and desaturation reactions. 
For example, oleate (18: 1 cis-/i9 fatty acid) can be elongated to a 20: 1 cis-/i 11 fatty acid. 
Alternatively, a second double bond can be inserted to yield an 18:2 cis-!i6, !i9 fatty acid. 
Unsaturated fatty acids in mammals are derived from palmitoleate (16:ln-7), oleate (18:ln-
9), linoleate (18:2n-6) or linolenate (18:3n-3). The number of carbon atoms from the (1)-
end of a derived unsaturated fatty acid to the nearest double bond identifies the precursor. 
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Since A 12 and A 15 desaturase enzymes do not exist in vertebrates, linoleic and linolenic 
acids are essential fatty acids. 
Table 1.3 Precursors of unsaturated fatty acids. 
Precursor 
Linolenate (n-3) 
Linoleate (n -6) 
Palmitoleate (n -7) 
Oleate (n -9) 
Formula 
CH3-CH2-CH=CH-R 
CH3-(CH2)4-CH=CH-R 
CH3-(CH2)s-CH=CH-R 
CH3-(CH2)1-CH=CH-R 
Mammals lack the enzymes to introduce double bonds at carbon atoms beyond C-9 in the 
fatty acid chain. Hence, mammals cannot synthesize linoleate (18:2 cis A9, A 12) and 
linolenate (18:3 cis A9, A12 A15). Linoleate and linolenate are the two dietary essential fatty 
acids. The term essential means that they must be supplied in the diet because they are 
required by the organism and cannot be endogenously synthesized. Linoleate and 
linolenate supplied by the diet are the starting points for the synthesis of the n-6 
(arachidonic acid} and n-3 (eicosapentaenoic acid and docosahexaenoic acid) PUFAs, 
respectively (Fig. 1.20). 
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18:2 A9, A12 
(Linoleic acid, n-6 precursor) 
Cz✓ \ A6 desaturase 
20:2 A11, A14 18:3 A6, A9, A12 
20:3 As, A11, A14 l A5 desaturase 
20:4 A5, As, A11, A14 
(Arachidonic acid) 
DIET 
18:3 A9, A 12, A 15 
(Linolenic acid, n-3 precursor) l A 6 desaturase 
18:4 A6, A9, A12, A15 
20:4 As, A11, A14, A17 l A 5 desaturase 
20·5 A5 As A11 A14 A17 
. ' ' ' ' 
(Eicosapentaenoic acid) 
24:5 A9,A12,A1s,A1s,A21 ! A 6 desaturase 
24:6 A6,A9,Al2,Al5,A18,A21 
- C2 ~ ~ - oxidation 
22:6 A4, A7, A10, A13, A16, A19 
(Docosahexaenoic acid) 
Fig.1.20 Pathways for the biosynthesis of n-6 and n-3 fatty acids by desaturation and 
chain elongation in animal tissues. 
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Arachidonate, a 20:4 cis As, As, A 11 , A14 fatty acid is a major precursor of several classes of 
signal molecules namely, prostaglandins, prostacyclins, thromboxanes and leukotrienes 
(Fig. 1.21). · 
PLA2 DG lipase 
Phospholipids AA Diacylglycerols 
I 
Lipoxygenase Prostaglandin Synthase/cycloxygenase 
Leukotrienes Prostaglandin H2 
Prostacy1/lin ~ Synthase . Tirromboxane 
Synthases 
Prostacyclin Other Thromboxanes 
prostaglandins 
Fig. 1.21 Breakdown of phospholipids. 
Also, eicosapentaenoic acid (EPA), a 20:5 cis As, As, A11, A14, A17 fatty acid is a precursor 
for eicosanoids. On the other hand, docosahexaenoic acid (DHA), a 22: 6 cis A4, A7, A10, 
A13, A16, A19 fatty acid is not a substrate for the production of eicosanoids. The major PG 
classes are denoted PGA through PGI; a sub~cript denotes the number of C-C double 
bonds outside the ring. PGs with 2 double bonds such as PGE2, are derived from 
arachidonic acid; the other 2 double bonds of AA (the precursor) are lost in forming a five-
member ring. Prostacylin and Thromboxanes (TX) are related compounds arising from a 
nascent PG. Alternatively, AA can be converted to leukotrienes by the action of the 
lipoxygenase. These compounds, were first found in leukocytes, containing three 
conjugated double bonds - hence the name. Prostaglandins, prostacyclins, leukotrienes and 
thromboxanes are called eicosanoids because they contain 20 carbon atoms. They are all 
local hormones since they are short-lived. They alter the activities of the cells in which 
they are synthesized and of adjoining cells. Contrary to the activities of global hormones 
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such as insulin and glucagon, the nature of the effect of eicosanoids may vary from one cell 
type to another. Prostaglandins stimulate inflammation, regulate blood flow to particular 
organs, control ion transport across membranes, modulate synaptic transmission and affect 
sleep patterns/rhythms. 
1.8.12 Biosynthesis of phospholipids 
Phosphatidate (diacylglycerol-3-phosphate) is a common intermediate in the synthesis of 
phosphoglycerols and TAGs. The pathway starts with glycerol-3-phosphate, formed 
primarily by the reduction of dihydroxyacetone phosphate and to a lesser extent by the 
phosphorylation of glycerol. Glycerol-3-phosphate is acylated by acyl CoA yielding 
lysophosphatidate, which is again acylated by acyl CoA to form phosphatidate (Fig. 1.22). 
These acylations are catalyzed by glycerol phosphate acyl transferase. In most 
phosphatidates, the fatty acyl chain attached to C1 is saturated, whilst the one attached to C2 
is unsaturated. 
AcylCoA CoA AcylCoA CoA 
H2COH-CHOH-CH20-P03 2--~~_..L:;....__ ... ~ H2C-O-CO-R1\, L H2C-O-CO-R1 
I 
Glycerol-3-phosphate 
I 
HO-CH 0 R2-CO-O-CH 
Fig. 1.22 
I II 
H2C-O-P-O-
I 
o-
Lysophosphatidate 
Acylation of glycerol-3-phosphate. 
I 
H2C-O-P032-
Phosphatidate 
The pathways for the synthesis of TAGs and phosphoglycerides diverge at phosphatidate. 
In the synthesis of TAGs, phosphatidate is hydrolyzed by a specific phosphatase forming a 
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diacylglycerol (DAG), which is then acylated to a TAG, in a reaction catalyzed by 
diglyceride acyl transferase (Fig. 1.23). These enzymes are associated in a TAG synthase 
complex bound to the endoplasmic reticulum membrane. 
H2O Pi Acyl CoA CoA 
Phosphatidate v_ H2C-O--CO-R1 '\,_ L H2C-O--CO-R1 
, I I 
R2-CO-O-C-H R2-CO-O-C-H 
I I 
H2C-OH CH2-0-CO-R3 
Diacylglycerol (DAG) Triacylglycerol (TAG). 
Fig.1.23 Synthesis of TAG. 
In the synthesis of phosphoglycerides, several pathways can be followed. One de novo 
synthetic pathway begins with the formation of cytidine diphosphodiacyl glycerol (CDP-
DAG) from phosphatidate and cytidine triphosphate (CTP) (Fig. 1.24). This reaction is 
driven forward by the hydrolysis of PPi. 
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CTP PPi 
Phosphatidate 
CDP-DAG 
Fig.1.24 , Synthesis of cytidine diphosphodiacyl glycerol (CDP-DAG). 
The activated phosphatidyl unit, reacts with the hydroxyl group of a polar alcohol. If the 
alcohol is serine, it yields PS and cytidine monophosphate (CMP) (Fig. 1.25). 
NH3+ 
I 
CDP~DAG + HO-CH2-C-COO- ~<-~> Phosphatidylserine + CMP 
Fig.1.25 
I 
H 
Serine 
Synthesis of phosphatidylserine (PS). 
In the same way, PI is formed by the transfer of a DAG phosphate unit from CDP-DAG to 
inositol. PE and PC can be formed from PS (Fig. 1.26). In bacteria, decarboxylation of PS 
by a pyridoxal phosphate enzyme yields PE. 
NH3+ 
I w HC-C01 CO? 
JH2 11__ 
I 
0-R 
PS 
NH3+ 
I 
HC-H 
I 
CH2 
I 
0-R 
PE 
v► 
W(CH3)3 
I 
HC-H 
I 
CH2 
I 
0-R 
PC 
Fig. 1.26 Synthesis of phosphatidylethanolamine and phosphatidylcholine. 
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Phosphoglycerides can also be synthesized from a CDP-alcohol intermediate. In 
mammalian cells, PC is synthesized via a pathway utilizing choline supplied by the diet. 
Choline is phosphorylated by ATP to phosphoryl choline, which then reacts with CTP 
forming CDP-choline. The phosphoryl choline unit of CDP-choline is then transferred to a 
DAG to form phosphatidylcholine (Fig. 1.27). Similarly, PE can be synthesized from 
ethanolamine, by forming CDP-ethanolamine intermediate by analogous reactions. On the 
other hand, PE can be formed from PS by the enzyme-catalyzed exchange of ethanolamine 
for the serine moiety of the phospholipid. 
HO-CH2-CH2-N+(CH3)3 
Choline 
0 
II 
ATP 
o--P-O-CH2-CH2-W(CH3)3 
6- R Phosphatidyl 
choline 
Fig.1.27 Synthesis of PC. 
ADP 
► 
CMP 
0 
II 
o--P-O-CH2-CH2-W(CH3)3 
I 
o-
DAG 
0 
v= 
~m 
II + 
-o-r-O-CHz-CHz-N (C1½)3 
0 
I 
-o-P-O -_Cytidine 
II 
0 CDP-Choline 
Some phospholipids posses an ether unit instead of an acyl unit at C1• Glyceryl ether 
phospholipids are synthesized starting with dihydroxyacetone phosphate. Acylation by a 
fatty acyl CoA yields a 1-acyl derivative that exchanges with a long-chain alcohol forming 
an ether at C1. The keto-group at C2 is reduced by NADPH, to form an alcohol. The 
resulting alcohol is acylated by a long-chain CoA. Removal .of the 3-phosphate group 
53 
yields l-alkyl-2-acylglycerol, which then reacts with CDP-choline yielding the other analog 
of PC (Fig. 1.28). 
AcylCoA 
HOH2C-CO-CH20Pl'" ~A R'-CO-O-CHz-CO-CH20P32-
- ► 
Exchange 
Acylation 
NADP+ NADPH 
R1-0-CH2-CHOH-CH20PO/- ◄ ~ 
Fig. 1.28 
V AcylCoA 
~ CoA 
Reduction 
0 CH2-0-R1 
II I 
R2-C-O-CH 
I 
CH20H 
Transfer of a 
pl}.osphocholine 
moiety 
O ~C-O-R1 
II I 
R2-c-o-CH O 
I II + 
~c-o-1~o-c~-C8i-N(CJ\)3 
0 
l-alkyl-2-acyl phosphatidylcholine 
(an ether phospholipid). 
Synthesis of an ether phospholipid. 
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Platelet activating factor (P AF) is an ether phospholipid with striking activity. PAF 
induces blood platelet aggregation and dilation of blood vessels. The presence of an acetyl 
group at C2 increases the solubility of this lipid in the aqueous environment of membranes. 
Plasmalogens are phospholipids containing a, f3-unsaturated ether at C 1• Phosphatidal 
choline, the corresponding plasmalogen to PC, is formed by the desaturation of a I-alkyl 
precursor (Fig. 1.29). 
I-Alkyl precursor 
Fig.1.29 Synthesis of phosphatidal choline. 
1.8.13 Breakdown of phospholipids 
Phosphatidal choline 
(a plasmalogen) 
Phospholipids are broken down by a group of phospholipases. Phospholipase enzymes 
preferentially hydrolyze substrates located in the membrane bilayers, micelles or 
lipoprotein particles, acting on the interfacial location at the boundary of water and a 
condensed lipid phase. There are four different groups of phospholipases classified 
according to their specificities namely: phospholipases A1, A2, C and D. The bonds 
hydrolyzed by these enzymes are shown in Fig. 1.30. 
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Fig.1.30 Specificity of phospholipases. 
Phospholipase A1 (PLA1) hydrolyses the acyl group from the sn-1 position of 
glycerophospholipids generating FFAs (usually saturated fatty acids) and LPLs. 
Phospholipase A2 (PLA2) hydrolyses the ester bond of glycerophospholipids at the sn-2 
position generating FFAs (usually unsaturated fatty acids) and LPLs. Phospholipase C 
(PLC) hydrolyses the phosphodiester bond linking the phosphorylated alcohol unit to the 
acylated glycerol moiety. Phospholipase D (PLD) hydrolyses the ester bond linking the 
alcohol unit to the phosphorylated glycerol moiety. 
Of the four different phospholipase enzymes, PLA2 will be focused upon in this review 
because of its implications in the neuropathophysiology of schizophrenia. 
1.8.14 Phospholipase A2 (PLA2) 
Phospholipase A2 (PLA2; EC 3.1.1.4) enzymes catalyze the breakdown of phospholipids 
yielding free fatty acids (FFAs) and lysophospholipids (LPLs). They have two major roles. 
Many of them serve as digestive enzymes present in high concentration in intestinal juices, 
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bacterial secretions and venoms. They generate highly active signal molecules or their 
immediate precursors (Fig 1.21 ). 
PLA2 lipolytic enzymes are widely distributed in nature. They are well-characterized 
proteins with respect to their catalytic and pharmacological activities. PLA2s specifically 
hydrolyze the,sn-2 ester bond of phospholipids (van Deenen and de Haas, 1963), displaying 
enhanced activity towards lipids in lamellar and micellar aggregates both in membranes and 
at other lipid - water interphases (Ramirez and Jain 1991; Jain et al., 1995). These enzymes 
have been classified into· 11 groups (I - XI) occurri~g as extra-cellular and intra-cellular 
PLA2s (Six and Dennis, 2000). 
Extracellular PLA2s are abundant in mammalian pancreatic juices and in the venoms of 
snakes and insects and display diverse roles, including blood platelet aggregation (Waite, 
1988). They have been divided into different groups I, II, ID, V, IX, X and XI based on 
their molecular weight, substrate specificity, amino acid sequence and disulphide bond 
pattern (R~netseder et al., 1985; Farooqui et al., 1992; Ackermann and Dennis 1995; Six 
and Dennis, 2000). Groups I, II, III, V, IX, X and XI are designated secretory PLA2 
(sPLA2). They are small proteins of 119 to 143 amino acids, with low molecular weights 
ranging between 12 and 18 kDa (Ami and Ward, 1996; Six and Dennis, 2000). These 
PLA2s are characterized by their dependency on millimolar calcium, and lack of preference 
for arachidonate over other fatty acids at the sn-2 position. They also contain disulfide 
bonds that are essential for catalytic activity. 
Intracellular PLA2s are often membrane associated and are involved in phospholipid 
metabolism, signal transduction and other varied essential cellular functions (Mukherjee et 
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al., 1994). They have also been classified into groups-IV, VI, VII and VIII according to 
molecular weight, substrate specificity, amino acid sequence, calcium - dependency and 
disulphide bond pattern. They have higher molecular weights ranging from 26 - 114 kDa 
requiring none or nano-molar calcium levels (Six and Dennis, 2000) for activity. 
The different isoforms of PLA2 have been shown to demonstrate different substrate 
specificities, may be localized in different cell types within the CNS, and they posses 
different mechanisms of activation (Farooqui et al., 1992). A comparison of the properties 
of the different forms of PLA2 enzymes suggests that these proteins constitute a family of 
enzymes responsible not only for the degradation of membrane phospholipids, but also for 
the generation of unsaturated free fatty acids and lysophospholipids (Farooqui et al., 
1997a). At physiological levels both these metabolites act as second messengers, but at 
high concentrations they are cytotoxic to cells acting as detergents producing changes in the 
activities of membrane enzymes (Weltzien, 1979; Farooqui and Horrocks, 1991). At lower 
concentrations, they produce changes in membrane fluidity and permeability thereby 
affecting normal cellular functions (Chao and Olson, 1993; Moolenaar, 1995). A second 
messenger is an intracellular mediator formed by the binding of an effector to a receptor. 
Of all the different classes the 85 kDa group IV PLA2 enzyme is of particular interest 
because of its implications in schizophrenia. 
Group IV PLA2s are intracellular enzymes that characteristically have higher molecular 
mass ranging from 61 - 114 kDa (Six and Dennis, 2000). These PLA2 are generally 
localized in the cytosol, preferring arachidonate (AA) at the sn-2 position of their 
phospholipid moiety and resisting inactivation by reducing agents. They are designated 
cytosolic phospholipase A2 (cPLA2). The catalytic activity of type IV PLA2s results in the 
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release of arachidonic acid, a precursor of eicosanoids, which is implicated in triggering 
inflammatory reactions (Kudo et al., 1993). Type IV PLA2s are further classified into two 
groups based on their calcium (Ca2+) dependency as either Ca2+ - dependent enzymes 
requiring 10 - 1,000 nM calcium or Ca2+ - independent. They have also been classified 
according to their substrate preference, molecular weight and pH optimum. The 85 kDa 
cPLA2 has been purified, sequenced, and cloned from neuronal, non-neuronal tissues and 
the U937 human lymphoma cell line (Clark et al., 1991; Kramer et al., 1991; Stephenson et 
al., 1994). 
Arachidonic acid has been implicated in both physiological (synaptic plasticity) and 
pathophysiological (neurodegenerative) processes (Katsuki and Okuda, 1995). It's 
functions include the modulation of ion channels and the regulation of the activity of many 
enzyme proteins such as protein kinase A, protein kinase C, NADPH oxidase, GTPase, and 
the platelet - derived growth factor receptor (Farooqui et al., 1997a). AA inhibits 
glutamate uptake that is mediated by excitatory amino acid transporters in intact cells, 
tissue slices, amino synaptosomes and various types of neuronal and glial cell cultures. 
(Zerangue et al., 1995). 
Eicosanoids, which are derived from polyunsaturated fatty acids (AA) (Fig. 1.21), exert 
their pleitropic effects on cellular functions that implicate them as important mediators of 
both normal homeostatic and pathological states in cellular functions~ They are metabolites 
of AA affecting various human neutrophil functions (Goetzl and Pickett, 1981; Serhan et 
al., 1984 and Ford-Hutchinson, 1997). The stimulation of neutrophils with various stimuli 
such as.zymosan (Waite et al., 1979), calcium ionophore (Stenson and Parker, 1979), and 
chemotactic factor (Hirata et al., 1979), triggers the release of AA from membrane 
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phospholipids, particularly PI and PC. PI is potentially the most important source of 
arachidonate, due to its unusual enrichment in this fatty acid (Holub and Kukcis 1971; 
Bockman et al., 1981; Majerus et al., 1984). Walsh et al., 1981, provided more evidence 
that the release of arachidonate from human neutrophils occurs by the action of a 
phospholipase A2. Normally, AA and LPLs are recycled through a series of energy -
dependent reactions. As a result the normal phospholipid content of neuronal membranes is 
not altered and intracellular concentrations of free arachidonate and·LPLs are maintained at 
low physiological levels. 
In the human brain, cPLA2 is predominantly located in the astrocytes of the gray matter 
(Stephenson et al., 1994). In non-neuronal tissues, cPLA2 activity is regulated by 
phosphorylation/dephosphorylation processes involving the translocation of this enzyme 
from the cytosol to the plasma membrane (Kramer et al., 1993). In primary cultures of 
neuronal cells, arachidonic acid released from membrane phospholipids can be stimulated 
by several neurotransmitters including dopamine, nor-epinephrine, serotonin and glutamate 
(Piomelli, 1994). This release is mediated primarily by PLA2 activity linked to receptors 
through a G-protein (Axelrod, 1990). The interaction of glutamate and N-methyl-D-
aspartate (Nl\IDA) with excitatory amino acid receptors produces a marked increase in the 
AA release from membrane phospholipids of the striatal, hippocampal, and hypothalamic 
neurons and cerebellar granule cells (Dumuis et al., 1988). 
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Fig. 1.31 Functions of PLA2 in the brain. (Ai) and (Aii) represent the strategic points 
of interest in this study for the demonstration of antioxidant and anti-PLA2 activities by 
PUF As and certain dietary antioxidants. 
1.8.15 PLA2 and membrane repair 
PUF As in membrane phospholipids are highly susceptible to peroxidative damage 
(Farooqui et al., 1994). Peroxidized PLs in cell membranes may yield a membrane-packing 
defect, thus making the sn-2 ester bond more vulnerable to PLA2 action (Farooqui et al., 
1997a). Many studies have implicated phospholipid hydroperoxides as better substrates for 
PLA2 activity in comparison with the native ( unperoxidized) phospholipids (McLean et al., 
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1993). The hydrolysis of lipid peroxides removes peroxidized fatty acyl chains, which are 
reduced and re-esterified (van Kuijk et al., 1987). As a result, PLA2 activity repairs and 
restores the appropriate physico-chemical state of membranes preventing the peroxidative 
cross-linking reactions, without which peroxidized lipids would accumulate producing 
devastating alterations in cell membrane functions (Farooqui et al., 1997a). 
1.8.16 PLA2 and neurodegeneration 
The stimulation of PLA2 has been reported in many neurodegenerative diseases including 
schizophrenia (Gattaz et al., 1995; Ross et al., 1995); ischaemia (Rordorf et al., 1991; Edgar 
et al., 1982) head injury (Shohami et al., 1989), spinal cord injury (Farooqui and Horrocks, 
1991); and Alzheimer's disease (Stephenson et al 1996). For instance, studies have shown 
a significant increase in plasma and serum PLA2 activity in drug-free schizophrenic 
patients, compared to healthy and non - schizophrenic psychiatric controls (Gattaz et al., 
1987, 1990; Noponen et al., 1993). The stimulation of PLA2 coupled with the increase in 
the breakdown of membrane phospholipids may be harmful to neuronal cells in the 
following ways: 
- Loss of essential membrane phospholipids resulting in the accumulation of FF A, 
LPL and platelet activating factors (PAFs). 
- Accumulation of FFA which may set an uncontrolled "arachidonic acid cascade" in 
motion, thus setting the platform for increased production of free-radicals and 
reactive oxygen species leading to lipid peroxidation and damage to membrane 
proteins and even DNA. 
· - Calcium influx through increased phospholipid breakdown leads to sustained 
activation of protein kinase C (PKC) and its translocation from cytosol to plasma 
62 
membrane. The stimulation -and translocation of PKC may be involved in 
neurodegeneration (Farooqui and Horrocks, 1991). 
1.9 THE HUMAN BRAIN AND OXYGEN 
The brain is an extremely complex organ and the understanding of its structure and function 
has evolved over centuries. With the advent of tools such as neuro-imaging and neuro-
physiology researchers can see the living, feeling, thinking human brain at work. The brain 
is responsible for merging molecular, genetic and biochemical information with 
information from the world. 
Within the brain, there are 2 cell types: neurons (nerve cells) and glial cells. Neurons are 
responsible for transmitting (sending and receiving) nerve impulses or signals to and from 
the brain whereas the glial cells provide neurons with nourishment, protection and 
structural support. Collectively, there are more than 100 billion neurons in the brain, 
consisting thousands of distinct types. Each neuron communicates with another via 
specialized structures known as synap,ses. Over 100 distinct brain .chemicals, called 
neurotransmitters, communicate across these synapses in the brain. The communication 
system or circuit, formed by hundreds or thousands of neurons is termed 
neurotransmission, which gives rise to complex mental behavioural responses. 
During fetal development, genes drive the brain formation resulting in a specific and highly 
organized structure. Early developments of the brain can be influenced by environmental 
factors · such as mother's nutrition, alcohol consumption, tobacco smoking, other 
psychoactive substances or exposure to radiation. After birth and throughout life, all types 
of life-experiences have the ability to generate immediate communication between and 
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among neurons as well as to initiate molecular processes that remodel synaptic connections 
(Hyman, 2000). Hence, new synapses can be weakened, strengthened, created or existing 
ones removed. Hence, information processing within the circuit will be changed to 
accommodate the new experience. 
The human brain requires oxygen and its mitochondrial activity is very high to meet energy 
demands for neuronal activity (Halliwell and Gutteridge, 1999). As a result, the brain is 
always under high oxidative stress. Oxidative stress is an imbalance between oxidants and 
antioxidants, in favour· of the oxidants potentially leading to damage (Halliwell and 
Gutteridge, 1999). Oxidants are formed as a normal product of aerobic metabolism but can 
be produced at elevated rates under pathophysiological conditions. The brain is enriched 
with lipids particularly PUFAs, which are highly susceptible to peroxidation 
(Hajimohammadreza and Brammer, 1990). As much as 20% of the brain by dry weight 
consists of PUFAs mostly AA and DHA (Horrobin, 1996). Often electrons escape from the 
electron transport chain and react with molecular oxygen to generate free radicals, which 
can cause peroxidative damage to lipids in mitochondrial membranes. Exce&sive 
generation of free radicals may result in oxidative damage to membrane lipids, proteins or 
nucleic acids causing extensive cellular dysfunction or even death. Peroxidative damage to 
cell membranes has been implicated in the neuropathophysiology of many psychiatric 
illnesses including schizophrenia and Alzheimer's disease (Reddy and Yao, 1996; Peet, et 
al., 1999). 
1.10 LIPID PEROXIDATION 
The brain is particularly vulnerable to free radical damage as it is a highly oxygenated 
organ utilizing 20% of the total oxygen required by the body (Lambertsen, 1980). In 
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addition, it is enriched with iron and PUFAs (O'Brien and Sampson, 1965) and relatively 
poor in antioxidant enzymes such as catalase (Halliwell and Gutteridge, 1986; Halliwell 
1989). PUFAs are highly susceptible to attack by free radicals (Bielski et al., 1983) due to 
lowered bond dissociation energy of their allylic hydrogens (Fig. 1.32). 
LH A, r 7 ► LO- /""'( LOOH Fe
2+ 
► Loo· + 
·oH 
R" RH Oi L'H L"' ► LO., etc. 7 
Oi 
Fig. 1.32 The lipid peroxidative process. LH: lipid; L9: lipid radical; Lo·: lipid 
peroxyl radical; LOOH: lipid hydroperoxide; Loo·: lipid hydroperoxyl radical; ·oH: 
hydroxyl radical; R·: substrate radical and RH: reduced substrate. 
The degenerative propagation reactions in lipid membranes are usually accompanied by the 
formation of a wide variety of products, including alkanes, aldehydes (such as hydroxy 
alkenals) and carbonyl compounds. Hydroxy alkenals are toxic by themselves; they may 
serve as second messengers for radical damage (Humad et al., 1988). Peroxidative damage 
to neuronal cells may affect membrane transport systems and permeability causing loss of 
mitochondrial energy production, gene expression and therefore receptor-mediated 
phospholipid - dependent signal transduction, which may explain the altered information 
processing observed in schizophrenia (Mahadik et al., 2001). 
1.10.1 Free radicals 
Free radicals, some of which are also referred to as reactive oxygen species (ROS), play an 
essential role both in human health and disease. They are generated under normal 
physiologic conditions during aerobic metabolism (Mahadik and·Mukherjee, 1996a). They 
are extreme! y important in normal metabolic processes. A small proportion of these 
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radicals have p~ysiologic roles but the remaining are inactivated by antioxidant enzyme 
systems (Burton and Ingold, 1989; Halliwell and Gutteridge, 1990a). Free radicals are 
generally very reactive molecules possessing an unpaired electron. The life of a free 
radical has three stages: initiation, propagation and termination. 
Free radicals ,have 2 major sources: endogenous and exogenous. Endogenous sources of 
free radicals include those generated intracellularly, acting within the cells, and those 
formed within the cell but released into the surrounding area. Exogenous sources include 
irradiation, alcohol, solvents and some medication such as anti-neoplastic drugs, some 
antibiotics and anesthetics (Halliwell and Gutteridge, 1986). Free radicals may be 
produced by the activation of phagocytes and the immune system as a whole, lipid 
peroxidation, electron transfer system in the mitochondria, ischaemia, and trauma (McCord, 
1987; Gutteridge, 1995). These intracellular free radicals may occur as a result of the 
activity of certain oxidases, lipoxygenases, cycloxygenases, dehydrogenases and 
peroxidases. Electron transfer from metals· such as iron to oxygen - containing molecules 
can also initiate free radical reactions. A wide range of free radical molecular species is 
endogenously formed. The singlet oxygen is not a free radical but nevertheless ·a reactive 
oxygen species capable of causing cellular damage (Machlin and Bendich, 1987). 
Not all free radicals cause fatal injury. For example, white blood cells involved in the 
immune response of the body produce and mobilize oxygen-containing free radicals to 
destroy fungi, viruses and other foreign bodies they ingest. Furthermore, free radicals 
govern the production of complements and prostaglandins, which are vital to the protection 
and physiological functions of the body. Also, the liver utilizes free radicals in the process 
of detoxification. Free radicals may be generated by normal catalytic reactions by the 
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activities of enzymes and transport molecules, for example, xanthine oxidase and aldehyde 
oxidase. These two enzymes. generate the superoxide anion radical by the addition of a 
single electron to molecular oxygen (Fig. 1.33). 
+ e ---+ o;-
Fig.1.33 , The generation of the superoxide anion radical (mitochondrial error). 
, Cellular mitochondria are the major sources of endogenous free radical utilized in the 
synthesis of ATP from· ADP, the primary energy currency of the body. Auto-oxidation 
reactions produce free radicals from the spontaneous oxidation of biological molecules 
involved in non-enzymatic electron transfers. Examples of compounds that may undergo 
auto-oxidation in the body include: thiols, hemoglobin and catecholamines. In all of these 
auto-oxidation reactions, superoxide is the main free radical species produced initially. 
Metals, such as copper, iron, mercury, beryllium and silver, may produce free radicals and 
are believed to derive their toxic effects from their inherent ability to transfer electrons, 
thus generating free radicals (Miller et al., i990). These free radicals can adversely affect 
cellular health by producing lipid peroxidation of intracellular membranes and cross 
linkages of membrane macromolecules (Potwarka, 1999). When irradiated water is 
ionized, an electron is removed from the molecule, leaving .an ionized water molecule. The 
species resulting from the radiolysis of water are the free radicals H. and OH. and e - (aq.) 
(hydrated electrons). They are highly reactive having a lifetime of 10-9 - 10-11 seconds. 
The hydroxyl radical (OH) is extremely reactive. Water presents the largest number of 
target molecules in a cell; most of the energy transfer goes on in water when a cell is 
irradiated. Oxygen is an excellent electron acceptor and can combine with H. to form a 
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peroxyl radical (HO/). Free radicals have a relatively short half-life, therefore the 
determination of their levels can be difficult. 
1.10.2 Free radical damage 
Free radical damage may involve any cell. The human body contains an estimated 100 
trillion cells,, each containing various organelles, all having specific functions. The 
organelles are membrane-bound complex bodies. The membranes surrounding these 
organelles are vital dynamic structures important in controlling the passage of nutrients and 
excretory products involved in cellular metabolism. They are also necessary for the 
organization of cellular enzymes. When highly reactive free radicals come in contact with 
these membranes, they can initiate lipid peroxidation and membrane destruction (Mahadik 
et al., 1994), which may result in the loss of the organization of cellular enzymes, a 
disturbance in the distribution of nutrients and even cellular metal dysfunction, leading to 
degenerative disease processes. The health problems associated with alcohol consumption 
and smoking, are related to free radical damage (Davidson et al., 1998; Zimmer et al., 1998; 
Yao et al., 2000). Copper, manganese, iron and other trace redox - active transition metals 
have been implicated in the neuropathology of schizophrenia (Gattaz et al., 1990). These 
metals are essential in most biological reactions ( e.g. in the synthesis of DNA, RNA and 
proteins) and as co-factors of various enzymes, particularly those involved in respiration, 
thus their deficiency can lead to disturbances in the central nervous system and other organ 
functions. Excessive tissue accumulation of redox-active transition.metals can be cytotoxic 
particularly because perturbances in metal homeostasis result in an array of cellular 
disturbances characterized by oxidative stress and increased free radicals production. 
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The total number of free radicals is unknown. An estimated 10,000 free radicals bombard 
each body cell daily. This amounts to a high free radical activity since the body contains 
about 100 trillion cells. As such, if all free radicals were deadly, humans would cease to 
exist. Antioxidants, present as cellular components, delay or even inhibit the damaging 
effects of free radicals (Halliwell and Gutteridge, 1999). An.antioxidant is any substance 
that, when present at low concentrations compared to that of the oxidizable substrate, 
significantly delays or prevents the oxidation of that substrate (Halliwell and Gutteridge, 
1999). 
1.11 BIOMARKERS OF LIPID PEROXIDATION 
Oxidative stress induced by the action of free radicals or reactive oxygen species (ROS) in 
biological· membranes produce several by-products (also known as biomarkers). Lipid 
peroxides are the major products resulting from free radical damage. In humans and 
animals, lipid peroxides are degraded into a wide variety of products such as: 
- Volatile hydrocarbons (alkanes) measurable in exhaled air. For example, ethane 
and pentane. The measurement of alkanes as an index of lipid peroxidation was 
first suggested by Riely et al. (1974). They investigated the relationship 
between tetrachloromethane administration and ethane exhalation in mice. 
Kivits et al. (1981) demonstrated that n-3 PUFA oxidation resulted in increased 
ethane excretion, while n-6 PUF A oxidation yielded increased excretion of 
pentane. n-3 and n-6 are the most abundant PUFAs in cell membranes. 
- Aldehydic products, such as hydroxy alkenals and malonyldialdehyde (NIDA). 
These are also known as . Thiobarbituric acid reactive substances (TBARS) 
(Humad, 1988). In vitro studies using microsomes incubated with Fe2+/ADP 
showed the formation of MDA (Frank et al., 1980). 
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- Isoprostanes. These are a group of -prostaglandin (PG) - like compounds 
recently discovered. They are produced by a reaction between AA and free 
radicals (Morrow et al., 1990). 
As the name implies, antioxidants combat oxidative stress. They prevent rancidity. They 
protect against damage by free radicals. When free radicals are generated in the living 
system, a wide variety of antioxidants come into play: enzymatic and non-enzymatic 
antioxidants. 
The composition of antioxidant defenses differs from cell to cell; tissue to tissue and 
between organisms. Antioxidant activity may be accomplished by inhibiting the initiation 
of the free radical; directly or indirectly scavenging generated free radicals; or by raising 
the endogenous antioxidant defenses (that is by increasing expression of genes coding the 
antioxidant enzymes). 
1.12 ANTIOXIDANTS 
There are two major classes of antioxidants: the enzymatic and non-enzymatic. 
1.12.1 Enzymatic antioxidants 
All eukaryotic cells contain powerful antioxidant enzymes. The three major classes are: 
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSHPx). 
SOD is widely distributed in the human brain and in virtually all eukaryotic cells (Halliwell 
and Gutteridge, 1999). Its activity steadily increases with age. There are three types of 
SOD. One is the copper-zinc metallo-enzyme, predominantly located in the cytosol, but 
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some appear to be present in lysosomes, peroxisomes, nucleus and the inter-membrane 
space of the mitochondria (Fridovich, 1995). Another is the manganese metallo-enzyme 
predominantly localised in the mitochondria (Mahadik and Mukherjee, 1996b). The third is 
the iron containing metallo-enzyme, which has never been found in animal tissues. It is 
present in some bacteria and some higher plant tissues (Halliwell and Gutteridge, 1999). 
SOD converts the superoxide anion radical (02·- ), in the presence of substrates providing 
protons, to hydrogen peroxide (H2O2) (Mahadik and Scheffer, 1996). The ubiquitous 
location of SOD provides sufficient protection against the superoxide anion radical during 
normal physiological conditions. 
CAT is primarily localized in peroxisomes, lysosomes, and mitochondria (Vitorica et al., 
1984). It is a heme-containing metallo-enzyme, which converts hydrogen peroxi<i:e formed 
by SOD to water and molecular oxygen. Hydrogen peroxide (H2O2) is toxic and when 
present in sufficient quantities can interfere with normal metabolic reactions. CAT is 
considered to be ineffective for protection against free radical damage to cytosolic and 
nuclear components, where H2O2 is spontaneously converted into hydroxyl radicals ( •OH) 
in the presence of transition metals (Mahadik and Scheffer, 1996). It is believed that low 
levels of CAT contribute to oxidative stress by H2O2 in peroxisomal disorders (Mahadik 
and Scheffer, 1996). 
GSHPx is predominantly localized in the cytosol with low levels in the mitochondria. It 
has high levels in neuronal cell areas prone to oxidative damage (Savolainen, 1978; 
Brannan et al., 1980). GSHPx is a selenium containing metallo-enzyme (Cohen and 
Hochstein, 1963). It constitutes a very small proportion of brain selenium and its levels are 
influenced by dietary availability of selenium (Rafferty et al., 2003). GSHPx effectively 
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protects against cytosolic damage by eliminating H2O2 and lipid peroxides by reduction 
using glutathione. 
Brain levels of both CAT and GSHPx are low, while SOD levels are high. Since, the brain 
contains oxy-radical sensitive polyunsaturated fatty acids (Cohen and Greenwald, 1983; 
Martin et al., 2002), the brain is particularly exposed to oxidative injury (Ames et al., 
1981). 
1.12.2 Non-enzymatic antioxidants 
These exist in the form of nutrients taken up only from the diet. Examples of these are: 
vitamin C, vitamin E, and the carotenoids. 
Vitamin C is also known as ascorbate because it exists in the ionized form under 
physiological conditions. It is a water-soluble antioxidant functioning more in the aqueous 
environment. Sources in the diet include capsicums, vegetables and citrus fruits. Ascorbic 
acid scavenges the 0 2 --, HO2 • and oH· · radicals. It inhibits lipid peroxidation by 
hemoglobin - or myoglobin - H2O2 mixtures and is a powerful quencher of singlet oxygen. 
Vitamin C inhibits oxidative damage by scavenging radicals generated from certain drugs 
such as phenylbutazone (Halliwell and Gutteridge, 1999). 
Vitamin C (Fig. 1.34) has a dichotomous action in the body (Halliwell and Gutteridge, 
1999). In excessive amounts, it may act as a pro-oxidant in the presence of transition 
metals such as copper and iron. 
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Fig. 1.34 Ascorbic acid (vitamin C). 
The principal role of vitamin E (a·- tocopherol) is to protect tissues against destructive 
oxidation (Burton et al., 1983; Pryor, 1984). Sources in the human diet include leafy 
vegetables, nuts and oi,ls. Vitamin E inhibits lipid peroxidation by scavenging peroxyl 
radicals. It is fat-soluble and functions mostly in the hydrophobic environment of the 
human cell (Burton et al., 1983). 
Fig. 1.35 Vitamin E ( a - tocopherol). 
Carotenoids are plant-derived pigments found in animals and microorganisms. They occur 
widely in bacteria, fungi and algae, where they can be useful taxonomic markers. 
Carotenoids occur extensively in marine invertebrates. They give bright colours to any 
substance in which they occur. Sources of carotenoids include tomatoes, carrots, broccoli 
and sea foods. 
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The carotenoids are isoprenoid compounds biosynthesised by tail-to-tail linkage of two C20 
geranyl-geranyl diphosphate molecules. This produces the parent C40 carbon skeleton 
from which all the individual variations are derived (Fig. I 36). 
Fig. 1.36 The 40-carbon skeleton from which all carotenoids are derived. The broken 
lines represent the C5 (isoprene) units. 
They are a group of hydrophobic molecules with little or no solubility in water. They are 
thus expected to be restricted to hydrophobic areas in the cell, such as the inner core of 
membranes, except when associated with proteins which allow them access to an aqueous 
environment (~ritton, 1995). In vivo, the overall shape, size and hydrophobicity of a 
carotenoid are obviously major features that determine the ability of a carotenoid to fit into 
sub cellular structures. Polar functional groups provide a focus for interactions with more 
polar molecules in order to allow the carotenoid to participate in events in an aqueous 
subcellular medium or at an interface or membrane. Being highly hydrophobic, carotenoids 
show a strong tendency to aggregate and crystallize in aqueous media. The accumulation 
of carotenoids as micro-crystalline aggregations is common in the chloroplasts of higher 
plants (e.g. lycopene in tomato) (Pfander et al., 1994). Aggregation changes the physical 
properties of carotenoids (light absorption and chemical reactivity). Changes in carotenoid 
size and ease of solubilization affect the ease of absorption and bio-availability in animals 
and their ability to enter and function in sub-cellular structures (Gruszecki and 
Sielewiesiuk, 1990). 
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About 600 carotenoids have been isolated from natural sources (Stahl, and Sies, 1996) all 
classified under two groups of carotenoids namely: 
- Hydrocarbons called carotenes such as a - and f3 - carotene. (3-carotene is 
converted to vitamin A (Moore, 1957) in the liver and the intestine (Krinsky et 
al., 1993). About 50 carotenes are known to have pro-vitamin A activity 
(Olson, 1989). 
- Oxygenated carotenoids called xanthophylls such as lutein, cryptoxanthin, 
canthaxanthin (CX), zeaxanthin (ZX) and asthaxanthin (AX). 
A large proportion of the known carotenoids have antioxidant activity and may also be 
involved in enhancing immune responses, gap junction and carcinogen metabolizing 
enzyme activity (Wang, 1994; Stahl et al., 1997). Carotenoids have been reported to have 
the ability to quench singlet oxygen and peroxyl radicals (Krinsky, 1989; Edge et al., 1997). 
Since oxidative stress places a burden on the entire cell / organ, it is not surprising that 
stress in one cell affects the redox balance in other cells. This same principle applies to 
antioxidants. 
1.12.3 Combination of antioxidants 
It has been reported that dietary (3-carotene can mediate an increase in the activities of the 
antioxidant enzymes: SOD, and CAT induced by high fat diets (Blakely et al., 1988). The 
concept that antioxidants interlock in their protective effects and that the levels of all the 
antioxidants in the network are important, rather than just a single antioxidant, raises the 
possible importance of supplementing with an antioxidant cocktail rather than a single 
antioxidant (Keaney and Frei, 1994). 
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Polar carotenoids such as- AX. are more effective in situations where free radical attack 
occurs at the liquid/aqueous interphase. However, if radicals were generated in the lipid 
phase, less polar carotenoids such as f3-carotene will yield more antioxidant effect (Ojima et 
al., 1993). However, it has been reported that when different antioxidants are present 
together, there is an additive effect for conferring resistance to lipid peroxidation (Packer, 
1993). This effect could be due to the fact thatthe different antioxidants protect at different 
physical locations within the cell membranes rather than physical interactions bet~een 
antioxidants. Vitamin E for example, mitigates oxidation at the outer surface while 
carotenoids and vitamin A are protective in the interior of the membrane (Niki et al., 
1995a). 
Furthermore, a-tocopherol prevents auto-oxidation of carotenoids at physiological 
concentrations (Handelman et al., 1991) and can scavenge the carotenoid peroxyl radical 
before it propagates peroxidation (Niki et al., 1995a). Conversely, protection of vitamin E 
by carotenoids may also be important when singlet oxygen attack is a factor (Ojima et al., 
1993). 
1.13 AIMS 
T~e main aim was to investigate the influence on PLA2 activity and antioxidant efficacy 
exerted by a range of essential polyunsaturated fatty acids and antioxidants, which will 
allow advancement in the progress towards the ultimate aim of increasing the 
understanding of the mechanism of action of EPA and other PUFAs in the treatment of 
schizophrenia and possibly other related neuropsychiatric disorders. 
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The human histiocytic lymphoma cell line (U937) was chosen as a model for the research 
for the following reasons: (i) previous studies on schizophrenic skin macrophages 
suggested reduced availability of arachidonic acid owing to an increase in PLA2 activity 
(Ward et al., 1998), (ii) head space analysis has previously been used to detect volatile 
product of lipid peroxidation, in U937 cells (North et al., 1994), (iii) PLA2 has been 
purified and characterized in U937 monocytes (Kramer et al., 1991) and (iv) U937 cells 
have very low levels of polyunsaturated fatty acids (Obermeier et al., 1995) and high PLA2 
expression (Kramer et al., 1991), thereby, mimicking the conditions reported in 
schizophrenic patients. · 
The Highland Psychiatric Research Foundation (HPRF), Inverness, was active in studying 
the clinical use of antioxidants and phospholipase A2 inhibitors in the treatment of 
psychiatric illnesses. The biotechnology group of the Scottish Association for Marine 
Science (SAMS), Oban, was interested in looking for new products of marine organisms 
containing a wide range of carotenoids. Also, collaborative research was performed with 
The Victoria Infirmary, Glasgow Southern NHS Trust, Glasgow. 
1.14 OBJECTIVES 
This study (i) measured oxidative stress after challenging U937 cells with oxidants (ii) 
determined if oxidative stress increases fatty acid uptake into phospholipids or 
phospholipid breakdown into fatty acids (iii) determined the effects of PUFAs especially 
EPA and DHA on the uptake and release of AA (iv) determined PLA2 
activity/concentration and oxidative stress response of U937 cells to pre-treatment with 
PUFAs and several antioxidants (v) compared cell response- after pre-treatment with 
PUFAs with/without antioxidants (vi) determined the effects of oxidative stress on PLA2 
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expression and (vii) established the existence of coupling in vitro between PLA2 activation 
and oxidative stress. 
1.15 HYPOTHESES 
( 1) Oxidative stress increases fatty acid release and reduces the uptake of cellular 
phospholipids. 
(2) PLA2 activity and expression is enhanced with oxidative stress. 
(3) Pre-treatment of U937 cells with PUFA~, especially EPA, increases the uptake of 
AA but decreases its release. 
(4) EPA but not DHA inhibits oxidative stress in U937 cells. 
(5) Dietary antioxidants inhibit oxidative stress and reduce AA release. 
(6) Combinative treatments of U937 cells with the dietary antioxidants especially the 
carotenoids inhibit the over-expression and activity of PLA2. 
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CHAPTER 2: U937 CELL COUNTS AND VIABILITY MEASUREMENTS 
2.1 INTRODUCTION 
Cells in vivo grow in a highly controlled and complex environment. On removal from 
their natural environment, they are dispersed from a histological configuration, where 
cell contact plays an important role, into a simplified growth medium. Cell culture 
lacks neuronal and hormonal regulation and the other intermediate metabolites present 
in fluids in situ. Cells in culture are in a foreign environment, therefore, stress 
conditions C,an only be minimized by attention to environmental optimization, an 
important factor being the nutritional condition, replacing the natural environment. This 
environment affects all physiological and metabolic events. Many nutrients have been 
identified as being essential for cell growth, for· example, glutamine and glucose have 
been associated with playing key roles in cell behaviour. In addition to nutrient balance 
many physicochemical factors such as agitation, mixing and oxygen supply are of 
crucial importance to in vitro cell health and viability. 
In this study, the U937 monocytic cell line is used as a model for neuronal lipid 
metabolism and breakdown. U937 is a well-characterized human lymphoma histiocytic 
cell line of Caucasian origin. Monocytes are cells with a diameter of 14 to 20 microns 
(van Furth et al., 1970) and a large folded nucleus. Mammalian cells can generally be 
preserved for extended periods by storage in liquid nitrogen (LN2), recovered and re-
established in culture. For optimal recovery of viable cells, rapid thawing and 
immediate dilution in culture· medium is required to reduce the toxic effects of the 
cryopreservative, dimethyl sulphoxide (DMSO). When cells are established in culture, 
they divide and the density increases. For optimal growth, the cells should not be over-
crowded. The culture medium must be renewed or replaced depending on the optimal 
cell density for the cell type in use. 
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To measure the performance, achieve reproducibility or make comparative studies, a 
m~thod of quantifying cell population is required. The method used here utilizes a 
microscopic counting chamber (haemocytometer) and is simple, quick, cheap and 
requires only a small fraction of cells from a suspension. There are several types of 
haemocytometers on the market. The Improved Neubauer has proved to be the most 
popular. A thick, flat cover slip rests on the counting chamber at a distance of 0.1 mm 
above the slide base, with two chambers. The slide base has accurate engraved rulings 
on it, comprising 1 mm squares, some of which are further divided into smaller squares. 
This method is based on the principle that live cells can be differentiated from dead 
cells using the physical property of refractive index. 
To ascertain that a cell culture has reached its optimum level of growth before routine 
. sub-culturing and storage, before and after the addition of certain potentially toxic 
chemicals, it is necessary to obtain a measure of the viability and cell population. The 
screening of agents that rpay be cytotoxic to cells is of great importance prior to 
experiments. Testing the toxicity of water-soluble compounds presents no inherent 
problems regarding extraneous additives but testing of water-insoluble agents generally 
require the inclusion of various often toxic solvents. Thus it is important to know the 
maximum tolerable concentration of the potentially toxic bio-active compounds that 
will be used in this study on the in vitro system employed. Two different methods of 
cell viability measurements are used in this study, both well established. One is the 
Trypan Blue dye exclusion method and the other is the lactate dehydrogenase (LDH) 
activity method. 
Trypan Blue is a staining dye distinguishing viable from non-viable cells. Trypan Blue 
acts by penetrating cells with lost membrane integrity. As such non-viable cells are 
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stained blue, granular and /or fragmented while viable cells remain unstained, intact and 
refractive. The use of stains such as Trypan b~ue are subjective and cannot give 
absolute values, cell numbers and take no account of differences in cell size/mass. This 
method is quick and cheap requiring only a small fraction of the total cells from a cell 
suspension. 
The LDH · activity method measures lactate dehydrogenase, an intracellular enzyme 
present in culture supematants due to leakage, giving a quantitative value for the loss of 
cell viability. It is a non-invasive method of cell viability measurement. The principle 
is based on the following reaction: 
Pyruvate + NADH + Ir + lactate 
The activity of LDH can be measured as the reduction of pyruvate to lactate (Vassault, 
1983). The reduction is coupled to the oxidation of NADH to NAD+, which is 
measured spectrophotometrically at 340 nm. The equilibrium is on the side of NAD+ 
and lactate. Due to the fact that NADH has a high absorbance at 340 nm compared to· 
NAD+, the reaction is measured as the rate of decrease in absorbance at 340 nm. This 
study utilizes a colorimetric LDH assay kit (Sigma) based on the reduction of a 
tetrazolium dye. The LDH kit used measures cell membrane integrity as a function of 
the amount of cytoplasmic LDH released into the medium. In other words, it measures 
LDH leakage into the cell medium. The resulting coloured compound is measured 
spectrophotometrically at 490 nm. 
This study utilizes the Trypan Blue method consistently for cell counts and viability . 
determinations prior to cell treatments with the various agents. After ensuring 
consistent and reproducible results between Trypan Blue and LDH viability methods, 
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the LDH activity assay was chosen over the Trypan Blue method because of its non-
invasive nature and speed of analysis. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Hanks balanced salt solution (HBSS), RPMI 1640, heat-inactivated foetal bovine serum, 
gentamicin solution (50 mg/ml), dimethyl sulphoxide (DMSO), new-born calf serum 
(NCS), 30% (w/w) hydrogen peroxide (H2O2), fatty-acid-free bovine serum albumin 
(BSA), iron sulfate (FeSO4), 70% tert-butyl hydroperoxide (t-BHP), HPLC grade 
methanol (MeOH), ethanol (EtOH), chloroform (CHC13) and hexane (CJf 14), stearic 
acid (SA), oleic acid (QA), arachidonic acid (AA), ascorbic acid, vitamin E, f3-carotene, 
astaxanthin, 0.4% Trypan Blue solution and LDH {TOX-7) assay kit were purchased 
from Sigma-Aldrich, UK. Eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) were obtained from Nu-chek Prep., Denmark. U937 cells were a kind gift from 
the Scottish Antibody Production Unit (SAPU), Lanarkshire, Glasgow. 
2.2.2 Glassware and plastic preparations 
All glassware used was washed in De-con and nano-pure water, autoclaved at 121 °C for 
30 min and dried before use. All other apparatus were sterile before use with all 
experiments performed under a laminar flow hood ( class II). 
2.2.3 0937 cell culture 
2.2.3.1 Thawing of cells 
U937 cells used in this study were ·gifted as 1 ml frozen samples from SAPU, Gl3:sgow. 
A 1 ml vial containing 1.0 x 106 cells/ml was thawed rapidly in a water bath set to 37°C. 
The vial was observed and removed from the water bath as soon as two-thirds of the 
82 
medium thawed. The. vial was disinfected by spraying with 70% ethanol (EtOH) and 
wiped dry with a paper towel. Its contents were transferred into a 15 ml centrifuge tube 
containing 10 ml of ice-cold Hanks balanced salt solution (HBSS) in a class II laminar 
flow hood. The tube contents were mixed thoroughly by careful inversion and 
centrifuged at 250 g for 5 min at 4°C. Cell supernatant was discarded into a sterile 
beaker before the addition of 10 ml of freshly prepared culture medium (CM). Culture 
medium C01'tained RP1vll 1640 supplemented with 10% foetal bovine serum (FBS), 2 
mM L-glutamine and 0.05 mg/ml gentamicin. Using a sterile plugged glass Pasteur 
pipette, suspended cells were transferred into a 25 cm2 culture flask and placed in a CO2 
incubator set to 5% CO2/95% air and 37°C in a humid environment for 24 h. The flask 
cap was loosened sufficiently to allow gas exchange. 
2.2.3.2 Continuous culture of cells 
Cells, in suspension, were inspected microscopically and discarded if there was any sign 
of bacterial contamination. Bacterial contamination was initially detected by a colour 
change in the cell medium and under the microscope for movements. Otherwise, cells 
were transferred from the 25 cm2 culture flask into a 75 cm2 flask containing 10 ml of 
freshly prepared CM. Cells were counted every 2 days and maintained at viability> 
85% and density between 0.5 and 1.0 x 106 cells/ml by the addition or replacement of 
fresh CM. Addition of culture medium was achieved by splitting flask contents 
depending on the cell density and supplementing with fresh medium. The replacement 
of culture medium was by centrifuging cell suspensions, discarding supernatant and re-
suspending cells in fresh CM. Microscopic examination of cells was performed daily. 
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2.2.3.3 Storage of Cells 
0.2 - 0.4 x 106 cells/ml with viability> 90% were transferred into appropriate sterile 
centrifuge tubes and centrifuged at 250 g for 5 min at 4°C. Supematants were discarded 
and without any delay, cells were re-suspended in 1 ml of ice-cold freezing medium 
(FM), which contained 90% newborn calf serum (NCS) and 10% dimethyl sulphoxide 
(DMSO). Cells were transferred rapidly into labelled 1 ml sterile vials and immediately 
frozen at -80°C. After 24 - 48 h, vials were transferred into -200°C liquid nitrogen 
(LN2) freezers until needed. Cells from one vial were re-established in culture to ensure 
the viability of the working cell bank (WCB). 
2.2.3.4 Cell counting 
A homogenous suspension. of cells to be counted was prepared by careful aspiration and 
dispensing using a Pasteur pipette, noting the volume. The haemocytometer and cover 
slip were cleaned by spraying with 70% EtOH and dried with a paper towel. The edge 
of the cover slip was moistened and placed centrally over the counting area and across 
the grooves. Gently and lightly, the cover slip was moved back and forth over the 
chamber until Newton rings appeared, indicating that the cover slip was in the correct 
position to allow accurate counting i.e. the depth of the chamber was now 0.1 mm. 
After ensuring a homogenous cell mixture, a small amount of cell suspension was 
transferred to both chambers of the haemocytometer by carefully touching the edge of 
the cover slip with the pipette tip and allowing each chamber to fill by capillary action. 
Using a light microscope at low power, focussed on the chamber, all the cells in each of 
the 25 center squares were counted using a tally counter, one side of the chamber at a 
time. This procedure was repeated to get 4 readings. The total cell count is equal to 
average count x volume of cell suspension x 104 (where 104 is the conversion factor 
from 0.1 mm3 to ml). 
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2.2.4 Cell viability measurements 
2.2.4.1 Trypan Blue dye-exclusion n:ethod 
An aliquot of cell suspension was taken after careful mixing into 0.5 ml eppendorf tubes 
containing equal volumes of 0.4% Trypan Blue solution and mixed by aspiration and 
dispension using a Pasteur pipette. A sample was drawn and transferred to each of the 
haemocytometer counting chambers. Using an inverted_ light microscope at low power, 
the number qf stained and un-stained cells was counted. 
Table 2.1 Trypan Blue dilutions. 
Cells Trypan blue 
0.1 ml 0.1 ml 
0.1 ml 0.3 ml 
Total number of viable cells = A x B x C x 104• 
Total number of non-viable cells =Ax B x D x 104• 
Total number of cells = A x B x (C + D) x 104. 
Dilution factor 
2- fold 
4 - fold 
Where A represents the volume of cell suspension; B, the dilution factor of Trypan blue 
(Table 2.1); C, the average number of unstained cells; D; the average number of stained 
cells and 104, the conversion factor from 0.1 mm3 to 1 ml. 
Cell yiability was expressed as the ratio of the number of unstained cells to the sum of 
stained and unstained cells. Throughout this study, an aliquot of cell suspension was 
diluted in a 1: 1 (v/v) ratio with 0.4% Trypan Blue and counted with a haemocytometer. 
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2.2.4.2 Lactate dehydrogenase (WH) activity assay 
As instructed on the Sigma LDH assay kit {TOX-7) product, cultures were re~oved 
from the incubator into the laminar flow hood and centrifuged at 250 g for 5 min at 4°C. 
Background absorbance of an empty, sterile 96-well plate was measured at 690 nm 
using the EL 340 microplate reader. A 50 µl aliquot of cell supernatant was transferred 
into each well of the plate before the addition of 25 µl of the LDH assay mixture using a 
multi-chann~l pipette. The LDH assay mixture contains equal amounts of the LDH 
assay substrate, enzyme preparation and dye solution and was prepared just before use. 
The plate was covered with an aluminium foil and placed in a dark cupboard for 25 min. 
The reaction was terminated by adding 7 .5 µl of 1 N HCl to each well using a multi-
channel pipette and the absorba:nce was immediately measured spectrophotometrically 
at 490 nm. The final absorbance readings were expressed as the difference between the 
absorbance readings at 490 nm.and 690 nm (Abs49onm-690nm). 
2.2.5 Analysis of hydrogen peroxide (H202) 
Initial concentrations of hydrogen peroxide were analysed by the method of Treadwell 
and Hall (1924). 1 ml of 30% (w/w) H2O2 was added to 99 ml of water in a 100 ml 
volumetric flask and mixed thoroughly. 10 ml of the resulting solution was transferred 
into a clean beaker and diluted to a final volume of 350 ml before the addition of 25 ml 
of 7.5 N sulphuric acid (H2SO4). The mixture was titrated with freshly prepared 0.1 N 
potassium permanganate (KMnO4) until the formati~n of a permanent pink colour. This 
method was based on the following reaction: 
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Molar calculations from the above equation: 
n2M1V1 = n1M2V2 (where "n" represents the molar ratios, "M'', the molar 
concentrations, "V", volume (ml) and subscripts 1 and 2 representing KMnO4 and 
H2O2, respectively). Therefore, M2 = (n2M1 V 1)/(n1 V 2). 
2.2.6 Cell treatments 
2.2.6.1 With ,Oxidants 
(A) With Hydrogen peroxide (H202) 
The concentration of H2O2 was determined by titration with KMnO4 as earlier described 
(2.2.5). A stock solution of H2O2 was prepared at" a concentration of 10 mM. To obtain 
0 to 1000 µM final concentration of H2O2 in cell suspensions, 0 to 100 µl of the stock 
solution was further diluted with CM to a final volume of 0.9 ml. U937 cells were 
washed twice in HBSS (by centrifugation) and re-suspended in CM. 0.1 ml aliquots of 
cell suspensions, each containing 0.5 x 106 cells/ml and viability > 85% were 
transferred into each well of a 24-well plate and incubated with 0.9 ml of H2O2 solution 
in CM at 37°C and 5% CO2 in a humid environment. H2O2 concentration ranged from 0 
- 1 mM. All cells used were from the same population. After incubation for 24 h, cells 
were transferred into 1.5 ml eppendorf tubes and 10 µl aliquots taken for Trypan Blue 
analysis (2.2.4.1). Thereafter, the cells were centrifuged at 250 g for 5 min at 4°C and 
aliquots of cell supernatant taken for LDH analysis (2.2.4.2). 
(B) With tert- butyl hydroperoxide (t-BHP) : iron sulfate (FeSO4) 
Cells were counted as previously described (2.2.3.4), adjusted to contain 0.5 x 106 
cells/ml, washed twice in HBSS (by centrifugation) and re-suspended in HBSS. 0.1 ml 
aliquots of cell suspensions each containing 0.5 x 106 cells were transferred into each 
well of a 24-well plate. Treatments were started by the addition of 0.9 ml of freshly 
87 
prepared oxidant solution in HBSS or HBSS only as the control. The oxidant contained 
a mixture of tert butyl hydroperoxide (t-BHP) and iron sulfate (FeSO4) in a 1: 1 molar 
ratio prepared from stock solutions of 2 mM t-BHP and 5 mM FeSO4 in HBSS. Cells 
were then incubated at 37°C and 5% CO2 in· a humid environment. For the dose-
dependent experiment, final t-BHP: FeSO4 molar concentrations were varied from 50: 
50 to 1000 : 1000 (µM) with an incubation time of 30 min. The time course 
experiments ,were carried out over O to 24 h with 750 : 750 µM t-BHP : FeSO4 final 
oxidant mixture concentration. The O h experiment involved the rapid addition of the 
oxidant mixture to the cell suspension and centrifuging immediately afterwards. 
All treatments were terminated by centrifugation at 4000 g for 5 min at 4°C after the 
transfer of cell suspensions into 1.5 ml eppendorf tubes. Thereafter, supernatants were 
taken for LDH analysis. 
2.2.6.2 With Organic solvents 
Four organic solvents, all HPLC - grade (methanol, ethanol, chloroform and hexane) 
were tested for their toxicities in U937 cells. These solvents were sterile-filtered using 
Corning nylon, sterile, syringe filters (0.22 µm). A serial dilution from 0.2% to 1.0% 
(v/v) was carried out aseptically in CM by the addition of 2 to 10 µl of solvents. 0.9 ml 
of CM containing the solvents to be tested was added to each well of a 24-well plate 
already containing 0.1 ml of cell suspension. Each well contained 0.5 x 106 cells/ml, all 
from the same population. The final solvent concentration varied from 0.2% to 1.0% 
(v/v). In all experiments, controls contained cells in CM only without the solvent of 
interest. Cells were incubated for 24 h at 37°C and 5% CO2 in a humid environment. 
-All treatments were stopped by centrifuging at 250 g for 5 min at 4°C, prior to LDH 
analysis. 
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2.2.6.3 With fatty acids 
Fatty acids (F~s) were complexed to fatty-acid-free ·bovine serum albumin (BSA) 
aseptically at a molar ratio of 2.5: 1 before CM supplementation. Fatty acid (FA) 
solutions in EtOH ranging from 2.5 to 10 mM were prepared from a 100 mM stock 
solution and stored under nitrogen after sterile filtration using nylon syringe filters. FA 
: BSA complexes were prepared by the addition of an equal volume of 2.5 - 10 mM of 
FA to 1 -4 JnM of BSA respectively and further diluted with CM to a final volume of 
0.9 ml. CM supplemented with FA (0.9 ml) was then added to 0.1 ml of cell 
suspension in each well of a 24-well plate. Untreated experiments involved cells in CM 
only and "vehicle only" controls, cells in CM with 0.4% (v/v) ethanol. Each well 
contained 0.5 x 106 cells/ml. Cells were incubated for 24 hat 37°C and 5% CO2 in a 
humid environment. Final fatty acid concentration ranged from 10 to 40 µM. The 
EtOH concentration in the culture medium was 0.4% (v/v), which had no effect on cell 
viability as measured by LDH analysis (2.3.5.3). _ 
Cells were incubated with 10 µM of individual fatty acids (SA, OA, AA, EPA, DHA) 
complexe~ with- fatty-acid-free BSA in the molar ratio 2.5 : 1 using equal volumes of 10 
mM FA and 4 mM BSA. In controls, EtOH instead of FA was complexed with BSA. 
Cells were incubated in 4 ml suspensions at 0.5 x 106 cells/ml in 25 cm2 culture flasks. 
All flasks were loosely capped and incubated at 37°C and 5% CO2 in a humid 
environment for 3 d (72 h). 
Cells were also incubated with 40 µM of each fatty acid (SA, OA, AA, EPA or DHA) 
or ethanol only (control) complexed to BSA at a molar ratio 2.5: 1 without medium 
change for 72 hours. Incubations were performed in 4 ml cell suspensions at 0.5 x 106 
cells/ml in 25 cm2 culture flasks. After 3 days, cells .were washed twice in HBSS and 
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cell densities re-adjusted to contain 0.5 x 106 cells/ml. Cell suspensions were 
centrifuged at 250 g for 5 min at 4 °C, supernatant discarded and cells re-suspended in 
freshly prepared CM without fatty acid or ethanol (control) supplementation for a 
further 3 days. 
For all experiments, reactions were terminated by centrifuging at 250 g for 5 min at 4°C, 
prior to LD}f analysis. 
2.2.6.4 With antioxidants 
(A) Ascorbic acid · 
A 100 mM stock solution of ascorbic acid was. prepared in nano-pure water, sterile 
filtered using polyethersulfone, 0.2 µm- pore size Corning filters and stored at 2 - 8°C 
for a month. By serial dilution, 4 - 20 mM ascorbic acid solutions were prepared from 
100 mM stock solutions just before use. CM supplemented with ascorbic acid to a final 
volume of 0.9 ml was added to each well of a 24-well plate containing 0.1 ml of cell 
suspension. Final concentration of ascorbic acid varied from O mM to 500 mM. Each 
well contained 0.5 x 106 cells/ml. Controls were incuba!ed with CM only. All reactions 
were stopped by centrifuging at 250 g for 5 min at 4°C and supernatants taken for LDH 
analysis. 
(B) a-tocopherol 
A stock solution of a-tocopherol was prepared at 100 mM in ethanol and stored under 
nitrogen at 2 - 8°C for a month. 10 - 50 mM a-tocopherol in ethanol was prepared by 
serial dilution from 100 mM stock solution and diluted in the culture medium to obtain 
10 - 40 µM finalconcentrations in 1 ml cell suspensions. 0.9 ml of CM supplemented 
with a-tocopherol was added to each well of a 24-well plate containing 0.1 ml of cell 
90 
suspension. Each well contained 0.5 x 106 cells/ml. For controls, cells were incubated 
with CM with 0.1 % (v/v) of ethanol only. Final ethanol concentration in cell 
suspensions was 0.1 % (v/v) in all wells. All reactions were stopped by centrifuging at 
250 g for 5 min at 4°C before LDH analysis. 
(C) p.carotene/ Astaxanthin 
A 100 mM .stock solution of (3-carotene or astaxanthin was prepared in chloroform, 
sterile-filtered using a Corning nylon sterile syringe filter, 0.2 µm pore size and stored 
under nitrogen at - 20°C for a month. 3 mM - 12 mM (3-carotene or astaxanthin was 
prepared in CHCb by serial dilution from the 100 mM stock solution. CM 
supplemented with aliquots of 3 - 12 mM (3-carotene or astaxanthin (0.9 ml final 
volume) was sonicated for 5 s in an ice bath and sterile - filtered using nylon syringe 
filters. 0.9 ml of carotenoid supplemented CM, was added to each of a 24-well plate 
containing 0.1 ml of cell suspension. Final concentration of ·(3-carotene or astaxanthin 
varied from O to 12 µM. Each well contained 0.5 x 106 cells/ml. Untreated cells 
involved incubations in CM only and "vehicle only" controls containing 0.1 % (v/v) of 
chloroform. The CHCb concentration in the culture medium in all experiments was 
0.1 % (v/v). 
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2.3 RESULTS 
2.3.1 0937 cells 
10/29/99 1 ·I ·s2·22AM Exp: o 0992 secs Zoom: 2.0 
U937cells(29/09) 
Fig. 2.1 
100mm. 
U937 cells in culture (x 2000 magnification). Scale bar represents 
2.3.2 Cell growth of 0937 cells 
U93 7 cells were grown over 9 days at 3 7°C and 5% CO2 in a humid environment in a 
CO2 incubator. Cells were counted on day 1, 3, 5, 7 and 9 immediately after thawing. 
Frozen cells were thawed from LN2 and established in culture as earlier described in 
sections 2.2.3.1 and 2.2.3.2. Under these conditions, U937 cells grew in a linear fashion 
(Fig. 2.2). Cells were initially grown in 25 cm2 culture flasks on day O of thawing. 10 
ml of freshly prepared culture medium (CM) was added to cells in 75 cm2 culture flasks 
on day 1 of thawing giving a final volume of 20 ml that was maintained in all flasks 
throughout the course of the experiment. 
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Continuous U937 cell culture over 9 days after thawing from LN2 . 
Results show means ± 95% confidence intervals (Cls) of counts from triplicate flasks 
performed in duplicates. Correlation coefficient (R2) = 0.9977; P < 0.05; DF = 1. Cell 
growth was not extended over 9 days because flasks need to be split after the ninth day 
for optimal cell growth and viability. 
2.3.3 Cell viability monitoring 
Cells were recovered from LN2 at viability > 90% (Table 2.2) and a high viability 
maintained for 7 days. On day 9 however, viability significantly decreases below 90% 
due to the cell density. As the cells become over-crowded, they tend to encroach on 
each other, thus reducing cell viability as shown in Table 2.2. 
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Table 2.2 Viability of U937 cells over 9 days. Means ± 95% Cls from duplicate 
experiments (n = 3). 
Culture time (d) Viability (Fraction) Cells/ml (x 106) 
Day 1 0.9195 ± 0.0128 0.3861 ± 0.0111 
Day3 0.9269 ± 0.0175 0.3917 ± 0.0086 
Day5 0.9330 ± 0.0137 0.5433 ± 0.0214 
Day7 0.9396 ± 0.0157 0.7500 ± 0.0098 
Day9 0.8823 ± 0.0034 0.9033 ± 0.0346 
Cell viability on day 9 ·differed significantly from days 1, 3, 5 and 7 when Tukey's 
pairwise comparisons was carried out post analysis of variance (One-Way ANOVA F = 
10.64, P < 0.01, DF = 4). 
2.3.4 Comparison of Trypan Blue and LDH methods of viability measurements 
To investigate the relationship between Trypan Blue and LDH activity methods of cell 
viability measurements, U937 cells were incubated with hydrogen peroxide at 
concentrations ranging from O - 1 mM for 24 h. Thereafter, the cells were counted by 
dye-exclusion and the extent of membrane leakage established by measuring LDH in 
cell supematants. There was a dose-dependent decrease in cell viability by Trypan Blue 
and an increase in LDH leakage with increasing H20 2 concentrations when compared to 
controls (Fig.2.3). The Trypan Blue method is invasive, laborious, time-consuming and 
prone to bias by the naked eye. On the contrary, the LDH assay is non-invasive, rapid 
and to a great extent, eliminates operator errors which may occur during sampling, 
dilution, mixing, chamber filling and inaccurate counting with the Trypan Blue method. 
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U937 cells were subjected to oxidative stress with O - 1 mM H2O2 for 24 h prior to 
Trypan Blue and LDH analysis. Fig. 2.3, shows Trypan Blue results calculated as a 
fraction of the total cell count and LDH results were expressed as Absorbance at ( 490 -
690) nm (2.2.4.2). When a cell suspension is stained with Trypan Blue, viable cells stay 
small, round and refractile whereas non-viable or dead cells become swollen, larger and 
dark blue enabling the determination of both the total count of cells per ml and 
percentage qf viable cells. Cells were counted within 2 · minutes of staining with the 
dye. The higher the fraction obtained for viable cells the healthier the cell suspension. 
On the other hand, the LDH assay assumes that LDH leaks after damage to the cell 
membrane and that all activity is rapidly reieased from damaged cells into the 
surrounding environment. Hence, the higher the rate of leakage of LDH activity, the 
greater the extent of cell damage or death i.e. cell suspensions with higher enzyme 
activity have been exposed to more membrane damage. 
For all treatments, parameters such as pH, dissolved oxygen concentration, medium 
composition and culture age that may modulate LDH release rate were kept constant. 
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Both methods of viability measurements showed similar results (Fig. 2.3) bearing in 
mind that the higher Trypan Blue levels for via?le cells produce lower LDH activity~ A 
correlation of LDH absorbance values with increasing H2O2 concentrations gave a 
better correlation (R2 = 0.98, P < 0.01; N = 5) than Trypan Blue values correlated with 
H2O2 concentrations (R2 = 0.962, P < 0.01; N = 5), although the difference .was not 
significant. this study shows a high correlation between both methods however, the 
LDH activity method was chosen for routine viability determinations because it gave a 
higher correlation with increasing toxicity and it also limits operator errors and bias. 
2.3.5 LDH activity results 
. 2.3.5.1 Effects of hydrogen peroxide on LDH in U937 cells 
Cells were incubated for 24 h in supplemented CM supplemented with O to 1 mM H2O2 
(Fig. 2.4). LDH increased significantly with increasing H2O2 concentration (One-Way 
ANOVA F = 2.8 x 104, P < 0.01, DF = 5). Tukey's pairwise comparisons showed a 
significant difference from controls at concentrations ~ 0.4 mM. There was no 
difference however at H2O2 concentration of 0.2 mM compared to controls. There was 
a linear LDH increase with increasing H2Q2 levels (R2 = 0.959). 
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Fig. 2.4 LDH leakage from the incubation of U93 7 cells with 0 - 1 mM H2O2 for 
24 h. Means± 95% Cls (n = 5). 
2.3.5.2 Effects of oxidative stress with t-BHP: FeSO4 on U937 model systems 
In order to determine the effects of oxidative stress on U93 7 cell membrane integrity, 
cells were treated with a mixture oft-BHP and FeSO4. Fig. 2.5 (A) shows the results 
for cells treated with varying concentrations of the radical oxidizing system oft-BHP 
and F e2+ for 3 0 min. 
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Fig. 2.5 U93 7 cells were incubated with various concentrations of the radical 
oxidizing system (t-BHP:FeSO4) . Cell viability was expressed as absorbance values 
(490 - 690) nm. Points represent means ± 95% Cis of cells from 4 replicate wells. 
Dose response of cells to oxidant mixture after 30 min of incubation (A), and time 
dependent response of cells to 750: 750 µM oft-BHP: FeSO4 oxidant mixture over 24 
h (B) at 37°C and 5% CO2 in a humid environment (n = 4). 
There was a concentration - dependent increase in membrane leakage of LDH 
(Kruskall-wallis H = 22.91, P < 0.01, DF = 6). Dunn's test showed a significant 
difference in LDH released into the culture medium at concentrations~ 750 : 750 µM 
for 30 min compared to controls. 
24.0 
The effect of treatment with 750 µMt-BHP and 750 µM FeSO4 over a time course of 0 
- 24 h was also investigated and the LDH values are as shown in Fig. 2.5 B. Tukey' s 
pairwise comparison shows a significant loss of membrane integrity after 30 min of 
exposure compared to the Oh control (one-way ANOVA F = 403 .84, P < 0.01 ; N = 4). 
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A correlation of absorbance with time showed a significant linear relationship between 
the variables (R2 = 0.961; P < 0.01; N = 4) (Fig. 2.5 B). · 
For the dose-dependent experiment, LDH leakage was negligible at concentrations ~ 
500 : -500 µM oxidant levels. However at 750 and 1000 µM oxidant mixture 
concentrations, a significant increasing membrane leakage was observed. There was a 
154% and 242% increase at 750 and 1000 µM oxidant concentration respectively 
compared to control values. After the treatment of cells with 750 : 750 µM oxidant 
mixture, LDH activity after ½, 1, 2, 4, 8 and 24 h was 8, 22, 25, 71, 78 and 89% 
respectively above the ·control. 
2.3.5.3 With different organic solvents 
Cells exposed to methanol, ethanol, hexane and chloroform in concentrations ranging 
from 0.2% to 1.0% (v/v) were analysed for LDH leakage into the medium as a measure 
of cell membrane integrity loss associated with toxicity. This study was conducted to 
determine the tolerance levels of U937 cells to these organic solvents, which will later 
be used to dissolve certain water-insoluble agents. Of the solvents tested, o~ly 
chloroform had no significant effect on cell viability (Fig. 2.8) all the others were toxic 
to cells at different solvent concentrations. After Tukey's pairwise comparisons, 
methanol (Fig. 2.6) showed a significant increase in LDH release at concentrations ~ 
0.6% (v/v) (one-way ANOVA F = 34.27, P < 0.01, N = 4); ethanol (Fig. 2.7), at levels~ 
0.8% (v/v) (one-way ANOVA F = 38.61, P < 0.01, N =4); hexane (Fig. 2.9), had 
significant LDH leakage in cells incubated with ~ 0.6% (v/v) (one-way ANOV A F = 
32.14, P < 0.01, N =4) whereas, cells treated with chloroform showed no significant loss 
of membrane integrity at these concentrations (one -way ANOVA F = 1.12, P > 0.05, N 
= 4). All observations were made after 24 h. 
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Fig. 2.6 LDH release after 24 h of incubation with 0 - 1 % (v/v) methanol. a: Indicates significant difference from solvent-untreated controls (0% 
v/v); b: 0.2% v/v; c: 0.4% v/v; d: 0.6% v/v; e: 0.8% v/v and f: 1.0% v/v by one-way ANOVA at P < 0.01. Values represent means± 95% Cls of 
duplicate experiments (n = 4). 
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Fig. 2.7 LDH release after 24 h of incubation with 0 - 1 % (v/v) ethanol. a: Represents significant difference from solvent-untreated controls (0% 
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2.3.5.4 With fatty acids 
To investigate the possible toxic effects of fatty acids on cell viability, U937 cells were 
incubated with 0 - 40 µM of the saturated fatty acid SA (18:0), the monounsaturated 
fatty acid OA-(18:1), or the very long chain PUFAs AA (20:4n-6), EPA (20:5n-3) and 
DHA {22:6n-3) all complexed with BSA for 24 h after which the extent of membrane 
leakage was determined. Tables 2.3 and 2.4 shows absorbance values after the 
treatment of.cells with SA, OA, AA, EPA and DHA for 24 h compared to controls. 
Table 2.3 Effects of SA, OA and AA on LDH leakage after·24 h of incubation. 
Values represent means ± 95 Cls from two independent experiments (n = 4). "No 
treatment" represents cells in CMl O only and "vehicle only", cells treated with 0.4% 
v/v of ethanol. 
Concentration SA OA AA 
No treatment 0.1569 ± 0.0014 0.1630 ± 0.0012 0.2197 ± 0.0053 
Vehicle only 0.1554 ± 0.0101 0.1637± 0.0047 0.2289 ± 0.0057 
l0µM 0.1573 ± 0.0107 0.1638 ± 0.0047 0.2255 ± 0.0041 
20µM 0.1622 ±0.0123 0.1653 ± 0.0029 0.2311 ± 0.0116 
30µM 0.1668 ± 0.0159 0.1658 ± 0.0048 0.2211 ± 0.0162 
40µM 0.1661 ± 0.0137 0.1667 ± 0.0026 0.2345 ± 0.0134 
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Table 2.4 Effects of EPA and DHA on I.DH leakage after 24 h of incubation. 
Values represent means ± 95 Cls from two independent experiments (n = 4). "No 
treatment" represents cells in CMlO only and "vehicle only", cells treated with ethanol 
(0.4% v/v). 
Concentration EPA DHA 
No treatment 0.1449 ± 0.0033 0.2446 ± 0.0103 
Vehicle only 0.1460 ± 0.0019 0.2260 ± 0.0065 
l0µM 0.1450 ± 0.0042 0.2312 ± 0.0111 
20µM 0.1506 ± 0.0053 0.2383 ± 0.0114 
30µM 0.1513. ± 0.0020 0.2383 ± 0~0057 
40µM 0.1533 ± 0.0049 0.2492 ± 0.0164 
Neither SA, OA, AA, EPA nor DHA showed significant effects on I.DH leakage into 
culture supernatant after 24 h of treatment with 0 - 40 µM complexed with BSA in a 
2.5: 1 molar ratio when compared to untreated cells (No treatment). For SA (one-way 
ANOVA F = 0.68, P > 0.05, DF = 5); OA (one-way ANOVA F = 0.56, P > 0.05, DF = 
5); AA (one-way ANOVA F = 1.15, P > 0.05, DF = 5); EPA (one-way ANOVA F = 
2.72, P > 0.05, DF = 5) and DHA (one-way ANOVA F = 2.36, P > 0.05, DF = 5). This 
study shows no marked increase in I.DH release at FA concentrations ranging from 0 to 
40 µM when complexed with BSA in U937 cells after 24 h incubation. See appendix 
for reasons for the choosing certain statistical methods of analysis over others. 
To determine the effect of prolonged treatment of cells with fatty acids, cells were 
incubated with 10 µM SA, OA, AA, EPA and DHA for 3 days. Results showed no 
significant effects on I.DH release after extended treatments with these fatty acids for 3 
days (one-way ANOVA F = 1.57, P > 0.05, DF = 5, N = 4) (Table 2.5). 
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Table 2.5 LDH leakage in· U937 cells incubated with 10 µM SA, OA, AA, EPA 
and DHA for 72 h. 
Means± 95% Cls for duplicate experiments (n = 4). 
Fatty Acid LDH Absorbance values 
Control (Ctrl) 0.2180 ± 0.0079 
Stearic Acid (SA) 
Oleic Acid (OA) 
Arachidonic Acid (AA) 
Eicosapentaenoic Acid (EPA) 
Docosahexaenoic Acid (DHA) 
0.2153 ± 0.0040 
0.2201 ± 0.0050 
0.2236 ± 0.0045 
0.2234 ± 0.0033 
0.2220 ± 0.00049 
The effect of 40 µM FA on cells was investigated over a prolonged period (72 h), a 
concentration that was otherwise non-toxic to U937 cells after 24h of incubation. Cells 
incubated with the PUFAs showed a higher LDH leakage than control cells. Multiple 
comparisons of LDH results after 72 h with 40 µM levels of the five different fatty acids 
with control, showed a significant difference between treatments (One-way ANOV A F 
= 117.65, P < 0.01, DF = 5). Tukey's pairwise comparison showed no significant 
difference between the saturated fatty acid (SA), the monounsaturated. fatty acid (OA) 
compared to controls. However, there was a significant increase in LDH levels with the 
three polyunsaturated fatty acids (AA, EPA and DHA) compared to controls. The 
highest LDH leakage was however, surprisingly obtained with EPA treatment which, 
was found to be significantly higher than that quantified with AA and even DHA. 
Washing with HBSS and re-suspension of cells in freshly prepared CM, with fatty acid 
withdrawal and incubation for a further 3 days showed no reversal of these toxic effects. 
Tukey's pairwise comparisons (one-way ANOV A F = 38.41, P < 0.01, DF = 5) (Fig. 
2.10). 
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To determine if the membrane leakage observed in U937 cells after 72 h incubation 
with 40 µM AA, EPA and DHA could be reversed, cells were washed, diluted to a 
density of 500000 cells/ml and re-established in culture with fatty-acid-free CM. 
Though the effects were not reversed, there was a significant decrease in the extent of 
membrane leakage observed after six days when compared to controls (ANOV A; F = 
36.35, P < 0.01 , DF = 1). When compared to controls, there was a 47, 44 and 31% 
decrease in LDH leakage with AA, EPA and DHA treatments respectively, after re-
incubation in a fatty-acid-free medium. 
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2.3.5.5 Treatment of cells with Antioxidants 
(A) Ascorbic acid 
To examine the effect of ascorbic acid on U937 cell membrane integrity, cells were 
incubated with O - 500 µM ascorbic acid for 24 hand the LDH leakage into culture 
medium was measured. LDH leakage was negligible at these ascorbic acid 
concentrations (Table 2.6). 
Table2.6 LDH activity with increasing ascorbic acid concentration. U937 cells 
(500000 cells/ml) were exposed to O - 500 µM ascorbic acid for 24 h in culture 
medium. Absorbance readings represent means ± 95% Cls for two independent 
experiments (n = 4). 
Ascorbic acid concentration 
0µM 
I00µM 
200µM 
300µM 
400µM 
500µM 
Absorbance ( 490 - 690) nm 
0.4764 ± 0.0053 
0.4752 ± 0.0057 
0.4750 ± 0.0059 
0.4794 ± 0.0057 
0.4870 ± 0.0034 
0.4919 ± 0.0183 
There was no significant increase in the loss of membrane integrity with ascorbic acid 
concentrations ranging from O - 500 µM (One-way ANOV A F = 2.42, P > 0.05, DF = 
5, N = 4). 
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(B) a-tocopherol 
CM was supplemented with 0 - 50 µM a-tocopherol with ethanol as the vehicle at 0.1 % 
(v/v) final ethanol concentration (1 µI/ml) for 24 h (Table 2.7). Thereafter, LDH 
activity was determined. 
Table 2.7 Effects of a-tocopherol on LDH activity in U937 cells after 24 h of 
incubation. Means± 95% Cis of two independent experiments (n = 4). 
a-tocopherol concentration 
OµM 
l0µM 
20µM 
30µM 
40µM 
50µM 
Absorbance (490-690) nm 
0.3888 ± 0.0139 
0.3897 ± 0.0141 
0.3836 ± 0.0054 
0.3845 ± 0.0083 
0.3923 ± 0.0040 
0.4077 ± 0.0150 
One-way ANOV A showed no significant difference in LDH activity between treatments 
(F = 2.43, P > 0.05, DF = 5, N = 4) when comparedto controls (0.1 % v/v ethanol only) 
(Table 2.7). 
(C) With carotenoids 
To check the toxic levels of B-carotene and astaxanthin in U937 cells by measuring 
LDH leakage from membranes, cells were incubated with O - 12 µMB-carotene and 
astaxanthin using 0.1 % (v/v) of chloroform as the vehicle of transport. 
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Table 2.8 LDH effects with ~-carotene and astaxanthin after 24 h of incubation. 
Absorbance values represent means ± 95% Cls of two independent experiments (n = 4). 
"No treatment" represents cells in CM only and "vehicle only", cells in CM with 0.1 % 
v/v of chloroform. 
Concentration ~-carotene Astaxanthin 
No treatment 0.2009 ± 0.0082 0.6436 ± 0.0065 
Vehicle only 0.1993 ± 0.0050 0.6419 ± 0.0065 
3µM 0.1968 ± 0.0066 0.6435 ± 0.0082 
6µM 0.2067 ± 0.0067 0.6387 ± 0.0052 
9µM 0.2082 ± 0.0093 0.6413 ± 0.0116 
12µM 0.2058 ± 0.0049 0.6432 ± 0.0030 
There was no significant difference between all treatments (Table 2.8): ~-carotene 
(One-way ANOV A F = 1.66, P > 0.05, DF = 5, N = 4) and astaxanthin (One-way 
ANOVA F = 0.25, P > 0.05, DF = 5, N = 4). 
2.4 DISCUSSION AND CONCLUSION 
The objective of this chapter was to evaluate the tolerance levels of U937 cells to the 
various agents that will be used later on in this study for several purposes, using a 
measure of the cell membrane integrity. U937 cell biology is used in this study to 
investigate the aetiology and pathogenesis of schizophrenia and to explore the options 
for its treatment. A good recovery of cells at high viability from liquid nitrogen with a 
steady growth rate was obtained and established prior to all viability analysis. The 
Trypan Blue dye-exclusion and lactate dehydrogenase assays are both well-established 
methods of cell viability measurements. My choice of the LDH over the Trypan Blue 
method was because it limits human errors amongst other reasons. 
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Cytosolic lactate dehydrogenase release into the culture medium is a permeability assay 
differing. from other methods because it is a non-invasive means of identifying 
membrane damage (Wroblewski and La Due, 1955). LDH activity is measured in cell 
and tissue supematants by following the conversion of exogenously added lactate to 
pyruvate and simultaneously measuring the increase in absorbance resulting from the 
conversion of added NAD to NADH (Wroblewski and La Due, 1955). The assay is 
based on the, premise that cellular damage will inevitably result in the loss of the ability 
to maintain and provide energy for metabolic function and growth. There was a 
significant correlation between Trypan Blue and LDH activity methods of cell viability 
measurements (R2 = 0:94, _P < 0.05) in cells exposed to O to l mM levels of hydrogen 
_ peroxide. The distinct advantage of the LDH assay is that numerous samples can be 
processed simultaneously and analyzed automatically using a microplate reader in 
reasonable short periods of time. 
2.4.1 Treatment with oxidants 
When confronted with stressors, chemical or environmental, organisms at both cellular 
and _ molecular levels respond to acclimatize themselves to their new environment. 
Oxidative stress is one such stimulus that can induce cellular adaptation. Lee and Um 
(1999), reported that the treatment of U937 cells with micromolar levels of H2O2 for 8 -
24 h promotes resistance to a subsequent challenge with high concentrations that would 
otherwise be lethal. Hydroxyl radicals, formed from hydrogen peroxide, react very 
quickly with almost every type of molecule found in living cells: sugars, amino acids, 
phospholipids, DNA bases and organic acids. It is the most reactive oxygen radical 
known. During the 'respiratory burst' of phagocytes and many other cell types, some 
H2O2 is released into the surrounding fluids. Provided that H2O2 can be stopped from 
forming destructive OH• radicals, it may act as a useful intercellular signal between 
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cells. Low levels of oxidative· stress, which can be achieved by the addition of H2O2, 
have been reported to stimulate in vitro cell proliferat~on. On the contrary, higher levels 
of oxidative stress usually decrease cell proliferation in culture and may have toxic 
effects. 
H2O2 has been reported to be toxic to most cell types in vitro at or above 10 - 100 µM 
levels (Halliwell and Gutteridge, 1999). This study however shows no significant effect 
on cell viability measured by both the LDH and Trypan Blue assays on exposure of 
U937 cells to 200 µM H2O2 for 24 h as reported by Lee and Um, 1999. It has been 
demonstrated that H2O2 can elevate GSHPx levels in U937 cells, thus enhancing the 
cell's capacity to consume H2O2 (Lee and Um, 1999). 
It is known that macrophages including monocytes, can be activated to kill micro-
organisms and tumour cells as an essential facet of immunity to intracellular parasites 
and tumours (Murray et al., 1983; Nathan et al., 1983; Bryne et al., 1986). Enhanced 
antimicrobial and antitumour activity has been shown to be dependent on an increased 
capacity of activated macrophages to produce tqxic forms of oxygen, particularly H2O2 
(Adams and Nathan 1983; Murray, 1983). Macrophages produce toxic forms of oxygen 
by the activity of an NADPH oxidase similar to that of neutrophils. The oxidase 
contains FAD protein and a low-potential cytochrome b_245 (Cross et al., 1983; 1985; 
Berton et al., 1985). 
Reactive oxygen species (ROS), such as hydrogen peroxide, superoxide and hydroxyl 
radical, have been widely accepted as common signal mediators in a number of 
activation pathways (Finkel, 1998). An increased state of intracellular ROS is referred 
to as oxidative stress. Monocytes, as circulating blood cells, are easily affected by 
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dietary-derived peroxides and antioxidants present in the plasma. Devaraj et al., 1996, 
reported that the supplementation of diets with a tocopherol in humans affects cellular 
function of monocytes. Moreover, monocyte cells, due to their involvement in 
inflammatory processes, are likely to find themselves in an oxidative environment in 
vivo. This study shows that the oxidant mixture oft-BHP and FeSO4 increases the loss 
of cell membrane integrity in U937 cells in a dose - and time - dependent fashion (Fig. 
2.5). In a previous study, t-BHP on its own has been reported to kill U937 cells in a 
concentration (0 - 1.0 mM) and time dependent (after 6 and 24 h) manner (Guidarelli, 
1996). 
The exposure of hydroperoxides to transition metals such as Fe2+ results in the 
formation of further reactive radicals, including alkoxyl (LO•) and peroxyl species 
(Gebicki and Gebicki, 1993; Davies et al., 1995), thus propagating peroxidative 
reactions. It is perhaps pertinent to note that U937 cells, as phagocytes are capable of 
generating oxidants for anti-microbial defence, and might therefore be expected to have 
enhanced antioxidant protection. As such, it is possible that the deleterious effect 
observed at 750: 750 µMt-BHP: FeSO4 concentration on U937 cell membrane integrity 
was due to induced peroxidative damage. 
2.4.2 Treatment with organic solvents 
The careful selection of a solvent is a necessary requirement for tp.e testing of water -
insoluble compounds in a cell culture system. Testing of solvent toxicity must be 
evaluated prior to experiments (Crawford and Braunwald 1991). The results obtained in 
this study show that a concentration of 0.6% (v/v) of methanol and hexane; 0.8% (v/v) 
of ethanol has a toxic effect on cells. However, chloroform ~ 1 % (v/v) had no 
significant effect on cell membrane integrity. 
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Taken together, this study shows that organic solvents can be toxic to cells even at 
concentrations below 1 % (v/v). Thus, ethanol was chosen as the solute for fatty acids at 
final concentrations ~ 0.6% (v/v) and chloroform, though not toxic ~ 1 % (v/v) for 
carotenoids in cell suspensions. 
2.4.3 Treatment with fatty acids 
Fatty acids exist in every cell in the body in high quantities interacting with various 
cellular components, mainly the membrane. Changes in the relative amounts of free 
fatty acids in a membrane may contribute a major factor to the physiological role of the 
membrane. For example, in neuronal cells, the conduction of electrical signals along 
the axon is dependent on the exchange of ions between the inner and outer walls of the 
membrane. This process is largely dependent on the membrane fluidity, flexibility and 
permeability which in tum, control the physiological role of the ionic channel. Changes 
therefore in fatty acid levels ultimately affect membrane functions as shown in this 
study (Fig. 2.10). Since the presence of fatty acids above physiological levels is known 
to be cytotoxic, it is essential to use positive methods of addition of these substances as 
well as to determine their toxic levels in the system of interest. The concentrations of 
fatty acids used in this study may be found in the human plasma by dietary 
supplementation (Liebich et al., 1991). Fatty acids were also complexed to BSA and 
thus, these experiments were performed under similar physiological conditions. It has 
been suggested that PUP As affect the proliferation of leukaemia cells in vivo as 
demonstrated in mice bearing the myeloid leukaemia T27 A (Jenski et al., 1995). Since 
the U937 model is a leukaemia cell line, the loss of membrane integrity obtained with 
40 µM PUFAs over 3 days could result from this. However, a better biochemical 
understanding of how PUFAs affect cell membrane integrity and ultimately cell death is 
necessary. Although several studies have suggested a protective role of fatty acid 
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binding proteins against high 'intracellular FA concentrations (Kaikaus et al., 1990; 
Veerkamp et al., 1991; Vork et al., 1993; Glatz and van der Vusse, 1996), or even free 
radicals (Samanta et al., 1989), this and the study by Zimmerman and Veerkamp (2001), 
show no evidence for such roles. 
In a study by Finstad et al. (1998), it was found that PUFAs especially AA, EPA and 
DHA reduc~d cell multiplication, loss of membrane integrity and caused DNA 
fragmentation in some leukaemia cell lines including U937-1 cells when used above 
certain levels. However, these responses were reported to be dependent on cell type. 
This study demonstrates no significant difference in LDH leakage in U937 cells 
incubated for 24 h with Oto 40 µM of SA, OA, AA, EPA and DHA compared to 
controls when complexed with fatty-acid-free BSA in the molar ratio 2.5 : 1 (Tables 2.3 
and 2.4). After the treatment with 10 µM of these five fatty acids for 72 h, there was no 
significant increase in the loss of membrane integrity. However, when these cells were 
incubated with 40 µM for 72 h, there was a significant difference between treatments 
(Fig. 2.10). There was no difference in LDH parameter obtained with 40 µM SA or OA 
compared to controls. A striking effect however, was that the greatest damage was 
obtained with cells incubated with 40 µM EPA and not 40 µM DHA after 3 days. 
Finstad et al., (1998), reported negligible number of cells with leaky membranes after 3 
days when treated with 60 µM EPA but appreciable at concentrations ~ 120 µM. In 
contrast, the present study shows a significant increase in LDH leakage in U937 cells 
when treated with 40 µM EPA for 3 days. A possible explanation for this is that the 
EPA used was partially oxidised as packaged by the manufacturer. However, this 
possibility appears not to be the case as shown in subsequent chapters. This study 
shows that the treatment of U937 cells with 40 µM PUFAs (AA, EPA and DHA) for 3 
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days increased the loss of membrane integrity significantly while -SA and OA had no 
significant effect at that same c_oncentration. 
To investigate if the increase in LDH activity in cells incubated with 40 µM PUFAs 
were reversible upon removal of these fatty acids from the medium, cells were 
incubated for 3 days with PUFAs (AA, EPA or DHA). The cells were then washed, 
diluted to a c;lensity of 0.5 x 106 cells/ ml and re-incubated in a fatty-acid-free medium 
for three more days. After pre-incubation for three days LDH leakage was higher in 
cultures exposed to AA, EPA and DHA but not with SA or OA compared to controls 
(Fig. 2.10). Re-incubation of cells in a fatty-acid-free medium for three more days 
showed reduced toxicity of the PUFAs (AA, EPA a!1d DHA), with the U937 cells on the 
road to recovery. The prolonged presence or withdrawal of SA or OA had no effect on 
LDH leakage. Similarly, Finstad et al. (1998), reported a reversible effect of EPA when 
U937 cells were re-incubated in an EPA-free medium. 
Finstad et al., (1998), found a reduction in cell number and an increased degree of 
apoptosis in cells treated_ with· 60 µM EPA after 3 days and these effects were not 
counteracted by pre-treating these cells with antioxidants such as vitamin E and C, 
suggesting that the damage was not oxidatively induced. It is however possible that 
PUFAs may interfere with cell proliferation of cancer cells by the formation of lipid 
:peroxidation bye-products (Chajes et al., 1995). This study has demonstrated that 
polyunsaturated fatty acids can reduce membrane integrity of U937. cells at certain 
concentrations over prolonged periods. The extent of cell membrane damage has been 
reported to vary from one cell line to another (Finstad et al., 1998). 
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Even though re-incubation of cells in a fatty-acid-free medium for three more days did 
not completely reverse the damaging effects of PUFAs on cell viability, there was a 
significant decrease in LDH leakage compared to the results obtained in the presence of 
PUFAs. This suggests that prolonged withdrawal of these FAs may eventually lead to a 
complete reversal producing similar results obtained to that of controls. For follow-up 
experiments, U937 cells were incubated with 0 - 40 µM fatty acids concentrations for 
times :5; 24 h, unless otherwise stated and with 10 µM levels for time periods over 24 h. 
2.4.4 Treatment with antioxidants 
(A) With ascorbic acid (Vitamin C) 
It is well established that mammalian cells lack the ability to synthesize ascorbic acid 
but express transport systems that mediate the cellular uptake of the vitamin (Guidarelli, 
2001). In solution ascorbic acid undergoes metal-catalysed oxidation to 
dehydroascorbic acid, with the concomitant formation of superoxides and hydrogen 
peroxide (Carr and Frei, 1999). Ascorbic acid (Vitamin C) is a major water soluble 
antioxidant, found in the aqueous compartments of cells and extracellular fluids, 
capable of scavenging reactive oxygen species (Chou and Khan, 198_3; Chesney et al., 
1991; Buettner and Jurkiewicz, 1996). 
Vitamin C, also known as ascorbic acid, occurs at concentrations between 30 and 100 
µM levels in the human plasma. Millimol~ levels in different cell types are sufficient 
to exert antioxidant effects (Halliwell and Gutteridge, 1999). This study shows that no 
significant increase in LDH activity at 0 - 500 µM ascorbic acid levels. However, 
concentrations of ascorbic acid that will subsequently be used will vary from 0 - 400 
µM because there was no significant increase in LDH leakage in U937 cells at these 
levels. 
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(B) a-tocopherol 
a.-tocopherol, a potent fat-soluble antioxidant vitamin sequestered in the hydrophobic 
interior of membranes, quenches lipid peroxidation (Burton et al., 1983). It has been 
· suggested that the distribution of vitamin E reflects the degree of its saturation in 
membrane lipids (Buttris and Diplock, 1988). However, there is a controversy as to the 
exact subcellular distribution of vitamin E. Mitochondria are generally found to be 
relatively rich in vitamin E, but its distribution between the inner and outer membranes 
is still unclear (Oliveira et al., 1969; Buttris and Diplock 1988). There was no 
significant difference in LDH leakage in cells incubated with O - 50 µM levels of 
vitamin E for 24 h. However concentrations < 50 µM will be used henceforth in this 
study. 
(C) With Carotenoids 
Carotenoids are water insoluble antioxidants found in nano-molar concentrations in 
human serum and breast milk (Khachik et al., 1997). For this study a member of the 
two carotenoids groups was employed: f3-carotene for hydrocarbons and astaxanthin for 
xanthopylls. Concentrations of f3-carotene and astaxanthin varying from O to 12 µM 
showed no significant changes in cell membrane integrity after 24 h treatment. 
Carotenoids are unstable and therefore stock solutions change over time due to 
oxidative breakdown (Hess et al., 1991). Being highly hydrophobic, carotenoids show a 
strong tendency to aggregate and crystallise in aqueous media. The accumulation of 
carotenoids as micro - crystalline aggregations is common in the chloroplasts of higher 
plants (e.g. lycopene in tomato) (Pfander et al., 1994). Aggregation changes the 
physical properties of carotenoids (light absorption and chemical reactivity). Changes 
in carotenoid size and ease of solubilization affect the ease of absorption and bio-
availability in animals and their ability to enter and function in sub-cellular structures 
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(Gruszecki, and Sielewiesiuk, ·1990). In this study, the carotenoids used were dissolved 
in chloroform and sonicated briefly to improve the ease of absorption into cellular 
fractions whilst preserving its stability. Carotenoid concentrations, therefore, used 
subsequently in following chapters of this study ranged from Oto 12 µM because these 
levels did not affect cell membrane integrity. 
2.4.5 ConcJusion 
In conclusion, this chapter demonstrates that U937 cells are fast dividing cells with a 
steady growth when maintained at 0.5 to 1.0 x 106 cells/ml. It also shows a good 
correlation between the lactate dehydrogenase activity quantified in culture medium and 
the Trypan Blue dye exclusion method of cell viability measurements. In addition, it 
shows the sensitivity of U937 cells to PUFAs especially EPA. Therefore, to evaluate 
the possible use of n-3 fatty acids in future schizophrenia therapy, a better 
understanding of the biochemical mechanisms responsible for the loss of membrane 
integrity is required. 
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CHAPTER 3: FATTY ACID INCORPORATION INTO CELLULAR 
PHOSPHOLIPIDS 
3.1 INTRODUCTION 
Fatty acids are essential components of cell membrane phospholipids. They determine 
membrane properties and modify signal transduction mechanisms across cell 
membranes .. These include pathways involving the formation of second messengers 
after the enrichment of cells with n-3 and n-6 polyunsturated fatty acids (PUFAs) 
(Swann et al., 1990; Weber et al., 1991). Free fatty acids (FFAs) are rapidly and 
completely absorbed into membrane lipid fractions with large chain fatty acids, 
normally more than 99%, bound to serum proteins (Fenton et al., 2000). In the brain, 
the binding of FF As . to proteins is accompanied by a swift dissociation rate and 
exchange of unbound and unincorporated essential fatty acids· between the brain and 
blood. As such, the uptake of .FFAs by the brain is buffered against short-term 
fluctuations in blood levels, primarily reflecting the metabolic needs of the brain for 
these fatty acids (Banks et al., 1997). 
Of the polyunsaturated fatty acids, docosahexaenoic acid (22: 6n-3) is the longest and 
most unsaturated fatty acid commonly found· in the phospholipids of biological 
membranes. It represents a major component of membranes of a few specialized tissues 
including the brain, sperm and retinal rod outer segments, where DHA can account for 
up to 50 mol% of the total fatty acids (Hendriks et al., 1976; Salem et al., 1986). 
The goal of this qualitative study was to determine whether the different fatty acid 
supplements were incorporated into the phospholipids of U937 cells after the 
enrichment of the culture medium with 40 µM levels of SA, OA, AA, EPA or DHA and 
incubation for 24 h. 
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3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Fatty-acid-free bovine serum albumin (BSA), stearic acid (SA), oleic acid · (OA), 
arachidonic acid (AA), phosphatidyl choline, 0.4% Trypan Blue, Hanks balanced salt 
solution (HBSS), RP:MI 1640, foetal bovine serum (FBS), 200 mM L-glutamine,. 50 
mg/ml gentamicin solution, HPLC-grade chloroform, hexane, diethyl ether, methanol 
and ethanol,, glacial acetic acid, potassium chloride (KCl), 2", 7"-dichlorofluorescein, 
sulfuric acid, toluene, potassium hydrogen carbonate (KHCO3), butylated hydroxy-
toluene (BHT) and nonadecanoic acid methyl ester were purchased from Sigma-
Aldrich, UK. Eicosapentaenoic acid (BP A) and docosahexaenoic acid (DHA) were 
from Nu-:-chek Prep., Denmark. LK5D - Whatman TLC plates were supplied by Fisher 
Scientific, UK. 
3.2.2 U937 cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM L-
glutamine and 0.05 mg/ml gentamicin at 37°C in a humidified incubator with 5% 
CO2/95% air. For all experiments, cells were maintained .at 0.5 x 106 cells/ml at 
viability> 90% by Trypan Blue dye exclusion. 
3.2.3 Treatment of cells with fatty acids 
1.5 x 107 cells at 0.5 x 106 cells/ml were supplemented with 40 µM (final concentration) 
of SA, OA, AA, EPA or DHA using aliquots of 10 mM FA stock solutions. FAs were 
complexed with BSA at a molar ratio of 2.5:1. Control cells were incubated with 
ethanol/BSA complex. Cells were incubated in 30 ml suspensions in 75 cm2 culture 
flasks for 12 h to allow for the incorporation of fatty acids into cellular phospholipids. 
Thereafter, a homogenous cell mixture was ensured by careful aspiration and dispensing 
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using a Pasteur pipette. 10 ml ·of cell suspension was transferred into 15 ml centrifuge 
tubes and FA uptake was terminated by centrifugation at 4000 g for 5 min at 4°C. Cells 
were washed twice each time with 10 ml of HBSS and re-suspended in 0.2 ml of ice- · 
coldHBSS. 
3.2.4 Lipid extraction 
Extraction of total cellular lipids from pelleted cells was performed by a modified 
method of Folch et al. (1957). Lipids in 0.2 ml of cell pellets were extracted with 0.8 
ml of ice-cold chloroform (C): methanol (M) (2: 1 v/v) in 1.5 ml eppendorf tubes. The 
cell suspension was so'nicated for 3 x 10 s with 10 s intervals in an ice-bath followed by 
the rapid addition of 0.2 volumes of ice-cold methanol (0.2 ml) to reduce the density of 
the extracting solvent (Radin, 1988). Suspensions were mixed briefly with a vortex 
mixer and centrifuged at 4000 g for 3 min at 4°C. Centrifugation was used instead of 
filtration to convert all non-lipid residues into compact pellets due to the small sample 
size. An aliquot of 0.8 ml of the supernatant, containing the lipid residue, was 
transferred into labelled, sterile Pyrex tubes and lipid extraction was repeated as 
previously performed but this time, 1.05 ml of supernatant was carefully drawn. The 
two supernatants were combined and the pellets were discarded. 
Thereafter, 0.88% KCl was added as 25% of the existing volume (0.5 ml). Tubes were 
shaken and allowed a few minutes for separation into two phases. 0.8 ml o~ the organic 
(bottom) layer was transferred into a clean vial and lipids left in the Pyrex tubes were 
re-extracted by the addition of 800 µl of C: M (2: 1, v/v with 0.01 % BHT). 0.6 ml of 
the bottom layer was drawn, combined with the previous extract and evaporated to 
dryness under a gentle stream of nitrogen (N2). The extract was re-suspended in 0.03 
ml of C: M (2: 1, v/v) with 0.01 % BHT and stored at -20°C. 
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3.2.5 Thin layer chromatographic separations 
A solvent system of hexane: diethyl ether: acetic acid, 70: 30: 1.3 (v/v/v) was prepared. 
Using a micro-Pasteur pipette, 20 µl aliquots of lipid extracts were spotted on LK5D 
plates under a stream of N2 with reference phosphatidyl choline standard on a separate 
lane for identification purposes. The plates were run in a chamber pre-saturated with 
100 ml of the solvent system above. After the solvent front reached 1-2 cm from the 
top, plates w,ere dried under a stream of N2 until free of acetic acid odour. Afterwards, 
plates were sprayed with 0.1 % (w/v) 2', 7'-dichlorofluorescein in ethanol. Lipid spots 
corresponding to standard phospholipid bands were viewed and marked under UV lights 
and scraped into clean ·Pyrex tubes. 
3.2.6 Conversion of lipids into methyl esters (FAMES) 
To each tube (above), 2 ml of 1 % sulfuric acid in methanol (v/v) and 1 ml of toluene 
were added to solubilize the triacylglycerols. Each tube was flushed with N2, mixed by 
vortexing in tubes tightly sealed with Teflon-lined screw caps and heated at 50°C 
overnight. After chilling the tubes briefly on ice, 5 ml of hexane containing 0.01 % 
BHT and 2 ml of KHCO3 (2%, w/v) were added. After thorough shaking of tubes, 4 ml 
of the upper organic layer was transferred into pre-weighed vials and evaporated to 
dryness. Lipid extraction was repeated by the addition of 3 ml of hexane containing 
0.01 % BHT and 1 ml of KHCO3 (2%, w/v). 3 ml of the upper layer was combined with 
the previous extract and re-evaporated to dryness under nitrogen. Vials were re-
weighed and the total FAMES weight was calculated as the difference between the two 
weights. Methyl ester extracts were stored in hexane at a concentration of 10 mg/ml 
with nonadecanoic acid methyl ester (Cl9: 0) used as the internal standard, added as 
10% of the total mass of FAMES in each sample (using 1 µM stock solution in hexane). 
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Fatty acid peaks were identified according to the retention times of standard compounds 
of methyl esters and quantified using C19: 0 as internal standard. 
3.2. 7 Gas-liquid chromatography 
Fatty acid methyl esters were analysed on a Perkin-Elmer 8320 gas chromatograph 
fitted with a capillary column (Zebron ZB-WAX, 100% polyethylene glycol, 30 m, 0.25 
mm ID, 0.25, µm FD and hydrogen as the carrier gas at 33 cm/s). The oven temperature 
was programmed from 160 °C to 240 °C at 4°C/ minute, holding at 240 °C for 10 
minutes. The flame ionization detector (FID) temperature was set to 300 °C, an 
injection volume of 2· µl, injection temperature of 290 °C and a split ratio of 100: 1. 
Fatty acids were identified according to the retention times of standard fatty acid methyl 
esters and quantified using C19:0 as the internal standard. 
3.3 RESULTS AND DISCUSSION 
The phospholipid fatty acid profile demonstrates that untreated U937 cells are relatively 
rich in the saturated - (14:0, 16:0 and 18:0) and monounsaturated - (16:ln-7; 18:ln-7 
and 18:ln-9) fatty acids whereas, they contain low levels of the polyunsaturated fatty 
acids (20:4, 20:5 and 22:6) (Table 3.1). The supplementation of culture medium with 
40 µM SA, OA, AA, EPA or DHA led to a rapid increase in the levels of the respective 
fatty acids incorporated into the phospholipid fractions of U937 cells. Yano et al., 2000 
showed that elevation in PUF A concentrations in cellular phospholipids -was 
accompanied by decreases in the levels of the saturated- and monounsaturated fatty 
acids found in U937 cell phospholipids. 
The incorporation of fatty acids especially the PUFAs (AA, EPA and DHA) into 
phospholipid fractions of U937 cells has previously been studied in detail (North et al., 
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1994; Obermeier et al., 1995; Yano et al., 2000). As such, this study was limited to 
demonstrating that these fatty acids (SA, OA, AA, EPA and DHA) are indeed readily 
and rapidly taken up by U937 cells in culture. Although the present study suggests that 
AA or EPA incorporated into cellular phospholipids post supplementation was higher 
than DHA levels, it is important to bear in mind that this study was not replicated. 
More so, previous studies have shown that DHA is easily taken up into U937 cell 
-phospholipiqs (North et al., 1994; Obermeier et al., 1995; Yano et al., 2000). 
Table 3.1 Fatty acid composition of the phospholipid fraction of U937 cells 
supplemented with or without 40 µM SA, OA, AA, EPA, DHA or ethanol (controls) for 
12 h. Values were expressed in µM based on the concentration of internal standard 
added. Values represent data from a single experiment (n = 1). 
Fatty acid supplement 
FA Control SA OA AA EPA DHA 
(µM) (None) 18:0 18: 1 (n-9) 20: 4 (n-6) 20: 5 (n-3) 22: 6 (n-3) 
14:0 0.87 0.41 0.33 0.56 0.51 0.42 
16:0 14.36 9.47 8.96 5.29 5.98 6.00 
16:1 (n-7) 2.32 0.75 0.82 1.07 1.02 0.85 
18:0 3.79 9.20 5.06 6.62 5.19 4.22 
18:1 (n-7) 2.41 2.08 2.04 3.26 4.81 2.65 
18:1 (n-9) 3.09 3.49 8.36 3.80 3.69 2.62 
18:2 (n-6) 0.27 0.20 0.20 0.23 0.19 0.30 
20:4 (n-6) 1.55 1.28 1.10 4.36 1.96 1.34 
20:5 (n-3) 0.20 0.39 0.20 0.26 4.41 0.59 
22:6 (n-3) 0.23 0.17 0.20 0.28 0.18 1.50 
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Since U937 cells normally have low levels of the polyunsaturated fatty acids (Fig. 3.1) 
namely: AA, EPA and DHA (North et al., 1994; Obermeier et al., 1995; Yano et al., 
2000), supplementation of the culture medium with these PDF As is required to increase 
the PDF A contents of these cells. 
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Fig. 3.1 Gas chromatographic traces of fatty acid methyl esters of control U93 7 
cell phospholipids in culture medium without fatty acid supplementation. A: myristic 
acid (14:0); B: palmitic acid (16:0); C: palmitoleic acid (16: ln-7); D: stearic acid (18 :0); 
E: oleic acid (18 : ln-9); F: vaccenic acid (18: ln-7); G: linoleic acid (18: 2); H: internal 
standard (19:0); I: arachidonic acid (20:4n-6); J: eicosapentaenoic acid (20:5n-3); K: 
docosahexaenoic acid (20:6n-3). 
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3.4 Conclusion 
In conclusion, this study has shown that U937 cells are capable of incorporating freely 
available fatty acids including the PUFAs (AA, EPA and DHA) into their cellular 
phospholipids after 24 h of incubation at 37°C and 5% CO2 in a humid environment. 
This information shows that these cells possess basal. phospholipase and 
lysophospholipase activity under normal incubation conditions. 
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C~PTER 4: LIPID PEROXIDATION EXPERIMENTS (MEASUREMENTS 
OF LIPID HYDROPEROXIDES) 
4.1 INTRODUCTION 
Lipids have fundamental structural and functional roles in all membranes including 
those of _neuronal cells. Lipid peroxidation in biological membranes is considered to be 
one of the major mechanisms of cellular injury in organisms subjected to oxidative 
stress (De Zwart et al., 1999). The oxidation of PUFA-rich lipids and their 
susceptibility to oxidative damage varies between humans, their red blood cells, low-
density lipoproteins, in health and disease states. Lipid peroxidative stress in the 
nucleus may contribute to histone modification such as amino acid oxidation, protein-
protein cross links and.DNA-protein cross links. Nucleosome histones protect the DNA 
from free-radical mediated damage (Enright et al., 1992) and histone detachment/re-
attachment are closely linked with transcription and replication. Furthermore, this 
"shuttling of histones" contributes to DNA repair and thus requires functionally intact 
proteins. It has been demonstrated that oxidatively-modified histones have the ability to 
damage DNA directly by cross linkage (Jones et al., 1993; Altman et al., 1995). 
Therefore, the -selective and efficient degradation of oxidatively damaged nuclear 
proteins, possibly due to lipid peroxidation, appears to be essential for the maintenance 
of genomic integrity (Ullrich et al., 2000). The chemical mechanism of lipid 
peroxidation involves three stages: initiation, propagation and termination. 
Lipids+ R• ---► L• 
---► LOO• 
LOO• + Lipids L• + LOOH 
Where R • is the radical initiator, L•, the lipid radical, LOO•, the lipid peroxide radical 
and LOOH, the lipid hydroperoxide. 
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It is now widely accepted that cellular damage induced by uncontrolled iron-catalysed 
free-radical-mediated oxidative stress is implicated in an array of pathological diseases 
including inflammatory disorders (Blake et al., 1983; Trenam et al., 1992), 
atherosclerosis (Smith et al., 1992; Witztum, 1994) and neurodegenerative disorders 
(Olanow and Arendash, 1994; Behl et al., 1994; Gerlach et al., 1994; Gassen and 
Youdim, 1997). The generation of free radicals and subsequent oxidative modification 
of biomolecµles such as lipids, proteins and nucleic acids is inevitable for aerobic 
organisms. While low levels of free radicals have proved to be involved in important 
physiological functions such as signal transduction leading to gene expression and cell 
proliferation (Suh, et, al., · 1999; Brar, et al., i999), excessive amounts have been 
implicated in a variety of pathological conditions including schizophrenia (Mahadik and 
Mukherjee, 1996a; Ramchand et al., 1996; Mahadik et al., 2001). Schizophrenia is a 
serious mental disease, the aetiology of which is yet unknown. Growing evidence 
indicates that disturbed phospholipid metabolism contributes to the disorder (Horrobin, 
1996). Several studies have reported controversial results in the levels of essential fatty 
acids in schizophrenic patients but more consistent is the finding of reduced linoleic 
acid (18: 2 n-6), AA (20: 4n-6) and DHA (22: 6n-3) in erythrocyte membranes and 
plasma of schizophrenic patients (Glen et al., 1994; Peet et al., 1995; Fenton et al., 
2000). Since the brain has high oxygen consumption, and is rich in lipids and transition 
metals, it is at particular risk of oxidative damage. Elaborate antioxidant defense 
systems exist therein to protect against oxidative stress. Lipid peroxidation has also 
been implicated in schizophrenia by the finding of increased levels of TBARS and 
exhaled pentane in expired air (Kovaleva et al., 1989; Phillips et al., 1993), suggesting 
an increase in membrane phospholipid breakdown (Glen et al., 1994). 
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Free radicals are unstable molecules implicated in many neurodegenerative diseases 
such as schizophrenia, Alzheimer's disease and Parkinson's disease. Just as free radical 
damage to heart and blood vessels may lead to heart attacks (Heinle et al., 2002), attack 
on brain cells may impair mental acuity over time. In fact, the brain may bear the brunt 
of free· radical damage since it is highly enriched with PUFAs, a favourite target for 
these radicals. 
Biological systems have evolved complex protective strategies against free radical-
induced damage, which is kept in check by the antioxidant defense system, comprising 
the enzymatic and non.:.enzymatic components. The putative nature of this system 
involving antioxidant dietary nutrients such as ascorbic acid, a-tocopherol and the 
carotenoids (such as ~-carotene and astaxanthin), could disarm the harmful free radicals 
before the damage occurs in neuronal cells. ~-carotene (for the carotenes) and 
astaxanthin (for the xanthophylls) were used as medium supplements in this study to 
determine the antioxidant activities of carotenoids. Burton and Ingold, (1984), first 
proposed the mechanism by which carotenoids might quench lipid radicals in biological 
cell membranes. It involves the transfer of excitation energy from singlet oxygen (10 2) 
to the carotenoid, resulting in the formation of the carotenoid triplet (Krinsky, 1988): 
+ Carotenoid + 3Carotenoid 
In a subsequent reaction, the excitation energy is harmlessly dissipated through 
rotational and vibrational interactions between the carotenoid triplet and the solvent, 
thus regenerating the original carotenoid molecule: 
3Carotenoid ► Carotenoid + heat. 
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In this way, carotenoids can act in a catalytic manner, neutralizing the potentially 
. . 
harmful singlet oxygen molecule (Foote et al., 1970), and thereby function as an 
antioxidant preventing oxidation reactions. The limits on this type of protection appear 
to be the number of conjugated double bonds in the molecule, with a maximum 
protection being seen with those having nine or more such bonds. The presence of 
additional functional groups on these molecules, such as allylic or non-allylic hydroxyl 
groups, does, not seem to alter the quenching characteristics of carotenoid pigments 
(Krinsky, 1995). 
If carotenoids functioned truly in a catalytic fashion in this reaction, cells and animals 
could obtain a lifetime supply of protection by synthesizing or ingesting a sufficient 
supply of carotenoid pigment to quench all of the available '02• However, this is not 
possible because there is a chemical reaction in addition to the physical reaction which 
limits the ability of carotenoids to protect against '02 (Foote 1970) thus destroying the 
carotenoid molecule in the process. Under physiological oxygen tensions, the reaction 
rate of carotenoids with peroxyl radicals appears to be sufficient to prevent the 
abstraction of allylic hydrogens from neighboring lipids thus, inhibiting lipid 
peroxidation (Burton, 1989). 
U937 cells are known to contain glutathione (GSH), a non-enzymatic antioxidant 
(Nardini et al., 1998). T-BHP-ind~ced oxidative stress has been reported to result in the 
depletion and oxidation of intracellular GSH in U937 cells (Latour et al., 1995; Nardini 
et al., 1998). It is generally accepted that ascorbic acid, a-tocopherol, ~-carotene and 
astaxanthin act as antioxidants in the protection of biological membranes from free 
radical-mediated damage. Ascorbic acid (vitamin C) concentration in healthy human 
plasma is about 200 µM with the brain having the highest concentration compared to 
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other tissues (Mahadik and Scheffer, 1996). a.-tocopherol, like the carotenoids f3-
carotene and astaxanthin are lipid-soluble and therefore effectively prevent plasma and 
lipid peroxidation (Burton and Ingold, 1984; Terao, 1989; Burton and Ingold, 1990). 
Although the detailed mechanisms by which free radicals lead to cellular oxidative 
damage are not yet fully understood, lipid peroxidation in cell membranes is considered 
to be critically involved (De Zwart et al., 1999). There are several ways of monitoring 
lipid peroxidation, including: the determination of oxygen uptake, loss of lipid 
substrates such as PUP As and the accumulation of peroxidation by-products such as 
hydroperoxides and thiobarbituric acid reactive substances (TBARS). As shown in 
chapter three, U937 cells are relatively poor in polyunsaturated fatty acids. Thus, 
culture medium was supplemented with PUP As with or without antioxidants before the 
induction of oxidative stress. In this chapter, the susceptibility of biological samples to 
lipid peroxidation was determined by the exposure of PUPA-enriched U937 cells to the 
lipid peroxidation initiator (t-BHP/Fe2+) and lipid hydroperoxides produced were 
measured colorimetrically. The antioxidant efficiency of ascorbic acid, a.-tocopherol, 
f3-carotene and astaxanthin in preventing the accumulation of lipid hydroperoxides in 
PUPA-enriched U937 cells was also studied. 
Tissue measurements of lipid peroxidation in systems exposed to oxidative stress differ 
considerably in the sensitivity of the method employed. It may be determined. by 
measuring the initial products of lipid peroxidation such as conjugated dienes and lipid 
hydroperoxides or the lipid peroxidation breakdown products such as aldehydes. The 
method employed in this study detects lipid hydroperoxides using the ferrous 
oxidation/Xylenol orange (FOX) method (Jiang et al., 1991). Samples were subjected 
to oxidative stress by a system containing tert-butyl hydroperoxide (t-BHP) and Fe2+. 
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Iron, though required for normal cell growth and proliferation, is potentially harmful in 
excessive amounts, catalysing the formation of free radicals via Fenton chemistry (Linn, 
1998). The exposure of hydroperoxides to transition metal ions such as copper or iron 
yields further reactive radicals including alkoxyl (LO•) and peroxyl (LOO•) radicals 
(Davies, 1996). Studies have shown that lipid hydroperoxides can give rise to further 
oxidative damage by propagative processes (Chapter one). U937 cell response to 
oxidative injury induced by. t-BHP (an organic hyreperoxide) and Fe2+, was 
investigated. Since it has previously been shown that U937 cells lose their cell 
membrane integrity in response to an oxidising mixture oft-BHP and FeSO4 (Chapter 
two), this chapter aims to examine the relationship between this loss and the 
accumulation of lipid hydroperoxides in cell membranes of models. 
Xylenol orange is a good chelator and quantitative indicator of a wide range of cations, 
including iron, binding Fe3+ but not Fe2+, at acidic pH, giving a coloured Fe (ill)-
xylenol orange complex (Gay et al., 1999). This reaction is insensitive to oxygen 
concentrations. To date most methods available for the measurement of lipid 
peroxidation have limitations either of reproducibility, sensitivity, rapidity or accuracy. 
For instance, the popular TBARS assay has been criticised for its lack of specificity and 
accuracy; and the nonexclusive, indirect and inefficient nature of MDA formation from 
lipid oxidation products. Since MDA is also a secondary product of oxidative injury to 
DNA and perhaps, other non-lipid biomolecules, its formation cannot be automatically 
indicative of lipid peroxidation in complex systems containing any potential non-lipid 
MDA source. This is particularly true if the system is exposed to harsh oxidative 
conditions primarily for the derivatization of MDA (Janero, 1990). 
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The goal of the present study was to investigate the sensitivity to induced peroxidative 
dama~e, in U937 cells, with or without fatty acid modifications of their cellular 
phospholipids. In addition, the study examined the effects of some dietary antioxidants 
on the susceptibility of these cells to oxidative stress, in vitro. This study describes a 
modified version of the FOX assay (Jiang et al., 1991), a rapid, sensitive and cost-
effective method for the measurement of lipid hydroperoxides (LOOH). The assay is 
based on the ,oxidation of Fe2+ by LOOH, in the presence of the dye, xylenol orange. 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
Xylenol orange (o-cresolsulfonephthalein-3-3 '-bis-(methyliminodiacetic acid sodium 
salt), ammonium iron (II) sulfate hexahydrate, hydrogen peroxide (H2O2), tert-butyl 
hydroperoxide (t-BHP), iron sulfate (FeSO4), butylated hydroxytoluene (BHT), stearic 
acid (SA), oleic acid (OA), arachidonic acid (AA), ascorbic acid, vitamin E, ~-carotene, 
astaxanthin, sulfuric acid (H2SO4) and HPLC-grade methanol (99 .9%) and ethanol 
(99.9%) were purchased from Sigma-Aldrich, UK. Eicosapentaenoic acid (EPA) and 
c;Iocosahexaenoic acid (DHA) were obtained from Nu-chek Prep., Denmark. 
4.2.2 Glass and plastic preparations 
All glassware used was washed in de-con and nano-pure water, autoclaved at 121 °C for 
30 min and dried in an oven before use. All other apparatus used were sterile with all 
experiments (prior to absorbance measurements) performed under a laminar flow hood 
(class II). 
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4.2.3 Ferrous oxidation/xyleilol orange (FOX) assay 
4.2.3.1 Preparation of FOX reagent 
1000 ml of reagent was prepared containing 900 ml of pure methanol, 100 ml of 0.25 M 
H2SO4, 0.88 g of BHT (in order to inhibit further peroxidation within the assay itself), 
0.076 g of xylenol orange, and 0.098 g of ammonium iron (II) sulfate hexahydrate. The 
FOX reagent was stored in Schott bottle at 2 - 8°C. 
4.2.3.2 FOX assay 
The standard assay protocol used for all U937 cell extracts follows: samples were 
sonicated for 3 x 10 s in an ice bath with an interval of 10 s and centrifuged at 250 g for 
2 min at 4°C. Thereafter, a sample: reagent mixture was prepared in a 1: 9 (v/v) ratio by 
transferring 0.02 ml (20 µl) of the supernatant into each well of a 96-well plate and 
adding 0.18 ml (180 µl) of the FOX reagent using a multi-channel pipette. Plates were 
carefully sealed with pressure-sensitive Costar plate-sealers and lids, and then wrapped 
with aluminium foil paper and incubated in the dark at room temperature for 12 - 24 h 
( overnight) unless stated otherwise. Absorbance at 560 nm was read using the EL340 
microplate reader and lipid peroxide concentrations calculated from Beer's law using an 
apparent extinction coefficient of 4.3 x 104 M-1cm-1 fort-BHP at 560 nm (Jiang et al., 
1991). 
4.2.4 Method validation 
4.2.4.1 Maximal time points 
In order to determine the maximum incubation time at room temperature required for 
the formation of Fe (ill)-xylenol orange complex, standard peroxides were used. 
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(A) With hydrogen peroxide (H202) 
A stock solution of 200 mM H2O2 was prepared and further diluted to 2 mM and then 
0.3 mM concentrations. All H2O2 solutions were stored in dark bottles at 2 - 8°C. 20µ1 
of 0.3 mM H2O2 was transferred into each well of a 96 - well plate and mixed with 180 
µI of FOX reagent (1: 9, v/v). The absorbance at 560 nm was immediately read over 45 
min at room temperature using the EL340 microplate reader. The final H2O2 
concentratioJ} per well measured over time was 30 µM. 
(B) With t-BHP: FeS04 
0.2 M t-BHP and 0.6 mM FeSO4 stock solutions were prepared in nano-pure water just 
before use. 0.2 Mt-BHP was further diluted to 0.6 mM in water. 10 µI each of 0.6 mM 
t-BHP and FeSO4 was mixed and transferred into a 96-well plate, and 180 µI of the 
FOX reagent was added using a multi-channel pipette. In order to determine the 
maximum time required for the formation of Fe (ill)-xylenol orange complex, 
absorbance was read at 560 nm at the indicated times over 24 h · with the EL340 
microplate reader at room temperature. Final concentration of t-BHP: FeSO4 per well 
was 30: 30 µM. 
(C) With increasing FeS04 levels 
A stock solution of 10 mM FeSO4 was prepared just before use. Concentrations varying 
from O to 1000 µM were prepared by serial dilution to a Jina~ volume of 20 µI, which 
was mixed with 180 µI of the FOX reagent in 96-well plates. Plates were incubated at 
room temperature for 30 min in the dark before absorbance was read at 560 nm. 
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4.2.5 Cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM L-
glutamine and 0.05 mg/ml gentamicin at 37°C in a humidified incubator with 5% 
CO2/95% air. For all experiments? cells were maintained at 0.5 x 106 cells/ml at 
viability > 90% by the Trypan Blue dye-exclusion method of viability measurements. 
4.2.6 Treatment of cells with t-BHP: FeS04 
Stock solutions of 2 mM t-BHP and 5 mM FeSO4 were prepared fresh just before use. 
Oxidative stress was induced by the addition of 0.9 ml of freshly prepared oxidant 
mixture in HBSS (or ·HBSS only as the controi) to 0.1 ml of HBSS - washed cell 
suspension in 24-well plates. Incubations followed at 37°C and 5% CO2 · in a humid 
environment. For the dose-dependent assay, cells were incubated with 0: 0 to 1000: 
1000 µM final concentrations oft-BHP: FeSO4 for 30 min under the conditions stated 
above. In order to determine the incubation time required for the generation of a 
detectable, significant increase in the amount of lipid hydroperoxides produced in U937 
cells incubated at 37°C under oxidative stress, a time course experiment was carried out 
with a final oxidant concentration of 750: 750 µM t-BHP: FeSO4 over 24 h. The O h 
experiment involved an immediate centrifugation of cell suspension after the rapid 
addition of the oxidant mixture to the cell suspension. 
All treatments were terminated by centrifugation at 250 g for 5 min at 4°C prior to the 
subjection of cells to oxidative stress. 
4.2. 7 Sample preparation 
U937 cell treatments post- oxidation (1 ml, final volume) were stopped by centrifuging 
at 250 g for 2 min at 4°C in 1.5 ml eppendorf tubes. 0.9 ml of supernatant was carefully 
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aspirated and discarded. Cell pellets (0.1 ml) were dislodged from the tube walls and 
resuspended in 5 times volume (0.5 ml) of ice-cold methanol (1: 5, v/v). Samples were 
stored immediately at-70°C for a maximum of 2 days prior to FOX analysis. 
4.2.8 -Enrichment of U937 cells with Fatty acids 
Fatty acids (SA, OA, AA, EPA or DHA) were complexed to fatty-acid-free bovine 
serum alburrvn (BSA) at a molar ratio of 2.5: 1 and supplemented with culture medium 
(CM). Fatty acid solutions were complexed to BSA because in vivo, these acids are 
transported in the blood bound to albumin. Ethanolic FA solutions ranging from 2.5 to 
10 mM were prepared from a 100 mM stock solution and stored under nitrogen after 
sterile filtration using nylon syringe filters. FA: BSA complexes were prepared by the 
addition of an equal volume of 2.5 - 10 mM of FA complexed with l -4 mM of BSA 
respectively and further diluted with CM to a final volume of 0.9 ml. FA-
supplemented culture medium (0.9 ml) was then added to 0.1 ml of cell suspension in 
each well of a 24 - well plate. Controls were cells incubated with 0.4% (v/v) ethanol 
only, representing the final ethanol concentration in all FA treatments, which has been 
shown to have no effect on cell viability as measured by LDH analysis (section 2.3.5.3). 
Each well contained 0.5 x 106 cells/ml. Cells were incubated for 24 hat 37°C and 5% 
CO2 in a humid environment. Final fatty acid concentration ranged from 10 to 40 µM. 
Cells were also incubated with 40 µM of each of the fatty acid: SA, OA, AA, EPA or 
DHA or ethanol only (controls) complexed to BSA at a molar ratio 2.5: 1. Incubations 
were performed in 24-well plates at.0.5 x 106 cells/ml. 
For all experiments, after 24 h of FA treatments, cells were washed twice in HBSS by 
centrifuging at 250 g for 5 min at 4°C and resuspended in 100 µl of HBSS. Cell 
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suspensions were then transferred from 1.5 ml eppendorf tubes into new and sterile 24-
well plates. 900 µl of HBSS only (without oxidants) or oxidant mixture in HBSS 
(freshly prepared from 2 mM t-BHP and 5 mM FeSO4 stock solutions, just before use) 
were carefully mixed with cell suspensions and incubated at 37°C and 5% CO2 for 30 
min in- a humid environment before sample preparation and FOX analysis. The final 
oxidant concentration in each well was 750: 750 µM oft-BHP: FeSO4• All reactions 
were termin~ted by centrifugation at 1000 g at 4°C for 2 min. Controls represent cells 
incubated with 0.4% (v/v) ethanol with or without the subjection to oxidative stress, as 
indicated. 
4.2.9 Supplementation of ascorbic acid, a-tocopherol, fl-carotene and astaxanthin 
with the culture medium of U937 cells 
4.2.9.1 With increasing antioxidant concentrations 
100 mM stock solutions of ascorbic acid in water, a-tocopherol in ethanol, (3-carotene 
and astaxanthin in chloroform_ were prepared. Ascorbic acid and a-tocopherol were 
stored at 2 - 8°C, while fl-carotene and astaxanthin at - 20°C. 4 - 16 mM ascorbic acid, 
10 - 40 mM a-tocopheroi and 3 -12 mM fl-carotene and astaxanthin were prepared by 
serial dilution. Culture medium (CM) was supplemented with aliquots of 4 - 16 mM 
ascorbic acid, 10 -40 mM a-tocopherol and 3 -12 mM fl-carotene or-astaxanthin, all to 
a final volume of 0.9 ml. Antioxidant supplemented CM (0.9 ml), was added to each 
well of a 24 - well plate containing 0.1 ml of cell suspension after appropriate 
treatments in the case of the carotenoids where 0.9 ml of carotenoid - supplemented 
CM was sonicated for 5 sin an ice-bath and sterile - filtered using nylon syringe filters. 
Each well contained 0.5 x 106 cells/ml. Final concentrations of antioxidants varied from 
0 - 400 µM for ascorbic acid, 0 - 40 µM for a-tocopherol and O - 12 µM for fl-carotene 
or astaxanthin. Antioxidant-supplemented CM cultured cells were incubated at 37 °C 
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and 5% CO2 in a humid environment for 10 min prior to the addition of 40 µM AA, 
EPA or DHA. Aliquots of 10 mM PUFAs (AA, EPA and DHA) were complexed with 
4 mM BSA (as performed earlier) and then added to the cell suspensions. The final 
volume of cell suspension/well was 1 ml. Plates were then incubated for a further 24 h 
in conditions stated above. FA-untreated controls were cells incubated with 0.4% (v/v) 
of ethanol only and FA-treated controls with 40 µM PUFA, both without antioxidant 
supplementation. For all experiments with antioxidants (single or mixture), both 
controls were subjected to oxidation as well as the other treatments. 
4.2.9.2 With individual antioxidants 
Cells were incubated with the highest concentration of antioxidants used above ( 400 
. . 
µM ascorbic acid, 40 µM a-tocopherol, 12 µM B-carotene or astaxanthin) and 40 µM 
levels of the PUFAs AA, EPA or DHA following the protocols described above and 
incubated for a further 24 hat 37°C and 5% CO2 in a humid environment. Each well 
contained 0.5 x 106 cells/ml. 
4.2.9.3 With antioxidant mixtures 
Cells were also incubated with a mixture of antioxidants for 10 min before CM 
supplementation with 40 µM PUFAs (AA, EPA or DHA) as described earlier. Controls 
were U937 cells incubated with 40 µM fatty acid only for 24 h without antioxidant 
supplementation. Final antioxidant concentrations used were 400 µM ascorbic acid, 40 
µM a-tocopherol, 12 µM B-carotene and 12 µM astaxanthin. 
For these sets of experiments with antioxidants, cells were washed twice in HBSS after 
24 h of treatments, by centrifuging at 250 g for 5 min at 4°C and re-suspended in 100 µ1 
of HBSS. Cell suspensions were then transferred from 1.5 ml eppendorf tubes into new 
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24-well plates for oxidation experiments. 900 µl of oxidant mixture in HBSS (prepared 
from 2 mM t-BHP and 5 mM FeSO4 just before use) were carefully mixed with cells 
suspensions and incubated at 37°C and 5% CO2 for 30 min before sample preparation 
and FOX analysis. All reactions were terminated by centrifugation at 1000 g for 2 min 
at 4°C.-
For all expef!ments with single antioxidants, both FA-untreated and FA-treated controls 
were .subjected to oxidation with 750: 750 µM t-BHP: FeSO4 as well as the other 
treatments. Likewise, in the case of antioxidant mixtures, controls were also oxidant-
stressed with the same radical system. 
4.3 RESULTS 
4.3.1 Maximal incubation time for the formation of xylenol complex 
Initial studies involved the use of hydroperoxide standards instead of the tissue extracts 
to study the mechanism of the formation of Fe(ill)-xylenol orange complex. This 
complex is formed by a reaction of H2O2 or the oxidation mixture (t-BHP + FeSO4) 
with Fe2+ in the presence of xylenol orange. Hydrogen peroxide was incubated with 
FOX reagent for 45 minutes at room temperature with readings at 560 nm, taken every 
5 min (Fig. 4.1). The colour obtained was stable overnight at room temperature. With 
H2O2, the reaction was complete in 15 minutes (One-way ANOV A: F = 3738.71, P < 
0.01, DF = 9). Tukey's pairwise comparison showed no significant increase in 
absorbance readings at 560 nm at times ~ 15 min. of incubation performed at room 
temperature. 
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Fig. 4.1 Colour development at room temperature using the FOX reagent with 30 
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FOX assay with standard 30: 30 µMt-BHP : FeSO4 at room temperature 
over 24 h. Means± 95% Cls of three independent experiments (n = 4). 
The maximal incubation time required for the formation of Fe (ID)-xylenol orange 
complex with the standard oxidant mixture oft-BHP and FeSO4, was determined by 
incubating the oxidants at a concentration of 30 : 30 µM with the FOX reagent. 
Absorbance was then measured at 560 nm over 24 h (Fig. 4.2). The reaction was 
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complete in 12 h (One-way ANOVA F = 593.84, P < 0.01, DF = 36). Tukey' s pairwise 
comparisons showed no significant increase in absorbance values at incubation times :2: 
12 hat room temperature. 
Hydrogen peroxide and t-BHP plus FeSO4 were used for standard peroxide 
measurements for the determination of the maximal incubation time required prior to 
absorbance readings. 
4.3.2 Standard curve of hydroperoxides 
Reactivity of hydrogen peroxide as a standard hydroperoxide with FOX reagent was 
tested after 30 min of incubation with the FOX reagent at room temperature. 
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Fig. 4.3 Standard curve of hydrogen peroxide (H2O2) in the 0 - 20 µM range. 
Peroxides were measured at 560 nm with the FOX assay. Means± 95% Cis of two 
independent experiments ( n = 3). 
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The data plotted in Fig. 4.3 fit a simple linear model (R2 = 0.998, P < 0.01). As 
expected there is a linear increase in absorbance monitored at 560 nm with increasing 
H2O2 concentration. 
4.3.2.2-With iron (II) sulphate FeS04 
In order to establish that standard FeSO4 on its own does not contribute to the colour 
development, observed with the oxidant mixture oft-BHP: FeSO4 and the FOX reagent, 
the FOX assay was performed with varying concentrations of FeSO4 (Table 4.1). There 
was no reaction observed in the assay FeSO4 concentrations ranging from 0 - 1000 µM 
after incubations for 30 min at room temperature· (Table 4.1). Results shown in Table 
4.1 confirm that Fe2+ must be oxidized by peroxides to Fe3+ to obtain the Fe (ill)-
xylenol orange complex. 
Table 4.1 Reactivity of_ iron (II) sulphate (FeSO4) in the FOX assay. 
Means± 95% Cls of duplicate experiments (n = 4). 
[Iron sulphate] 
0µM 
lOOµM 
500µM 
1000 µM 
Absorbance at 560 nm 
0.1475 ± 0.0044 
0.1468 ± 0.0012 
0.1465 ± 0.0030 
0.1483 ± 0.0040 
Data analysis by one-way ANOV A showed no significant difference between 
treatments (F = 0.21, P > 0.05, DF .= 3). Fe(II) on its own exhibited no reactivity with 
xylenol orange in the assay. 
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4.3.2.3 With the oxidant mixture (t-BHP: FeS04) 
To obtain a standard curve with the oxidant mixture, a 1:1 molar ratio oft-BHP: FeSO4 
with varying concentrations from 0 - 1000 µM levels was incubated at room 
temperature overnight with the FOX reagent prior to the measurements of absorbance 
(Fig. 4.4). There was a linear increase in absorbance monitored at 560 nm with 
increasing t-BHP: FeSO4 levels (R2 = 0.968, P < 0.01) confirming the expectation that 
the greater the concentration of peroxides, the higher the optical density measured with 
the FOX assay. 
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Fig. 4.4 Standard curve of t-BHP mixture with FeSO4 in a 1: 1 molar ratio at 
concentrations from 0 to 1000 µM. Data points represent means ± Cls of two 
independent experiments (n = 4). 
4.3.3 Treatment of cells with oxidants 
The next sets of experiments were designed to test that xylenol orange could be used to 
quantify lipid peroxides in U93 7 cell extracts. 
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4.3.3.1 Time-course assay with U937 cells 
For a time-dependent effect of the oxidant mixture (t-BHP: FeSO4) on the production of 
lipid hydroperoxides, cells were treated with 750: 750 µM oxidant mixture (1: 1 molar 
ratio) for varying incubation times from O to 24 h at 37°C and 5% CO2 in a humid 
environment (Fig. 4.5). 
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U937 cells incubated for varying time periods of O - 24 h with 750: 750 
µM oft-BHP: FeSO4 at 37°C and 5% CO2 in a humid environment. The amount of 
Fe(III)-xylenol orange complex formed after overnight incubation at room temperature 
was measured spectrophotometrically at 560 nm using the EL340 microplate reader. 
Points represent means± 95% Cis from duplicate, independent experiments (n = 4). At 
0 h, the oxidant mixture was added to the cells and the reaction was stopped by 
centrifugation immediately after its addition. Apparent extinction coefficient fort-BHP 
at 560 nm was 4.3 x 104 M 1cm-1 (Jiang et al., 1991). 
There is a significant increase in the accumulation of lipid peroxides with increasing 
incubation time of cells (Fig. 4.5) with the radical oxidizing system oft-BHP and FeSO4 
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(One-way ANOVA F = 74.00~ P < 0.01, DF = 7). Tukey's comparisons showed a 
significant difference between cells without oxidant and the O h treatment with oxidant. 
There was a significant increase in lipid peroxidation between the O h and 0.5 h 
treatments. There was no significant difference between results obtained after the 
incubation of cells with oxidants for 0.5 h and ~ 4 h treatments. At incubation times of 
1 h ~ 24 h however, results were not significantly different. A correlation of 
concentration of lipid peroxides with incubation time (0-24 h) showed an approximately 
linear response between variables {R2 = 0.81, P < 0.01). 
4.3.3.2 Dose-dependent assay of extracts from t-BHP: FeS04 treated U937 cells 
For the dose-dependent experiment of cell extracts, the amount of lipid hydroperoxides 
increased with increasing oxidant concentration ranging from 0/0 to 1000/1000 µM 
levels of t-BHP/FeSO4, as expected. Cells were treated in HBSS with oxidants and 
incubated for 30 min at 37°C and 5% CO2 prior to sample preparation for the FOX 
assay (Fig. 4.6). 
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Fig. 4.6 The effects of increasing concentrations of t-BHP:FeSO4 (1: 1 molar 
concentration) on the reduction of Fe (ID)-xylenol orange complex. Means± 95% Cls 
of two independent experiments ( n = 4). 
Statistical analysis showed a significant increase in the amount of lipid hydroperoxides 
with increasing oxidant concentration (One-way ANOV A F = 378.56, P < 0.01, DF = 
5). Tukey' s pairwise comparison failed to show any significant difference between 
controls (0/0 µM) and 50/50 µM of oxidant treatment after 30 min of incubation with 
cells at 3 7°C and 5%CO2 in a humid environment. However, there was a significant 
increase in the amount of lipid hydroperoxides obtained between each of the other 
treatments. A linear relationship was observed with increasing oxidant concentration in 
U937 cells oxidised for 30 min (R2 = 0.973, P < 0.01). 
149 
4.3.4 Fatty acid treatments 
4.3.4.1 With Oxidation 
In order to examine whether the amount of lipid hydroperoxide produced increases with 
rising fatty acid levels, cells were treated with 0 - 40 µM FA for 24 h prior to oxidation 
with 750: 750 µM of t-BHP: FeSO4 {Tables 4.2 and 4.3). Pre-oxidation, cells were 
washed twice in HBSS ( 4.2.8). 
Table4.2 Effects of 0 to 40 µM SA and OA treatments on the formation of lipid 
hydroperoxides. Means of lipid peroxide concentration (µM) ± 95% Cls of two 
independent experiments (n = 4). Controls were treated with 0.4% v/v ethanol for 24 h. 
Concentration SA OA 
Unoxidized control 2.6395 ± 0.0360 2.7209 ± 0.0335 
Oxidized control 7.1337 ± 0.0441 9.1453 ± 0.1000 
l0µM 7.1337 ± 0.0301 9.2413 ±0.0365 
20µM 7.1279 ± 0.0603 9.2238 ± 0.0834 
30µM 7.1657 ± 0.0377 9.2093 ± 0.0811 
40µM 7.1715 ± 0.0253 9.2180 ± 0.0459 
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Table 4.3 Effects of PUFA treatments on the formation of lipid hydroperoxides. 
Means (µM) ± 95% Cis of two independent experiments (n = 4). 
Concentration AA EPA DHA 
Unoxidized control 2.7064 ± 0.0440 2.6192 ± 0.0781 2.7151 ± 0.0389 
Oxidized control 6.8052 ± 0.0285 8.0581 ± 0.0246 8.1047 ± 0.0161 
l0µM 6.8198 ± 0.0237 8.0727 ± 0.0420 8.0959 ± 0.0365 
20µM 6.8692 ± 0.0388 8.1192 ± 0.0410 8.1366 ± 0.0504 
30µM 6.8663 ± 0.0197 8.2006 ± 0.0440 8.2248 ± 0.0675 
40µM 6.9797 ± 0.0459 8.2442 ± 0.0208 8.2267 ± 0.0400 
In tables 4.2 and 4.3, controls represent cells incubated with ethanol (0.4 %, v/v instead 
of the fatty acid) with ( oxidized control) or without (unoxidized control) oxidant 
mixtures. There was no significant increase in FOX reactive substances (FOXRS) with 
increasing SA (One-way ANOV A F = 0.94, P > 0.05, DF = 4) and OA (One-way 
ANOV A F = 0.96, P > 0.05, DF = 4), varying from 10 - 40 µM for 24 h when 
compared to oxidized controls. However, there was a marked increase in the formation 
of lipid peroxides in incubations with the oxidant mixture compared to oxidant-
untreated controls (Table 4.2). 
Treatment of cells with the polyunsaturated fatty acids AA, EPA and DHA for 24 h 
prior to oxidation for 30 min (Table 4.3), showed significant increase _in the formation 
of lipid hydroperoxides with increasing FA concentrations. For AA, (One-way 
ANOVA F = 16.73, P < 0.01, DF = 4); EPA (One-way ANOVA F = 19.60, P < 0.01, 
DF = 4) and DHA (One-way ANOV AF= 6.81, P < 0.01, DF = 4). In comparison with 
oxidized controls, there was a significant increase in FOXRS at AA concentrations 
equal to 40 µM, EPA and DHA levels ~ 30 µM. 
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It is noteworthy that comparisons employed in Tables 4.2 and 4.3 were only performed 
with increasing concentrations of the same FA and not between different FA treatments 
because experiments were performed on different days, using reagents made up on 
separate days and cells from different cell populations, thereby generating uncontrolled 
variations. Hence for these reasons, appropriate controls were included for each set of 
experiments and thus, in this study, lipid peroxide concentrations were calculated from 
Beer's law using an apparent extinction coefficient of 4.3 x 104 M-1cm-1 for t-BHP 
(Jiang et al. , 1991) at 560 nm. 
To investigate the degree of susceptibility of the five different fatty acids to 
peroxidation, CM was supplemented with 40 µM of each of the five fatty acids 
complexed with BSA in a 2.5 : 1 molar ratio, for 24 h. Cells were then washed twice in 
HBSS before further incubation for 30 min with 750: 750 µM t-BHP: FeS04 in HBSS 
(Fig. 4.7). 
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Fig. 4.7 FOX assay after 24 h treatment of U937 cells with 40 µM of each FA 
before oxidation for 30 min with t-BHP: FeS04. Means± 95% Cls (n = 4). The letters: 
a, b and c represent significant differences between means at P < 0.01 . 
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There was a significant difference with fatty acid treatments (One-way ANOV A F = 
68.12, P < 0.01, DF = 5). Tukey's pairwise. comparisons showed no significant 
difference between SA and OA compared to controls, confirming the results obtained 
earlier (Table 4.2). As expected, from results obtained in Table 4.3, there was a marked 
increase in FOXRS with the PUFAs (AA, EPA and DHA) compared to controls, SA 
and OA. EPA and DHA treatments yielded results markedly higher than that obtained 
with AA, altµough there was no significant increase in FOXRS production between the 
two treatments (Fig. 4.7). The increase in the accumulation of lipid hydroperoxides 
with fatty acids suggests that the degree of unsaturation of fatty acid plays a critical role 
in lipid peroxidation susceptibility of the U937 monocyte cells. 
4.3.4.2 Without oxidation 
In order to determine the effects of fatty acid treatments without oxidation, U937 cells 
were pre-treated with and without 10 µM levels of the five different fatty acids (SA, 
OA, AA, EPA and DHA) for 24 h, washed twice in HBSS and re-suspended in HBSS 
only for 30 min (Fig. 4.8). 
In Fig. 4.8, controls represent cells treated with the vehicle only (0.4% v/v, ethanol) for 
24 h. There were no significant differences in the accumulation of lipid peroxides after 
30 min when compared to their respective controls (0 µM) with SA (T = 2.44, P > 0.05, 
DF = 6); OA (T = 1.86, P > 0.05, DF =6) and AA (T = 0.35, P > 0.05, DF = 6). 
However, in comparison to their controls, the concentration of lipid peroxides decreased 
significantly with EPA and DHA treatments: EPA (T = 4.55, P < 0.01, DF = 6); DHA 
(T = 3.61, P < 0.05, DF = 6). With EPA versus control, there was 7.3% decrease and 
7.8% with DHA versus control. 
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Interestingly, EPA and DHA appear to suppress lipid peroxidation without induced-
oxidation but produce a revered effect upon oxidative stress. Taken together, studies 
show that increasing accumulation of lipid hydroperoxides observed with the PUF As is 
as a combined effect of the PUF As and oxidants, as expected. 
4.3.5 With antioxidants 
To characterize the antioxidant effects of ascorbic acid, a-tocopherol, P-carotene and 
astaxanthin, U93 7 cells were incubated with these antioxidants IO min before 40 µM 
PUF A supplementation. After 24 h, the production of lipid hydroperoxides was 
monitored spectrophotometrically at 560 nm after the subjection of cells to oxidation for 
30 min with 750: 750 µM t-BHP: FeSO4 at 37°C. Antioxidant concentrations chosen 
were dependent on LDH results obtained in chapter two. Figs. 4.9 to 4.12 show the 
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effects of varying the concentrations of either the water-soluble (ascorbic acid) or lipid-
soluble ( a-tocopherol, f3-carotene and astaxanthin) antioxidants on the formation of 
lipid hydroperoxides as monitored at 560 nm from U937 cells incubated with oxidants 
for 30 min at 37°C. Having established the marked difference between FA-untreated 
cells treated with and without oxidants (Tables 4.2 and 4.3), subsequent experiments do 
. not report data for controls with vehicle-treated cells without the oxidant. 
(A) With ascorbic acid 
The effect of the addition of O - 400 µM ascorbic acid in cells exposed to 750: 750 µM 
t-BHP: FeSO4 is shown in Fig. 4.9. When ascorbic acid treatments were compared with 
oxidized FA-treated controls, Tukey's pairwise comparisons showed a significant 
decrease in the total hydroperoxide formed in U937 cells with 400 µM ascorbic acid 
concentration for all three PUFAs: AA (One-way ANOV A F = 38.30, P < 0.01, DF = 
5); EPA (One-way ANOVA F = 78.88, P < 0.01, DF = 5); DHA (One-way ANOVA F 
= 59.83, P < 0.01, DF = 5). The presence of AA, EPA or DHA in U937 cells gave 
significantly higher lipid hydroperoxide values than incubations without PUFA 
supplementation. 
(B) With a-tocopherol 
Methanolic-extracts from cells incubated with O - 40 µM a-tocopherol for 24 h were 
analysed for lipid hydroperoxide using the colorimetric assay based on Fe (III)-xylenol 
orange complex formation post oxidation with 750: 750 µM t-BHP: FeSO4 for 30 min 
(Fig. 4.10). Co-treatment with AA, significantly suppressed the formation of lipid 
hydroperoxides at a-tocopherol ~ 10 µM below that obtained with oxidized FA-treated 
controls (One-way ANOVA F = 9.04, P < 0.01, DF = 5). In fact, there was no 
significant difference between unoxidized FA-untreated controls and a-tocopherol 
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levels ~ 10 AM. At 40 µM a-tocopherol, there was a significant decrease by 7 .5 % in 
the accumulation of FOXRS comp~ed to unoxidized FA-treated controls. With EPA 
(One-way ANOVA F = 7.13, P < 0.01, DF = 5), there was no significant difference 
between unoxidized FA-untreated controls and 10 - 40 µM a-tocopherol treatments. 
Similarly, in incubations containing DHA (One-way ANOV AF= 5.29, P < 0.01, DF = 
5), Tukey' s pairwise comparisons showed a significant reduction in the formation of 
lipid hydroperoxides at a-tocopherol concentrations > 10 µM when compared to 
oxidized FA-treated controls. The dose-dependent decrease in the accumulation of 
FOXRS observed in extracts with increasing a-tocopherol levels as monitored at 560 
nm was, however, not significantly different between the concentrations used. 
( C) With P.carotene 
In order to test that the pre-treatment of U937 cells with ~-carotene for 24 h induces 
potent antioxidant effects, cells response to oxidation with 750: 750 µMt-BHP: FeSO4 
for 30 min was assessed for the production of lipid peroxides by the FOX assay. As 
shown in Fig. 4.11, treatment of cells with 3 - 12 µM ~-carotene led to a decrease in the 
amount of lipid hydroperoxides generated. With 40 µM AA (One-way ANOV A F = 
41.05, P< 0.01, DF = 5), Tukey's pairwise comparisons showed a concentration-
dependent decrease in lipid peroxidation with increasing ~-carotene levels, significantly 
different at concentrations> 9 µM when compared with oxidized FA-treated controls. 
At 12 µM ~-carotene there was a 15.8 % decrease in the concentration of FOXRS when 
compared to unoxidised FA-treated controls and this was significant. With 40 µM EPA 
(One-way ANOV A F = 4.88, P < 0.05, DF = 5), a significant decrease in lipid 
peroxidation was observed with 12 µM ~-carotene treatment, compared to oxidized FA-
treated controls. Experiments with 40 µM DHA (One-way ANOV A F = 18.02, P < 
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0.01, DF = 5), produced a dose-dependent decrease in the accumulation of lipid 
hydroperoxides with increasing (3-carotene, significant at 12 µM levels. 
(D) With astaxanthin 
To examine whether the presence of 0 - 12 µM astaxanthin conferred protection against 
oxidative stress induced by 750: 750 µMt-BHP: FeSO4, U937 cells were pre-treated 
with astaxanthin and PUFAs for 24 h prior to oxidation for 30 min. Fig. 4.12 shows 
astaxanthin as a potent antioxidant at 12 µM when compared to oxidized FA-treated 
controls. With AA (One-way ANOV A F = 43.72, P < 0.01, DF = 5), there was a 
significant decrease in' lipid peroxidation at 12 µM astaxanthin compared to unoxidized 
FA-treated controls. Similarly, with EPA(One-way ANOVA F = 16.99, P < 0.01, DF = 
5) and DHA (One-way ANOV A F = 6.26, P < 0.01, DF =5) there was a significant 
reduction in induced peroxidation at 12 µM astaxanthin concentrations. 
For all experiments with antioxidants, there was a significant increase in lipid 
peroxidation with oxidized FA-treated controls when compared with unoxidized FA-
treated controls. 
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4.3.5.1 Comparison of individual antioxidant effects 
To compare the antioxidant activities of ascorbic acid, a-tocopherol, f3-carotene and 
astaxanthin, cells were pre-treated with these antioxidants and AA, EPA or DHA for 24 
h, after which they were exposed to 750: 750 µMt-BHP: FeSO4 in HBSS and incubated 
for 3ff min at 37°C and 5% CO2 in a humid environment. Final antioxidant 
concentrations used were 400 µM ascorbic acid, 40 µM a-tocopherol, 12 µM f3-
carotene and 12 µM astaxanthin. The ability of these antioxidants to inhibit lipid 
oxidation was evaluated with the FOX assay at 560 nm. 
The presence of the · four antioxidants markedly inhibited the generation of lipid 
hydroperoxides when U937 cells were oxidatively stressed. The amounts of lipid 
hydroperoxide produced after the incubation of U937 cells with either 400 µM ascorbic 
acid, 40 µM a-tocopherol, 12 µM f3-carotene or 12 µM astaxanthin coupled with the 
PUFAs (AA, EPA or DHA) for 24 h before oxidation, were determined (Fig. 4.13). 
Comparative measurements of antioxidant activity after t-BHP/Fe2+ induced 
peroxidation indicated that 12 µM astaxanthin was.the most powerful antioxidant in all 
three experiments with AA (One-way ANOVA F = 53.14, P < 0.01, DF = 5); EPA 
(One-way ANOVA F = 17.53, P < 0.01, DF = 5); or DHA (One-way ANOVA F = 
36.58, P < 0.01, DF = 5). All antioxidant treatments gave significantly lower 
concentrations of FOXRS compared to oxidized FA-treated controls in the following 
order: ascorbic acid < a-tocopherol < f3-carotene < astaxanthin for all three PUF As 
(AA, EPA and DHA). 
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4.3.5.2 With a combination of antioxidants 
To study the interactive effects ·between antioxidants, combinations of two different 
agents were incubated with U937 cells in addition to PUFA (AA, EPA or DHA) for 24 
h prior to oxidation (Figs. 4.14 to 4.16). The relationship between optical density and 
the amount of hydroperoxide produced was evaluated when antioxidant mixtures were 
incorporated into U937 cells. The most potent combination of antioxidants against lipid 
·peroxidation,induced by the radical-mediated system of t-BHP/Fe2+ in U937 cells was a 
mixture of ascorbic acid (vc) and a-tocopherol (ve). For AA (Fig. 4.14) (One-way 
ANOVA F = 64.76, P < 0.01, DF = 9); EPA (Fig. 4.15) (One-way ANOVA F = 151.96, 
P < 0.01, DF =9) and DHA (Fig. 4.16) (One-way ANOVA F = 67.56, P < 0.01, DF = 9). 
Charts show the antioxidant power in an ascending order of magnitude (Figs. U-W). 
With AA, there was a 63% reduction in hydroperoxide yield with a combination of 
ascorbic acid and a-tocopherol compared to controls, whereas individually, there was a 
19.9% and 35.7% decrease with ascorbic acid and a-tocopherol respectively suggesting 
a synergistic activity of these two antioxidants. In the same manner, results from EPA 
experiments yielded a 46.4% decrease with vc+ve compared to controls, and 17.4% or 
17.6% with ascorbic acid or a-tocopherol respectively. Furthermore, DHA treatments 
with a mixture of vc+ve resulted in a 47% decrease compared to controls and 16% or 
21 % decrease with vc (ascorbic acid) or ve (a-tocopherol) alone respectively. From the 
three experiments with AA, EPA or DHA, all antioxidant combinations yielded better 
antioxidant effects than that obtained with individual treatments (Figs. 4.14 to 4.16). 
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Overall, the fat-soluble antioxidants (a-tocopherol, (3-carotene and astaxanthin), on their 
own conferred a better antioxidant protective effects against the formation of lipid 
hydroperoxides initiated by the radical oxidizing system of 750: 750 µMt-BHP: FeSO4 
than the water-soluble antioxidant (ascorbic acid). 
4.4 DISCUSSION AND CONCLUSION 
The purpose, of this study was to assess the susceptibility of U937 cells to oxidative 
stress after cellular enrichment with the polyunsaturated fatty acids AA, EPA and DHA 
for 24 h. A second objective was to determine the effectiveness of the antioxidants: 
ascorbic acid, a-tocopherol, (3-carotene and astaxanthin, both individually and as 
mixtures in the U937 cell model. 
In the FOX-modified assay used here to study lipid peroxidation, hydrogen peroxide 
and tert-butyl hydroperoxide were used as standard peroxides for the determination of 
the incubation time required for the completion of Fe (Ill)-xylenol orange complex 
formation. With H2O2, the reaction was complete in 15 min whereas i_t took 12 h fort-
BHP. Since oxidation· in U937 cell model was induced with the t-BHP/Fe2+ system, 
measurement at 560 nm of Fe (ill)-xylenol orange complex formed was performed after 
incubation at room temperature for 12 - 24 h in the dark, based on th_e results obtained 
in Fig. 4.2. A standard curve with increasing concentrations of H2O2 (Fig. 4.3) or t-
BHP/Fe2+ (Fig. 4.4) gave good positive correlations with absorbance at 560 nm, 
showing an increase in optical density with increasing hydroperoxide concentration. 
FOX assay with FeSO4 alone yielded no increase in colour intensity therefore, showing 
that the presence of Fe (II) in the standard oxidant mixture did not contribute to the 
increasing optical density obtained with t-BHP/Fe2+ radical system employed. 
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This research shows that lipid hydroperoxides can be detected after 30 min of 
incubating U937 cells with 750: 750 µMt-BHP: FeSO4 when compared to the 0 h 
experiment (in which the oxidant mixture was added and the reaction stopped 
immediately) by the FOX· assay (Fig. 4.5). The accumulation of lipid hydroperoxides 
increased with time. As expected, the concentration of lipid peroxides increased with 
the exposure of U937 cells to increasing oxidant concentrations (Fig. 4.6). The 
exposure of :t.J937 cells tot-BHP has previously been reported to give a dose- and time-
dependent increase in lipid peroxidation by-products (Nardini et al., 1998; Spickett et 
al., 2001), and this is supported by the results obtained in the present study. The 
amount of lipid hydroperoxide produced was found to be dependent on the severity and 
length of the oxidative treatment. Spickett et al (2001) su~jected U937 cells to t-
BHP/Fe2+ levels varying from 0.05 to 1 Mt-BHP and 0.01 M Fe2+ levels to obtain total 
ion current (TIC) traces by LC-MS to detect lipid oxidation. This suggests that U937 
cells are quite resistant to high levels of oxidation over short time courses (Spickett et 
al., 2001). This is not surprising because these cells are phagocytes, capable of 
generating oxidants for anti-microbial defence and thus may be expected to possess 
inherent antioxidant protection. 
A concentration of 750: 750 µMt-BHP: FeSO4 was chosen based on viability results 
obtained in chapter two. On the basis that this concentration had a significant effect on 
LDH leakage in U937 cells compared to controls, the efficacy of antioxidants in 
affecting the accumulation of lipid hydroperoxides was tested in response to a 
substantial degree of oxidative stress, induced with the above concentration. From now 
· on, this oxidative condition of t-BHP/Fe2+ (750/750 µM) treatment will also be referred 
to as the oxidant mixture. Alkoxyl and peroxyl radicals produced by the oxidant 
mixture initiate lipid peroxidative processes (Latour et al., 1995). 
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4.4.1 Fatty acid treatments · 
In comparison to untreated controls, pre-treatment for 24 h with 10 µM EPA or DHA 
significantly reduced the generation of lipid peroxides whilst there were no differences 
observed with SA, OA or even AA when cells were incubated in HBSS only without 
oxidation (Fig. 4.8). The notion that the PUFAs purchased from the manufacturer were 
partially oxidised, as previously suggested in chapter two, is ruled out here. · This 
suggests tha~ the presence of these long chain, highly-unsaturated fatty acids (EPA and 
DHA) in cell membranes influences a number of membrane functions including 
affecting membrane permeability· to electrolytes and non-electrolytes (Williams and 
Hazel, 1993) present in the surrounding environment (CM) some of which may induce 
lipid peroxidative damage, under normal conditions without oxidation. On the other 
hand, the incubation of U937 cells with SA or OA showed no significant difference in 
lipid peroxidation compared to controls when challenged with oxidants. However, 
enrichment with equal amounts of PUFAs (AA, EPA and DHA) increased the 
susceptibility of these cells to peroxidative damage, which increased linearly with the 
degree of unsaturation (Fig. 4.7). This is consistent with the study by Maziere et al 
(1998) who reported elevations in intracellular lipid peroxidation products in low-
density lipoproteins. Hsu et al. (2000) found that cultured U937 cells mainly contained 
fatty acids with 14 - 18 carbon atoms and PUFAs such as AA, present only as minor 
components. It can therefore be said that the treatment of U937 cells with PUFAs AA, 
EPA and DHA makes the cells more susceptible to oxidative damage, in terms of the 
content of lipid hydroperoxides produced. 
This study demonstrates that under equal conditions of oxidative stress, fatty acids 
oxidize at different rates and produce lipid hydroperoxides in a manner related to their 
degree of unsaturation. In agreement with this study is the finding that the production 
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of lipid _peroxides, as evaluated by an iodometric method, was higher with the PUF As 
(AA, EPA and DHA) in comparison to SA and OA (Visioli et al., 1998). However, that 
study reported lower peroxide levels with EPA compared to AA and DHA when 
oxidation was stimulated with - 2, 2'-azo-bis-(2-amidinopropane) dihydrochloride 
(AAPH) in non-esterified fatty acid micelles in vitro. In contrast, an increase in the 
formation of lipid hydroperoxides was found with increasing fatty acid unsaturation 
using U937 ,cell models (Fig. 4.7). The results obtained by Visioli et al (1998) may 
have been due to the system employed because fatty acids in biological cell membranes 
are present in esterified forms in triacylglycerols, phospholipids and cholesterols thus 
affecting their susceptibility to oxidative stress. 
This study clearly demonstrates that U937 cells pre-cultured with PUFA of the n-6 
(AA) and n-3 (EPA and DHA) series are more susceptible to peroxidative damage as 
evaluated by the FOX assay after the exposure of FA-enriched U937 cells to t-BHP/Fe2+ 
radical system for 30 min. Glycerophospholipids in the adult brain account for ::::: 20-
25% of the dry weight (Farooqui et al., 2000). Most PUFAs used by the brain for the 
synthesis of these glycerophospholipids are not made in the central nervous system 
(CNS), but are transported there from the gastrointestinal tract (Horrocks and Yeo, 
1999), from the diet or produced in the liver. Free radicals target cellular components 
indiscriminately, including lipids, proteins and DNA. Hydroperoxides, produced from 
these reactions can further decompose over time to other toxic substances such as 
malonyldialdehyde, which can damage adjacent cells, membrane-bound enzymes and 
receptors, resulting in membrane breakdown, cytotoxicity and enzyme modification 
(Ernster, 1993). It is, therefore, not surprising that there is growing evidence in support· 
of free radical mediated damage in schizophrenia (Reddy and Yao, 1996), a disease also 
with an impaired antioxidant defense mechanism (Reddy et al., 1991). 
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4.4.2 Antioxidants 
The effectiveness of an antioxidant has been attributed partly to the intrinsic chemistry 
of the compound and partly to the environment in which that chemistry' is expressed. 
The lipid-soluble antioxidants used in this study were added to CM as solutions in 
organic solvents; ethanol for a-tocopherol and chloroform for the carotenoids. Since 
chloroform is immiscible with water, the solvent problem was circumvented by 
sonicating the carotenoid - supplemented CM, briefly in an ice bath, into small micelles 
prior to U937 cell addition, aiding cellular uptake. Carotenoids are unstable and the 
stock solutions may change over time due to oxidative breakdown or the carotenoid 
may come out of the solution due to its tendency to crystallize when stored at -20°C in 
the freezer (Hess et al., 1991). To overcome this problem, stock solutions were stored 
only for 2 months at -20°C. 
Populations with low intakes of dietary antioxidants such as vitamins C, E and f3-
carotene appear to have a higher risk of early development of degenerative diseases 
commonly associated with aging (Gey, 1993; Heliovaara et al., 1994). A number of 
·human, animal and in vitro studies have demonstrated the protective effects of f3-
carotene against lipid peroxidative damage (Kunert and Tappel, 1983; Franke et al., 
1994). Supplementation of rats with 1 g/kg body weight of astaxanthin reduced the 
lysis of red blood cells subjected to oxidative stress (Miki, 1991). Also dietary 
supplementation with f3-carotene has been shown to protect mice against lipid 
peroxidation induced by methyl mercuric chloride (Anderson and Anderson, 1993) and 
to reduce the concentration of biomarkers of lipid peroxidation detected in serum 
(Mobarhan et al., 1990; Gottleib et al., 1993) and pentane in exhaled breath (Allard et 
al., 1994) in human subjects. 
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Ascorbic acid, a-tocopherol, (3-carotene and ~staxanthin have received considerable 
attention as putative antioxidants with _the ability to attenuate oxidative stress, 
ameliorating cellular dysfunction resulting from free-radical induced oxidative injury to · 
cellular components. Biological antioxidants can be grouped into two groups: 
preventive - and chain - breaking antioxidants. Preventive antioxidants reduce the 
initiation of lipid peroxidation by suppressing the production of chain-initiating radicals 
whilst the other group interferes with propagative oxidative processes by trapping the 
chain -initiators and/or chain propagators (such as the alkoxyl and peroxyl radicals) of 
peroxidation (Niki, 1987). Carotenoids are generally classified as preventive 
antioxidants due to their ability to deactivate singlet oxygen responsible for the 
formation of lipid hydroperoxides (Foote and Denny, 1968), thus suppressing 
hydroperoxide-dependent lipid peroxidation (Terao et al., 1980; Matsushita and Terao, 
1980). Also, carotenoids are able to act as chain-breaking antioxidants (Krinsky and 
Deneke, 1982). 
a-tocopherol is a chain-breaking antioxidant which acts by trapping peroxyl radicals 
and in tum donating a hydrogen atom. ·on the other hand (3-carotene or related 
carotenoids, seems to act by a mechanism in which the chain-propagating peroxyl 
radical is trapped by the addition to the conjugated polyene system_ of the carotenoid 
other than by hydrogen donation (Burton and Ingold, 1984). The resulting carbon-
centered radical is stabilised by resonance because of the delocalisation of the unpaired 
electron in the conjugated carotenoid polyene-system leading to chain termination. 
Terao (1989) reported that astaxanthin was more resistant to oxidative chain reaction 
than (3-carotene, confirming the results obtained in this study (Fig. 4.13). At 
physiological concentrations, carotenoid contents of the human plasma are much higher 
than that found in some primates and non-primate mammals (Cutler, 1984). It has been 
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reported that the major carotenbid species of the human plasma include f3-carotene at 
0.1-0.2 µg/ml and lycopene at 0.2-0.5 µg/ml (Terao, 1989), concentrations much lower 
than those employed in this study. 
Ascorbic acid (vitamin C) acts as a_ chain-breaking antioxidant (Niki et al., 1984). 
Although vitamin C is a potent water-soluble antioxidant, at high concentrations it is 
also· known to act as a pro-oxidant, especially in the presence of iron (Carr and Frei, 
1999). In this study however, its presence in U937 cells inhibited lipid peroxidation, 
when the cells were exposed to oxidation mixture for 30 min in HBSS at 37°C and 5% 
CO2 in a humid environment. Vitamin E (also known as a-tocopherol) is more 
effective against lipid peroxidation than vitamin C (Niki et al., 1984). Vitamin Eis the 
major chain-breaking antioxidant found in biological membranes (Burton et al., 1983; 
Ingold et al., 1987). This property has been reported to depend primarily on the 
phenolic group in its chromanol ring, rather than the side-chain (Burton and Ingold 
1989; Niki et al., 1995b ). 
Humans accumulate both groups of carotenoids in the plasma and tissues. The 
distribution of each carotenoid is rather different among organs. For instance, 
zeaxanthin (ZX) and lutein were the major carotenoids in the macular area of the human 
retina, while a, f3-carotene, lycopene, cryptoxanthin, zeaxanthin (ZX) and lutein are 
dominant in the human plasma (Palace et al., 1999). The major storage organs for 
carotenoids are the liver and adipose tissues (Parker, 1989). Dietary intake varies 
between individuals in serum concentrations (Parker 1989). Carotenoid concentrations 
vary between sexes, geographical location, age, alcohol consumption (Stahl and Sies, 
1996) and cigarette smoking (Sinclair et al, 1990). Carotenoids show a sequence of 
astaxanthin > f3-carotene, in terms of their ability to inhibit lipid peroxidation and this is 
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supported by previous studies (Terao, et al., 1992; Goto et al., 2001). This is in support 
ofthe results obtained in this study (Fig. 4.13). 
Apart from -a benign and transient yellowing of the skin in heavily supplemented 
individuals, no adverse effect of B-carotene has been reported (Diplock, 1995). 
Carotenoids are being increasingly investigated as important components of the diet, 
exerting powerful antioxidant influences on human health and diseases. For example, 
male and female sea-urchin gonads (rich in carotenoids) are a valuable food commodity 
in countries such as Japan and Portugal. 
As well as their ability to quench singlet oxygen radicals, carotenoids can also react 
with free radicals. The quenching of singlet oxygen by carotenoids mainly leads to 
energy dissipation as heat whereas, the reactions of carotenoids or any of the other 
antioxidants with free radicals leads to electron transfer. However, the unpaired 
electron characterizing the free radical is not lost in these reactions, possibly leading to 
propagative peroxidative reactions in the absence of fresh antioxidants. 
4.4.2.1 Combination of antioxidants 
a-tocopherol, being a fat-soluble antioxidant, is effective against oxidative injury in 
plasma membranes. However, it cannot prevent against damage in cytosolic regions. 
Therefore the results obtained with a mixture of vitamins C and E (Figs 4.14 to 4.16) 
did not come as a total surprise, although the highest antioxidant protection was 
expected with a mixture of vitamin C and either of the carotenoids particularly 
astaxanthin because the highest protection resulted from the use of astaxanthin on its 
own when compared to the other antioxidants used (Fig. 4.13). Adjunctive treatment of 
vitamins C and/or E in conjunction with antipsychotic drugs such as haloperidol and 
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clozapine are already in use in·the treatment of schizophrenia (Aruoma and Halliwell, 
1987; Linday et al., 1995). A combination of vitamin C and E has also been reported to 
possess a synergistic effect in inhibiting oxidative processes (Tappel, 1962; Leung et al., 
1981; Cort, 1982). 
The effects of combining antioxidants as a measure against lipid peroxidation have 
previously ]?een investigated, in order to determine the co-operative interactions 
between these agents. This study demonstrates positive antioxidant interactions 
between a-tocopherol and the carotenoids (~-carotene and astaxanthin) in agreement 
with previous studies by Palozza and Krinsky, 1991; 1992, reporting a delay in the loss 
of microsomal tocopherols in the presence of ~-carotene. 
It has been reported that dietary ~-carotene can mediate an increase in the activities of 
the antioxidant enzymes: SOD, and CAT induced by high fat diets (Blakely et al., 
1988). The concept that antioxidants interlock in their protective effects and that the 
levels of all the antioxidants in the network are important, rather than just a single 
antioxidant, raises the possible importance of supplementing with an antioxidant 
cocktail rather than a single antioxidant (Keaney and Frei, 1994). Polar carotenoids (the 
xanthophylls such as astaxanthin) are more effective in situations where free radical 
attack occurs at the lipid/aqueous interphase. However, if radicals were generated in the 
lipid phase, less polar carotenoids such as the carotenes will yield more antioxidant 
effect (Ojima et al., 1993). 
The interaction of carotenoids and vitamin Awith vitamin Eis not as widely considered 
as the interaction between vitamins C and E. Studies have shown that the antioxidant 
effects of vitamin A, carotenoids and vitamin E are interchangeable in contrast to the 
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relationship between vitamins · C and E. For instance, there is -no strong evidence 
suggesting that vitamin A and/or carotenoids regenerate vitamin E from its radical form, 
whereas vitamin C does (Tesoriere et al., 1993). However, when these different 
antioxidants are present together, there is an additive effect for conferring resistance to 
lipid peroxidation (Packer, 1993). This effect could be due to the fact that the different 
antioxidants protect at different physical locations within the cell membranes rather than 
physical interactions between antioxidants. Vitamin E for example, mitigates oxidation 
at the outer surface while carotenoids and vitamin A are protective in the interior of the 
membrane (Niki et al., 1995a). 
Furthermore, a-tocopherol prevents the auto-oxidation of carotenoids at physiological 
concentrations (Handelman et al., 1991) and can scavenge the carotenoid peroxyl 
radical before it propagates peroxidation (Niki et al., 1995a). Conversely, protection of 
vitamin Eby carotenoids may also be important when singlet oxygen attack is a factor 
(Ojima et al 1993). Co-operative interactions between the antioxidant enzymes inherent 
in U937 cells, water- and fat-soluble dietary antioxidants, has been exploited in this 
research as potential_ treatments for schizophrenia. 
4.4.3 Conclusion 
The data in this study indicate that carotenoids are potent antioxidants in U937 cells 
after 30 min of induced oxidation with the oxidant mixture. Taken together, this report 
demonstrates that t-BHP/Fe2+ - induced oxidation in PUFA-enriched U937 cells is 
inhibited by the antioxidants: ascorbic acid, a-tocopherol, ~-carotene and astaxanthin, 
to varying degrees with astaxanthin being the most effective after 30 min of oxidation. 
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Compared to free radicals, lipid peroxidation products are generally more stable and 
capable of diffusing within cells or even escaping from the cell, thereby attacking 
targets far from· the site of origin of the free-radical. Using the t-BHP: FeSO4 system as 
a pro-oxidant, peroxidation was inhibited by an ascorbic acid concentration of 400 µM 
(Fig. 4:9), a-tocopherol at a concentration as low as 10 µM (Fig. 4.10), ~-carotene (Fig. 
4.11) and astaxanthin at 12 µM (Fig. 4.12). 
Since oxidative stress places a burden on the entire cell/organ, it is not surprising that 
stress in one cell can affect the redox balance in other cells. The same principle applies 
to antioxidants. For example, in vitro experiments showed that vitamin C reduces the 
vitamin E radical (tocopheryl radical) back to vitamin E, thus extending the 
effectiveness of Vitamin E (Keaney and Frei, 1994; Halliwell and Gutteridge, 1999). 
In conclusion, the present work demonstrates that the generation of lipid 
hydroperoxides increases with increasing polyunsaturated fatty acid concentrations, also. 
depending on the degree of unsaturation. It also shows that lipid peroxidation by-
products (lipid hydroperoxides) accumulate in U937 cells over tim~ under oxidative 
stress. Indeed, pre-treating U937 cells with all the antioxidants (ascorbic acid, a-
tocopherol, ~-carotene and astaxanthin) used in this study showed potent inhibition of 
lipid peroxidation at certain concentrations, with astaxanthin exerting the highest 
antioxidant activity. A mixture of ascorbic acid and a-tocopherol gave the greatest 
antioxidant protection observed after 30 min of incubation with the oxidant mixture. 
Overall, the data reported here provide more evidence in favour of the crucial role of the 
protective action of t~e dietary antioxidants against t-BHP/Fe2+ induced lipid 
peroxidation with antioxidant combinations more potent than individuals. 
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CHAPTER 5: LIPID PEROXIDATION EXPERIMENTS (PRELIMINARY 
STUDY BY HEADSPACE ANALYSIS) 
5.1 INTRODUCTION 
Free radical-induced lipid peroxidative damage in schizophrenia is being increasingly 
investigated using in vitro systems. The presence · of membrane phospholipids at 
locations where these free radicals are generated render them accessible targets for lipid 
peroxidation since the polyunsaturated fatty acids (PUFAs) especially, are highly 
susceptible to reactions with free ·radicals (Halliwell and Gutteridge, 1990b ). 
Furthermore, the measurement of generated hydrocarbons is rapidly becoming a tool for 
the analysis of lipid peroxidation in biological systems. 
Both in vitro (North et al., 1994) and in vivo (Kivits et al., 1981; Kovaleva et al., 1989) 
studies have utilized the measurement of volatile hydrocarbons, mainly ethane and 
pentane, as a validated method of measuring lipid peroxidative damage. In studies 
conducted by Kivits et al., (1981), the feeding of rats with various fatty acids 
demonstrated that the oxidation of n-3 PUFAs yielded increased ethane levels in 
exhaled breath while n-6 PUFAs produced pentane. Since ethane is less easily 
metabolized to carbon dioxide (CO2) than pentane, it is considered to be a better 
indicator of lipid peroxidation (Allerheiligen et al., 1987). However, it has been shown 
that ethane is produced in smaller quantities than pentane in humans (Wade and Van 
Rij, 1985). A major problem with pentane apart from its ease of degradation to CO2 is 
that GC-MS techniques do not differentiate it from isoprene because they co-elute on 
many gas chromatograph columns. As such pentane is easily confused with isoprene 
peaks generating inaccurate determinations {Springfield and Levitt, 1994). 
The volatile hydrocarbon test is appealing because it is a useful, non-invasive method of 
measuring lipid peroxidation, both in vivo and in vitro in the study of several 
pathological conditions such as schizophrenia, where lipid peroxidative damage has 
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bee_n extensively implicated. There is considerable interest in the measurement of 
hydrocarbons in vivo especially in humans, as a measure of lipid peroxidation since 
exhaled breath can be easily collected and trapped in closed chambers for analysis. 
Therefore, the purpose of this study was to quantify volatile hydrocarbons generated by 
U937 cells previously enriched with equal concentrations of different fatty acids, having 
variable degrees of susceptibility to peroxidative attack, before exposure to t-BHP/Fe2+ 
at a concentr:ation already established to induce lipid peroxidation by the measurement 
of lipid hydroperoxides (Chapter four). 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Fatty-acid-free bovine serum albumin (BSA), stearic acid (SA), oleic acid (QA), 
arachidonic acid (AA), 0.4% Trypan Blue dye solution, Hanks balanced salt solution 
(HBSS), RP1v11 1640, foetal bovine serum (FBS), 200 mM L-glutamine, 50 mg/ml 
gentamicin solution, HPLC-grade ethanol, tert butyl hydroperoxide, and ferrous sulfate 
heptahydrate (FeSO4. 7H2O) were obtained from Sigma-Aldrich, UK. Eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) were supplied by Nu-chek Prep. Inc., 
Denmark. Sodium sulphate (Na2SO4) filters were from Jones Chromatography Ltd., 
UK. 
5.2.2 Glassware and plastic preparations 
All glassware used was washed in de-con and nano-pure water, autoclaved at 121°C for 
30 min and dried in an oven before use. All other apparatus were sterile with all_ U937 
cell treatments performed under a class II laminar flow hood. 
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5.2.3 Cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM L- . 
glutamine and 0.05 mg/ml gentamicin at 37°C in a humidified incubator with 5% 
CO2/95% air. For all experiments, cells were maintained at 0.5 x 106 cells/ml at 
viability> 90% by Trypan Blue dye exclusion method of viability measurements. 
5.2.4 Cell treatments 
Stock solutions of 100 mM fatty acid concentrations were prepared in ethanol and 
stored under nitrogen after sterile filtration using nylon syringe filters. By further 
dilutions, 10 mM stock solutions of all fatty acids were prepared. U937 cells adjusted 
to contain 0.5 x 106 cells/ml were treated with 10 mM aliquots of the FAs: SA, OA, AA, 
EPA, DHA or 0.4% v/v of ethanol (controls) complexed with aliquots of 4 mM stock 
solutions of fatty-acid-free BSA in a 2.5: 1 molar ratio. Cells were incubated in 20 ml 
suspensions in 75 cm2 culture flasks at 37°C and 5% CO2 in a humid environment. The 
final concentration of fatty acids in 20 ml cell suspensions per flask was 40 µM. After 
24 h of incubation with the different FAs in freshly prepared CM, cells were washed 
twice, each time with 20 ml of HBSS/0.2% BSA by centrifugation at 250 g for 5 min at 
4°C and re-suspended in 475 µl of HBSS in 50 ml centrifuge tubes. Stock solutions of 2 
mM t-BHP and 5 mM FeSO4 were freshly prepared in HBSS. To 475 µ1 of cell 
suspensions, 525 µ1 of t-BHP/Fe2+ mixture was added to make a final volume of 1.0 ml 
and 750 µM t-BHP/Fe2+ of oxidant concentration. Using sterile needles screwed to 20 
ml sterile syringes (Becton Dickinson and Co., UK), cell suspensions were transferred 
into the syringes, with 20 ml headspace. Needles were carefully stuck into solid rubber 
bungs (size 15) ensuring that the needle barrel was completely inserted. The syringes 
were shaken and incubated at 37°C for 2 h. Thereafter, needles were carefully and 
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rapidly unscrewed and connected to automatic thermal desorption (ATD) tubes via 
Na2S04 filters (Fig. 6.1). 
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Fig. 5.1 Schematic diagram of the procedure for the transfer of trapped gas 
produced by U937 cells. A: U937 cells treated with or without 750 µM t-BHP/Fe2+; B: 
20 ml syringe; C: connector; D: Na2SO4 filter; E: ATD tube. 
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The 20 ml headspace gas was trapped in Perkin-Elmer N930-7000 ATD tubes packed 
with Carbotrap 300 and capped. The headspace samples were· analysed for ethane, 
butane and pentane using the GC-mass spectrometer (Perkin-Elmer Turbo Mass) 
(HPRF patent). ATD tubes were desorbed on to the cold trap for 20 min at 320°C and 
the volatile hydrocarbons liberated were swept onto 30m x 0.32 mm PLOT GC columns 
(PEQ) using helium (2 ml/min) as the carrier gas. The detection of hydrocarbons was 
performed by flame ionization with the oven set to 45°C for 3 - 10 min and ramped at 
14°C per minute to 200°C, at which point it was held for 2 minutes. 
Quantification of ethane, butane and pentane production was accomplished by mass 
spectra (ethane at rn/z = 30; butane and pentane at rn/z = 43) and separation of authentic 
gas mixtures C1-C6 hydrocarbons (Supelco, Inc.). Standard curves were established 
using C1-C6 n-paraffins (methane, ethane, propane, n-butane and n-pentane at 15.0, 
15.1, 14.9, 14.9 and 14.5 ppm, respectively) in helium, as the carrier gas, for the 
quantification of hydrocarbon peaks whilst a standard curve of ethane (0-1.5 ng/L) was 
run in nitrogen (N2), as the carrier gas, to quantify the standards. Ethane, butane and 
pentane eluted at 2.55, 9.62 and 12 minutes, respectively. 
5.3 RESULTS 
With increased lipid peroxidation in biological systems, the production of 
hydrocarbons, as by-products, can be used as a measure of the extent of such oxidative 
injury. Figs. 5.2 and 5.3 show the amounts of ethane and butane generated by U937 
cells enriched with 40 µM levels of the fatty acids SA, OA, AA, EPA, DHA or 0.4% 
v/v, ethanol (for controls) for 24 h. This study began by determining whether t-
BHP/Fe2+ was capable of causing the generation of volatile hydrocarbons from fatty 
acid-treated U937 cells. To this end, the cells, pre-treated with 40 µM levels of SA, 
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OA, AA, EPA, DHA or 0.4% v/v, ethanol (for controls) were exposed to 750 µM 
concentrations of t-BHP/Fe2+ for 2 h at 37°C. As shown in Fig. 5.2, treatment of U937 
cells with · t-BHP/Fe2+ significantly increased the production of ethane, a C2 
hydrocarbon, most notably in control cells treated with the oxidant, but without any 
fatty acid supplementation (Ox). As expected, the lowest level of ethane was generated 
in control cells exposed neither to fatty acids nor oxidants (- Ox) but surprisingly, cell 
treatments ~ith all FAs used especially the PUFAs (AA, EPA or DHA) appeared to 
inhibit ethane generation (Fig. 5.2). 
To compare results obtained in cells pre-incubated with equal concentrations of the 
various fatty acids used, ethane generation, in ppb/1.0 x 107 cells, was expressed as a 
percentage of that generated from oxidized controls (Ox), which represented 100%. A 
comparative study of unoxidized controls (- Ox), SA, OA, AA and EPA showed that 
the production of ethane was significantly lowest in controls incubated without oxidants 
(one-way ANOVA F = 237.65, P < 0.01, DF = 4). The generation of ethane from U937 
cells increased significantly from SA- to OA-, reducing significantly with AA- and 
EPA-pre-treatments. There was no significant difference between ethane generated 
from EPA- or DHA- treated cells (T = 1.39, P > 0.05, DF = 2). Although EPA-
treatment of U937 cells yielded ethane levels that were significantly higher than 
unoxidized controls (- Ox), there was no significant difference between DHA 
treatments and controls without oxidants {T = 1.29, P > 0.05, DF = 2). Compared with 
un-supplemented U937 cells (- Ox), there was approximately 60%, 93%, 65%, 9% and 
4% increases in ethane production with SA (18: 0), OA (18: 1), AA (20: 4), EPA (20: 5) 
and DHA (22: 6) - treatments, respectively. 
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Fig. 5.2 Effect of fatty acid modification on free radical - mediated ethane 
generation in U937 cells (1.0 x 107). Data points represent means± 95% Cls (n = 3). 
The letters: a, b, c, d and e denote significant differences between means at P < 0.05. 
The treatment of U937 cell controls with 750 µM t-BHP/Fe2+ (Ox) resulted in the 
generation of butane, a C4 hydrocarbon, as well (Fig. 5.3). Similar to the trend observed 
in U93 7 cells with ethane production, there was a striking difference between oxidant-
treated controls (Ox) and all other treatments. U937 cell-treatments with 40 µM SA 
generated butane levels significantly higher than oxidant untreated controls (T = 12.58, 
P < 0.05, DF = 2). Whilst there was no significant difference in butane generation 
between unoxidized controls (- Ox) and DHA - pre-treated U937 cells (T = 1.54, P > 
0.05, DF = 2), EPA - pre-treatment (T = 20.47, P < 0.01 , DF = 4) resulted in levels 
significantly higher than unoxidized controls (- Ox). Tukey' s pairwise comparisons of 
butane generation from all FA-treated cells showed a significant increase in butane 
production from SA to OA (one-way ANOVA F = 98.06, P < 0.01, DF = 4). However, 
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there was a marked decrease in butane levels in a gradual manner with corresponding 
cells pre-cultured with 40 µM AA > 40 µM EPA > 40 µM DHA. 
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Oxidant-induced generation of butane by U937 cells grown for 24 h in 
FA-supplemented CM. Values of butane are expressed in ppb after 2 h of oxidative 
stress at 37°C. Means± 95% Cls (n = 3). Letters: a - e indicate significant difference 
between treatments (P < 0.01). 
The suppression of volatile hydrocarbon production ( especially ethane) from U93 7 cells 
enriched with F As especially the PUF As (EPA and DHA), observed in the present 
study, probably reflects the unsuitability of headspace analysis in the detection of the 
susceptibility of n -3 PUF As to peroxidative damage, the abundance of which has 
previously been shown to increase the generation of ethane upon oxidative injury in 
biological systems. 
Fig. 5.4 shows the amount ofpentane generated by U937 cells enriched for 24 h with 40 
µM concentrations of the different fatty acids (SA, OA, AA, EPA or DHA). 
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Surprisingly, with induced oxidation, the production of pentane, a Cs hydrocarbon, 
appeared to increase with increasing degree of FA unsaturation. 
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Fig. 5.4 Effect of FA supplementation of U93 7 cell culture medium for 24 h on 
oxidant-induced generation of pentane. Values were expressed in ppb (a) and as 
percentages of that generated from oxidant treated controls (b ). Data points represent 
means ± 95% Cls (n = 3). Letters a and b indicate significant differences between 
treatments at P < 0.01. 
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Pentane levels were significantly lower in unoxidized controls (- Ox) than in all other 
treatments involving induced oxidation (one-way ANOVA F = 58.07, P < 0.01, DF = 
6). Tukey' s pairwise comparisons showed that there were no significant differences 
between oxidant-treated controls (Ox) and all FA-treatments. However, there were 
significant differences between the different FA-treatments. U937 cells treated with 40 
µM SA generated pentane levels significantly lower than all PUPA (AA, EPA or 
DHA)-treate,d cells. Contrary to expectations, there were no significant differences 
between OA, AA, EPA and DHA-pretreatments. Since pentane is an alkane produced 
by the decomposition of lipid peroxides generated from n-6 fatty acids, the highest 
levels were expected to be generated from AA-pre-incubated cells but this was not the 
case. However, it remains obvious that oxidative stress increases the generation of 
pentane. 
From the results shown above, it is impossible to determine the origin of pentane 
generation from U937 cells pre-treated with the n-3 PUFAs without the inclusion of 
experiments determining the change in membrane fatty acid profile. 
5.4 DISCUSSION AND CONCLUSION 
The aim of this preliminary study was to investigate the production of volatile 
hydrocarbons from U937 cells grown in CM supplemented with/without different fatty 
acids, under conditions of oxidative stress. Lipid peroxidative damage to biological cell 
membranes especially when enriched with highly unsaturated .fatty acids such as AA, 
EPA and DHA, is frequently associated with the generation of volatile hydrocarbons 
such as ethane and pentane. The present study demonstrated that the human lymphoma 
U937 cells generate butane as well as ethane and pentane during peroxidative processes 
with or without fatty acid modifications of the cellular phospholipids. 
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The presence of PUFAs of the n-3 series (DHA) was previously shown by North et al. 
(1994) to enhance the susceptibility of U937 cells to generate ethane in comparison to 
cells enriched with equal concentrations of oleic acid. In contrast, this preliminary 
study demonstrates that after 2 h of induced oxidative stress with 750 µM t-BHP/Fe2+ in 
U937 cells modified with different fatty acids (SA, OA, AA, EPA or DHA), the lowest 
amount of ethane was observed in cells pre-incubated with EPA (20: 5, n -3) or DHA 
(22: 6, n-3). , The present study suggests that the treatment of U937 cells with the n-3 
PUFAs (EPA or DHA) for 24 h, suppresses ethane production in comparison to SA, OA 
or AA. Collectively, pre-incubation of these cells with 40 µM concentrations of all the 
fatty acids employed (SA, OA, AA, EPA and DHA), appeared to reduce the amount of 
ethane and butane generated upon oxidation, and increase pentane, when compared to 
oxidized controls (Ox). In contrast to findings from previous studies using neoplastic 
murine leukemia L1210 cells (Bums and Wagner, 1991), this study suggests that the 
treatment of U937 cells with AA, EPA or DHA conferred protective roles against 
oxidant-induced peroxidative damage as measured by ethane and butane generation in 
the following order: AA< EPA< DHA. Surprisingly, pentane was generated in the 
order: AA < EPA < DHA. It is important to note that pentane production (in ppb) by 
U937 cells in culture are much lower than ethane or butane levels. This could indicate 
that the n-3 lipid peroxides degrade to form ethane at a faster rate than the n-6's to 
pentane. Another possible explanation for the detection of lower pentane levels with n-
6 pre-treated cells may be that most of the pentane generated was metabolized to carbon 
dioxide in the 2 h of inducing oxidative stress. A time course experiment of headspace 
sample collection is required to confirm this speculation. 
Previously, studies in vivo of expired air from rats demonstrated a linear increase in 
ethane levels over a period of three hours when these rats were fed with n-3 rich diets 
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(cod liver oil), whereas there was no increase observed in ethane generation in control 
rats fed with n-3 poor diets (Odeleye et al., 1990). In contrast, the present data indicate 
that, in U937 cells, ethane generation is lower in EPA or DHA enriched cells post 
oxidation in comparison to oxidized controls. This could be because oxidation was 
induced for 2 h only and PUF A-treated cells require more time for the production· of 
ethane in comparison to FA-untreated but oxidized controls (Ox). Or perhaps these 
cells need to_ be cultured in n-3 PUPA-rich medium for periods much longer than 24 h 
prior to oxidation experiments in order to determine susceptibility to peroxidative 
damage by ethane and pentane measurements. Since this is a preliminary study, more 
work is required to investigate ethane, butane and pentane generation in U937 cells 
cultured in PUFA-rich medium. 
5.4.1 Conclusion 
The present study shows a relationship between lipid peroxidation and the generation of 
the volatile hydrocarbons, ethane (C2), butane (C4), and pentane (C5), with the C2 and 
C4 hydrocarbons both produced in like manners in U937 cell model systems. This 
suggests that ethane, pentane · as well as butane can be formed as by-products of lipid 
peroxidation. The differential effects of the PUF As in the generation of volatile 
hydrocarbons: ethane, butane and pentane, requires further investigation. With PUFA 
(AA, EPA or DHA) treatments, the present study demonstrates that these cells suppress 
the generation of ethane and butane when compared to oxidized controls (Ox) and at the 
same time increase pentane levels. Although the technique of GC headspace is rapid, 
sensitive and suitable for biological materials, involving no sample workup, whether the 
method is ideal for the measurement of peroxidative susceptibility as affected by the 
fatty acid composition of cellular phospholipids in biological samples in vitro, requires 
further study. 
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CHAPTER 6: OXIDANT-INDUCED ARACIDDONIC ACID RELEASE 
6.1 INTRODUCTION 
Arachidonic acid (AA) is an important membrane component, required for the 
maintenance of cellular viability under normal and pathological conditions. The vast 
majority of the available arachidonic acid is stored in acylated form within membrane 
phospholipids, and the free acid is preferentially released from phospholipid molecules 
via the hydrolytic activity of form of the cytosolic phospholipase A2 (cPLA2) enzyme 
(Tran et al., ,1996). AA is a key intermediate in a diversity of signal transduction 
pathways. The rate limiting step in the initiation o~ the arachidonic acid cascade is its 
release from membrane phospholipids, resulting in the production of inflammatory 
mediators such as prostaglandins, leukotrienes and thromboxanes (Smith 1989; 
Rzigalinski et al., 1996). It has also been suggested that AA and/or its metabolites are 
involved in the regulation of intracellular free calcium levels (Mochizuki-Oda et al., 
1993; Tornquist et al., 1994; Wu et al., 1994; Chow and Jondal, 1990) and the 
activation of low molecular weight GTPase activating proteins (Ligeti et al., 1993; 
Chuang et al., 1993; Homayoun and Stacey, 1993). 
Agonist stimulated fatty acid mobilization by the calcium ionophore, A23187, is 
specific for AA and a few structurally related PUFAs such as EPA, which gives a 
quantitatively similar response to that of AA. DHA, however, is not released in 
response to agonists such as A23187 (Rosenthal et al., 1995). Studies with a variety of 
radiolabelled-PUFAs, show that agonist stimulated response is highly selective for fatty 
acids with a cis-5 double bond, but not particularly stringent for chain lengths over the 
range of C18 - C21 (Rosenthal et al., 1989). However, physiological conditions 
causing cell damage can result in the release of other fatty acids such as oleic acid and 
DHA (Rosenthal and Jones, 1988). 
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AA is an intermediate in the reacylation and deacylation of membrane phospholipids 
(Lands pathway). In this pathway, AA is cleaved from phospholipids by PLA2 and re-
incorporated by acyltransferases (MacDonald and Sprecher, 1989; Yamashita et al., 
1997; Lands, 2000). In resting cells, reacylation prevails whilst deacylation is the 
dominant reaction in activated cells. AA incorporation into phospholipids is critically 
dependent on the availability of lysophospholipid receptors. 
The human histiocytic lymphoma cell line (U937), is a rich source of cPLA2, and has 
been a standard line for the purification of the human form of the enzyme (Diez and 
Mong, 1990; Clark et al., 1990; Kramer et al., 1991). Therefore, in this study, this cell 
line was chosen to investigate oxidant-stimulated AA release and its inhibition by the 
incorporation of various known antioxidants. U937 cells contain high levels of the 110 
kDa, Ca2+-dependent PLA2 enzyme (Clark et al., 1990; Kramer et al., 1991; Sharp et al., 
1991; Dennis 1994). PLA2 has been implicated in schizophrenia (Gattaz et al., 1987; 
1990). While several different types of PLA2s including the Ca2+-dependent and 
independent cPLA2 have been identified in U937 cells, Clark et al (1990) reported that 
there was no measurable secretory PLA2 able to block the Ca2+ -stimulated AA release 
in these cells suggesting that cPLA2 was mainly responsible for this release. It has 
recently been shown that phosphorylation of cPLA2 coupled with an influx of Ca2+ 
alone are not sufficient to activate the enzyme to release free AA in U937 cells (Burke 
et al., 1997). The differentiation of U937 cells, however, enables cPLA2 to function in a 
catalytic fashion. While undifferentiated cells have large amounts of phosphorylated 
cPLA2s and can be stimulated to induce a calcium influx, they are unable to release AA. 
Recently, U937 cells have been reported to express both group IV PLA2s (cPLA2) and 
the group VI PLA2 (iPLA2) (Hsu et al., 2000). But the inhibition of iPLA2 with 
bromoenol lactone suicide substrate, suppressed neither AA incorporation nor its release 
193 
in U937 cells stimulated with A23187 (Hsu et al., 2000). However, Balboa and 
Balsinde (2002), showed that hydrogen peroxide induced AA release in U937 cells by 
the activation of iPLA2 independent of cPLA2 activity. 
The cytosolic form of PLA2 (cPLA2) is localized in the cytoplasmic fraction of un-
stimulated cell homogenates and translocates to the membrane fraction in response to 
physiologica,l (sub-micro to micro - molar) elevations of intracellular free calcium. 
cPLA2 is activated by phosphorylation followed by the translocation of the 
phosphorylated enzyme to the membrane in a Ca2+-dependent manner (Clark et al., 
1991). cPLA2 has a high preference for arachidonic acid at the sn-2 position of the 
phospholipid molecule (Leslie et al., 1988; Clark et al., 1991) whereas iPLA2 does not 
(Ackermann et al., 1995). cPLA2 is enriched in brain cells (Gattaz et al., 1995) playing 
an important role in the regulation of the physico-chemical properties of the neuronal 
membranes thus influencing receptor function and signal transduction (Farooqui et al., 
1992). 
Blood cells (Balsinde et al., 1988), plasma (Gattaz et al., 1987), serum (Gattaz et al., 
1990; Noponen et al., 1993) and platelet membranes (Gattaz et al., 1995) have 
frequently been used to draw analogies to brain tissues regarding membrane 
abnormalities in neuropsychiatric disorders. In these reports, PLA2 activity was 
increased. The mechanism for PLA2-mediated neural injury was proposed to be by 
glutamate receptor-mediated over-stimulation of PLA2, producing changes in membrane 
phospholipid composition, permeability and fluidity. These changes in membrane 
properties, allow enhanced calcium influx, leading to an uncontrolled sustained increase 
in cytosolic calcium levels, which may in tum be responsible for increased lipid 
breakdown, proteolysis and a disruption in the membrane structure (Farooqui and 
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Horrocks,· 1991 ). These processes along with the accumulation of lipid peroxidation by-
products, over extended periods, may be responsible for neurodegeneration. 
The calcium dependent isoform of cPLA2 has been implicated in dopaminergic 
signaling (Vial and Piomelli, 1995) whilst the calcium-independent PLA2 performs a 
key role in cellular fatty acid incorporation into phospholipids (Balsinde et al., 1995). 
Chronic oxi~ative stress was reported to result in a specific increase in calcium-
independent PLA2 activity (Kuo et al., 1995). Ross et al., (1999) reported increased 
calcium-independent PLA2 activity in the temporal cortex of schizophrenic patients, and 
this was related to oxidative stress coupled with a dysfunction in the fatty acid 
metabolism in schizophrenia. They also reported a decre~se in calcium-dependent 
PLA2 activity in the temporal cortex, in relation to an increase in dopaminergic activity 
(Ross et al., 1999). Ross et al (1997) used two different analytical methods 
(fluorometric and radiometric) to measure serum PLA2 in schizophrenic patients. In 
that study, PLA2 activity was increased in the serum of schizophrenic patients when 
analyzed with the fluorometric method, whereas the other method showed no significant 
difference between patients and control subjects. Further analysis showed that each 
method measured the activity of two different PLA2 enzymes: the calcium - dependent 
(requiring 100 - 1000 Nm Ca2+) and independent enzymes, and that the latter was the 
over-active enzyme in the schizophrenic patients observed. 
The specificity of phospholipase enzymes often limits the choice. of phospholipids. that 
· can be employed in the assay. Ancillary concerns when working with phospholipase 
assays include the fact that all cells contain the basic repertoire of lipolytic enzymes 
required to maintain normal phospholipid metabolism. Since products may be produced 
by several pathways, radiolabelled fatty acids can be liberated from the sn-2 position of 
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the phospholipids by a PLA2; the combined activity of a PLA1 and a lysophospholipase; 
or even by the activity of a PLC and a lipase. This ambiguity precludes one from 
readily determining the positional specificity of an enzyme in biological cells. 
The radiometric method of detection is the most sensitive and most widely used PLA2 
assay, requiring the use of radiolabelled phospholipids or fatty acids (as in this case), 
which can b~ expensive. The assay employed in the present study follows hydrolysis by 
directly measuring the liberation of AA, one of the hydrolysis products. This assay is 
discontinuous requiring the separation of the radioactive substrate from the labelled 
products. These separations are quite time consuming and laborious but very effective 
and sensitive. The most commonly used separation method employs thin layer 
chromatography (TLC) after solvent extraction of the lipids. Since all the reactants and 
products extract into the organic phase, it is necessary to separate these compounds, 
prior to quantification by liquid scintillation spectroscopy. TLC has the advantage that 
reactants and products can both be identified and quantified. In addition, if all the 
compounds are equally extracted, any losses in extraction will equally affect all 
components thereby generating accurate results. Even if the absolute amounts of the 
components vary, the ratio of the component as well as the rate calculated from it 
remains unaffected. TLC is a separation technique based on the principle that the 
components of a mixture are made to separate as a mobile phase acts in conjunction 
with a solid (stationary) absorbent phase. 
Despite the physiological significance of the PLA2s, both its measurement and the 
understanding of its mechanism of action have posed several problems. As such, 
numerous assays including titrametric, acidimetric, radiometric, spectrophotometric and 
fluorometric methods have been developed over the years. The radiometric method 
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(Katsumata et al., 1986) was· used in this study due to its high sensitivity and 
reproducibility although it suffers the demerits of being discontinuous, time-consuming 
and expensive. In this study, 3H- labelled AA was incorporated into phospholipids and 
the release of 3H-AA into the extracellular medium on stimulation was quantified. The 
intensity of the radioactivity released was used as an indication of the activity of PLA2. 
This radiolabelled AA-release method has previously been used extensively in the 
investigation, of the involvement of PLA2 in several processes including phospholipid 
metabolism, host defense, signal transduction and apoptosis (Balsinde et al., 1994; 
Zhang et al., 1998; Ramanadham et al., 1999; Hsu et al., 2000; Balboa and Balsinde, 
2002). 
Since oxidative stress, PLA2 and the PUFAs play an important role in schizophrenia, 
this study was designed to investigate the effects of oxidative stress on AA release and 
PLA2 activity. The present study is designed to extend the understanding of the 
stimulatory role of oxidants with PUPA-supplementation and the inhibitory effects of 
certain dietary antioxidants in the regulation of radiolabelled - arachidonic acid release 
in U937 cells, as a measure of the activity of a form of the phospholipase A2 (PLA2) 
enzyme. 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Fatty-acid-free bovine serum albumin (BSA), stearic acid (SA), oleic acid (OA), 
arachidonic acid (AA), phosphatidyl choline, 0.4% Trypan Blue dye solution, Hanks· 
balanced salt solution (HBSS), RPMI 1640, foetal bovine serum (FBS), 200 mM L-
glutamine, 50 mg/ml gentamicin solution, ascorbic acid, vitamin E, {3-carotene, 
astaxanthin, HPLC-grade chloroform, hexane, diethyl ether, methanol and ethanol, 
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glacial acetic acid, potassium chloride (KCl), Iodine crystals, butylated hydroxy-toluene 
(BHT), tert butyl hydroperoxide, ferrous sulfate· heptahydrate (FeSO4. 7H2O) and 
sodium thiosulfate (Na2S2O3) were obtained from Sigma-Aldrich, UK. 
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were supplied by Nu-
chek Prep. Inc., Denmark. Optiphase Hisafe 2 liquid scintillation cocktail and [5, 6, 8, 
9, 11, 12, 14, 15-3H] free arachidonic acid (3H-AA, 100 Ci/mmol) were purchased from 
Perkin-Elmer Life Sciences, ·UK. LK5D - Whatman TLC plates were from Fisher 
Scientific, UK. 
6.2.2 Glassware and plastic preparations 
All glassware used was washed in de-con and nano-pure water, autoclaved at 121 °C for 
30 min and dried in an oven before use. All other apparatus used were sterile with all 
U937 cell treatments performed under a class II laminar flow hood. Solvent extractions 
and thin layer chromatographic analysis · were done in the designated area in the 
radiation suite. 
6.2.3 Cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% PBS and 2 mM L-
glutamine and 0.05 mg/ml gentamicin at 37°C in a humidified incubator with 5% 
CO2/95% air. For all experiments, cells were maintained at 0.5 x 106 cells/ml at 
viability > 90% by Trypan Blue dye exclusion method of viability measurements. 
6.2.4 Assay of 3H-AA release 
6.2.4.1 With oxidants 
U937 cells (0.1 ml in CM) were labelled with 0.1 µCi/ml of 3H-AA in 0.9 ml of CM for 
24 hat 0.5 x 106 cells/ml in 24-well culture plates. Thereafter, cells were washed twice 
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with 1 ml 0.2% BSA (w/v) in HBSS (HBSS/0.2% BSA) by centrifuging at 250 g for 5 
min at 4°C each time and re-suspended in 0.1 ml of HBSS only. Cells were washed in 
BSA to ensure the removal of all unincorporated freely-available fatty acids. Stock 
solutions of 2 mM t-BHP and 5 mM FeSO4 were freshly prepared just before use in 
HBSS: Oxidative stress was induced by the addition of 0.9 ml of oxidant mixture (t-
BHP and FeSO4) in HBSS (or HBSS alone for controls) to 0.1 ml of cell suspension in 
fresh 24-welJ plates and incubated at 37°C and 5% CO2 in a humid environment. For 
the time-dependent assay, cells were incubated with a final oxidant concentration of 
750: 750 µMt-BHP: FeSO4 (or HBSS only for controls) over 6 h under the conditions 
stated above. The blank (0 h) experiment involved cells incubated in HBSS only for 6 
h. The dose-dependent assay was carried out with cells incubated with 0: 0 to 1000: 
1000 µM final concentrations of oxidant mixture for 4 h. All experiments involved 
radiolabelling with 0.1 µCi/ml 3H-AA for 24 h at 37°C and 5% CO2 in a humid 
environment. 
All reactions were terminated rapidly by centrifuging at 4000 g for 3 min at 4°C prior to 
solvent extraction of lipids and thin layer chromatographic (TLC) analysis. 
6.2.5 Treatment of cells with fatty acids (F As) 
6.2.5.1 With increasing concentrations 
Fatty acids (SA, OA, AA, EPA or DHA) were complexed to fatty-acid-free BSA at a 
molar ratio of 2.5: 1 and supplemented with 3H-AA/CM before addition to cell 
suspensions as follows: ethanolic FA solutions ranging from 2.5 to 10 mM were 
prepared from a· 100 mM stock solution and stored under nitrogen after sterile filtration 
using nylon syringe filters. FA: BSA complexes were prepared by the addition of an 
equal volume of 2.5 - 10 mM of the FA complexed with 1 - 4 mM of BSA respectively 
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and further diluted with CM supplemented with 3H-AA (3H-AA/CM) to a final volume 
of 0.9 ml. FA-supplemented culture medium (0.9 ml) was then added to 0.1 ml of cell 
suspension in each well of a 24 - well plate. Controls involved cells incubated with 
0.4% (v/v) ethanol and 3H-AA only, representing the final ethanol concentration in all 
FA treatments, previously shown to have no effect on cell viability as measured by 
LDH analysis (section 2.3.5.3). Each well contained 0.5 x 106 cells/ml and 0.1 µCi/ml 
3H-AA. Cells were incubated for 24 h at 37°C and 5% CO2 in a humid environment. 
Final fatty acid concentration ranged from 10 to 40 µM. 
6.2.5.2 With a single FA concentration 
Cells were also incubated with 0.1 µCi/ml 3H-AA and 10 µM of each of the fatty acids: 
SA, OA, AA, EPA or DHA or ethanol only (controls) complexed to BSA at a molar 
ratio 2.5: 1. Incubations were performed in 24-well plates at 0.5 x 106 cells/ml for 24 h 
at 37°C and 5% CO2 in a humid environment. In one set of experiments, cells were 
incubated in HBSS only for 4 h without oxidation, in the other cells were subjected to 
oxidative stress (750 µM t-BHP/Fe21. Controls involved cells incubated with 0.4% 
(v/v) of ethanol complexed with an equal volume of 1 mM BSA. 
6.2.5.3 Prolonged supplementation of cells with F As 
U937 cells were continuously cultured for 18 days in CM supplemented with 10 µM 
levels (final concentration) of the FAs (SA, OA, AA, EPA or DHA) at 37°C and 5% 
CO2 in a humid environment. For controls, cells were incubated with 0.4% (v/v) 
ethanol (final volume) complexed with 1 mM BSA (equal volumes). All FAs were 
complexed with BSA in a 2.5: 1 molar ratio. · Cells were maintained in 8 ml cell 
suspensions at 0.5 x 106 cells/ml in 25 cm2 culture flasks every 3 days. The incubation 
medium was totally renewed with freshly prepared CM supplemented with 10 µM of 
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the FA complex every 3 days. ·On day 17, U937 cells were re-adjusted to contain 0.5 x 
106 cells/ml and re-suspended in 24-well plates for a further 24 h in freshly prepared 
CM supplemented with 10 µM of the fatty acid and 0.1 µCi/ml 3H-AA. Final volume of 
cell suspension per well was 1.0 ml. After a total of 18 days, the cells were subjected to 
oxidative stress for 4 has in section 6.2.7. 
Cell viability and cell density was monitored every 3 days and maintained at 0.5 x 106 
cells/ml at a viability > 90% by the Trypan Blue dye-exclusion method. Excess cell 
suspensions were discarded and treated appropriately. 
6.2.5.4 Cell-associated free fatty acids (3H-AA) 
U937 cells were treated with 10 µM FAs (SA, OA, AA, EPA or DHA) and 0.1 µCi/ml 
following the protocol used above. Cells were incubated in 1 ml suspensions in 24-well 
plates at 0.5 x 106 cells/ml at 37°C and 5% CO2 in a humid environment for 24 h. Cells 
were washed twice with HBSS/0.2% BSA and incubated with the oxidant mixture (750 
µM t-BHP/Fe2+) for 4 h (see section 6.2.7). Thereafter, the reaction was stopped by 
centrifugation ( 4000 g for 3 min at 4°C) and 0.9 ml of supernatant were removed and 
discarded. Cell pellets (0.1 ml) were dislodged from walls of 1.5 ml eppendorf tubes 
.followed by extraction of cellular lipids (see section 6.2.8.2). 
All experiments were designed to include a set of U937 cells treated with 0.1 µCi/ml 
3H-AA only for the determination of the total incorporated radioactivity into cellular 
phospholipids. These sets of experiments were stopped after 24 h of incubation at 37°C 
and 5% CO2 in a humid environment prior to 3H-AA release experiments. 0.5 x 106 
cells/ml from each well, were centrifuged at 250 g for 5 min and 4°C, washed twice in 
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HBSS/0.2% BSA. Cells were then re-suspended in 0.1 ml of HBSS and extracted 
following the procedure for the extraction of cellular lipids (see section 6.2.8.2). 
6.2.6 Supplementation of U937 cell culture medium (CM) with ascorbic acid, a-
tocopherol, fl-carotene and astaxanthin 
6.2.6.1 With increasing antioxidant concentrations 
100 mM stock solutions of ascorbic acid in water, a-tocopherol in ethanol, B-carotene 
and astaxanthin in chloroform were prepared. Ascorbic acid and a-tocopherol were 
stored at 2 - 8°C, while B-carotene and astaxanthin at - 20°C. By serial dilution, 4 - 16 
mM ascorbic acid, 10 - 40 n;1M a-tocopherol and 3 -12 mM B:carotene and astaxanthin 
were prepared. Culture medium (CM) was supplemented with aliquots of 4 - 16 mM 
ascorbic acid, 10-40 mM a-tocopherol and 3 -12 mM B-carotene or astaxanthin, all to 
a final volume of 0.8 ml. Antioxidant supplemented CM (0.8 ml), was added to each of 
a 24 - well plate containing 0.1 ml of cell suspension after appropriate treatments (in the 
case of the carotenoids 0.8 ml of carotenoid - supplemented CM was sonicated for 5 s 
in an ice-bath and sterile - filtered using nylon syringe filters). Each well contained 0.5 
x 106 cells/ml. Final concentrations of antioxidants varied from 0 - 400 µM for 
ascorbic acid, 0 - 40 µM for a-tocopherol and 0 - 12 µM for B-carotene or astaxanthin. 
U937 cells were then incubated with each antioxidant for 10 min before the addition of 
0.1 ml of0.l µCi/ml 3H-AA/CM and a further incubation for 24 hat 37°C and 5% CO2 
in a humid environment. Oxidized and unoxidized controls involved cells incubated 
with and without 750 µM t-BHP/Fe2+, respectively. 
Cells were also incubated in antioxidant-supplemented CM (0.9 ml) at 37 °C and 5% 
CO2 in a humid environment for 10 min prior to the addition of 0.1 µCi/ml 3H-AA and 
10 µM AA, EPA or DHA (0.1 ml). Final antioxidant concentrations used varied from 
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100 - 400 µM ascorbic acid; '10 - 40 µM a-tocopherol; 3 - 12 µM ~-carotene or 
astaxanthin. Aliquots of 2.5 mM PUFAs (AA, EPA or DHA) were complexed with 1 
mM BSA and then added to . the cell suspensions. The final volume of cell 
suspension/well was 1.0 mL Plates were then incubated for a further 24 h under the 
conditions stated above. Oxidized and unoxidized controls were cells incubated with 10 
µM PUFA (AA, EPA or DHA) only (without antioxidant) with and .without oxidation 
with 750 µM t-BHP/Fe2+, respectively. 
6.2.6.2 With individual and mixtures of antioxidants 
Cells were incubated with the highest concentration of each of the antioxidants used 
above ( 400 µM ascorbic acid, 40 µM a-tocopherol, 12 µM ~-carotene or astaxanthin). 
The individual experiment involved the incubation of cells with single or mixtures of 
antioxidants (for 10 min) and then with 10 µM of the PUF As AA, EPA or DHA and 0.1 
µCi/ml 3H-AA following the protocols described above and incubated for a further 24 h 
(using 24-well plates) at 37°C and 5% CO2 in a humid environment. Each well 
contained 0.5 x 106 cells/ml. 
The blank experiments were incubated neither with antioxidant, PUF A nor oxidant but 
with the radiolabel only. Oxidant-untreated controls involved U937 cells cultured 
without media supplementation with neither antioxidant(s) nor PUFA but with oxidant. 
Oxidized controls were cells cultured without antioxidant(s) but with 10 µM PUFA and 
oxidation. All incubations were performed for 24 h before oxidative stress was induced. 
Final antioxidant concentrations used were 400 µM ascorbic acid, 40 µM a-tocopherol, 
12 µM ~-carotene and 12 µM astaxanthin. 
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For these sets of experiments with antioxidants, cells were washed twice in HBSS/0.2% 
BSA. Oxidation reactions followed the protocol in section 6.2.7. Unoxidized controls 
were not subjected to oxidation whilst oxidized controls were. All experiments were 
radiolabelled with 0.1 µCi/ml 3H-AA (final concentration), supplemented with CM. 
6.2.7 Oxidant-induced 3H-AA release assay 
For all experj.ments involving radiolabeling for 24 h, cells were washed twice in 1 ml of 
HBSS/0.2% BSA by centrifuging each ti~e at 250 g for 5 min at 4°C and re-suspending 
in 0.1 ml of HBSS. Cell suspensions·were then transferred from 1.5 ml eppendorftubes 
into new and sterile 24-well plates. Thereafter,· 900 µl of oxidant mixture in HBSS 
(freshly prepared from 2 mM t-BHP and 5 mM FeSO4 stock solutions, just before use) 
were carefully mixed with cell suspensions (0.1 ml) and incubated at 37°C and 5% CO2 
for 4 h in a humid environment. The final oxidant concentration used in each well was 
750: 750 µM oft-BHP: FeSO4 in HBSS henceforth referred to as 750 µM t-BHP/Fe2+ 
unless otherwise stated. 
All reactions were terminated after 4 h unless stated otherwise, by centrifugation at 
4000 g for 3 min at 4°C prior to lipid extraction and TLC of extracts. 
6.2.8 Lipid extraction 
6.2.8.1 3H-AA release into the incubation medium 
After the subjection of cells to oxidative stress, an 800 µl aliquot of supernatant was 
removed and transferred into glass Pyrex tubes containing 4 ml of ice-cold chloroform: 
methanol (2: 1, v/v) (Folch et al., 1957), and 1 ml of 0~88% KCl was added as 25% of 
the existing volume. The mixture was shaken and allowed to separate into two layers. 
An aliquot of the bottom organic layer (0.5 - 2.0 ml) was transferred into a clean vial 
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and evaporated to dryness under a gentle stream of nitrogen. Extracts were re-
suspended in 30 µl of 3.33 mM cold AA in chloroform: methanol (2: 1, v/v) with 0.01 % 
BHT in air-tight vials and stored for a maximum of 72 h at - 20°C prior to TLC analysis 
of 3H-AA released. 
6.2.82 3H-AA incorporated into phospholipids or cell-associated 
For the ana~ysis of incorporated 3H-AA or cell-associated free 3H-AA, 0.8 ml (8 
volumes) of ice-cold, chloroform: methanol (2: 1, v/v) was added to 0.1 ml of cell 
suspension. Cells were sonicated for 3 x 10 s with an interval of 10 s in an _ice bath 
followed by the rapid addition of 0.2 ml (0.2 volumes) of ice-cold methanol. 
Suspensions were mixed briefly with a vortex mixer and centrifuged at 4000 g for 3 min 
at 4°C. Centrifugation was used to convert all non-lipid residues into compact pellets 
instead of filtration due to the small sample size. 0.7 ml of supernatant was transferred 
into labelled Pyrex tubes and 0.2 ml (25% of the existing volume) of 0.88%KC1 
solution was added. Tubes were well shaken and allowed a few minutes for separation 
into two phases. Aliquots of 0.1-0.2 ml of the bottom layer were transferred into sterile 
vials and evaporated to dryness under a stream of nitrogen. Cellular extracts were re-
suspended in 30 µl of 3.33 mM unlabelled AA in chloroform: methanol (2: 1, v/v with 
0.01 % BHT) in air-tight vials and stored for a maximum of 72 hat - 20°C prior to TLC 
analysis of cell-associated 3H-AA. For 3H-AA incorporated into phospholipids, extracts 
were re-suspended in 30 µl of chloroform: methanol (2: 1, v/v with 0.01 % BHT) and 
stored in airtight vials at - 20°C before TLC. 
6.2.9 Thin layer chromatographic separations 
A solvent system of hexane: diethyl ether: acetic acid, 70: 30: 1.3 (v/v/v) was made up 
and stored in Schott bottles. Using a micro-Pasteur pipette, 10-20 µl aliquots of lipid 
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extracts were spotted on LK5D plates under a stream of nitrogen gas with reference 
phosphatidyl choline and unesterified AA co-chromatographed as standards on separate 
lanes for identification purposes. The plates were· run in a chamber pre-saturated with 
100 ml of the solvent system above. After 50 - 55 min, plates were dried with cool air 
from a hair dryer for ~ 30 s in a fume cupboard until free of the acetic acid odour. 
Thereafter, plates were exposed to iodine vapour produced from iodine crystals in a 
dosed tank. Lipid spots corresponding to standard phospholipid - -(for total AA 
incorporation) and AA- (for 3H-AA release into the supernatant and cell-associated 3H-
AA) bands were outlined with a needle. The TLC plates were removed from the tank 
and iodine was allowed to sublime. Spots (:::; 2 cm2) were scraped with a scalpel and 
transferred via a small plastic funnel into 7 ml scintillation vials containing 0.4 ml of 
1 % Na2S203, in order to reduce the iodine to iodide ion, thus decolorizing the mixture 
and minimizing quenching (as modified by Horrocks and Ansell, 1967). 4.0 ml of 
optiphase hisafe 2 liquid scintillation cocktail was added, mixed vigorously by 
vortexing and radioactivity was quantified by liquid scintillation spectroscopy in 
disintegrations per minute using the 1219 Rackbeta liquid scintillation counter by LKB 
Wallac. 
Extracellular 3H-AA release was expressed as the percentage of radioactivity released 
into the culture medium compared with total incorporated radioactivity. Cell-
associated, free 3H-AA was expressed ~s the percentage of radioactivity of free 3H-AA 
in cells compared with total incorporated radioactivity. 
6.3 RESULTS 
Initial experiments were performed to determine oxidant-stimulated release of [3H]-
labelled arachidonic acid from undifferentiated U937 cells. In a previous chapter, a 
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mixture oft-BHP and FeSO4 induced both dose- and time- dependent lipid peroxidative 
damage in U937 cells. In this study, the question of whether induced-oxidative stress 
was capable of causing the release of 3H-AA into the extracellular fluid was 
investigated, since PLA2 is present in high concentrations in U937 cells (Kramer et al., 
1991). - For this purpose, U937 cells were treated with or without varying amounts of 
the gxidant mixture and for various· periods of time. It was found that 3H-AA was 
released froI? prelabelled cells. after 4 h of incubation at 37°C under the conditions 
tested as shown in (Fig. 6.1). The release was not significant between O and 3 h of 
incubation with 750 µM t-BHP/Fe2+ but afterwards it proceeded linearly from 3 to 6 h 
therefore suggesting that oxidative stress enhance·s free AA release in U937 cells. The 
use of HBSS/0.2% BSA to wash the cells after 24 h of radiolabelling allows the 
trapping of all-free 3H-AA remaining in the culture medium. BSA binds fatty acids, 
making it unavailable for cellular incorporation into phospholipds. Thus, washing of 
cells twice ensures the removal of unmetabolized AA, prior to the release experiments. 
Fig. 6.1 shows the effects of treating U937 cells with 750 µM t-BHP/Fe2+ in HBSS over 
a period of 6 h at 37°C and 5% CO2 in a humid environment. Reactions were stopped at 
different time points, and free 3H-AA in the extracellular medium was isolated by TLC 
and expressed as a fraction of the total incorporated fatty acid by liquid scintillation 
counting. 
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Fig. 6.1 Time course of 3H-AA release in U93 7 cells treated with the oxidant 
mixture of 750: 750 µM oft-BHP: FeSO4 (750 µM t-BHP/Fe2+). Means± 95% Cls of 
triplicate independent experiments (n = 4). 
Since in previous studies 750 µM t-BHP/Fe2+ gave substantial detectable effects on both 
cell membrane integrity and lipid peroxidation, the effects of oxidative stress on 3H-AA 
release was observed initially using that same concentration in U93 7 cells monitored 
over time. Increasing effects of t-BHP/Fe2+ on 3H-AA release were observed in cells 
after periods ~ 3 h of incubation and maximal at 5 h, under the conditions stated above 
(One-way ANOVA F = 383.51, P < 0.01, DF = 5). Tukey' s comparisons showed no 
significant difference between the O and< 3 h time periods. However, 3H-AA release 
was significant after 3 h when compared to controls (0 h). 3H-AA release increased 
over time in a linear fashion (R2 = 0.955, P < 0.01). There was a time lag of about 3 h 
before t-BHP/Fe2+-induced AA release proceeded linearly, for 2 more hours but at a 
slower rate after 5 h. Based on these results, all subsequent experiments involved 
challenging U937 cells with t-BHP/Fe2+ for 4 h prior to AA release analysis. 
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Thereafter, U937 cells labelled with 0.1 µCi/ml of 3H-AA were exposed to different 
concentrations of t-BHP/Fe2+ for 4 h (Fig. 6.2). 
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Fig. 6.2 Concentration- dependent response ofU937 cells to 3H-AA release with 
varying concentrations oft-BHP/Fe2+. Means± Cls of two independent experiments (n 
=4). 
Fig. 6.2 shows the dose-response of the t-BHP/Fe2+ effect on the release of3H-AA from 
pre-labelled U937 cells. There was no significant increase in AA release at 
concentrations ~ 250 µM of the oxidant mixture compared with controls (One-way 
ANOVA F = 160.41, P < 0.01 , DF = 4). Again, maximal effects of the oxidant-induced 
AA release were observed at a concentration~ 750 µM when compared to controls. As 
shown in Figs. 6.1 and 6.2, 750 µM t-BHP/Fe2+ induced a dose - and time - dependent 
release of3H-AA in these cells. 
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6.3.1 With fatty acid concentrations 
To examine the role of fatty acids on 3H-AA release, U937 cells were cultured in CM 
supplemented with varying concentrations of fatty acids (SA, OA, AA, EPA or DHA) 
as well as 0.1 µCi/ml AA for 24 h at 37°C and 5% CO2 in a humid environment. 
Afterwards, cells were challenged with 750 µM t-BHP/Fe2+ for 4 h in HBSS. 
Table 6.1 Effects of SA and OA (after 24 h) on oxidant-induced 3H-AA release. 
Values are expressed as a percentage of the total incorporated 3H-AA. Means± Cls (n 
=4). 
Concentration SA OA 
Unoxidized control 0.3018 ± 0.1155 0.6775 ± 0.0557 
Oxidized control 2.0104 ± 0.1150 1.6212 ± 0.1039 
l0µM 2.0397 ± 0.2744 1.5726 ± 0.1019 
20µM 1.9890 ± 0.1665 1.5379 ± 0.1330 
30µM 2.3597 ± 0.2962 1.5989 ± 0.0526 
40µM 2.4626 ± 0.2213 1.6223 ± 0.1228 
Pre-incubation of cells for 24 h with 10 - 40 µM concentrations of SA or OA (Table 
6.1) showed no significant difference between 3H-AA released into the extracellular 
medium when compared to oxidized controls (0 µM). For SA (One-way ANOV A F = 
89.78, P < 0.01, DF = 5), Tukey's pairwise comparisons showed a significant difference 
between unoxidized controls and all treatments involving the oxidant. Similarly with 
OA (Kruskall-Wallis H = 12.28, P < 0.05, DF = 5), there was a significant difference 
between unoxidized controls and all other treatments. Comparing all treatments with 
oxidants ( oxidized controls to 40 µM), there was no significant difference observed 
(Kruskall-Wallis H = 3.83, P > 0.05, DF = 4). Neither the presence of SA nor OA in 
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concentrations varying from 0...:.. 40 µM significantly affected the release of 3H-AA into 
the cell supernatants induced-oxidation in U937 cells when compared to oxidant-treated 
controls (Table 6.1). 
Table 6.2 Effects of AA, EPA or DHA (after 24 h) on the release of 3H-AA into the 
extn1cellular medium. Means± Cls (n = 4). 
Concentratio,n AA EPA DHA 
Unoxidized control 0.4094 ± 0.0562 0.4286 ± 0.0922 0.5257 ± 0.1699 
Oxidized control 2.0146 ± 0.2528 2.2391 ± 0.1429 1.6136 ± 0.1911 
l0µM '3~9517 ± 0.4920 5.0210 ± 0.9812 4.2215 ± 0.7375 
20µM 6.9470 ± 0.7720 7.8794 ± 0.7136 4.8876 ± 1.3070 
30µM 6.6159 ± 1.1044 7 .6487 ± 1.5199 6.9101 ± 0.9959 
40µM 8.1778 ± 1.4553 8.4568 ± 0.8343 6.5364 ± 0.7934 
To assess the effects of PUFAs on oxidant-induced AA release, cells were pre-treated 
with varying concentrations of each of the PUFAs (AA, EPA or DHA) and the 
radiolabel (3H-AA) for 24 h (Table 6.2). Thereafter, cells were washed twice in 
HBSS/0.2% BSA to ensure the removal of unincorporated free fatty acids. Using the 
oxidant mixture at 750 µM t-BHP/Fe2+ concentration, cells were challenged for 4 hat 
37°C and 5% CO2 in a humid environment. With AA-pretreated cells (Table 6.2), 3H-
AA release proceeded linearly from oxidized controls to 20 µM levels, after which it 
began to plateau (One-way ANOVA F = 115.70, P < 0.01, DF = 5) (Table 6.2). 
Likewise, the same was observed with EPA-treatments of U937 cells (One-way 
ANOVA F = 117.49, P < 0.01, DF = 5). DHA-pretreatments generated a linear increase 
in the release of 3H-AA over the concentration range of 0 - 30 µM DHA levels (One-
way ANOV A F = 69.20, P < 0.01, DF = 5). Unlike results obtained from cells 
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pretreated with the saturated {SA) or the monounsaturated (OA) fatty acids, pre-
incubation of U937 cells with the PUFAs (AA, EPA or DHA) produced a dose-
dependent elevation in 3H-AA release into the extracellular medium as quantified by 
liquid scintillation spectroscopy following-TLC separations. Oxidant treatment with the 
radical~mediated system of 750 µM t-BHP/Fe2+ in serum free medium (HBSS) for 4 h 
indic;,ated that the PUF As (AA, EPA or DHA) generated a concentration-dependent 
increase in r~lease of 3H-AA into the supernatant. Tables 6.1 and 6.2 suggest that 3H-
AA release may be coupled to peroxidation in U937 cells. For all experiments with SA, 
OA, AA, EPA or DHA, there was a dramatic enhancement in U937 cell release of 3H-
AA in oxidant-treated· controls compared to those oxidant-untreated controls, with an 
average increase> 200% to< 600%. 
The stimulation of PUPA-enriched U937 cells with the oxidant mixture resulted in 
increased AA release by 96% (AA), 124% (EPA) and 162% (DHA) in comparison to 
oxidized controls when used at 10 µM PUF A concentrations (Table 6.2). There was a 
linear relationship between PUFA concentration and oxidant-induced AA release: AA 
(R2 = 0.936, P < 0.01); EPA (R2 = 0.914, P < 0.01) and DHA (R2 = 0.923, P < 0.01). 
Since a marked increase in 3H-AA release was observed with all three PUFA treatments 
at 10 µM levels when compared to oxidized controls, subsequent experiments involving 
AA, EPA or DHA were conducted at this concentration. 
To provide further evidence for the coupling of oxidant-induced 3H-AA release to the 
vulnerability of U937 cells pretreated with the fatty acids SA, OA, AA, EPA or DHA, 
experiments were conducted with equivalent concentrations of each of the fatty acids 
(10 µM) and 0.1 µCi/ml 3H-AA for 24 h before subjection to the same level of oxidative 
stress (750 µM t-BHP/Fe2+ in HBSS) (Fig. 6.3) or HBSS only (Fig. 6.4). 
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Effects of 24 h incubation with 10 µM levels of S~ 0~ AA, EPA or 
DHA and 3H-AA (0.1 µCi/ml) on AA mobilization in U937 cells treated with 750 µMt-
BHP/Fe2+. Means ± 95% Cls of two independent experiments (n = 4). Letters: a, b, c 
and d represent significant differences between treatments at P < 0.01. 
Statistical analysis by one-way ANOV A (F = 131.25, P < 0.01, DF = 6), showed no 
significant difference between oxidized controls and 10 µM SA or 0~ although there 
was an increase in 3H-AA release with increasing unsaturation (Fig. 6.3). There was a 
significant increase with PUF A treatments when compared to oxidant-treated controls. 
Comparative differences between cells treated with 10 µMS~ 0~ AA, EPA or DHA 
demonstrated that the presence of the PUF As promoted increased 3H-AA hydrolytic 
release of 35% (AA), 69% (EPA) and 48% (DHA) of the total incorporated 3H-AA 
compared to controls. There was a marked increase (P < 0.0001) in 3H-AA release in 
U937 cells exposed to oxidants compared to unoxidized controls (- Ox). AA release 
into the extracellular medium was significantly higher in EPA- than AA- treated cells (P 
< 0.01). However, there were no significant differences observed either between EPA-
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and DHA-treatments or AA and DHA pre-treated cells. Surprisingly, a sequential trend 
in the stimulation of AA release with increasing degree of fatty acid unsaturation, was 
not observed. On the average, though not significant (P > 0.01), EPA- but not DHA-
treatment stimulated the highest AA release from U93 7 cells in this comparative 
experiment (Fig. 6.3). 
Examination of the effects of incubating FA-treated U937 in HBSS only (Fig. 6.4) 
demonstrated enhanced AA release with EPA and DHA compared to controls even 
though there was no oxidation involved (One-way ANOV AF= 5.62, P < 0.05, DF = 5). 
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Fig. 6.4 Effects ofHBSS only on AA release from U937 cells pre-treated for 24 h 
with 10 µM fatty acids and 3H-AA. * Represents significant differences at P < 0.05 
(one-way ANOVA followed by Tukey's pairwise comparisons), between FA treatment 
and controls (ctrl). Means ± 95% Cls (n = 4). Letters: a and b denote significant 
differences between means (P < 0.05). 
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There was no significant difference between controls, SA-, OA- and AA-treated cells. 
AA release from EPA- and DHA-treated cells, were 48% and 54% higher than controls, 
respectively (Fig. 6.4). 
Taken logether, comparisons of results between FA·-enriched U937 cells treated with 
and _:without oxidants (Fig 6.3 and Fig. 6.4, respectively), showed that there was a 
marked incr~ase in AA release when the cells were stimulated with 750 µM t-BHP/Fe2+ 
than without. These results suggest that the presence of EPA or DHA on its own in 
U937 cells stimulates AA-release with or without oxidants when compared with 
controls, SA or OA. However, AA-treatment was neither significantly different from 
controls nor EPA/DHA when cells were incubated for 4 h without the oxidant (Fig. 6.4). 
To investigate the possible involvement of prolonged fatty acid - pretre.atment of U937 
cells, oxidant-induced 3H-AA release after 18 days of CM-supplementation with 10 µM 
concentrations of the fatty acids SA, OA, AA, EPA or DHA was determined. The 
culture medium was renewed every 3 days after viability measurements > 90% and re-
adjustments of the cell density to 0.5 x 106 cells/ml both monitored by the Trypan Blue 
dye-exclusion method. 
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Fig. 6.5 Effects of prolonged fatty acid treatments (18 days) on AA release from 
U937 cells. Means ± 95% Cls (n = 4). Letters: a, b, c and d represent significant 
differences between means (P < 0.01). 
Unlike AA release from U93 7 cells treated with 10 µM levels of the F As for 24 h, the 
data shown in Fig. 6.5, demonstrate a markedly significant 3H-AA release with EPA 
compared to all other treatments (One-way ANOVA F = 214.47, P < 0.01, DF = 6). As 
expected, there was a significant difference between oxidant-untreated controls (- Ox) 
and treatments with the oxidant (750 µM t-BHP/Fe2+). With continuous 
supplementation ofU937 cells with the fatty acids for 18 days, one might expect to find 
a release not only of the radiolabelled fatty acid but also of the supplemented fatty acid 
independent of its degree of unsaturation, thus significantly evening out 3H-AA release 
in all treatments. To address this possibility, cells were labelled with 0.1 µCi/ml 3H-AA 
just 24 h prior to exposure to 750 µM t-BHP/Fe2+. However, oxidation induced no 
significant differences between oxidized controls (Ox) and SA or OA (Fig. 6.5). Again, 
there was a significant increase in 3H-AA release with PUF A (AA, EPA or DHA) -
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pretreatments compared to oxidant-treated controls (Ox). Surprisingly, the influence of 
prolonged EPA treatments of U937 cells produced a. striking increase in AA release, 
significantly higher than that released from all other treatments including AA and even 
DHA. There was however no significant difference observed in 3H-AA released from 
incubations between cells pre-treated with AA or DHA for 18 days. 
Since contr~l experiments involving FA-pretreated cells alone for 18 days without 
oxidation were not included in this study, this experiment does not confirm the 
speculation that prolonged EPA treatment on its own stimulates AA release without 
oxidant-activation. It ·is important to conduct further studies to answer this question 
concerning the unexpected results (Fig. 6.5). 
6.3.1.1 Cell-associated free fatty acids 
The amount of cell-associated free 3H-AA upon oxidative stimulation showed no 
significant differences between SA/OA/ AA treatments and oxidized controls (Fig. 6.6). 
There was a significant difference observed between oxidized controls (Ox) and EPA 
treated cells only (One-way ANOV A F = 38.21, P < 0.01, DF = 6). Neither was there 
any significant difference between AA and EPA nor AA and DHA. However, a 
significant difference between EPA and DHA treatments was found. The level of free 
3H-AA associated with the cells (not incorporated into phospholipids) was in agreement 
with its release into the medium, particularly with EPA treatments compared to oxidant-
treated controls (Fig. 6.6). 
217 
1.4 
1.2 
-
Q) 
bl) 
= .... 
= Q) 
(,J 
s.. 
Q) 
5 
~ 0.8 
e= 
-e 0.6 Q) 
= 
·o 
0 
~ 
~ 0.4 = 
..!. 
~ 
u 
0.2 
0 
-Ox Ox SA OA 
Fatty acid 
C 
AA EPA DHA 
Fig. 6.6 Cell-associated free fatty acids in FA-enriched U937 cells treated with 
750 µM oft-BHP/Fe2+ for 4 h. Means± 95% Cls of two independent determinations (n 
= 4). Letters: a, band c denote significant differences between means (P < 0.01). 
6.3.2 With antioxidants 
Given the high capacity ofU937 cells to release 3H-AA into the extracellular fluid upon 
induced-oxidative stress, the question of whether pre-treatment with antioxidants 
inhibited this response was examined. For this purpose, U937 cells were treated 
initially with or without antioxidants and 3H-AA for 24 h prior to oxidant-induced 3H-
AA release experiments. The presence of ascorbic acid at 100 - 400 µM concentrations 
in U937 cells further increased 3H-AA release into the medium (Fig. 6.7a), suggesting 
that ascorbic acid enhanced pro-oxidative effects thereby stimulating AA mobilization 
rather than acting as an antioxidant, exerting suppressive effects on the oxidative 
process (One-way ANOV AF= 226.19, P < 0.01 , DF = 5). 
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Fig. 6.7 3H-AA release m U937 cells pre-treated for 24 h with varymg 
antioxidants concentrations, before the exposure of cells to the oxidant mixture (a) With 
0 - 400 µM ascorbic acid; (b) with 0 - 40 µM a-tocopherol; ( c) with 0 - 12 µM j3-
carotene and (d) with 0 - 12 µM astaxanthin. Data points represent the means± 95% 
Cls (n = 4). 
Ascorbic acid at concentrations 2::: 100 µM in the cells generated a dramatic increase in 
the release of 3H-AA into the extracellular medium compared to oxidant-treated controls 
(Ox) after 4 h of incubation with 750 µM t-BHP/Fe2+. (Fig. 6. 7a). There was no 
significant difference between the effects of ascorbic acid at the concentration range 
used ( 100 - 400 µM). At 100 µM ascorbic acid 1 eve ls, there was 191 % increase in AA 
release and 244% at 200 µM compared to oxidized controls. The addition of 300 µM 
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yielded 185% increase in AA release and 175% at 400 µM. Although, with increasing 
ascorbic acid levels (300 -400 µM), there appears to be less deleterious oxidative 
effects, this decrease was not significant! y different from other ascorbic acid 
concentrations. a-tocopherol on the other hand, was a potent inhibitor of oxidant-
induced AA release at a concentration ~ 10 µM to 40 µM after 4 h of treating U937 
cells with 750 µM of the oxidant (One-way ANOV AF= 81.82, P < 0.01, DF = 5) (Fig. 
6.7b). At 10 µM a-tocopherol levels an 18% re~uction in AA release and 37% at 40 
µM compared to oxidized controls (Ox) were observed. Contrary to expectations, pre-
treatment of cells with 0-12 µM levels of the carotenoids, {3-carotene (One-way 
ANOVA F = 40.67, P < 0.01, DF = 5) (Fig. 6.7c) and astaxanthin (One-way ANOVA F 
= 142.13, P < 0.01, DF = 5) (Fig. 6.7d), showed no inhibitory effects on AA release 
compared to oxidized controls. In all experiments (Fig. 6.7), oxidant-untreated controls 
(- Ox) generated significantly lower 3H-AA amounts than oxidant-treated controls (Ox). 
Collectively, these results suggest that a-tocopherol confers the highest antioxidant 
effects in U937 cells over prolonged oxidative stress ( 4 h) compared to ascorbic acid or 
even the carotenoids, (3-carotene and astaxanthin, as measured by 3H-AA release into 
the extracellular fluid. 
To further define the role of these antioxidants on 3H-AA release, the effects of 
adjunctive treatments with varying concentrations of the antioxidants (ascorbic acid, a-
tocopherol, (3-carotene and astaxanthin), 10 µM PUFAs (AA, EPA or DHA) and 0.1 
µCi/ml 3H-AA for 24 h pre-oxidation were examined in U937 cells. Fig 6.8 shows the 
effects of 0- 400 µM ascorbic acid on PUPA-enriched cells subjected to oxidation for 4 
h under the condition stated earlier. 
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Fig. 6.8 Induced-AA release in U93 7 cells treated with 10 µM PUF As ( AA, EPA 
or DHA) and various concentrations of ascorbic acid. Means ± 95% Cls (n = 4). 
Letters: a, b c and d represent significant differences between means at P < 0.01. 
As shown in Fig. 6.8, ascorbic acid at 100 - 400 µM concentrations, promotes the pro-
oxidative effects of t-BHP/Fe2+ in PUF A-enriched U937 cells thus aggravating the 
effects already exerted by the oxidant system on its own. 100 - 400 µM ascorbic acid 
treatments further enhanced 3H-AA release compared to oxidized controls (Ox). With 
10 µM AA pre-treatment, there was a linear increase in AA release from 100 - 300 µM 
ascorbic acid concentrations after which it appears to reduce significantly at 400 µM 
level compared to other ascorbic acid concentrations (One-way ANOVA F = 112.68, P 
< 0.01, DF = 5). Results showed 153 - 193% increase in AA release with ascorbic acid 
concentrations ranging from 100 - 300 µMand 89% with 400 µM levels compared to 
oxidized controls (Ox). These results suggest a less toxic effect at 400 µM ascorbic 
acid levels in U93 7 cells co-treated with 10 µM AA. However, all ascorbic acid 
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treatments resulted in significantly higher AA release compared to both unoxidized (-
Ox) and oxidized (Ox) controls. 
Neither the presence of EPA nor DHA in U937 cells influenced the damaging effects of 
ascorbic acid at 0 - 400 µM levels. With both EPA and DHA treatments, there was a 
linear increase in AA release from unoxidized controls (- Ox) to 100 µM ascorbic acid 
concentratiol)., thereafter it began to plateau. With 10 µM EPA treatments, there was an 
average increase of 74% in 3H-AA release with ascorbic acid concentrations ranging 
from 100-400 µM compared to oxidant-treated controls (One-way ANOVA F = 41.17, 
P < 0.01, DF = 5). · With 10 µM DHA, ascorbic acid levels at 100 - 400 µM 
concentrations did not exert antioxidant properties in cells upon oxidation (One-way 
ANOVA F = 69.24, P < 0.01, DF = 5). At 100 µM ascorbic acid levels, there was 77% 
increase in AA release compared to oxidized controls, whereas there was a 29% 
increase with 400 µM levels. 
Taken together, it appears that the choice of PUFAs influence the activity of ascorbic 
acid. With DHA, ascorbic acid at 200 - 400 µM exerted neither aggravating nor 
inhibitory properties on AA release observed in U937 cells. On the other hand, for EPA 
treatments, 100 - 400 µM ascorbic acid treatments contributed to the pro-oxidative 
properties of the oxidant used hence generating 3H-AA release significantly greater than 
oxidized controls (Ox). There was a significant difference in 3H-AA release with AA 
pre-incubations co-treated with 100 - 400 µM concentrations of ascorbic acid compared 
to controls. This results suggest that the presence of EPA and AA contribute more to 
the pro-oxidative properties of ascorbic acid than DHA in U937 cells, to varying 
extents, in the following order of magnitude AA > EPA > DHA. Even though these set 
of experiments were not replicated, it remains pertinent that ascorbic acid (100 - 400 
222 
µM) enhances 3H-AA release from U937 cells exposed to oxidative stress by 750 µMt-
BHP/Fe2+. 
The effects of varying concentrations of the lipid-soluble antioxidant, a.-tocopherol, in 
U937 cells enriched with PUFAs were investigated (Fig. 6.9). 
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Effects of a.-tocopherol concentrations ranging from O - 40 µM levels 
and PUFA enrichment on 3H-AA release in U937 cells. Means± 95% Cls (n = 4). 
Letters: a, b, c and d indicate significant differences between means at P < 0.01. 
To determine the role of a.-tocopherol on in vitro oxidant-induced 3H-AA release by t-
BHP/Fe2+ post-PUFA enrichment, U937 cells were pre-treated with O - 40 µM a.-
tocopherol levels and 10 µM AA, EPA or DHA for 24 h prior to the induction of 
oxidative stress (Fig. 6.9). With AA treatment, there was a significantly lower 3H-AA 
release observed at 10 µM a.-tocopherol levels compared to oxidized controls (One-way 
ANOV AF= 17.83, P < 0.01, DF = 5). In fact, at a.-tocopherol concentrations ~ 10 µM, 
there was no significant difference between oxidant-untreated controls (- Ox), 
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suggesting a potent inhibitory role of a-tocopherol on AA-pre-treated U937 cells. EPA 
and DHA treatments genera~ed similar results with 3H-AA release significantly 
inhibited at a-tocopherol levels ~ 10 µM, compared to oxidant-treated controls (Ox): 
EPA (One-way ANOVA F = 47.01, P < 0.01, DF = 5); DHA (One-way ANOVA F = 
128.22, P < 0.01, DF = 5). With 10 µM EPA treatments, there was 30% decrement in 
3H-AA release at 10 µM a-tocopherol concentration and 60% at 40 µM levels when 
compared to,oxidant-treated controls (One-way ANOVA F = 47.01, P < 0.01, DF = 5). 
In DHA pre-treated cells, results demonstrated 10% inhibitory effects of a-tocopherol at 
10 µM concentrations and 51 % at 40 µM compared to oxidized controls. 
Overall, a-tocopherol conferred inhibitory effects on PUPA-treated U937 cells at 
concentrations~ 10 µM levels as measured by extracellular 3H-AA release. Its potency 
was greater in the presence of PUFA in the order: AA> EPA> DHA when compared to 
their respective oxidant-treated controls (Ox). 
To attempt to inhibit 3H-AA release induced by t-BHP/Fe2+, U937 c;ells co-treated with 
carotenoids, (3-carotene (Fig. 6.10) or astaxanthin (Fig. 6.11), and 10 µM PUFA for 24 h 
at 37°C and 5% CO2 in a humid environment were examined. Fig. 6.10 shows the 
effect of O - 12 µM (3-carotene concentrations on 3H-AA release. With AA (One-way 
ANOVA F = 13.75, P < 0.01, DF = 5), EPA (One-way ANOVA F = 105.64, P < 0.01, 
:OF= 5) and DHA (One-way ANOVA F = 65.12, P < 0.01, DF = 5) treatments, (3-
carotene at 3 - 12 µM levels manifested no protective antioxidant role in U937 cells. 
With all three PUFA treatments, there was no significant difference between oxidant-
treated controls (Ox) and 3 - 12 µM (3-carotene levels but as expected there was a 
significantly lower AA release from unoxidized controls (- Ox) when compared to all 
treatments involving the oxidant (Fig. 6.10). 
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Oxidant-induced 3H-AA release into the extracellular medium of U937 
cells treated with 10 µM PUFA (AA, EPA or DHA) and J3-carotene concentrations 
ranging from 0 - 12 µM. Means ± 95% Cls (n = 4). Letters: a and b represent 
significant differences between means at P < 0.01 . 
In a like manner, as shown in Fig. 6.11, treatments of PUF A-enriched U937 cells with 
0-12 µM astaxanthin concentrations did not result in the inhibition of 3H-AA release 
into the extracellular fluid after 4 h of induced oxidative stress at 37 °C and 5% CO2 in a 
humid environment: AA treatment (One-way ANOVA F = 9.65, P < 0.01, DF = 5); 
EPA (One-way ANOV AF = 46.84, P < 0.01, DF = 5) and DHA (One-way ANOV AF 
= 116.78, P < 0.01 , DF = 5). With 10 µM AA, EPA or DHA, there was a significant 
increase in oxidant-treated controls (Ox) compared to unoxidized controls (- Ox). 
There was no significant difference observed between oxidized controls and 3 - 12 µM 
astaxanthin treatments (Fig. 6.11). 
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Fig. 6.11 Oxidant-induced 3H-AA release from U937 cells treated with PUF As 
(AA, EPA or DHA) and astaxanthin concentrations ranging from O - 12 µM. Means± 
95% Cls (n = 4). Letters: a and b denote significant differences between means at P < 
0.01. 
The next series of experiments sought to determine whether it was possible to further 
suppress the release of 3H-AA into the extracellular fluid under the conditions stated 
earlier. To this end, the effects of several antioxidant combinations in PUF A-rich U93 7 
cells stimulated by the oxidant mixture, were examined. U93 7 cells were pre-treated 
with 10 µM AA, EPA or DHA coupled with antioxidants (individuals and mixtures) for 
24 h after which the cells were challenged with 750 µM t-BHP/Fe2+ for 4 h. The final 
antioxidant concentrations used in CM were 400 µM ascorbic acid, 40 µM a-
tocopherol, 12 µM P-carotene or astaxanthin on all occasions when used either 
individually or as combinations. 
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In order to determine whether the activation of 3H-AA release in U937 cells by 
oxidative stress stimuli is suppressed by pre:-treatment of cells with a combination of 
antioxidants, the possible effects of individual and mixtures of antioxidants on PUPA-
enriched cells were also examined (Fig. 6.12). The data in Fig. 6.12 clearly 
demonstrates that a-tocopherol on its own was the most effective antioxidant against 
the induced release of 3H-AA significantly inhibiting the amount of 3H-AA released into 
the medium ,compared with oxidant-treated controls (Ox): AA (One-way ANOV A F = 
451.77, P < 0.001, DF = 11); EPA (One-way ANOVA F = 340.34, P < 0.001, DF = 11) 
and DHA (One-way ANOVA F = 267.68, P < 0.001, DF = 11). Vitamin C (ascorbic 
acid) significantly increased AA release compared to oxidized controls. When ascorbic 
acid was combined with one other antioxidant, the presence of 40 µM a-tocopherol or 
12 µM astaxanthin but not 12 µM {3-carotene reduced the contributory pro-oxidative 
effects observed with ascorbic acid alone, though not significantly different from that 
observed in oxidant-treated controls (Ox). 
Studies also investigated whether the combination of antioxidants generated additive or 
.synergistic inhibition in the release of 3H-AA from U937 cells particularly combinations 
of a-tocopherol with astaxanthin or {3-carotene. Contrary to expectations, although 
there was a significant reduction in 3H-AA release with cells pre-treated with a-
tocopherol and either {3-carotene or astaxanthin, the reduction was not as significant as 
that observed with a-tocopherol on its own when compared to oxidant-treated controls 
(Fig. 6.12). These data therefore suggest that the presence of astaxanthin or {3-carotene 
somehow interferes with the activities of a-tocopherol, thus reducing the sole inhibitory 
effects of a-tocopherol conferred on U937 cells. It also demonstrates that either of 
these two carotenoids can act also as pro-oxidants, especially under prolonged oxidative 
stress such as that used in this study (t-BHP/Fe2+ for 4 h). 
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As previously shown, there was no significant difference between oxidant-treated 
controls (Ox) and treatments with 12 µM B-carotene · or 12 µM astaxanthin. With 
adjunctive treatments of cells with both ascorbic acid and a-tocopherol, although there 
was no conferred pro-oxidative influence contributing to the release of AA by ascorbic 
acid, neither was there observed any inhibitory effect of a-tocopherol compared to 
oxidized controls, demonstrating that the latter exerted its antioxidant properties by 
inhibiting further peroxidative damage by ascorbic acid. As such AA release in cells 
pre-treated with a-tocopherol and ascorbic acid was not significantly different from 
oxidant-treated controls (Fig. 6.12). 3H-AA release from oxidant-untreated control cells 
(- Ox) was markedly different at P < 0.01 from all other treatments studied. 
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6.4 DISCUSSION AND CONCLUSION 
The objective of this study was to investigate whether a relationship exists between 
oxidative stress and AA release into the extracellular fluid using the human lymphoma 
cell line U937 as a model. Following the establishment of coupling between these two 
processes, the effects of cellular pre-treatment with the PUFAs (AA, EPA or DHA) as 
weltas varying concentrations of the dietary antioxidants (ascorbic acid, a-tocopherol, 
~-carotene and astaxanthin) both individually and as mixtures were evaluated. 
Monocytic cells are naturally capable of producing highly reactive oxygen species such 
as superoxide anion arid hydrogen peroxide in response to a variety of stimulants (Lum 
and Roebuck, 2001). Although these metabolites play critical roles in vivo or in vitro in 
inflammatory processes such as host defense, chemotaxis and exocytosis of lysosomal 
contents (Snyderman and Pike, 1984; Hugli, 1984; Fisher et al., 1995), their production 
in uncontrolled amounts may lead to serious cellular dysfunctions. Oxidative injury 
(Mahadik et al., 2001), elevated phospholipid breakdown (Ross et al., 1997) and 
increased PLA2 activity (Gattaz et al., 1995) are often implicated in schizophrenia. 
Also, arachidonic acid release has been associated with oxidative damage in several cell 
types such as the vascular smooth muscles, stromal cells, striatal neurons, platelets and 
phagocytes (Chakraborti and Chakraborti, 1995; Rao et al., 1995; Boyer et al., 1995; 
Samant_a et al., 1998; Buschbeck et al., 1999; Birbes et al., 2000). 
In this study, a mixture of tert-butyl hydroperoxide and ifon sulfate (t-BHP/Fe2+) was 
used to investigate the release of arachidonic acid in U937 cells subjected to oxidative 
stress, and the data suggest that AA mobilization from cellular phospholipids is both 
dose - and time - dependent on the oxidant. This study shows that oxidant-induced AA 
release increases with increasing concentration of the PUFAs {AA, EPA or DHA) but 
230 
not SA or OA as previously reported by Robinson et al. (1998) .. Examination of the 
time course release of 3H-AA in response to BHP/Fe2+ revealed that.after an initial time 
lag of 3 h, the response proceeded linearly with time, showing signs of saturation after 
exposure of cells to the oxidant mixture for 5 h. 
The role of trace redox active transition metals such as iron is essential in many 
biological re~ctions such as the synthesis of DNA, RNA and proteins, and also as co-
factors of numerous enzymes, particularly those involved in respiration. The lack of 
these metals may therefore lead to dysfunctions in the CNS and other organ functions 
but their presence in excessive amounts can be cytotoxic, due to oxidative stress and 
increased free radical production as shown in this study. Macrophage-like cells in the 
CNS (microglia) are the major sites of ferritin bound iron and are thought to be partly 
responsible for oxidative damage in Parkinson's disease (Sayre et al., 1999). 
Saturated and mono-unsaturated fatty acids can be synthesized by the human body de 
novo. However, since mammals cannot introduce double bonds beyond the delta-9 
position in the fatty acid chain, linoleic and linolenic acid, the n-6 and n-3 series 
precursors respectively, must be supplied by the diet. Based on this, the effects of 
oxidation on AA released into the medium after the enrichment of U937 cells with 
various concentrations of different fatty acids (SA, OA, AA, EPA or DHA) ranging 
from 10 - 40 µM, were determined. Pre-incubation with these concentrations of SA or 
OA generated no significant differences in. AA released into .the extracellular fluid 
compared to oxidant-treated controls. Increased oxidant-induced AA release however 
appeared to be a general feature with increasing concentrations of the PUF As (AA, EPA 
andDHA). 
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In order to investigate the possible involvement of cPLA2 in the release of incorporated 
3H-AA, U937 cells, cells were cultured with equal amounts of the fatty acids SA, OA, 
AA, EPA or DHA in one single experiment (Fig. 6.4), before the induction of oxidative 
stress with t-BHP/Fe2+. Results demonstrated that neither SA nor OA, nor AA released 
3H-AAin an amount significantly different from controls whereas, EPA and DHA did. 
However, post-oxidation (Fig. 6.3) data showed whilst there was no significant 
difference b~tween SA or OA in comparison to oxidized controls, there were significant 
differences with PUPA-treated cells following 24 h of cellular pre-treatments in the 
following order: AA < DHA < EPA. When U937 cells were consecutively treated with 
these fatty acids over 18 days, a striking difference in AA release was observed between 
the PUP As with the greatest increase observed with EPA. A possible explanation for 
this marked increase in AA release with EPA - and not DHA - pre-treatment after 
continuous PUPA supplementation is that upon oxidative stress, the presence of EPA in 
U937 cells, results in a rapid accumulation of cell-associated free 3H-AA preceding its 
mobilization into the incubation medium over time, as suggested from Fig. 6.6, by a 
mechanism yet to be investigated. Whether certain gene expressions were altered by 
EPA but not DHA over the 18 days of continuous supplementation, thereby stimulating 
such markedly higher AA release upon oxidation, is unknown at present. Collectively, 
these results suggest that oxidative stress activates a PLA2 enzyme in PUPA-enriched 
U937 cells, which in tum triggers the release of AA from cell membrane phospholipids. 
AA is almost exclusively located at the sn-2 position of phospholipids, and some of the 
several pathways postulated for its release include: the direct hydrolysis of a 
phospholipase A2 (Bills et al., 1976; Billah and Lapetina 1982); hydrolysis by a 
phospholipase A1 followed by the action of a lysophospholipase (Van den Bosch, 1980; 
Irvine, 1982; Emilsson and Sundler, 1984); lipolysis by a PI-specific PLC followed by 
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the activity of a DAG lipase· (Mauco et al., 1978; Bell et al., 1979; Rittenhouse-
Simmons, 1979) or the sequential action of PLC, DAG kinase, and a phosphatidic acid 
specific PLA2 (Lapetina et al., 1981; Billah et al., 1981). These proposed mechanisms 
are not inhibitory of one another and may occur simultaneously. 
Amqng the different known types of phospholipase A2 enzymes, cPLA2, apart from 
occurring i~ high quantities (Rzigalinski et al., 1996), is considered as the key 
intracellular enzyme responsible for the release of AA in stimulated U937 cells 
(Kramer, 1994). Furthermore, Hsu et al. (2000) reported that changes in membrane 
lipid composition promote cPLA2 activation in differentiated U937 cells in a manner 
requiring neither the phosphorylation of the enzyme nor alterations in its level. In 
contrast to these observations, Balboa and Balsinde (2002), recently implicated iPLA2 
in hydrogen peroxide-induced AA release from U937 cells because treatment of the 
cells with bromoenol lactorie, a compound with marked selectivity for inhibiting iPLA2, 
resulted in a significant reduction in H2O2- activated AA release. 
Since all three forms of PLA2s (Ca2+-dependent/ independent cPLA2 and iPLA2) occur 
in U937 cells and it is well known that cPLA2 and not iPLA2 has a preference for AA at 
its sn-2 position, this conclusion argues against the possibility that iPLA2 is solely 
responsible for the mobilization of AA from H2O2-treated U937 cells. Perhaps the 
treatment of U937 cells with H2O2 sends a different signal to these cells thus activating 
AA release via a mechanism involving iPLA2 and not cPLA2 activation since these cells 
naturally produce H2O2 in response to a variety of agonists (Lum and Roebuck, 2001). 
Since AA is preferably located esterified at the sn-2 position of cellular phospholipids, a 
PLA2 is the key enzyme responsible for regulating the levels of free fatty acids (Dillon 
et al., 1997). However free AA levels available for eicosanoid synthesis represent a 
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balance between the amount · liberated by the activated PLA2 minus what is re-
incorporated back into phospholipids .by the acyltransferase ·enzymes (Chilton et al., 
1996). Therefore, the levels of available free fatty acids are efficiently controlled by the 
reacylation pathway as well (Chilton et al., 1996). Taking all these findings together, 
more work is required to investigate oxidant-stimulated AA release in U937 cells. 
The differen~es observed in the release of 3H-AA from U937 cells pre-treated with the 
polyunsaturated fatty acids: arachidonic, eicosapentaenoic and docosahexaenoic acids, 
will be discussed in more detail at the end of this study (Chapter nine). 
6.4.1 With antioxidants 
Despite the fact that vitamin E (a-tocopherol) is a powerful hydrogen atom donor 
towards free radicals, and particularly peroxyl radicals, it does not function as a 
generalized biological reducing agent, although its phenolate ion may reduce some 
transition metals in certain situations. In contrast, vitamin C (ascorbic acid) is an 
essential co-factor and an important biological reducing agent for iron, for instance. 
Vitamin C acts as a general reducing ~gent• toward a variety of oxidants, including 
supplying reducing equivalents in enzymatic reactions. Although it is truly one of the 
important water-soluble antioxidants, it is not unique in this role. Other hydrophilic 
antioxidants include uric acid (Peden et al., 1990), and glutathione (Halliwell and 
Gutteridge, 19~9). Therefore vitamin C, in contrast to vitamin E, has many other well-
established functions in addition to being an antioxidant, which is not its unique role. 
Vitamin E is the most important lipid-soluble peroxyl radical scavenger in human cells 
and acting as an antioxidant clearly is one of its principal roles and quite possibly the 
most important (Pryor, 2000). Both vitamins E and C have an aromatic hydroxyl group 
234 
capable of acting as an electron donor whereas carotenoids such as B-carotene is a 
hydrocarbon, and t~erefore a poor structural choice as a general reducing agent. 
In order to determine whether CM-:-supplementation with the dietary antioxidants 
(ascorbic acid, a-tocopherol, B-carotene and astaxanthin) inhibited oxidant-induced AA 
release in U937 cells, this study first examined the possible inhibition of incorporated 
3H-AA release by pre-treating the cells with the antioxidants alone for 24 h before 
oxidation (Fig. 6.7). This study demonstrates that ascorbic acid, an agent known to 
scavenge free radicals, also has the capacity to promote oxidative stress in U937 cells 
(Frei and Carr, 1999). · Vitamin C interacts with redox active transition metal ions such 
as iron and copper. The reduction of these transition metals by ascorbate ion can have 
deleterious effects in biological systems by the production of alkoxyl and hydroxyl 
radicals promoting peroxidative damage (Halliwell, 1996; Buettner and Jurkiewicz, 
1996). The relevance of this Fenton reaction has been a controversial issue in vivo 
because of the availability of the metal ions especially iron (Halliwell and Gutteridge, 
1986). Although free metal ions are thought to exist in low concentrations in vivo due 
to their prese:µce in sequestered forms in various binding proteins such as ferritin and 
transferrin (Halliwell and Gutteridge, 1986), these ions may be released during tissue 
injury subsequently reacting with vitamin C (Halliwell, 1996) thereby escalating 
peroxidative processes resulting in damaging consequences to the cells involved (Fig. 
6.7a). 
a-tocopherol - treatment in animal models reduced the formation of thromboxanes in 
stimulated platelets (Hamelin and Chan, 1983) and prostaglandin E2 in activated 
macrophages (Sakamoto et al., 1991). Since AA release by PLA2 is the rate-limiting 
step in the biosynthesis of the eicosanoid hormones, the inhibition of PLA2 activity 
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(Douglas et al., 1986; Cao et al:, 1987; Sakamoto et al., 1993) is generally referred to as 
the mechanism for the attenuation of the production of eicosanoids. In the present 
study, vitamin E inhibits the release of free AA reducing its availability for eicosanoid 
synthesis in oxidant- stimulated U937 cells, possibly by acting as a potent antioxidant. 
In contrast, vitamin E enrichment has also been shown to stimulate eicosanoid synthesis 
in some other cell types by causing an increase in AA release in cultured endothelial 
cells_ (Tran ~nd Chan, 1988); rat heart myoblastic cells (H9c2) (Tran et al., 1996) and 
prostaglandin 12 synthesis (Tran and Chan, 1990). The apparent difference in the 
activity of a-tocopherol between mammalian cell types illustrates the fragmented nature 
of the understanding of the contributions of vitamin E in the regulation of arachidonic 
acid release with the knowledge of its specific mode of actions still remaining an elusive 
concept. 
Considerable data suggest that excessive oxidative injury may be involved in the 
development of neurodegenerative diseases such as schizophrenia (Mahadik et al., 
2001), Alzheimer's disease (Markesbury, 1997) and Parkinson's disease (Ebadi et al., 
1996). Vitamin E intake has been reported to show protective roles against the 
occurrence of schizophrenia (Dorfman-Etrog et al., 1999), Alzheimer's disease (Sano et 
al., 1997) and Parkinson's disease (de Rijk et al., 1997). Vitamin E has also been 
shown to protect neurons from the effects of certain neurotoxic agents such as those 
from estradiol-induced neurotoxicity (Desjardins et al., 1992). Just like a-tocopherol, 
the carotenoids are lipid-soluble substances and potent scavengers of free radicals. 
However, neither ~-carotene nor astaxanthin exhibited any protective antioxidant effects 
against AA released after 4 h of induced-oxidative stress in U937 cells. Whilst the 
enrichment of U937 cells with a-tocopherol led to a marked inhibition of AA release 
~nto the incubation medium, ascorbic acid enhanced its release whereas the carotenoids 
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showed no significant effects. · This study supports the suggestion that a-tocopherol 
may be the major chain breaking antioxidant during cell-mediated oxidation (Reaven et 
al., 1993; Diaz et al., 1997). 
It is possible that the antioxidant effectiveness of ~-carotene or astaxanthin was not 
observed because the concentration used in this study, pertaining to the oxidation time 
( 4 h), was too small to elicit an effect. This assumption is based on the antioxidant 
effects observed with ~-carotene and astaxanthin in chapter two after 30 minutes of 
induced-oxidation. Or perhaps the nature of in vitro enrichment of U937 cells as 
micelles (in chloroform) may have resulted in the incorporation of the carotenoids in a 
fashion dissimilar to that normally obtained in vivo (Borel et al., 1996), thus masking 
the true antioxidant effects of these carotenoids. Furthermore, the carotenoid radical 
intermediate formed in the process of breaking lipid peroxidative chain reactions, may 
have contributed to the propagation of oxidation (Dugas et al., 1998) rather than 
breaking the chain just like a-tocopherol under certain conditions (Stocker et al., 1991; 
Bowry et al., 1992). It was demonstrated that a-tocopherol affects the structure and 
dynamic properties of membranes (Srivastava et al., 1983; Suzuki et al., 1993). Several 
studies have suggested that interactions between vitamin E and membranes play a 
critical role in its mechanisms of antioxidant action and stabilization of membranes 
(Gomez-Fernandez et al., 1989). At high concentrations, vitamin E can have destructive 
effects on membranes under the "electric" (tensed) environment found in living cell 
membranes, probably the reason for its low concentrations in biological membranes 
(Koronkiewicz et al., 2001). 
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6.4.2 Interaction between antioxidants 
In an attempt to characterize this observation further, this study investigated whether the 
inhibitory effects of the dietary antioxidants (ascorbic acid, a-tocopherol, ~-carotene 
and astaxanthin) would be more effective in combinations in PUFA-treated cells (Fig. 
6.12). -Of the four different dietary antioxidants used individually, only a-tocopherol 
conferred protective inhibitory effects on U937 cells by suppressing AA release. 
Nonetheless,. because 3H-AA release is inhibited by the presence of a-tocopherol in 
U937 cells, the effects of single and mixtures of antioxidants on its release, were 
compared. Oxidant-mediated 3H-AA release observed in U937 cells enriched with the 
dietary antioxidants (both individual and mixtures) is quite striking for two reasons: 
vitamin E single-handedly showed the greatest potency against the oxidant whereas 
when in combination with ~-carotene or even astaxanthin, these appeared to interfere 
with its actions making it less effective. 
Ascorbic acid treatment further contributed to the peroxidative damage observed by 
enhancing AA release from U937 cells. It is known that antioxidants influence one 
another by biological interactions. For example, a combination of vitamin C with 
vitamin E was reported to exert synergistic effects in schizophrenia (Kanofsky and 
Sandyk 1992). Also, Kanofsky and Sandyk (1992) previously repo_rted a synergistic 
effect between vitamins C and E in schizophrenia ameliorating the chronic symptoms 
observed in patients. In contrast, the present study demonstrates that vitamin C 
promotes AA release in t-BHP/Fe2+ - treated U937 cells but when used in combination 
with vitamin E, there is a reduction in the damage that would have been done by 
vitamin C. The effects of combining antioxidants as a measure of suppressing lipid 
peroxidation has previously been investigated in order to determine whether interactions 
exist between them. Palozza and Krinsky suggested some cooperation between 
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tocopherols and the carotenoids· (Palozza and Krinsky, 1991; 1992). They showed that 
synergy occurs between {3-carotene and a.-tocopherol with the·latter having a protective 
role over the former. On the other hand, a protective or reparative role of the 
carotenoids over a.-tocopherol in response to lipid peroxidation was also suggested in 
chicks (Mayne and Parker, 1989) and low-density lipoproteins (Packer, 1993). 
Ascorbic acid was found to protect a.-tocopherol and not {3-carotene in a fatty acid 
methyl ester, producing additive antioxidant effects against oxidation (Vile and 
Winterbome, 1988; Niki et al., 1995a). 
6.4.3 Conclusion 
In conclusion this chapter demonstrates that induced oxidative stress with t-BHP/Fe2+ 
stimulates arachidonic acid release in a time- and dose-dependent manner from U937 
cells. It also shows that some PUFAs especially EPA, stimulate AA release with or 
without oxidation. Oxidant-mediated AA release can be significantly suppressed by 
pre-treating these cells with a.-tocopherol. Depending on the conditions under which a 
system is monitored, all antioxidants can also exert pro-oxidative effects. 
It is however important to extend these studies to in vivo enrichments of carotenoids, 
ascorbic acid and a.-tocopherol individually and as combinations, in human subjects 
(however difficult this may be), to confirm the results presented herein. Overall the role 
of carotenoids as antioxidants in living systems requires much further understanding 
especially in terms of the underlying chemical and biochemical mechanisms of actions. 
Taken together, these results support a role for PLA2 - mediated AA release with 
oxidative stress. However, the particular PLA2 enzyme responsible for this activation 
requires further investigation. 
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CHAPTER 7: OXIDANT-INDUCED ARACIDDONICACID UPTAKE 
7.1 INTRODUCTION 
Membrane phospholipids are involved in apoptosis, regulation of enzyme activities, and 
generation of second messengers as well as serving as membrane anchors responsible 
for membrane fusion and antioxidants (Farooqui et al., 2000) such as plasmalogens, 
which -protect PUFAs from iron-induced lipid peroxidative damage (Sindelar et al., 
199Q). Phospholipids are integral components of neuronal membranes and they exist in 
a dynamic ,flux. They are maintained by continuous synthetic and degradative 
processes. Apart from being a reservoir for second messengers, they may be involved 
in many important processes such as apoptosis in brain tissues (Fadok et al., 1992). 
Apoptosis is a form of programmed cell death characterized by nuclear condensation, 
cell shrinkage, and bleb formation. During this process, the cell plasma membrane 
rapidly translocates PS to the outer leaflet where it functions as a signal on the dying 
cell for recognition and removal by phagocytosis by an unknown specific mechanism 
(Fadok et al., 1992). 
Saturated fatty acids particularly, palmitic and stearic, are usually located at the sn-1 
position of the phospholipid molecule whereas PUFAs such as AA, EPA and DHA are 
esterified at the sn-2 position. Whilst saturated fatty acids appear to have a role in 
neuroplasticity (Tone et al., 1987; Wakabayashi et al., 1994), PUFAs contribute to 
membrane fluidity, playing crucial roles in the maintenance of the orientation of internal 
and external membrane regions for interactions amongst intracellular organelles, at the 
same time providing an appropriate environment for maximal functioning of membrane 
associated proteins such as receptors, membrane-bound enzymes and ion-channels 
(Farooqui et al., 2000). Comparative studies of fatty acid compositions of the different 
phospholipid classes in different cell types from the adult rat cerebral cortex indicated 
that FA acid compositions in phospholipids varies from cell to cell. Differences also 
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occur among the different phospholipid classes (Porcellati, 1983). Therefore, to 
determine membrane compositions in vivo under physiological conditions, it is 
necessary to investigate the phospholipid composition of a particular suborganelle of a 
specific tissue and not of membrane fractions that may have been contaminated by other 
organelles. Furthermore, PUFA release by the catalytic activity of cPLA2 in responseto 
ago11ists such as A23187 in U937 cells is specific for AA and EPA but not DHA 
(Rosenthal e,t al., 1995). Collectively, these observations indicate that AA, EPA and 
DHA, each influence different effects in biological systems. 
PUFAs largely occur bound to serum proteins in biological systems. Protein binding is 
accompanied by rapid dissociation and exchange between the blood-brain barrier of 
unbound and unincorporated fatty acids (Banks et al., 1997; Fenton et al., 2000). 
Neural membranes are rich in PUFAs and so vulnerable to oxidative damage. 
Furthermore, the brain is rich in iron and surrounded by the cerebrospinal fluid, which 
contains little or no iron-chelating capacity. Since free radicals are generated during 
normal cellular processes (Halliwell, 1994), the fatty acid located at the sn-2 position is 
more susceptible to oxidative attack at the a-methylene carbon atom adjacent to the 
carbon-carbon double bond (Farooqui et al., 2000). 
Lipid hydroperoxides produced from such reactions are not completely stable in vivo 
and in the presence of iro~ can decompose further, propagating peroxidative chain 
reactions initiated in the first place by the free radical attack. They metabolise 
aldehydes, which can in tum cross-link enzymes and proteins making them inactive. 
Lipid peroxidative damage to neuronal membranes may lead to changes in 
physicochemical properties thus affecting the fluidity of these membranes and altering 
the orientation of optimal domains for the interaction of functional membrane proteins 
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(Farooqui et al., 2000). In addition, it may cause changes in the number of receptors 
and their affinity for neurotransmitters and drugs or inhibit ion pump operations thereby 
changing ion homeostasis. It has also been proposed that peroxidized membrane 
phospholipids in brain cells may produce a packing defect, making the sn-2 position 
more accessible to PLA2 action (McLean et al., 1993). Several investigators have 
suggested that phospholipid hydroperoxides are better substrates for the activity of 
PLA2 than t~e native lipid itself (McLean et al., 1993). The lipolysis of peroxidized 
lipids removes the oxidized fatty acyl chains, which are reduced and later re-
incorporated. Thus PLA2 action plays repairing and restorative roles in the maintenance 
of the physicochemical state of membranes. 
PLA2 and acyltransferase enzymes may participate in several key events that determine 
the turnover of phospholipids in cell membranes through the deacylation and 
reacylation cycle (Van den Bosch, 1980; Waite, 1987). This cycle is responsible for the 
introduction of PUF As into phospholipids, which are also broken down by the 
phospholipase A2 enzymes into lysophospholipids (LPLs). LPLs are re-esterified with 
free fatty acids to form other phospholipid molecules. The deacylation (hydrolytic) 
pathway is an important mechanism for the regulation of saturated and unsaturated fatty 
acyl contents of phospholipids in neural cell membranes (Yamashita et al., 1997). 
Among other various enzyme-regulating activities, LPLs serve as precursors of platelet 
activating factors (P AFs) (Weltzien, 1979). 
AA incorporation into phospholipids is unique when compared with other fatty acids. 
First, the mechanism responsible for the esterification of AA in a variety of cell types 
appears to be highly selective for this fatty acid (Irvine, 1982). Second, the major 
pathway for AA incorporation into phospholipids is not the de novo pathway, but by the 
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deacylation/reacylation cycle (Lands and Crawford, 1976). It is thought that this cycle 
is largely responsible for the remodelling of cellular phospholipids leading to the 
selective distribution of AA at the sn-2 position which is cleaved by PLA2 producing 
LPLs and this is rapidly re-esterified with another fatty acid by a CoA-dependent 
acyltrahsferase enzyme reforming a phospholipid (Hill, 1968; Dennis, 1987). AA 
uptalce into phospholipids is dependent on the availability of LPLs particularly LPC. In 
P388D1 ma,crophages (Balsinde . et al., 1995) and human polymorphonuclear 
neutrophils, the levels of LPC appear to be maintained by iPLA2 and not cPLA2 activity 
(Daniele et al., 1999). 
In schizophrenia, several reports have shown alterations in phospholipid metabolism 
(Pettegrew et al., 1991; Fujimoto et al., 1992). Perhaps, these observations can be 
explained by changes in the functioning of the LPL metabolising enzyme in the 
disorder. This study examined the esterification of AA into phospholipids after 
oxidation using U937 monocytic cells as models. Evidence is presented that a PLA2 
plays a role in this process by providing the LPL required for AA esterification into 
phospholipids. This study aims to provide more information on the enzymes involved 
in the metabolism of phospholipids, possibly allowing better understanding of their role 
in neuronal cell membranes. 
7.2 MATERIALS AND METHODS 
7.2.1 Materials 
[5, 6, 8, 9, 11, 12, 14, 15-3H] AA (3H-AA, 100 Ci/mmol) and Optiphase Hisafe 2 liquid 
scintillation cocktail were purchased from Perkin-Elmer Life Sciences, UK. The fatty-
acid-free bovine serum albumin (BSA), stearic acid (SA), oleic acid (OA), arachidonic 
acid (AA), phosphatidyl choline, ascorbic acid, vitamin E, ~-carotene, astaxanthin, 
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0.4% Trypan Blue dye solution, Hanks balanced salt solution (HBSS), RPMI 1640, 
foetal bovine serum (FBS), 200 mM L-glutamine, 50 mg/ml gentamicin solution, 
HPLC-grade chloroform, hexane, diethyl ether, methanol and ethanol, glacial acetic 
acid, potassium chloride (KCl), iodine crystals, butylated hydroxy-toluene (BHT), tert 
butyl -hydroperoxide, ferrous sulfate heptahydrate (FeSO4• 7H2O) and sodium 
thio~ulfate (Na2S2O3) were obtained from Sigma-Aldrich, UK. Eicosapentaenoic acid 
(EPA) and , docosahexaenoic acid (DHA) were supplied by Nu-chek Prep. Inc., 
Denmark. The LK5D - Whatman TLC plates were from Fisher Scientific, UK. 
7 .2.2 Glassware and plastic preparations 
All glassware used was washed in de-con and nano-pure water, autoclaved at 121°C for 
30 min and dried in an oven before use. All other apparatus used were sterile with all 
U937 cell treatments performed under a class II laminar flow hood. The laminar flow 
hood was cleaned regularly with 70% ethanol. Solvent extractions and thin layer 
chromatographic analysis were done in the designated area in the radiation suite. 
7 .2.3 Cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM L-
glutamine and 0.05 mg/ml gentamicin at 37°C in a humidified incubator with 5% 
CO2/95% air. For all experiments, cells were maintained at 0.5 x 106 cells/ml at 
viability> 90% by Trypan Blue dye exclusion method of viability measurements. 
7.2.4 Cellular uptake of 3H-AA into phospholipids 
7.2.4.1 Uptake under nonnal incubation conditions 
Unlabelled U937 cells were adjusted to contain 0.5 x 106 cells/ml in 24-well plastic 
culture plates (Costar). Initially 0.9 ml of exogenous 3H-AA (0.1 µCi/ml) in CM was 
244 
added to 0.1 ml of cell suspension for varying periods of time at 37°C and 5% CO2 in a 
humid environment. The final volume per well was 1.0 ml. At the indicated times, 
cellular uptake was terminated by centrifuging at 4000 g for 3 min at 4°C followed by 
measurements of radioactivity-remaining in the supernatant (7.2.7) and total 3H-AA 
incorporated into phospholipids (7 .2.8). 
7.2.4.2 OxitlfZtion of cells 
(A) Time dependent oxitlation before uptake 
0.5 x 106 cells/ml of unlabelled U937 cells were washed twice in HBSS by centrifuging 
at 250 g for 5 min at 4°C to remove serum-containing CM and re-suspended in 0.1 ml of 
HBSS in each well of a 24-well plate. Stock solutions of 2 mM t-BHP and 5 mM 
FeSO4 were prepared in HBSS just before use. Oxidative stress was induced by the 
addition of 0.9 ml of the oxidant mixture in HBSS (or HBSS only for controls) to 0.1 ml 
of cell suspension. Final volume was 1.0 ml/well. The final oxidant concentration used 
in all treatments was 750 µM t-BHP/Fe2+. The Oh experiment (controls) involved cells 
in HBSS only for 4 h before the uptake assay. After varying oxidation times (0-4 h), 
cell suspensions were rapidly transferred into 1.5 ml eppendorf tubes and reactions were 
stopped by centrifuging at 250 g for 5 min at 4°C. Cells were washed twice with 0.9 ml 
HBSS, re-suspended in 0.1 ml of CM and labelled by adding 0.9 ml of 3H-AA 
(0.lµCi/ml) in CM. After 4 h of further incubation, 3H-AA incorporation assay was 
terminated by centrifugation at 4000 g for 3 min at 4°C. Thereafter, uptake of 3H-AA 
into cellular phospholipids was measured (7.2.8). 
(B) Time-dependent uptake post-oxidation 
U937 cells adjusted to contain 0.5 x 106 cells/ml were initially treated/untreated with 
150 µM t-BHP/Fe2+ in HBSS (or HBSS only in a simultaneously conducted 
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experiment) in 24-well plates.· Oxidant solutions containing t-BHP and FeSO4 were 
freshly prepared just before use as previously stated. After 1 h of induced oxidation (or 
incubations in HBSS only), reactions were terminated by centrifugation at 250 g for 5 
min at 4°C. Cells were washed twice each time with 0.9 ml HBSS and re-suspended in 
0.1 ml- of freshly prepared CM. Oxidant-treated/untreated cells (0.1 ml in CM) were 
lab~lled by the addition of 0.9 ml of 3H-AA (0.lµCi/ml) in CM for 0 - 24 h. The final 
volume of c~ll suspension in each well was 1.0 ml. After the indicated time, uptake 
reactions were terminated by centrifugation at 4000 g for 3 min at 4°C followed by the 
measurements of total cellular uptake of 3H-AA into phospholipids (7 .2.8). 
7.2.5 With FA treatments 
7.2.5.1 Without oxidation 
(A) Simultaneous addition of FA and 3H-AA 
10 mM stock solutions of fatty acids (SA, OA, AA, EPA and DHA) were aseptically 
prepared in ethanol. They were used in U937 cell incubations complexed to fatty-acid-
free BSA at a molar concentration of 2.5: 1. CM was supplemented with FA: BSA 
complexes and 0.1 µCi/ml of 3H-AA to make a final volume of 0.9 ml, which was then 
added to 0.1 ml of cell suspension containing 0.5 x 106 cells/ml in each well of a 24-
well plate. Controls involved cells incubated with ethanol (0.4% v/v) complexed with 
BSA only. The final FA concentration was 10 µM and the final volume was 1.0 
ml/well. After 24 h of incubation at 37°C and 5% CO2 in a humid environment, uptake 
reactions were terminated by centrifugation at 4000 g for 3 min at 4°C and 3H-AA 
uptake into phospholipids was measured (7.2.8). 
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(B) With unlabelled FA before 3H-AA 
0.5 x 106 cells/ml were initially incubated for 24 h with 10 µM of the fatty acids: SA, 
OA, AA, EPA or DHA (or 0.4% v/v, ethanol for controls) complexed with BSA at 2.5: 
1 molar ratio. Afterwards, U937 cells were washed twice each time with 0.9 ml of 
HBSS/0.2% BSA by centrifugation at 250 g for 5 min at 4 °C and re-suspended in 0.1 
ml of freshly prepared CM. FA-treated cells were then labelled with 0.9 ml of 
exogenous 3~-AA (0.1 µCi/ml) in CM and incubated for a further 4 h under the 
conditions stated above. Final volume was 1.0 ml/well. Uptake reactions were stopped 
by centrifugation at 4000 g for 3min at 4°C followed by measurements of radioactivity 
incorporated into cellular phospholipids (7 .2.8). · 
7.2.5.2 With Oxidation 
Furthermore, 0.5 x 106 cells/ml were cultured in CM supplemented with 10 µM SA, 
OA, AA, EPA or DHA (or 0.4% v/v, ethanol for controls) at 37°C and 5% CO2 in a 
humid environment. After 24 h of incubation, cells were washed twice with 0.9 ml of 
HBSS/0.2% BSA by centrifugation at 250 g for 5 min at 4°C and re-suspended in 0.1 ml 
of HBSS. U937 cells were then treated with/without 750 µM t-BHP/Fe2+ (freshly 
prepared in HBSS from 2 mM t-BHP and 5 mM FeSO4 just before use) and incubated 
under the conditions stated above. After 1 h, oxidant-treated cells were washed twice 
with 0.9 ml of HBSS and re-suspended in 0.1 ml of CM in each well of a 24-well plate 
prior to labelling with 0.9 ml of 3H-AA (0.1 µCi/ml) in CM for a further 4 h. 3H-AA 
uptake reactions were stopped by centrifugation at 4000 g for 3 min at 4°C. Cellular 
uptake of 3H-AA into phospholipids was measured (7.2.8). 
Controls (Ox and - Ox) involved cells treated with ethanol (0.4% v/v) complexed with 
BSA and incubated with and without 750 µM t-BHP/Fe2+, respectively. 
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7.2.5.3 With prolonged FA treatment 
U937 cells were continuously cultured for 18 days in CM supplemented with 10 µM 
levels (final concentration) of the FAs (SA, OA, AA, EPA or DHA) at 37°C and 5% 
CO2 in a humid environment. All FAs were complexed with BSA in a 2.5: 1 molar 
ratio. - For controls, cells were incubated with 0.4% (v/v) ethanol (final volume) 
complexed with BSA. Cells were cultured in 8 ml cell suspensions at 0.5 x 106 cells/ml 
in 25 cm2 c~lture flasks. The incubation medium was totally renewed with freshly 
prepared CM supplemented with 10 µM of the FA complex every 3 days. On day 17, 
U937 cells were again re-adjusted to contain 0.5 x 106 cells/ml and re-suspended in 1 ml 
suspensions in 24-weH plates for a further 24 h in.freshly prepared CM. After a total of 
18 days, cells were washed twice in 0.9 ml HBSS/0.2% BSA by centrifugation at 250 g 
for 5 min at 4°C, re-suspended in 0.1 ml of HBSS and subjected to oxidative stress for 1 
h with 750 µM t-BHP/Fe2+ (prepared in HBSS from 2 mM t-BHP and 5 mM FeSO4 just 
before use). Oxidation reactions were terminated by centrifugation at 250 g for 5 min at 
4°C. Cells were washed twice with 0.9 ml of HBSS, re-suspended in 0.1 ml of freshly 
prepared CM and labelled with 0.9 ml of exogenous 3H-AA (0.1 µCi/ml) in CM for 4 h. 
Final volume of cell suspension per well was 1.0 ml. Thereafter, radioactivity of the 
total uptake of 3H-AA into cellular phospholipids was measured (7 .2.8). 
Controls (Ox and - Ox) involved U937 cells treated with ethanol (0.4% v/v) complexed 
with BSA and incubated with and without 750 µM t-BHP/Fe2+, respectively. Cell 
viability and cell density was monitored every 3 days and maintained at 0.5 x 106 
cells/ml at a viability > 90% by the Trypan Blue dye-exclusion method. Cell 
suspensions remaining after cell counts were discarded and treated appropriately. 
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7 .2.6 . With antioxidants 
100 mM stock solutions of ascorbic acid in water, a-tocopherol in ethanol, f3-carotene 
and astaxanthin in chloroform were aseptically prepared. Ascorbic acid and a-
tocopherol were stored at 2 - 8°C, while f3-carotene and astaxanthin were stored at -
20°C. By serial dilution, 16 mM ascorbic acid, 40 mM a-tocopherol and 12 mM f3-
carotene and astaxanthin were prepared. Culture medium (CM) was supplemented with 
aliquots of 16 mM ascorbic acid, 40 mM a-tocopherol and 12 mM f3-carotene or 
astaxanthin, all to a final volume of 0.8 ml. Antioxidant supplemented CM (0.8 ml), 
was added to each of a 24 - well plate containing 0.1 ml of cell suspension after 
appropriate treatments (in the case of the carotenoids where, 0.8 ml of carotenoid -
supplemented CM was sonicated for 5 s in an ice-bath and sterile - filtered using nylon 
syringe filters before use). Each well contained 0.5 x 106 cells/ml. Final concentrations 
of antioxidants used were 400 µM ascorbic acid, 40 µM a-tocopherol and 12 µM f3-
carotene or astaxanthin. U937 cells were then incubated for an initial 10 min with each 
of the antioxidants before the addition of 0.1 ml of PUFA: BSA complexes (2.5: 1 
molar ratio) in CM. The final PUFA (AA, EPA or DHA) concentration was 10 µ~ in 
1.0 ml cell suspensions. After 24 h of incubation, cells were washed twice with 
HBSS/0.2% BSA and re-suspended in 0.1 ml of HBSS followed by oxidation with 750 
µM t-BHP/Fe2+ for 1 h. Post-oxidation, cells were washed twice with 0.9 ml of HBSS 
and re-suspended in 0.1 ml of CM in each well of a 24-well plate. Thereafter, oxidant-
treated cells were labelled with 0.9 ml of exogenous 3H-AA (0.1 µCi/ml) in CM for 4 h 
under the conditions stated above. Blank experiments (- FA, - Ox) were U937 cells 
treated with ethanol (0.4% v/v) complexed with BSA without the induction of oxidative 
stress. Controls (Ox and - Ox) involved cells treated with 10 µM PUFA (AA, EPA or 
DHA) complexed with BSA in a 2.5: 1 molar ratio and treated with and without 750 µM 
t-BHP/Fe2+, respectively. 
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Uptake reactions were terminated by centrifugation at 4000 g for 3 min at 4°C followed 
by measurements of radioactivity ta½:en up into cellular phospholipids (7 .2.8). 
All incubations were performed at 37°C and 5% CO2 in a humid environment. All 
washings were performed at 250 g for 5 min .at 4°C and all terminations prior to the 
mea~urements of radioactivity achieved by centrifugation at 4000 g for 3 min at 4°C. 
7 .2. 7 Measurement of radioactivity remaining in the supernatant 
0.9 ml of supernatants were removed and transferred into labelled 20 ml scintillation 
vials. Cell pellets were washed once with 0.9 inl of HBSS/BSA and 0.9 ml of the 
supernatant was carefully removed by aspiration and combined with the previous 
supernatant. 12 ml of scintillation fluid was added to the combined supernatant, mixed 
by vortexing and assayed for radioactivity by liquid scintillation counting. 
Radioactivity was expressed as a percentage of the total radioactivity originally present 
in the medium. 
7.2.8 Measurement of cellular uptake of 3H-AA into phospholipids 
After final centrifugation, cell suspensions were washed once with HBSS/0.2% BSA 
and re-suspended in 0.1 ml of HBSS/0.2% BSA. For the analysis of 3H-AA 
incorporated into phospholipids, 0.8 ml (8 volumes) of ice-cold, chloroform: methanol 
(2: 1, v/v) (Folch et al., 1957) was added to 0.1 ml of cell suspension. Cells were 
sonicated for 3 x 10 s with an interval of 10 s in an ice bath followed by the rapid . 
addition of 0.2 ml (0.2 volumes) ofice-cold methanol. Suspensions were mixed briefly 
by vortexing and centrifuged at 4000 g for 3 min at 4°C. Centrifugation was used to 
convert all non-lipid residues into compact pellets instead of filtration due to the small 
sample size. 0.7 ml of supernatant was transferred into labelled Pyrex tubes and 0.2 ml 
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(25% of the existing volume)· of 0.88%KC1 solution w~ added. Tubes were well 
shaken and allowed a few minutes for separation into two phases. Aliquots of 0.2 ml of 
the bottom layer were transferred into sterile vials and evaporated to dryness under a 
stream of nitrogen. Cellular extracts were re-suspended in 30 µl of 3.33 mM exogenous 
PC in chloroform: methanol (2: 1, v/v with 0.01 % BHT) in airtight vials and stored for a 
max_i,mum of 72 hat - 20°C prior to TLC analysis of 3H-AA uptake. 
7 .2.9 Thin layer chromatographic separations 
A solvent system of hexane: diethyl ether: acetic acid, 70: 30: 1.3 (v/v/v) was made up 
and stored in Schott bottles. Using a micro-Paste"ur pipette, 10 - 20 µl aliquots of lipid 
extracts were spotted on LK5D plates under a stream of nitrogen gas with reference 
phosphatidyl choline (PC) co-chromatographed as standards on separate lanes for 
identification purposes. The plates were run in a chamber pre-saturated with 100 ml of 
the solvent system above. After 50 - 55 min, plates were dried with cool air from a hair 
dryer for ~ 30 s in a fume cupboard until free of the acetic acid odour. Thereafter, 
plates were exposed to iodine vapour produced from iodine crystals in a closed tank. 
Lipid spots corresponding to standard phospholipid bands (for total AA incorporation) 
were outlined with a needle (PL spots did not migrate from the origin). TLC plates 
were removed from the tank and iodine was allowed to sublime. Spots (~ 2 cm2) were 
scraped with a scalpel and transferred via a small plastic funnel into 7 ml scintillation 
vials containing 0.4 ml of 1 % Na2S2O3, in order to reduce the iodine to iodide ion, thus 
decolorizing the mixture and minimizing quenching (as modified by Horrocks and 
Ansell, 1967). 4.0 ml of optiphase hisafe 2 liquid scintillation cocktail was added, 
mixed vigorously by vortexing and radioactivity was quantified by liquid scintillation 
spectroscopy in disintegrations per minute using the 1219 Rackbeta liquid scintillation 
counter by LKB Wallac. 
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3H-AA incorporation into cellular phospholipids was expressed as a percentage of the 
total radioactivity originally present in the medium. 
7.3 RESULTS 
Initial -experiments were performed to determine the extent of incorporation of 
exogenous, radiolabelled AA into U937 cell phospholipids over time (0 - 24 h). As 
shown in Fig. 7.lA, 3H-AA was rapidly taken up by the cells with approximately 69% 
of the total 3H-AA added to the medium remaining in the supernatant after the first 30 
min of incubation suggesting that 31 % of the total radioactivity was cell-associated in 
this time. There is a good negative correlation between 3H-AA content remaining in the 
medium and time (R2 = -0.97, P < 0.01). Approximately 40% of the total radioactivity 
added to the cells was left in the incubation medium after 4 h of incubation and 10% 
after 24 h. The same pattern of 3H-AA uptake was observed in cell phospholipids after 
thin layer chromatographic analysis of lipid extracts (Fig. 7.lB) where the amount 
esterified into phospholipids increased linearly with incubation time (R2 = 0.977, P < 
0.01). There was an increase of 120% and about 300 % in 3H-AA incorporation into 
phospholipids at 4 and 24 h (respectively) of incubation when compared to cellular 
uptake at 30 min of incubation. 
The rate of incorporation of radioactivity into cell phospholipids was greatest within the 
first 30 min of incubation and this reduced with time. The average rate per hour of 3H-
AA uptake into phospholipids was approximately 97% greater at 30 min of incubation 
than that obtained at 24 h (Fig. 7.lB). This study demonstrates that the incorporation of 
3H-AA into phospholipids continues for 24 h in U937 cells with approximately 10% of 
the radiolabelled AA remaining in the medium after this time (Fig. 7.lA). 
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3H-AA incorporation into U937 cell phospholipids. Cells were 
incubated for O. 5 - 24 h and the total amount of AA remaining in the medium ( A) or 
aliquots of 3H-AA incorporated into phospholipids (B), was measured. Both were 
expressed as a percentage of total radioactivity originally added to the medium. Data 
points represent means± 95% Cls of two independent experiments (n = 4). 
253 
Whilst there was no significant increase in uptake between 0. 5 and 1. 0 h of incubation, 
it increased significantly at each of the other time points indicated over 1 h ( one-way 
ANOV AF= 154.93, P < 0.01, DF = 5). 
7.3.1 Time dependent oxidation pre-3H-AA uptake 
Given the ability of the U937 cells to rapidly incorporate 3H-AA into phospholipids, the 
effects of oxidation on its uptake were investigated (Fig. 7.2). 
0 0.5 1.0 2.0 3.0 4.0 
Oxidation time (h) 
Fig. 7.2 Effect of U937 cell treatments with 750 µM t-BHP/Fe2+ for varying 
periods of time (0 - 4 h) on the esterification of 3H-AA into phospholipids. Means± 
95% Cis of duplicate experiments (n = 4). 
To demonstrate the oxidant-stimulated turnover of membrane phospholipids, U937 cells 
were initially treated with 750 µM t-BHP/Fe2+ for 0 - 4 h in HBSS, washed twice to 
ensure the removal of t-BHP/Fe2+ remaining in the medium, before the addition of 0.1 
µCi/ml of3H-AA in freshly prepared CM. Based on the substantial uptake of 3H-AA 
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into cellular phospholipids after 4 h of incubation (Fig. 7.1), incorporation assay 
proceeded for 4 h under the conditions employed (Fig. 7.2). Interestingly, there was a 
significant increase in 3H-AA uptake into phospholipids after 30 min of oxidant 
treatment of U937. cells. The increase peaked at 1 h of oxidation after which there was a 
dramatic decrease in cellular uptake for the following 3 h ( one-way ANOV A F = 
216~.70, P < 0.01, DF = 5). This data demonstrates that the chronic exposure of U937 
cells to 750 _µM t-BHP/Fe2+ for> 1 h alters the acyltransferase enzyme in some way, 
dramatically reversing the uptake response initially observed with oxidation times ::; 1 h. 
This may be due to increasing loss of membrane integrity over time as shown earlier in 
chapter two. Interestingly, AA uptake at oxidation times> 1 h, coincides with results 
obtained with increasing AA release experiments over time ( chapter six), so it could be · 
that induced-oxidative stress with time stimulates AA release at a faster rate than its 
uptake in U937 cells. Based on this study, all subsequent oxidation reactions were 
performed with 750 µM t-BHP/Fe2+ for 1 h prior to 3H-AA uptake assays. 
7.3.2 Oxidant-induced 3H-AA uptake into phospholipids 
Fig. 7.3 shows the time-course of t-BHP/Fe2+-induced 3H-AA uptake into U937 cell 
phospholipids. 
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Time course of 3H-AA uptake into U937 cells pre-treated with or 
without 750 µM t-BHP/Fe2+ for 1 h in HBSS. Means± 95% Cis (n = 4). 
Data points in Fig. 7.3 were expressed as percentages of radioactivity incorporated into 
phospholipids compared to the total radioactivity originally added to the medium. AA 
incorporation into cellular phospholipids increased over time from 0.5 to 24 h in both 
oxidant-treated and untreated U93 7 cells. 
Fig. 7.3 shows that 3H-AA uptake increases significantly with increasing incubation 
time (one-way ANOVA F = 1261.65, P < 0.001, DF = 6). It also demonstrates a 
significant difference in 3H-AA uptake between U937 cells treated with and without 750 
µM t-BHP/Fe2+ for 1 h (one-way ANOVA F = 103.54, P < 0.001, DF = 1). This data 
indicate that 3H-AA incorporation into phospholipids is greater in U937 cells with 
induced-oxidation compared to cells untreated with the oxidant, suggesting an increase 
in the activity of the acyltransferase enzyme with oxidative stress. 
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7.3.3 With FA treatments 
The effect of different fatty acids on 3H-AA incorporation into phospholipids was 
investigated under different circumstances. 
7. 3. 3.1 Without oxidation 
(A) The first condition employed involved the exposure of U937 cells to either 10 
µM S~ O~ ~ EP~ DHA or ethanol (controls) concomitantly with 3H-AA (0.1 
µCI/ml) in CM for 24 h (Fig. 7.4). 
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Fig. 7.4 Effect of the simultaneous addition of ethanol (controls) or the fatty 
acids (S~ O~ ~ EPA or DHA) and 3H-AA on uptake into phospholipids with 
measurements performed after 24 h of incubation. Means± 95% Cls (n = 4). Letters: a 
and b denote significant differences between treatments (P < 0.01). 
As illustrated in Fig. 7.4, 3H-AA incorporation was neither affected by co-treatment 
with SA nor OA for 24 h but was significantly impaired by the presence of the 20-
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carbon PUFAs (AA and EPA) when compared to controls (one-way ANOVA F = 
37.31, P < 0.01, DF = 5). Interestingly, the uptake of 3H-AA was not significantly 
affected by the presence of DHA in the incubation medium. EPA-, though not 
significantly different from AA-treated cells gave the lowest observed uptake of3H-AA 
by approximately 8% when compared to controls. 
(B) Secondly, experiments examining the effects of incubating U937 cells with 10 
µM concentrations of the different fatty acids for 24 h before the uptake assay with 3H-
AA for 4 more hours were conducted. Cells were washed twice with HBSS/0.2%BSA 
to eliminate all unlabelled and unincorporated fatty acids previously added to the culture 
medium (Fig. 7.5). 
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Fig. 7.5 3H-AA incorporation into phospholipids (for 4 h) after previous 
treatments of U937 cells with unlabelled SA, OA, AA, EPA or DHA for 24 h. Values 
represent means ± 95% Cls (n = 4). Letters: a and b indicate significant differences 
between treatments (P < 0.01). 
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After 4 h of incubating FA-treated cells with 3H-AA, there was no significant difference 
in uptake with S~ O~ AA or DHA. However, uptake was significantly inhibited by 
the presence ofEPA in U937 cells (one-way ANOVA F = 8.06, P < 0.01 , DF = 5). The 
uptake assay with 3H-AA was conducted for 4 h because it was previously established 
that a high amount of3H-AA was incorporated into phospholipids at that time (Fig. 7.1). 
7.3.3.2 With oxidation 
In order to determine the effects of induced - oxidative stress on 3H-AA uptake in FA-
treated cells, U937 cells were pre-treated for 24 h and challenged with 750 µM t-
BHP/Fe2+ for 1 h before the uptake assay with labelled AA was performed for 4 h (Fig. 
7.6). 
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Effect of oxidation on 3H-AA incorporation (for 4 h) in FA - pre-
treated U937 cells. Means ± 95% Cis (n = 4). Letters: a, b and c denote significant 
differences between means (P < 0.01). 
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After induced oxidation, FA-treated U937 cells were exposed to 0.1 µCi/ml of 3H-AA 
for 4 h prior to lipid extraction and TLC analysis. As expected, comparison between the 
controls confirms that 3H-AA uptake markedly increases in U937 cells with oxidation 
(one-way ANOVA F = 22.85, P < 0.01, DP= 6). Pre-treatment with SA or OA showed 
no significant difference when compared with oxidized controls (Ox). However, pre-
incubations with the PUFAs (AA, EPA or DHA) demonstrate a significant reduction in 
the uptake o~ 3H-AA compared to oxidized controls (Ox). Whilst uptake of 3H-AA was 
significantly different in DHA-pre-treated cells compared to unoxidized controls (- Ox), 
there were no significant differences observed with AA or EPA treatments suggesting 
that AA and EPA presence suppressed the uptake of 3H-AA in U937 cells subjected to 
oxidative stress in a similar manner to controls untreated with oxidants (- Ox) (Fig. 
7.6). 
7.3.4 With prolonged FA treatment 
To further substantiate the above findings, experiments utilizing U937 cells 
continuously pre-cultured in CM-supplemented with 10 µM levels of the five different 
fatty acids were subjected to oxidation for 1 h prior to the conduction of cellular 3H-AA 
incorporation for 4 h (Fig. 7.7). 
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Incorporation of 3H-AA into cellular phospholipids after 18 days of 
continuous CM-supplementation with SA, OA, AA, EPA, DHA or ethanol (controls) 
followed by 1 h of induced oxidation. Data points represent means± 95% Cls (n = 4). 
Letters: a, band c indicate significant differences between treatments (P < 0.01). 
Prolonged FA-treatment of cells generated more pronounced effects of the PUF As 
especially EPA, in response to oxidant-induced 3H-AA uptake into U937 cell 
phospholipids. Again, the oxidation of U937 cells resulted in increased 3H-AA uptake 
in oxidant-treated cells (Ox) compared to unoxidized controls. 3H-AA incorporation 
was not affected by prolonged treatment with the saturated or monounsaturated fatty 
acids (SA or OA respectively) when compared to oxidant-treated controls ( one-way 
ANOVA F = 33.53, P < 0.01, DF = 6). Comparison of the PUFA-treated cells showed 
that the presence of DHA resulted in the highest observed 3H-AA uptake into cellular 
phospholipids. EPA-treatment showed the most suppressive effects on AA-uptake by 
approximately 40% lower than oxidized (Ox) controls. The suppressive effect was 
greater with EPA than AA-treatments. Whilst 3H-AA uptake was significantly lower in 
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AA and EPA treated cells compared to oxidized controls, pre-incubation with DHA 
showed no significant differences. In comparison to oxidant-untreated (- Ox) _controls, 
3H-AA uptake was markedly lower with EPA- whereas AA-pre-treated U937 cells were 
not. 
Surprisingly, the data represented in Fig. 7.7 (3H-AA uptake after FA pre-treatment for 
18 days) loo,ks strikingly more similar to that in Fig. 7.5 (without induced-oxidation) 
than Fig. 7.6 (with induced-oxidation), suggesting pronounced effects of the fatty acids 
alone and not that induced by pro-oxidants. Unfortunately this suggestion cannot be 
confirmed in the present study because control experiments did not include cells treated 
with the different fatty acids for 18 days without exposure to the oxidants. Future work 
is therefore required to investigate this possibility. 
7 .3.5 With Antioxidants 
To define the role of ascorbic acid, a-tocopherol, B-carotene and astaxanthin on 3H-AA 
incorporation into cellular phospholipids, U937 cells were pre-treated with 400 µM 
ascorbic acid, 40 µM a-tocopherol, 12 µ M B-carotene or 12 µM astaxanthin _in the 
presence of 10 µM AA, EPA or DHA for 24 h before the oxidant-stimulated 3H-AA 
uptake assay for 4 h was conducted. Fig. 7 .8 shows the effects of the different 
antioxidants and PUFA treatments on oxidant-induced 3H-AA uptake into the 
phospholipids of U937 cells. 
With AA treatment, there was no significant difference between U937 cells treated with 
(- Ox) and without (-AA, -Ox) 10 µM AA, both without oxidation (one-way ANOVA 
F = 102.29, P < 0.01, DF = 6). However, uptake of 3H-AA into cellular phospholipids 
in the blank treatment (- AA, - Ox) was significantly different from all treatments 
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involving oxidation. As observed earlier, no significant difference was observed 
between unoxidized (- Ox) and oxidized (Ox) controls, suggesting that U937 cell pre-
treatment with unlabelled AA stimulated no significant difference in 3H-AA uptake with 
induced oxidative stress. 
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Effect of antioxidants and 10 µM AA on oxidant-induced 3H-AA 
uptake into the phospholipids of U937 cells. Where: (- AA, - Ox) represents cells 
treated neither with AA nor oxidants; - Ox: control cells treated with AA without 
oxidants; Ox: cells treated with AA and oxidants; VC: AA+ 400 µM ascorbic acid; VE: 
AA + 40 µM a-tocopherol; f3-c : AA + 12 µM f3-carotene; and Ast: AA + 12 µM 
astaxanthin. All treatments with antioxidants were exposed to the oxidants. Means ± 
95% Cls (n = 4). Letters: a, b, c and d represent significant differences between 
treatments (P < 0.01). 
Unoxidized controls (- Ox) generated results that were significantly different from all 
treatments involving all the four different antioxidants. Although no significant 
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differences were observed between cells pre-treated with the . three lipid-soluble 
antioxidants ( a-tocopherol, (3-carotene and astaxanthin), when compared with oxidant-
treated controls (Ox), while a-tocopherol did not exert any effect on 3H-AA 
incorporation into cellular phospholipids, treatments with f3.:.carotene or astaxanthin 
resulted in significant but slight inhibition (P < 0.05) of 3H-AA uptake into cellular 
phospholipids. However, treatment with 400 µM ascorbic acid led to a dramatically 
significant reduction (P < 0.0001) in the uptake of 3H-AA after 1 h of induced 
oxidation. 
The effect of antioxidants and 10 µM EPA treatments on 3H-AA incorporation into 
U937 cell phospholipids is shown in Fig 7.9. As previously shown in Fig. 7.6, there 
was a significant decrease in 3H-AA uptake between EPA treated cells with and without 
induced-oxidation (one-way ANOVA F = 181.91, P < 0.01, DF = 6). Similar to results 
obtained with AA (Fig. 7 .8), this study showed no significant differences in uptake 
between cells treated neither with 10 µM EPA nor oxidants (- EPA, - Ox) and 
unoxidized controls. 
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Effect of four individual antioxidants and 10 µM EPA on oxidant-
induced 3H-AA uptake into the phospholipids ofU937 cells. Means± 95% Cls (n = 4). 
Data in Fig 7.9 show that 3H-AA uptake in stimulated EPA-treated U937 cell 
phospholipids were markedly suppressed (P < 0.005) with oxidation. Treatment with a-
tocopherol appeared to have no effect on U937 cells when compared with oxidized 
controls (Ox) whilst the presence of 12 µM J3-carotene and astaxanthin suppressed the 
uptake of AA. Ascorbic acid greatly reduced 3H-AA uptake by 77% compared to 
oxidant-treated controls (Ox). Letters: a, b, c and d denote significant differences 
between treatments (P < 0.01). 
The effect of treating U93 7 cells with 10 µM DHA and antioxidants on oxidant-
mediated 3H-AA incorporation into cellular phospholipids were also investigated (Fig. 
7.10). 
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Effect of DHA (10 µM) and four different antioxidants on the 
incorporation of3H-AA in U937 cell phospholipids. Means± 95% Cis (n = 4). Letters: 
a, b, c and d indicate significant differences between treatments (P < 0.01). 
This study examined whether treatment of U93 7 cells with or without antioxidants and 
DHA promote oxidant-induced 3H-AA uptake in U937 cells (Fig. 7.10). As previously 
reported, pre-incubation with DHA for 24 h showed no significant differences between 
cells treated with and without 10 µM DHA under oxidant-free conditions. In contrast to 
the response observed with AA or EPA treatments, induced-oxidation in DHA - treated 
cells generated a significant increase in 3H-AA uptake into cellular phospholipids ( one-
way ANOVA F = 181.88, P < 0.01, DF = 6). In a similar manner to results obtained 
with AA or EPA treatments, 400 µM ascorbic acid concentrations significantly reduced 
3H-AA uptake into cellular phospholipids of DHA-treated cells. Collectively, there 
were no significant differences in 3H-AA observed in U937 cells pre-treated with either 
of the lipid-soluble antioxidants ( a-tocopherol, J3-carotene or astaxanthin) when 
compared to controls. 
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7.4 DISCUSSION AND CONCLUSION 
Much work has been reported examining the role of oxidative stress in the release of 
arachidonic acid (AA) in schizophrenia but little has been done to study the effect of 
oxidation on AA incorporation into phospholipids. The primary aim of this work was 
therefore to determine the effects of induced-oxidation on AA uptake into the 
phospholipids of U937 cells. 
This study was important for determining whether PLA2 in oxidant-stimulated U937 
cells alters the endogenous AA pools in cellular phospholipids. For this purpose, 
experiments where the radiolabelled AA was added after cells had previously been 
exposed to 750 µM t-BHP/Fe2+ oxidant system, were performed. Since AA uptake is a 
rapid process in U937 cells (Fig. 7.1), uptake assays post-oxidation were conducted 
only for 4 h because an appreciable amount of 3H-AA was quantified in cellular 
phospholipids at that time (Fig. 7.3). Findings indicate that as the incorporation of 3H-
AA into cellular phospholipids increases the rate of uptake decreases over time. 
Even under normal incubation .conditions (in resting cells) without any form of 
activation, the capacity of U937 cells to incorporate AA into phospholipids by the 
reacylation pathway is high (Fig. 7 .1 ). For AA incorporation to occur, there must be 
LPL acceptors available, most likely by PLA2 hydrolytic activity. Thus, it can be said 
that U937 cells possess a basal PLA2 activity, enough to account for AA incorporation 
abilities. As different isoforms of PLA2 including cPLA2 (Kramer et al., 1991) and 
iPLA2 (Hsu et al., 2000) have been identified in U937 cells, under resting conditions, 
the exact PLA2 enzyme providing lysophospholipid acceptors for arachidonic acid 
reacylation into phospholipids is yet unknown. However kinetic studies of AA uptake 
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by U937 cells demonstrated that 3H-AA incorporation was nearly completed after 24 h 
of incubation with about 10% of radioactivity remaining in the culture medium. 
This study also demonstrated that U937 cells manifest a higher capacity to import 
exogenous 3H-AA into cellular phospholipids when subjected to oxidative stress (Fig. 
7 .2). The increase in AA incorporation into phospholipids increases dramatically for 1 
h followed ~y a rapid decrease in uptake indicating that there is a modification in the 
substrate required and/or enzyme responsible for the incorporation of AA, under 
prolonged conditions of oxidation. When the cells were incubated with 3H-AA in fresh 
medium after induced..:oxidation, cellular uptake c·ontinued over 24 h but at a higher rate 
in oxidant activated- U937cells (Fig. 7.3). 
7 .4.1 With fatty acids 
Unlabelled EPA treatment of U937 cells appeared to exert suppressive influences on the 
incorporation of labelled AA into cellular phospholipids (Figs. 7.4 and 7 .5). 
Interestingly, DHA treatment gave the opposite effects. It is likely that the differences 
observed in the response of these PUFAs (EPA and DHA) to 3H-AA uptake reflects the 
competitive nature between the C20 PUFAs (AA and EPA) for the sn-2 position of 
glycerophospholipids compared to DHA as suggested by Balsinde (2002). Although it 
was previously reported that EPA is preferentially taken up into PE over PC and AA 
into PC in U937 cells (Balsinde, 2002) it was also reported that PUFAs particularly AA, 
migrate between these phospholipid classes over time (Balsinde et al., 1994; Balsinde, 
2002). 
Without induced-oxidative stress, co-treatment of U937 cells for 24 h with the 
radiolabel and AA or EPA inhibit 3H-AA uptake while DHA does not, when compared 
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to controls (Fig. 7.4). Suppression of 3H-AA incorporation by unlabelled AA or EPA 
but not DHA is proposed to reflect reduction in lysophosphatidyl choline (LPC) 
acceptor molecules, the abundance of which is thought to limit the rate of AA 
incorporation and to be governed by PLA2 activity. Independent of the conditions 
employed, treatment of U937 cells with EPA appeared to have more inhibitory effects 
(son;ietimes insignificant as in Fig. 7.6) than DHA on 3H-AA uptake into cellular 
phospholipi~s. This decrease in 3H-AA uptake was definitely not due to loss of 
membrane integrity because over the 18 d period of continuous FA treatment, cell 
viability was > 90% in all treatments as monitored by the Trypan Blue dye-exclusion 
method. Since all FF As were washed off before· oxidation, it appears likely that BP A 
but not DHA in the esterified form, strongly competes with AA for the sn-2 position of 
phospholipids. However, this does not explain why 3H-AA uptake is more pronounced 
after extended periods of EPA-treatments. Another possible explanation is that EPA 
acts by inhibiting enzymes such as the acyltransferase, responsible for the reacylation of 
AA into phospholipids whilst DHA does not. 
In a recent study of. the phospholipid fraction in rat uterine stomal cells (U 111 cells), 
Luquain et al (2000) found that DHA but not AA or EPA, was selectively esterified 
extensively into alkenylacyl-glycerophosphoethanolamine (PE-plasmalogens) as well as 
a minor phospholipid designated as bis-(monoacylglycerol phosphate). In that study, 
the percentage of .labelled DHA quantified in PC and PS/PI reduced rapidly with a 
concomitant increase in BMP and PE. It is therefore possible that the high uptake of 
3H-AA observed with DHA-treated cells, similar to that obtained with SA or OA, was 
due to the rapid incorporation of the added free 3H-AA into LPC molecules poor in 
PUFAs, generated by a PLA2 enzyme in response to the induced oxidative stress. 
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Upon continuous FA treatments, the inhibitory effects of AA and EPA were pronounced 
whereas DHA- treated cells appeared to incorporate the most 3H-AA in comparison to 
the other two PUFAs. As shown in Fig 7.7, the incorporation of 3H-AA after induced-
oxidation was not affected by prolonged treatment of U937 cells with SA, OA or even 
DHA but was severely suppressed by the presence of unlabelled AA and EPA. These 
res~lts are in support of previously reported studies in U937 cells (Balsinde, 2002) and 
mouse peri~oneal macrophages (Fernandez et al., 1992). A possible reason for 
differences in 3H-AA uptake is that PLA2 activity may be subject to different 
mechanisms of regulation depending on the PUF A involved. 
The differences observed with the different fatty acids employed, namely: stearic, oleic 
and most especially the polyunsaturated fatty acids: arachidonic, eicosapentaenoic and 
docosahexaenoic acids, will be discussed in more detail at the end of this study. 
7.4.2 Antioxidants 
To determine the role of dietary antioxidants on oxidant-induced 3H-AA incorporation 
into cellular phospholipids, the effects of pre-incubating U937 cells with ascorbic acid, 
a-tocopherol, ()-carotene or astaxanthin coupled with AA, EPA or DHA were 
examined. Endogenous presence of ascorbic acid in U937 cells subjected to oxidative 
stress significantly reduced the uptake of 3H-AA into cellular phospholipids. Since 
ascorbic acid is capable of promoting iron-dependent oxidative damage (Winterboum, 
1981; Minetti et al., 1992), the decrease in AA incorporation may be due to the presence 
of a large proportion of inactive U937 cells with lost membrane integrity. Although the 
pro-oxidative effect of ascorbic acid was not obvious in chapter four (FOX assay) after 
induced-oxidation for 30 min, it should be noted that AA uptake assays were conducted 
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after twice that length of time (1 h), suggesting a time-lag phase for the peroxidative 
attribute of the ascorbate radical. 
On the other hand, ~-carotene and astaxanthin appeared to reduce the uptake of 3H-AA 
with AA or EPA-pre-treated cells but not with DHA whereas, a.-tocopherol showed no 
effect on 3H-AA uptake in oxidised U937 cells. A possible explanation for the failure 
of a.-tocopherol to influence fatty acid incorporation into phospholipids may be due to 
factors such as the location of the vitamin in the membrane, the rate and site of the 
peroxyl radical production and the form of interaction existing between the 
lysophospholipase enzyme, acyltransferases and the cell membrane post-oxidation. 
Likewise, the location of carotenoids in U937 cell membranes could affect their ability 
to function as antioxidants. 
Since the phenolic moiety of a.-tocopherol is likely oriented towards aqueous solutions, 
it can react with a water-soluble initiating radical to form the stable phenoxyl radical 
(Matsuo et al., 1989; Liebler et al., 1991). Since the phenoxyl radical must also 
terminate itself, it could react with an unoxidized lipid molecule instead, thus 
propagating peroxidative chain reactions in the process (Dugas et al., 1998). In an 
attempt to enrich U937 cells in vitro, ~-carotene and astaxanthin, may have been 
incorporated only near the surface and not necessarily in positions where they might be 
normally located in vivo (Borel et al., 1996). To this end, it is important to extend these 
studies to in vivo enrichments of these dietary antioxidants to confirm the results 
presented here. 
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7 .4.3 Conclusion 
In summary, from this study, it is obvious that oxidation plays an important role in the 
modulation of phospholipid fatty acid turnover by providing LPL acceptors required for 
the reacylation reaction. In ~ddition, results herein demonstrated that 3H-AA uptake is 
significantly dictated by the identity of the fatty acid composition already present in 
U937 cells. Whilst SA or OA does not influence 3H-AA incorporation, the PUFAs are 
involved in the determination of synthetic process of the formation of cellular 
phospholipids. 
Unlike the saturated fatty acids, AA and· other PUF As such as BP A do not generally 
enter cellular phospholipids by direct acylation via the de novo pathway, instead, at a 
later stage through direct acylation of previously-existing lysophospholipid (LPL) 
acceptors. Since LPLs are produced by the lipolytic action_ of PLA2 on phospholipids, 
this enzyme must play a significant role in the uptake of AA into phospholipids. 
However, much work is required to clarify the mechanisms responsible for LPL 
maintenance and the role of oxidation in phospholipid metabolism. 
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CHAPTER 8: PRELIMINARY CYTOSOLIC PHOSPHOLIPASE A2 (cPLA2) ELISA 
8.1 INTRODUCTION 
Cells in vivo must continuously adapt to stress stimuli such as free radicals and highly 
reactive oxygen species. In schizophrenia, the biochemical details underlying the 
relationships between oxidative injury and PLA2 activity subsequently leading to 
neurodegeneration, are yet to be clarified. PLA2s are a growing family of enzymes 
including a heterogenous collection of proteins with diverse roles in cell functions (Six and 
Dennis, 2000). Among this group is cPLA2, a cytosolic enzyme catalysing the hydrolysis 
of phospholipids at the sn-2 position generating free fatty acids, preferentially arachidonic 
acid (AA) and lysophospholipids. The release of AA is particularly relevant because it is 
the common precursor of the biologically active eicosanoids (Smith, 1992). AA and its 
metabolites can also act as first and second messengers in the modulation of a number of 
cellular processes (Axelrod et al., 1988). Therefore, the regulation of an AA-specific PLA2 
serves as a key control point for the synthesis of potent mediators of inflammatory 
responses and signal transduction pathways. 
The 85 kDa cytosolic PLA2 ( cPLA2) that migrates with an apparent mole~ular mass of 
~100 kDa (cPLA2), is expressed in a variety of cell types including the human monocytic 
cell line, U937 (Clark et al., 1990; Kramer et al., 1991; Sharp et al., 1991). The molecular 
details responsible for the signaling pathways of cPLA2 are thought to involve its 
phosphorylation (Channon and Leslie, 1990; Clark et al., 1991). One well-characterized 
mechanism of agonist-stimulated cPLA2-enzyme activation involves increased intracellular 
concentrations of Ca2+ (Channon and Leslie, 1990; Gijon et al., 1999) leading to its 
phosphorylation in vitro at a serine (Ser-505) amino acid residue (de Carvalho et al., 1996; 
Gijon et al., 1999). The observation that a large fraction of cPLA2s can be found 
phosphorylated even under basal or non-stimulated conditions, clouds the role of increased 
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phosphorylation of cPLA2 towards cellular agonist activation (Lin et al., 1993; Gijon et al., 
1999; Gijon and Leslie, 1999). In addition, it has been shown that cPLA2 has a high 
affinity for phosphatidylinositol 4, 5-biphosphate (PIP2) in cell membranes (Mosier et al., 
1998). Furthermore, studies have shown that cPLA2 can be activated to generate 
arachidonic acid (AA), without any increase in intracellular Ca2+ concentration (Balsinde et 
al., 2000). 
Another pathway implicated in cPLA2 activation involves the coupling of cPLA2 to 
receptors via G-proteins (Burch, 1989) and cPLA2.phosphorylation activated in vivo by a 
stimulated protein kinase C (PKC) in response to cell activation (Parker et al., 1987; Lin et 
al., 1993; de Carvalho et al., 1996; Gijon et al., 1999). There is growing evidence of the 
involvement of cPLA2 in receptor-mediated generation of eicosanoids and platelet 
activating factors in several pathological processes (Larsen and Henson, 1983) including 
the modulation of ion channels (Kim and Clapham, 1989) and neurotransmitter release 
(Piomelli and Greengard, 1990). 
The activation of cPLA2 by increased Ca2+ concentrations causes its translocation from the 
cytosol to the plasma membranes where the phospholipid substrate is localized (Channon 
and Leslie, 1990; Clark et al., 1991). Since oxidative injury is capable of altering 
membrane permeability and fluidity by modulations of cell membrane associated proteins 
such as the ion channels, its implication in neurodegeneration (Farooqui and Horrocks, 
1991) is no surprise.· It has been shown that PLA2 activity is increased in schizophrenia 
(Gattaz et al., 1995) and this has been associated with increasing oxidative stress in 
neuronal cell membranes (Scheffer et al., 1999). It is likely that oxidative stress stimuli 
increase the phosphorylation of cPLA2 above basal levels thereby, increasing its activity. 
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To further understand.the role of oxidant-induced over-activity of cPLA2, this preliminary 
study investigates the concentration of the enzyme in U937 cells exposed to a free radical 
mediating oxidant system, using a novel double antibody "sandwich" enzyme-linked 
immunosorbent assay (ELISA). 
An ELISA-ba,sed technique developed by the Biochemistry Department of the Victoria 
Infirmary NHS Trust (Glasgow) was used to measure cPLA2 levels in oxidant-activated 
U937 cells. The assay employs antibodies, which recognize the cPLA2 enzyme. The 
antibodies were used in this preliminary study to determine immunoreactivity of U937 cells 
treated with or without the oxidative stress stimuli after pre-incubations with the different 
fatty acids. 
8.2 MATERIALS AND METHODS 
8.2.1 Materials 
Fatty-acid-free bovine serum albumin · (BSA), stearic acid (SA), oleic acid (OA), 
arachidonic acid (AA~, 0.4% Trypan Blue dye solution,· Hanks balanced salt solution 
(HBSS), RPMI 1640, foetal bovine serum (FBS), 200 mM L-glutamine, 50 mg/ml 
gentamicin solution, HPLC-grade ethanol, tert butyl hydroperoxide, and ferrous sulfate 
heptahydrate (FeSO4• 7H2O) were obtained from Sigma-Aldrich, UK. Eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) were supplied by Nu-chek Prep. Inc., 
Denmark. 
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8.2.2 Glassware and plastic preparations 
All glassware used was washed in de-con and nano-pure water, autoclaved at 121°C for 30 
min and dried in an oven before use. All other apparatus used were sterile with all U937 
cell treatments performed in a class II laminar flow hood. 
8.2.3 Cell culture 
U937 cells were cultured in RPMI 1640 supplemented with 10% FBS and 2 mM L-
glutamine and 0.05 mg/ml gentamicin at 37°C in a humidified incubator with 5% CO2/95% 
air. For all experiments, cells were maintained at i.O x 106 cells/ml at viability > 90% by 
Trypan Blue dye exclusion method of viability measurements. 
8.2.4 Cell treatments 
U937 cells adjusted to contain 1.0 x 106 cells/ml were treated with the FAs: SA, OA, AA, 
EPA, DHA or 0.4% v/v of ethanol (controls) complexed with fatty-acid-free BSA in a 2.5: 
1 molar ratio. Cells were incubated in 1 ml suspensions in 24-well plates at 37°C and 5% 
CO2 in a humid environment. Final concentration of fatty acids in 1.0 ml cell suspensions 
per well was 10 µM. After 24 h of incubation with FAs, cells were washed twice with 
HBSS/0.2% BSAby centrifugation at 250 g for 5 min at 4°C and re-suspended in 0.1 ml of 
HBSS in new 24-well plates. Stock solutions of 2 mM t-BHP and 5 mM FeSO4 were 
freshly prepared in HBSS. Cells (0.1 ml in HBSS) were then treated with or without 0.9 ml 
of the oxidant mixture in HBSS. The final oxidant concentration in each well of a 24-well 
plate was 750 µM t-BHP/Fe2+. Cells treated without the oxidant mixture were incubated in 
HBSS only. Incubation proceeded for 1 h under the conditions stated above. Thereafter, 
reactions were stopped by centrifugation at 4000 g for 3 min at 4°C. Cells were washed 
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twice in HBSS and re-suspended in 0.1 ml of.HBSS. Cell pellets (0.1 ml) in HBSS were 
frozen immediately at -200°C in liquid nitrogen prior to the ELISA. 
8.2.5 cPLA2 ELISA technique 
Oxidant-treated cell samples were transported to the Biochemistry Department, Victoria 
Infirmary NHS Trust (Glasgow) in liquid nitrogen. On arrival, samples were transferred 
into a -70°C freezer for storage. Cell samples were analyzed using an as yet unpublished 
ELISA technique developed in their laboratory (MacDonald et al., 2000). For this reason, 
the method will not be disclosed in this thesis. 
8.2.6 Protein assay 
The protein content. of cell homogenates and supernates were determined by the Lowry 
method (Lowry et al., 1951) using bovine serum albumin as a reference standard. 
8.3 RESULTS 
To determine the effect of the different fatty acids on cPLA2 activity, U937 cells were 
incubated in Hanks balanced salt solution (HBSS) only for 1 hat 37°C and 5% CO2 in a 
humid environment. The ELISA technique for the measurement of the concentration of 
cPLA2 was used as a measure of the concentration of the enzyme. U937 cells pre-treated 
with 10 µM levels of SA, OA, AA, EPA, DHA or 0.4% v/v ethanol (control) for 24 h were 
washed twice to rid cells of unincorporated FAs prior to the exposure of cells to HBSS 
(without oxidation) or 750 µM t-BHP/Fe2+ (with oxidation). Post-oxidation, cells were 
washed again twice in HBSS to ensure the removal of all serum before the conduction of 
the ELISA. No significant difference in cPLA2 concentration with fatty acid treatments in 
cells treated with or without the oxidant mixture was observed (one-way ANOVA F = 2.35, 
277 
P > 0.05, DF = 5) (Fig. 8). To examine the overall effect of oxidative stress on cPLA2 
activity, U937 cell response was compared between cells treated with and without the 
oxidant mixture. Statistical analyses show a significant increase in cPLA2 activity with 
oxidative stress (one-way ANOVA F = 31.92, P < 0.001, DF = 1) (Fig. 8). 
Comparisons, of each set of U937 cells pre-incubated with fatty acids (treated with or 
without 750 µM t-BHP/Fe2+), showed no significant increases in cPLA2 levels with 
induced-oxidation: controls (T = 1.03, P > 0.05, DF = 6); SA- (T = 2.06, P > 0.05, DF = 6); 
EPA-_ (T = 1.04, P > 0.05, DF = 5) and DHA- (T = 1.59, P > 0.05, DF = 6) pre-treated U937 
cells. However, there were significant increases in cPLA2 levels with OA (W = 26.0, P < 
0.05, DF = 6) and AA (T = 7.70, P < 0.001, DF = 6) pre-treatments. In oxidant-treated 
U937 cells, cPLA2 levels increased by average values of 9% (controls); 24% (SA); 37% 
(OA); 38% (AA); 14% (EPA) 22% (DHA) when compared to counterpart FA-treated cells 
without the oxidant mixture. 
Since cPLA2 has a preference for AA - containing phospholipids, the marked oxidant-
activated increase in cPLA2 levels observed with AA enrichment of U937 cells is not 
surprising. It is however interesting that oxidation of the other PUFA (EPA or DHA) - pre-
treated U937 cells demonstrated no significant elevations in cPLA2 concentration. A 
possible explanation is that the large errors in this experiment may be disguising the effects 
of oxidation on cPLA2 concentration with EPA and DHA treatments. 
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Fig. 8 cPLA2 concentration in U937 cells pre-treated with 10 µM SA, OA AA, EPA, DHA or ethanol (for controls) prior to 
exposure to 750 µM t-BHP/Fe2+ for 1 h. Data points represent means± 95% Cis (n = 4). * Denotes significant differences 
between FA-enriched cells treated with and without the oxidant. 
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8.4 DISCUSSION AND CONCLUSION 
The aim of this study was to determine the effect of oxidation on cPLA2 concentration 
preliminarily, in fatty acid- enriched U937 cells. The data obtained are consistent with 
elevated cPLA2 levels in response to increased oxidative stress. 
In order to measure the effect of oxidative-stress on the· concentration of cPLA2, the 
enzyme was, immunoassayed from oxidized or unoxidized U937 cells pre-treated with 
or without the different fatty acids: SA, OA, AA, EPA or DHA. Afterwards, cPLA2 
was quantified. Under basal conditions (resting U937 cells), the concentration of cPLA2 
was high relative to FA-unsupplemented controls. In fact, there were no significant 
differences between controls and FA-enriched cells under both conditions investigated 
(with or without oxidation). With induced-oxidation however, cPLA2 concentrations 
were increased. These elevations in cPLA2 concentrations were significant only with 
OA- and AA- pre-treated U937 cells but not with controls, SA-, EPA- or DHA- treated 
cells. EPA and DHA are PUFAs, highly susceptible to peroxidative damage. It is 
likely that the presence of these PUFAs, promote cPLA2 activation in U937 cells in a 
manner that does not require the phosphorylation of the enzyme nor alterations in its 
concentration as previously suggested by Hsu et al., (2000). Or perhaps pre-treatment 
with EPA or DHA stabilizes cPLA2 in U937 cell membranes under such conditions of 
oxidative stress. 
In support of this study, Hatanaka (1996) previously showed a link between the 
formation of free radicals and activation of PLA2 in primary neuronal cell cultures. 
Besides, it has been suggested that oxidized· phospholipids are better substrates for 
cPLA2 activity than the native phospholipid itself, demonstrating a repairing role for 
cPLA2 in the removal of damaged lipids from cell membranes (McLean et al., 1993). 
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8.4.1 Conclusion 
In conclusion, this preliminary study shows an association between oxidative stress, 
cellular phospholipid fatty acid composition and increased cPLA2 activity although the 
exact mechanism of cPLA2 activation upon oxidation is yet to be fully understood. 
However, in view of the potential importance of these findings in schizophrenia 
research, this study needs to be repeated in other cell models. Clearly, further work is 
required to v,alidate the hypothesis of increased cPLA2 activity with elevated oxidative 
stress levels. 
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CHAPTER 9: GENERAL DISCUSSION, CONCLUSIONS AND FUTURE 
PROSPECTS· 
9.1 INTRODUCTION 
In the "Discussion and Conclusion" sub-sections at the end of previous experimental 
chapters, the findings most relevant to the objectives set out to achieve were 
highlighted. The main goal of this section is to link the observations made from the 
different studies together in order to form an overall picture of the various effects of the 
cell treatments employed and the relationships existing between these treatments and 
the responses triggered using the human·monocytic, leukemia U937 cell line. 
Several methods were. utilized in the investigation of the effects of oxidants (a mixture 
of tert-butyl hydroperoxide and Fe2+) on cell membrane integrity, modified cellular 
phospholipids, accumulation of certain by-products of lipid peroxidation (lipid 
hydroperoxides and volatile hydrocarbons) and arachidonic acid release and uptake in 
the hydrogen peroxide-producing U937 cell line. These methods provided more 
information on the cytotoxic levels of certain fatty acids, especially the PUFAs (AA, 
EPA and DHA), and dietary antioxidants (ascorbic acid, a-tocopherol, f3-carotene and 
astaxanthin) in these cells. It also demonstrated the mechaniSJ?1S possibly governing the 
response of U937 cells pre-treated with these agents upon induced-oxidation. 
9.2 CELL VIABILITY MEASUREMENTS 
This study showed that U937 cells are fast growing cells when maintained at 0.5-1.0 x 
106 cells/ml. In addition to demonstrating a good linear relationship between the 
Trypan blue dye-exclusion and lactate dehydrogenase methods of viability 
measurements, this study has shown that U937 cells are more sensitive to the PUFAs 
than the saturated (SA) and monounsaturated (QA) fatty acids. Of the PUFAs used, 
EPA was the most toxic to U937 cells when supplemented with CM at equal 
concentrations before cellular incubations at 37°C and 5% CO2 in a humid environment. 
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Neither SA nor OA had any effect on LDH leakage whereas the addition of equivalent 
concentrations of the PUF As did. Further research is required for a better biochemical 
understanding of mechanisms by which the PUFAs especially EPA, influence the loss 
of cell membrane integrity, without oxidative stress. 
Initi~l studies demonstrated that the enrichment of these cells with 100 - 400 µM levels 
of ascorbic apid, 10 - 40 µM of a-tocopherol, 3 - 12 µM concentrations of '3-carotene 
or astaxanthin did not alter cell membrane integrity significantly, establishing the 
tolerable concentrations of these agents in U937 cells prior to stress experiments with 
oxidants. 
9.3 FATTY ACID INCORPORATION 
· Preliminary experiments by gas chromatographic analysis of fatty acids after pre-
incubation of cells in FA-enriched CM demonstrated that U937 cells rapidly incorporate 
PUFAs into phospholipids. Data obtained suggest that these cells are rich in saturated 
(14:0, 16:0 and 18:0) and monounsaturated (16:ln-7, 18:ln-7 and 18:ln-9) fatty acids 
but very poor in the PUFAs (20:4n-6, 20:5n-3 and 22:6n-3) (North et al., 1994; 
Obermeier et al., 1995; Yano et al., 2000). However, supplementation with the PUFAs 
significantly increased their levels in cellular phospholipids after only 12 h of 
incubation. For fatty acid incorporation into phospholipids to occur, there must be pre-
exist~ng LPL acceptors. Since LPLs are generated by the hydrolytic action of PLA2 on 
phospholipids, this class of enzymes necessarily play a critical role in available-PUPA 
incorporation into cellular phospholipids in these cells, thereby demonstrating the 
existence of basal acyltransferase, lysophospholipase and phospholipase A2 activity 
under normal conditions of incubation. Previous studies have shown that U937 cells are 
rich in different isoforms of PLA2 including cPLA2 (Kramer et al., 1991) and iPLA2 
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(Balboa and Balsinde, 2002),- the exact mechanism therefore responsible for FA 
incorporation under resting conditions requires further investigation. 
9.4 EFFECTS OF THE FATTY ACIDS AND DIETARY ANTIOXIDANTS 
ON LIPID PEROXIDATION AND PHOSPHOLIPASE A2 ACTIVITY 
The_initial objectives and hypothesis outlined in chapter one will now be discussed in 
relation to the results obtained in this research in order to answer the following 
questions: 
- Is oxidative stress measurable in U937 cells? 
- Does oxidative·stress increase the uptake of fatty acids into phospholipids (PLs) 
or the breakdown of PLs? 
- How do the PUFAs (EPA andDHA) affect the release and uptake of AA under 
oxidative stress conditions? 
- Is the expression of PLA2 influenced by oxidative stress? 
- What are the effects of the antioxidants (ascorbic acid, a-tocopherol, f3-carotene 
and astaxanthin) on oxidative stress and PLA2 activity in PUFA-rich U937 cells? 
- Is-lipid peroxidation coupled with PLA2 activation in U937 cells? 
9.4.1 Is oxidative stress measurable in 0937 cells? 
Lipid peroxidation is a critical cellular process that occurs in aerobic organisms in 
response to oxidative stress. This process places a burden on the whole cell or organ 
and has been studied both in in vivo and in vitro animal model systems. The Ferrous 
oxidation/xylenol ·orange (FOX) assay was used to determine the susceptibility of U937 
cells to lipid peroxidative damage after fatty acid modifications of their cellular 
phospholipids. This study showed that fatty acids oxidize at different rates, yielding 
lipid peroxides, in a manner dependent on their degree of unsaturation, when examined 
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under conditions of equal oxidative stress. For confirmatory reasons, U937 cells pre-
treated with the same fatty acids were tested for volatile hydrocarbons (alkanes) 
generated post-oxidation by headspace analysis. In contrast to expectations, U937 cells 
generated ethane and butane in a decreasing fashion and· pentane in an increasing 
manner, with increasing levels of FA unsaturation. Since hydrocarbons are metabolised 
by tp.e decomposition of lipid peroxides (Halliwell, 1987; De Zwart et al., 1999), the 
mechanism ~esponsible for the production of lower levels of ethane and butane from 
cells pre-treated with PUFAs especially EPA and DHA, in comparison to SA and OA, 
is not yet clear. Likewise, the system by which these cells generate pentane with the 
different PUF As is not yet understood. A possible explanation may be that fatty acids 
oxidize at different rates, producing different by-products of lipid peroxidation, in a way 
independent of unsaturation levels, as previously suggested by Visioli et al. (1998). It 
may also be that there is a lag phase between ethane production from lipid peroxides in 
FA-treated cells upon induced oxidation. Whether the generation of volatile 
hydrocarbons from FA- pre-treated cells involves an enzyme activity is unknown at 
present. 
Taken together, this study shows that lipid peroxides and volatile alkanes (ethane, 
butane and pentane) can be quantified in U937 cells as biomarkers of lipid peroxidation. 
However, whether the technique of GC-headspace analysis of volatile hydrocarbons can 
be proposed as a suitable method of analysing by-products of lipid peroxidative damage 
in the U937 cell line requires much further investigation. Also, it suggests that several 
biomarkers of lipid peroxidative damage should be measured when studying the effects 
of treatments of oxidative stress whether in vitro or in vivo. 
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9.4.2 Does oxidative stress increase the uptake of fatty acids into phospholipids 
(PLs) or the breakdown of PLs? 
The radical-mediating system of 750 µM t-BHP/Fe2+ was used in this study to 
investigate the release and incorporation of radiolabelled AA This concentration had a 
significant effect on U937 cell membrane integrity compared to controls. Experiments 
indicated that AA release in U937 cells exposed to the oxidants is both dose- and time-
dependent. ~n resting U937 cells, the capacity to incorporate AA into phospholipids is 
high. Whilst prolonged oxidation (> 1 h) of untreated cells decreased the uptake of 
radiolabelled AA, short exposure (:5; 1 h) to 750 µM t-BHP/Fe2+ significantly increased 
the rate of incorporation into cellular phospholipids. 
Increasing evidence suggests that free radical-mediated damage contributes directly or 
indirectly to schizophrenia (De Zwart et al., 1999). The present study showed a 
significant relationship between the generation of lipid hydroperoxides, the reacylation 
of AA into cellular PLs and the hydrolysis of phospholipids, yielding second 
messengers: arachidonic acid and lysophospholipids (LPLs). LPLs are potentially toxic 
in nature due to their detergent-like properties and in high concentrations, both AA and 
LPLs can cause membrane disruption and ultimately cell lysis (Farooqui et al., 1997b). 
9.4.3 How do the PUFAs (EPA and DHA) affect the uptake and release of AA 
under oxidative stress conditions? 
The polyunsaturated fatty acids (PUFAs), especially EPA and DHA, are being 
increasingly investigated as possible treatments for a diverse array of human diseases. 
These include: atherosclerosis (Gil, 2002), cancer (Cowing and Saker, 2002), 
cardiovascular diseases (Nordoy et al., 2001), schizophrenia (Horrobin et al., 2002), 
depression (Puri et al., 2001) and many neurodegenerative disorders (Blondeau et al., 
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2002). These reports emphasize the importance of the PUFAs (both n-3 and n-6) as 
basic biomolecules in biological systems. Of the n-3 PUFAs, supplementary treatment 
with EPA but not DHA significantly improves symptoms of schizophrenia (Emsley et 
al., 2002). A number of points from the present study indicate similarities and striking 
differences in the response of U937 cells to oxidative stress post treatments with EPA or 
DHA for varying periods of time: 
- EPA _use, above certain tolerable concentrations, has stronger cytotoxic effects 
on U937 cell membrane integrity compared to DHA when used in equal 
concentrations and cells incubated for 3 days. 
- At equal concentrations, there were no· significant differences between the 
susceptibility of EPA and DHA pre-treated cells (for 24 h) to peroxidative 
damage as quantified by both the FOX assay and headspace analysis. 
Accumulation in lipid hydroperoxides increased with increasing concentrations 
of both EPA and DHA. 
- Neither EPA nor DHA inhibited oxidation under the conditions studied. 
Increasing concentrations of EPA or DHA promoted the release of radiolabelled 
AA into the extracellular medium when exposed to the oxidants. 
- In an attempt to gain further insight into the mechanisms influencing the 
response of U937 cells under oxidative stress conditions, the fatty acids (SA, 
OA, AA, EPA or DHA) were continuously supplemented with the culture 
medium (by complete replacement every 3 days) for 18 days before oxidation 
experiments for the determination of AA·· release_ and AA - uptake were 
conducted. Interestingly, there was a marked difference in AA release and 
uptake between cells treated with EPA and DHA. EPA strikingly promoted AA 
release and inhibited its incorporation into phospholipids in comparison to 
DHA-treated cells under oxidative stress conditions. This unexpected finding of 
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suppressed AA uptake with induced-oxidation indicates that prolonged EPA pre-
treatment totally reversed the stimulatory effects of oxidative stress observed in 
FA-untreated control cells. Whether such a response reflects an effect of EPA 
alone or an influence of the fatty acid triggered by the peroxidative process, is 
-unknown at present and should be a subject for future investigations. This 
information will be provided by repeating the experiment with controls for the 
prolonged fatty acid treatment including FA-treated cells alone without 
oxidative stress. It is however important to note that assays were conducted 
after pre-treating cells for 24 h with FAs and 3H-AA without oxidation (for AA 
release) (Fig. 6.4) and also after the simultaneous addition of FAs and 3H-AA for 
24 h without oxidation (for AA uptake) (Fig. 7.4). Based on these results, it is 
tempting to speculate that after continuous treatments of these cells with the 
fatty acids for 18 days, in the absence of the oxidants, AA release remains 
significantly higher and uptake markedly lower with EPA-treatments in 
comparison to DHA-treated cells. The 24 h assays without induced-oxidation 
suggest that these effects result from EPA treatment alone, not requiring the 
oxidant to become apparent. Further studies are therefore required to investigate 
this attractive possibility. 
Arachidonic acid (AA) is predominantly generated through the action of PLA2 by the 
hydrolysis of membrane phospholipids. Due to the pivotal role of PLA2 in the 
liberation of AA, the roles of SA, OA, AA, EPA and DHA in its release upon m_ddant 
stimulation were investigated. Neither SA nor OA demonstrated any significant effects 
on AA release. Of the PUFAs employed, EPA demonstrated dramatically different and 
significant effects when continuously supplemented with the culture medium over 18 
days. It appears likely_ that eicosapentaenoic acid stimulates the release of free AA, at 
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t~e same time inhibiting its uptake into cellular phospholipids after.the exposure of the 
cells to t-BHP/Fe2+. ·This conclusion argues against my initial hypothesis that EPA acts 
as an antioxidant, since t-BHP/Fe2+ stimulates AA release in FA-untreated U937 cell 
controls. How this oxidant-facilitated catalysis of AA release by EPA presence occurs 
is presently unknown, but a possible explanation is that the presence of EPA in U937 
cell phospholipids enhances the release of AA upon oxidation, thus ensuring its 
availability f ~r eicosanoid production. Also, it could be that EPA acts by blocking the 
re-incorporation of AA into cellular phospholipids, upon induced oxidation. Of note 
however, is the lack of control experiments designed to show the effects of the 
continuous (18 days) treatments of U937 cells with these fatty acids in HBSS only 
(without oxidants). This information is required to determine whether the differences 
observed in AA uptake and release between EPA ·and DHA occur only under conditions 
of oxidant-stimulation or under resting conditions as well. 
Eicosanoids are oxygenated derivatives of di-homo-y-linolenic acid (DGLA), AA, and 
EPA. The relative concentrations of these three fatty acids affect the type of 
eicosanoids produced because they compete for the cyclo-oxygenase (COX) and 
lipoxygenase (LOX) enzymes. Eicosanoids metabolised from AA are stronger 
modulators of cell functions than those produced by DGLA or EPA (Crawford, 1983). 
On the other hand, DHA is a substrate for neither the COX nor LOX enzymes, but this 
study suggests that it can reduce the synthesi~ of eicosanoids from AA by inhibiting the 
activity of a phospholipase A2 enzyme. Schizophrenic patients show reduced flushing 
in response to oral or topical niacin (nicotinic acid) compared to healthy controls, which 
can now be examined by the skin patch test (Ward et al., 1998). This abnormality has 
been shown in medicated and unmedicated schizophrenic patients in a study conducted 
in India (Shah et al., 1999). The mechanism underlying the niacin skin flushing is 
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based on the synthesis of prostaglandin D2 (PGD2) from arachidonic acid via the cyclo-
oxygenase pathway (Morrow et al., 1992). The niacin test provides further evidence of 
a dysfunction in lipid signalling mechanisms in schizophrenia. In tum, these results 
highlight the key role of EPA in modulating the availability of AA released for 
eicosanoid synthesis under oxidative stress. Whether this impairment occurs in brain 
cells.,as well as monocytes is not yet clear. 
The polyunsaturated fatty acids (AA, EPA and DHA) are derived from the essential 
fatty acids: linoleic and linolenic acid. Due to their crucial roles in signal transduction 
processes in the central -nervous system (CNS), the importance of these fatty acids in 
human health cannot be over-emphasized. This study gives an insight into the actions 
of these fatty acids under conditions of oxidative stress. Since U937 cells are naturally 
poor in AA, EPA and DHA (North et al., 1994; Obermeier et al., 1995; Yano et al., 
2000), raising their levels in these cells by CM-supplementation demonstrates the 
effects one might expect to observe in schizophrenia because cells from schizophrenic 
patients have also been shown to have depleted levels of these fatty acids (Mahadik et 
al., 1996). Furthermore, oxidative injury is often associated with AA mobilization from 
cells such as endothelial cells, platelets and phagocytes. Thus, interactions between 
peroxidative damage and AA release are of particular importance in biological systems. 
In an open study, the diets of 20 hospitalised schizophrenic patients with chronic 
symptoms were supplemented with EPA from fish oils on a daily basis for 6 weeks 
(Mellor et al., 1995). Over the trial period, improvements in schizophrenic symptoms 
were observed and these were associated with increased erythrocyte membrane 
concentrations of n-3 fatty acids. Of particular interest, was the case of a 31 year-old 
drug free patient with longstanding schizophrenia who showed an 80 - 85% 
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improvement after daily dietary supplementation with EPA for 6 months (Puri and 
Richardson, 1998). The present study might help to explain why EPA appears to play a 
role in the reduction of schizophrenic symptoms by enhancing AA release. It was 
suggested that fatty acids released by PLA2 activity along with their oxygenated 
metabolites (eicosanoids), play an important role in the regulation of neurotransmitters 
such as dopamine (Ross, in press). Perhaps the release of AA, markedly enhanced by 
EPA treatme,nt aids the generation of eicosan9ids in schizophrenia, in tum improving 
psychosis (Ross et al., in press). 
As shown in this study, the levels of fatty acids ii1 tissues reflect dietary intake (Zheng 
et al., 2001). For instance, reports from studies of normal volunteers receiving EPA and 
DHA supplementation, showed significant increases in n-3 fatty acids and reductions in 
the n-6 fatty acid compositions in the lipid fractions of the plasma, platelets and red 
blood cell membranes over 2 - 3 months (Prisco et al., 1996; Vidgren et al., 1997). 
Studies over longer periods of time suggest that FA levels in cholesteryl esters reflect 
intake over 1 - 2 weeks; red blood cells, over 1 - 2 months; and adipose tissues over 
years of intake (Katan.et al., 1997). Several studies have reported depleted levels of 
linoleic acid (18: 2n-6) (Vaddadi et al., 1986; Horrobin et al., 1989; 1991; Kaiya et al., 
1991; Fischer et al., 1992; Yao et al., 1994; Glen et al., 1994; Peet et al., 1995; Vaddadi 
et al., 1996); arachidonic acid (20: 4n-6); (Vaddadi et al., 1986; 1989; Horrobin et al., 
1989; 1991; Yao et al., 1994; Peet et al., 1995); eicosapentaenoic acid (20: 5n-3) 
(Fischer et al., 1992; Glen et al., 1994; Peet et al., 1995); docosapentaenoic acid (22: 5n-
3) (Vaddadi et al., 1986; 1989); and docosahexaenoic acid (22: 6n-3) (Vaddadi et al., 
1989; Bates et. al, 1991; Horrobin et al., 1991; Fischer et al., 1992; Glen et al., 1994; 
Peet et al., 1995) in schizophrenic patients compared to healthy controls. Provided that 
daily intake is not excessive, n-3 fatty acids are generally regarded as being safe ( < 3 _g 
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per day) (Department of Health and Human and Human Services, 1997). Whilst three 
of four double-blind trials of n-6 fatty acid supplementation of standard antipsychotics 
medication produced negative results (Fenton et al., 2000), trials with n-3 fatty acids 
yielded positive results (Mellor et al., 1995; P~et et al., 1996), further suggesting the 
importance of the PUFAs especially the n-3 FAs in improving schizophrenic symptoms. 
Most PUF~s used by neuronal cells for glycerophospholipid synthesis are not 
synthesized in the CNS but are transported to the brain from the gastrointestinal tract 
(Horrocks and Yeo, 1999). They are either dietary or produced in the liver from linoleic 
and linolenic acids. · The synthesis of glycerophospholipids takes place in the 
endoplasmic reticulum (ER). Newly formed phospholipids self-assemble into 
thermodynamically stable bi-layers, which form vesicles that detach from the ER and 
then travel by phospholipid transfer proteins (Alb et al., 1996) to other sites in order to 
donate their phospholipids to other membrane structures (Farooqui et al., 2000). This 
process utilizes ATP to overcome the concentration and electrical gradients between the 
inner and outer membranes. Glycerophospholipids in neuronal membranes are 
responsible for membrane fluidity, permeability, local curvature, molecular packing or 
hydration, ionic charge and reactivity to regulate the activities of membrane-bound 
enzymes and ion-channels (Crews, 1982; Freysz et al., 1982). Therefore, the vitality of 
fatty acids in life cannot be stressed enough. Furthermore, populations with a high 
dietary intake of n-3 fatty acids were reported to show lower frequencies of breast 
cancer (Kaizer et al., 1989) and several studies have reported reduced multiplication of 
malignant cultured cells with n-3 fatty acid supplementation (Chow et al., 1989; Rose · 
and Connolly, 1991; Anel et al., 1992; Chajes et al., 1995). 
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Deficiency as well as excess of ·PDF As can influence the extent of cell death (Rudolf et 
al., 2001). The present study indicates that the effects of the n-3 fatty acids, EPA and 
DHA, ranges from stimulation to inhibition when U937 cells were exposed to oxidants. 
Interestingly, EPA enhances AA release over DHA and also reduces its incorporation 
when used at equal concentrations under conditions of oxidative stress, thus suggesting 
the involvement of a PLA2 enzyme. 
Collectively, this study has shown that over periods of continuous treatments, EPA acts 
by enhancing oxidant-induced AA release post AA uptake for 24 h and inhibiting 3H-
AA uptake after induced-oxidative stress. It can ·thus be argued that its mechanism of 
action involves the regulation of AA levels found incorporated into phospholipids as 
well as maintaining its availability for prostaglandin synthesis when exposed to 
oxidants. Recently clinical trials with ethyl-EPA generated greater improvements in 
schizophrenic symptoms when it produced elevations in AA levels and vice-versa 
(Horrobin et al., 2002). However, in that study, the total lipid extracts from red blood 
cells of patients analysed for fatty acids were assumed to contain mainly phospholipids. 
Further definitive assays were not employed to separate phospholipids from fatty acids 
after lipid extractions. Although it may be that the extracts mostly contained AA-rich 
phospholipids, they may also have contained cell-associated freely available arachidonic 
acid in response to EPA treatments. If the former is true, a possible explanation for 
increased AA release and suppressed uptake observed in this study with EPA treatments 
may be that the concentration of EPA used herein (10 µM) is at the high end of the 
dose-response curve since clinical studies have shown that high amounts of EPA 
produces lower levels of incorporated AA into cellular phospholipids (Horrobin et al., 
2002). It is also possible that at lower concentrations ( < 10 µM) EPA promotes AA 
release and does not inhibit its uptake under oxidative stress conditions. Hence it is 
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necessary to conduct dose-dependent experiments of AA release and uptake with or 
without oxidative stress after continuous pre-treatment of cells with EPA. It is 
important to note that the quantity of AA released/incorporated, though significantly 
higher/lower in BP A .pre-treated cells is very low when compared to that still remaining 
incorporated in U937 cell phospholipids. 
9.4.4 Is the expression of PLA2 influenced by oxidative stress? 
The specific PLA2 enzyme responsible for stimulating AA release from phospholipids 
of U937 cells aft~r the exposure to oxidants is not yet known. Although preliminary 
experiments by the ELISA technique of quantifying cPLA2 expression in oxidant-
stimulated and unstimulated U937 cells pre-treated with the different fatty acids seemed 
to show increased activity with oxidation, this increase was not significant between all 
FA-treatments (with and without oxidants). It is therefore possible that the sn-1 
-
position of phospholipids is also extensively hydrolysed in U937 cells exposed to the 
oxidants, meaning that a PLA1 could also be involved in regulating oxidant-induced AA 
reacylation into phospholipids. Other possibilities are: that the PLA2 involved in 
oxidant-stimulated AA release may be a form of cPLA2 (group IV), the group VI, 
intracellular PLA2 (iPLA2) or even a yet unidentified isoform of PLA2• Of note, AA 
release experiments were conducted after 4 h of induced oxidation whereas the 
quantification of cPLA2 by ELISA was performed after 1 h. It is therefore possible that 
cPLA2 levels significantly increases in all FA treatments after 4 h rather than 1 h of 
exposure of U937 cells to the oxidant system. 
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9.4.5 What are the effects of the antioxidants (ascorbic acid, a-tocopherol, (3-
carotene and astaxanthin) on oxidative stress and PLA2 activity in PUF A-rich 
0937 cells? 
Of all individual and mixtures of antioxidants used, a-tocopherol was the most potent 
through.out this study. Although the carotenoids ((3-carotene and astaxanthin) did not 
function effectively during extended conditions of induced-oxidation (4 h), their 
potency was ,demonstrated in situation of short exposure (30 min) to the oxidants. This 
is probably because they were consumed rapidly or due to the conditions of high 
oxygen tensions employed (Pryor et al., 1988). Whilst a-tocopherol had no effect on 
AA uptake post-oxidation, (3-carotene and astaxanthin conferred slight effects. 
Ascorbic acid on the other hand strikingly promoted AA release and markedly inhibited 
its uptake when oxidation was stimulated with the iron-containing oxidant system (t-
BHP/Fe2+). 
Taken together, the present study demonstrates that antioxidant activity is affected by 
the length of time of exposure of U937 cells to the oxidant. It is therefore necessary to 
conduct experiments involving the continuous treatment of U937 cells with these 
antioxidants oyer longer periods before induced-oxidation. It is important to note that 
different processes are affected differently by the various antioxidants utilized in the 
present study. This suggests that "monotherapy" with antioxidants may not confer the 
best effects but the use of mixtures of antioxidants from the diet, may produce better 
results than a pill of one type. 
9.4.6 Is lipid peroxidation coupled with PLA2 activation in 0937 cells? 
This study has shown that arachidonic acid is released in response to oxidative stress in 
U937 cells as previously demonstrated in this and other cell systems (Chakraborti and 
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Chakraborti, 1995; Birbes et al.-, 2000; Balboa and Balsinde, 2002) but the mechanisms 
responsible for this effect are not entirely known. Since assays of AA release with t-
BHP/Fe2+ were conducted for 4 h after several washings of the cells with HBSS 
containing BSA, data suggest that PLA2 was activated in U937 cells in response to 
oxidation. 
Interestingly, when these cells were subjected to oxidation prior to uptake experiments, 
results revealed an increase in AA incorporation for 1 h after which there was a marked 
decline in uptake suggesting AA accumulation in the extracellular fluid over time. This 
study found that U937 cells treated with t-BHP/Fe2+ accumulate lipid peroxides over 
time in comparison to membranes from untreated cells. Taken together, the data 
suggest that the hydrolytic cleavage of cellular phospholipids by PLA2 is enhanced in 
peroxide-treated cells probably due to changes in the physico-chemical state of U937 
cell-membrane phospholipids in response to the accumulation of lipid peroxides, which 
was suppressed by the use of antioxidants such as a-tocopherol. 
9.5 GENERAL DISCUSSION 
Based on all these results, it is hypothesized that the short exposure of cells to oxidants, 
leads to the accumulation of lipid peroxides which in tum increase the uptake of 
arachidonic acid into cellular phospholipids. However under extended periods of 
oxidative stress (2:: 4 h), a decrease in AA incorporation is triggered due to the oxidation 
of membrane associated proteins (such as enzymes and receptors) concomitantly 
increasing extracellular concentrations of AA and LPLs, . continuous accumulation of 
which eventually leads to cell death and neurodegeneration. 
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In schizophrenia, it is clear that there is a genetic component involved (Torrey, 1992; 
McGuffin et al., 1995). It is also widely accepted that there is considerable contribution 
by environmental factors such as the diet (Obi and Nwanze, 1979; Peet et al., 1995). 
Whilst not much is known about the distinctive symptoms of schizophrenia instantly 
distinguishing it from other psychiatric disorders such as bipolar disorder, a great deal 
remains to be discovered about the cause of the disease itself. Greden and Tandon 
(1995) suggested that the "knowledge gaps" in the long-term treatment of schizophrenia 
and other neurodegenerati ve diseases· might be the most important issue facing 
psychiatry today based on the costs and consequences of maintaining improvements in 
severe psychiatric illnesses. 
It is well known that early treatment of schizophrenia is clearly beneficial and that 
dangers are associated with untreated psychosis. Therefore the diagnosis and treatment 
at the onset of the disease seem imperative. The prevention of relapse is also a critical 
factor.in the maintenance of schizophrenia treatment. Neuroleptics are associated with 
a variety of side effects and efforts to minimize these effects are necessary. Although 
the atypical anti psychotics cause less side effects, if the effic~cy of EPA supplement 
with vitamin E in the treatment of schizophrenia is established by large clinical studies 
in humans, it may represent a new class of treatment for schizophrenia with much less 
baggage. 
The above discussion on phospholipid metabolism, synthesis and breakdown, involving 
the PUP As and dietary antioxid.ants, does not describe the entire dynamics of 
phospholipid activities in brain tissues, but instead provides further insights into the 
biochemical and molecular complexity of membranes. It is hoped that this study on the 
uptake and release of fatty acids will initiate further studies not only on the mechanisms 
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involved in oxidant-induced PLA2 activity but also on individual activities of these fatty 
acids, their involvements in cell signalling and, ultimately, their roles in neuronal cell 
membranes. 
9.6 -CONCLUSIONS 
In keeping with the above notions, preliminary studies with EPA but not DHA-
treatments over time have yielded greater positive effects on the positive symptoms in 
schizophrenia in comparison to DHA (Peet et al., 2001). This finding is consistent with 
the possibility that the potency of individual n-3 PUFAs in altering cellular processes 
under conditions of oxidative stress, such as cell membrane leakage, AA release and 
uptake varies with PUF A type, concentration and time of exposure, as shown herein. It 
is noteworthy that the influence of PUFAs on these processes is possibly affected by the 
model system investigated and even the nature of examinations carried out whether in 
vivo or in vitro. It is not entirely clear whether n-3 PUFAs have direct influences on 
these cellular processes or if their metabolites are directly responsible. 
In summary, this research has shown a strong relationship linking peroxidative damage, 
AA release and uptake in the presence of the various fatty acids to the loss of membrane 
integrity and ultimately cell death. Although pre-treatment with ascorbic acid, a-
tocopherol, f3-carotene and astaxanthin inhibited lipid peroxidation, only a-tocopherol 
consi~tently conferred protective properties against oxidant-induced AA release from 
cellular phospholipids. Interestingly, none of the antioxidants at the concentrations used 
markedly influenced AA uptake post-oxidation. It is now important to apply this 
information in humans to determine whether the same effects are obtained. 
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9.7 FUTURE PROSPECTS 
The clarification of the effects of continuous treatments of U937 cells with EPA and 
DHA alone without induced-oxidation on AA release and uptake will be needed to fully 
understand the mechanisms involved in the therapeutic effects of the n-3. 
polyunsaturated fatty acids. 
Clearly, muc~ work is yet to be done to clarify the mechanisms responsible for oxidant-
induced AA release/uptake and the identification of the possible pathways and specific 
PLA2 enzyme(s) involved. This will assist in the provision of the fundamental 
knowledge required for future research aimed at understanding the roles of PUFAs, 
especially EPA, in the treatment of schizophrenia and.possibly other neurodegenerative 
diseases. 
Taking all these findings together, it is attractive to speculate that cPLA2 is responsible 
for the liberation of AA in oxidant-treated U937 cells. However, more work is needed 
to investigate this possibility. Due to the importance of acylation reactions in 
maintaining AA levels at physiological concentrations required for eicosanoid 
synthesis, it is necessary to confirm that oxidant-activated AA released with EPA 
treatments, actually yields eicosanoid production. 
Recent data have highlighted the fact that proteins are oxidised first before lipids in 
U937 cells (Gieseg et al., 2000), which may mean that the PLA2 enzyme responsible for 
catalysing AA release and uptake upon oxidation could be the oxidized form. Such a 
possibility as well as the involvement of EPA in enhancing oxidant-fnduced AA release 
requires further investigation. Further biochemical studies are also required to explore 
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the potential signalling mechanisms by which the PUFAs especially EPA, can act on 
gene expressions in vivo. 
This study demonstrates that a-tocopherol is more potent that ~-carotene, astaxanthin 
and ascorbic acid against lipid peroxidative . damage induced with t-BHP/Fe2+. 
How.ever, it is important to extend these studies (with individual and mixtures of 
antioxidants), to human subjects to confirm the results presented herein. The present 
study has shown that the polyunsaturated fatty acids exert pronounced effects in U937 
cells in culture demonstrating their biochemical potentials as pharmacological agents. 
300 
REFERENCES 
Abdalla DSP, Manteiro HP, Olivera JAC, Bechara CH. Activities of superoxide dismutase 
and glutathione peroxidase in schizophrenic and manic depressive patients. Clin Chem 
1986; 32: 805-807. 
Ackermann EJ, Conde-Frieboes K, Dennis EA. Inhibition of macrophage Ca2+-
independent phospholipase A2 by bromoenol lactone and trifluoromethyl ketones. J Biol 
Chem 1995; 270: 445-450. 
Ackermann EJ, Dennis EA. Mammalian calcium-independent phospholipase A2. Biochim 
Biophys Acta 1995; 1259: 125-136. · 
Adams DO, Nathan CF. Molecular mechanisms m tumor-cell killing by activated 
macrophages. Immunol Today 1983; 4 (6): 166-170. 
Alb JG, Kearns MA, Bankaitis VA. Phospholipid metabolism and membrane dynamics. 
Curr Opin Cell Biol 19Q6; 8: 534-541. 
Allard JP, Royall D, Kurian R, Muggli R, Jeejeebhoy KN. Effects of f3-carotene 
supplementation on lipid peroxidation in humans. Am J Clin Nutr 1994; 59: 884-890. 
Allerheiligen SRB, Ludden TM, Burk RF. The pharmacokinetics of pentane, a by-product 
of lipid peroxidation. Drug Metab Dispos 1987; 15: 794-800. 
Altman SA, Zastawny L, Cacciuttolo MA, Akman SA, DizdarogluM, Rao G. Formation of 
DNA-protein cross-links in cultured mammalian cells upon treatment with irons ions. Free 
Radie Biol Med 1995; 19: 897-902. 
American College of Neuropsychopharmacology/Food and Drug Administration Task 
Force. Neuroleptic syndromes associated with antipsychotic drug use. Arch Gen Psychiat 
1973; 28: 463-466. 
Ames BN, Carthcart R, Schwier E, Hochstein P. Uric acid an antioxidant in humans 
against oxidant - and radical - caused aging and cancer: A hypothesis. Proc Natl Acad Sci 
USA 1981; 78: 6858-6862. 
Anderson HR, Anderson O. Effects of dietary alpha-tocopherol and beta- carotene on lipid 
peroxidation by methyl mercuric chloride in mice. Pharmacol Toxicol 1993; 73: 192-201. 
Anel A, Naval J, Desportes P, Gonzalez B, Uriel J, Pineiro A. Increased cytotoxicity of 
polyunsaturated fatty acids on human tumoral B and T cell lines compared with normal 
lymphocytes. Leukemia 1992; 6: 680-688. 
Arni RK, Ward RJ. Phospholipase A2 - A structural review. Toxicon 1996; 34 (8): 827-
841. 
Aruoma 01, Halliwell B. Superoxide-dependent and ascorbate-dependent formation of 
hydroxyl radicals from hydrogen peroxide in the presence of iron. Biochem J 1987; 241: 
273-278. 
301 
Axelrod J, Burch RM, Jelsema CL. Receptor-mediated activation of phospholipase A2 via 
OTP-binding proteins: arachidonic acid and its metabolites as second messengers. Trends 
Neurosci 1988; 11: 117-123. 
Axelrod J. Receptor-mediated activation of phospholipase A2 and arachidonic acid release 
in signal transduction. Biochem Soc Trans 1990; 18: 503-507. 
Balboa MA, Balsinde J. Involvement of calcium - independent phospholipase A2 in 
hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. J Biol 
Chem 2002; 277: 40384-40389. 
Balsinde J, Balboa MA, Li WH, Llopis J, Dennis EA. Cellular regulation of cytosolic 
group N phospholipase A2 by phosphatidylinositol bisphosphate levels. J Immunol 2000; 
164: 5398-5402. 
Balsinde J, Barbour SE, Bianco ID, Dennis EA. Arachidonic acid mobilization in 
P3888D1 macrophages· is controlled by two distinct Ca2+-dependent phospholipase A2 
enzymes. Proc Natl Acad Sci USA 1994; 91: 11060-11064. 
Balsinde J, ·Bianco ID, Ackermann E, Conde-Frieboes K, Dennis EA. Inhibition of 
calcium-independent phospholipase A2 prevents arachidonic incorporation and 
phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 1995; 92: 
8527-8531. 
Balsinde J, Diez E, Schuller A, Mollinedo F. Phospholipase A2 activity in resting and 
activated human neutrophils. J Biol Chem 1988; 263: 1929-1936. 
Balsinde J. Roles of various phospholipases A2 in providing lysophospholipid acceptors 
for fatty acid phospholipid incorporation and remodelling. Biochem J 2002; 364: 695-702. 
Banks W, Kastin A, Rapoport S. Permeability of the blood-brain barrier to circulating free 
fatty acids. In: Yehuda S, Mostofsky D, eds. Handbook of essential fatty acid Biology, 
Biochemistry, Physiology, and Behavioral Neurobiology. New Jersey: Humana Press, Inc. 
1997: 3-14. 
Bates C, Horrobin DF, Ells K. Fatty acids in plasma phospholipids and cholesterol esters 
from identical twins concordant and discordant for schizophrenia. Schizophr Res 1991; 6: 
1-7. 
Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid B protein 
toxicity. Cell 1994; 77: 817-827. 
Bell RL, Kennerly DA, Stanford N, Marjerus PW. Diglyceride lipase: a pathway for 
arachidonate release from human platelets. Proc Natl Acad Sci USA 1979; 76: 3238-3241. 
302 
Berton G, Papini E, Cassatella MA, Bellavite P, Rossi F. Partial-purification of the 
superoxide-generating system of macrophages - possible association of the NADPH 
oxidase activity with a low-potential (-247MV) cytochrome-B. Biochim Biophys Acta 
1985; 810 (2): 164-173. 
Bielski BHJ, Arudi RL, Sutherland MW. A study of the reactivity of HO2- 10·- with 
unsaturated fatty acids. J. Bio. Chem. 1983; 258: 4759-4761. 
Billah MM, Lapetina EG, Cuatrecasas P. Phospholipase A2 activity specific for 
phosphatidic-acid - a possible mechanism for the production of arachidonic acid in 
platelets. J Biol Chem 1981; 256: 5399-5403. 
Billah MM, Lapetina EG. Formation of lysophosphatidylinositol in platelets stimulated 
with thrombin or ionophore A23187. J Biol Chem 1982; 257: 5196-5200. 
Bills TK, Smith JB, Silver MJ. Metabolism of C-arachidonic acid by human platelets. 
Biochim Biophys Acta 1976, 424: 303-314. · 
Birbes H, Gothie E, Pageaux JF, Lagarde M, Laugier C. Hydrogen peroxide activation of 
Ca2+ -independent phospholipase A2 in uterine stromal cells. Biochem Biophys Res 
Commun 2000; 276: 613-618. 
Blake RR, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge JMC. Effect of a 
specific iron chelating agent on animal models of inflammation. Ann Rheum Dis 1983; 42: 
89-93. 
Blakely SR, Slaughter L, Adkins J, Knight EV. Effects of f3 - carotene and retinyl 
palmitate on com oil-induced superoxide dismutase and catalase in rats. J Nutr 1988; 118: 
152-158. 
Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Polyunsaturated fatty acids induce 
ischemic and epileptic tolerance. Neuroscience 2002; 109 (2): 231-241. 
Bockman RS. Prostaglandin production by human-blood monocytes and mouse peritoneal-
macrophages - synthesis dependent on in vitro culture conditions. Prostaglandins 1981; 21 
(1): 9-31. 
Borel P, Grolier P, Armand M, Partier A, LaFont H, Lairon D, Azais-Braesco V. 
Carotenoids in biological emulsions: solubility, surface-to-core distribution, and release 
from lipid droplets. J Lipid Res 1996; 37: 250-261. 
Bowry V, Ingold K, Stocker R. Vitamin E in human low-density lipoproteins. When and 
how this antioxidant becomes a pro-oxidant. Biochem J 1992; 288: 341-344. 
Boyer CS, Bannenberg GL, Neve EP, Ryrfeldt A, Moldeus P. Evidence for the activation 
of the signal-responsive phospholipase A2 by exogenous hydrogen-peroxide. Biochem 
Phaimacol 1995; 50: 753-761. 
303 
Brannan TS, Maker HS, Weiss C, Cohen G. Regional distribution of. glutathione 
peroxidase in the adult rat brain. J Neurochem 1980; 35: 1013-1014. 
Brar SS, Kennedy TP, Whorton AR, Murphy TM, Chitano P, Hoida JR. Requirement for 
reactive oxygen species in serum-induced and platelet-derived growth factor-induced 
growth_of airway smooth muscle. J Biol Chem 1999; 274: 20017-20026. 
Britton G. Structure and properties of carotenoids in relation to function. FASEB J 1995; 
9 (15): 1551-1558. 
Buettner GR,, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations 
to avoid. Radiat Res 1996; 145: 532-541. 
Burch RM. G-protein regulation of phospholipase A2• Mol Neurobiol 1989; 3: 155-171. 
Burke JR, Davern LB, Gregor KR, Todderud G, Alford JG, Tramposch KM. 
Phosphorylation and calcium influx are not sufficient for the activation of cytosolic 
phospholipase A2 in U937 cells: Requirement for a Gi alpha-type G-protein. Biochim 
Biophys Acta 1997; 1341: 223-237. 
Bums CP, Wagner BA. Heightened susceptibility of fish oil polyunsaturated-enriched 
neoplastic cells to ethane generation during lipid peroxidation. J Lipid Res 1991; 32: 79-
87. 
Burton GW, Ingold KU. Mechanisms of antioxidant action: preventive and chain-breaking 
antioxidants. In: Miguel A, Quintanilha AT, Weber H, eds. CRC Handbook of Free 
Radicals and Antioxidants in Biomedicine. Volume II. Boca Raton: CRC Press Inc., 1990: 
29-43. 
Burton GW, Ingold KU. Vitamin E as an in vitro and in vivo antioxidant. Ann NY Acad 
Sci 1989;570:7-22. 
Burton GW, Ingold KU. ~ - carotene: an unusual type of lipid antioxidant. Science 1984; 
224: 569-573. 
Burton GW, Joyce A, Ingold JA. Is vitamin E the only lipid-soluble, chain-breaking 
antioxidant in human blood plasma and erythrocyte membranes? Arch Biochem Biophys 
1983;221:281-290. 
Burton GW. Antioxidant action of carotenoids .. J Nutr 1989; 119: 109-111. 
Buschbeck M, Ghomashchi F, Gelb MH, Watson SP, Barsch-Haubold AG. Stress stimuli 
increase calcium-induced arachidonic acid release through phosphorylation of cytosolic 
phosholipase A2• Biochem J 1999; 344: 359-366. 
Buttris, JL, Diplock AT. The relationship between a-tocopherol and phospholipid fatty 
acids in rat liver subcellular membrane fractions. Biochim Biophys Acta 1988; 962: 81-90. 
304 
Byrne GI, Lehmann LK, Landry GJ. Induction of tryptophan catabolism is the mechanism 
for gamma-interferon-mediated inhibition of intracellular Chlamydia-Psittaci replication in 
T24 cells. Infect lmmun 1986; 53 (2): 347-351. 
Cao YZ, Karmin 0, Choy PC, Chan AC. Regulation by vitamin E of phosphatidylcholine 
metabolism in rat-heart. Biochem J 1987; 247: 135-140. 
Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? 
FASEB J 1999; 13: 1007-1024. 
Chajes V, Sattler W, Stranzl A, Kostner GM. Influence of n-3 fatty acids on the growth of 
human breast cancer cells in vitro: relationship to peroxides and vitamin E. Breast Cancer 
Res Treat 1995; 34: 199-212. 
Chakraborti S, Chakraborti T. Down-regulation of protein kinase C attenuates the oxidant 
hydrogen peroxide-mediated activation of phospholipase A2 in pulmonary vascular smooth-
muscle cells. Cell Signal 1995; 7: 75-83. · 
Channon JY, Leslie CC. A calcium-dependent mechanism for associating a soluble 
arachidonoyl-hydrolyzing phospholipase A2 with membrane in the macrophage cell-line 
RAW 264.7. J Biol Chem 1990; 265: 5409-5413. 
Chao W, Olson MS. Platelet activating factor - receptors and signal transduction. 
Biochem J 1993; 292: 617-629. 
Chesney JA, Mahoney JR, Eaton JW. A spectrophotometric assay for chlorine-containing 
compounds. Anal Biochem 1991; 196: 262-266. 
Chilton FH, Fonteh AN, Surette ME, Triggiani M, Wrinkler JD. Control of arachidonate 
levels within inflammatory cells. Biochim Biophys Acta 1996; 1299: 1-15. 
Chou PT, Khan AU .. L-ascorbic acid quenching of singlet delta molecular oxygen in 
aqueous media: generalized antioxidant property of vitamin C. Biochem Biophys Res 
Commun 1983; 115, 932-937. 
Chow SC, Jondal M. Polyunsaturated free fatty acids stimulate an increase in cytosolic 
Ca2+ by mobilizing the inositol 1,4,5-trisphosphate-sensitive Ca2+ pool in T-cells through a 
mechanism independent of phosphoinositide turnover. J Biol Chem 1990; 265: 902-907. 
Chow SC, Sisfontes L, Bjorkhem I, Jondal M. Suppression of growth in a leukemic T cell 
line by n-3 and n-6 polyunsaturated fatty acids. Lipids 1989; 24: 700-704. 
Chuang TH, Bohl BP, Bokoch GM. Biologically-active lipids are regulators of Rac-center-
dot-GDI complexation. J Biol Chem 1993; 268: 26206-26211. 
Clark JD, Lin L.-L, Kriz RW, Ramesha CS, Sultzman LA, Lin A Y, Milona N, Knopf JL. 
A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+ -dependent translocation 
domain with homology to PKC and GAP. Cell 1991; 65: 1043-1051. 
305 
Clark JD, Milona N, Knopf JL. Purification of a 110-kilodalton cytosolic phospholipase A2 
from the human monocytic cell line U937. Proc Natl Acad Sci USA 1990; 87: 7708-7712. 
Cohen G, Greenwald RA, eds. Oxyradicals and their scavenger systems. Molecular 
aspects. Proc Third Intl Conference on superoxide and superoxide dismutase. NewYork: 
Elsevie:r Publishing Co. Inc., 1983. 
Cohen G, Hochstein P. Glutathione peroxidase in erythrocytes. Biochemistry, 1963; 2: 
1420-1428. 
Cort WM. Antioxidant properties of ascorbic acid in foods. Adv Chem Ser 1982; 200: 
533-550. 
Cowing BE, Saker KE. Polyunsaturated fatty acids and epidermal growth factor receptor 
mitogen-activated protein kinase signaling in mammary cancer. J Nutr 2002; 132 (12): 
1125-1128 Suppl. S. 
Crawford JM, Braunwald NS. Toxicity in vital fluorescence microscopy - effect of 
dimethylsulfoxide, rhodamine-123, and DH-low density lipoprotein on fibroblast growth-in 
vitro. In vitro Cell Dev Biol 1991: 27 (8): 633-638. 
Crawford MA. A background to essential fatty acids and their prostanoid derivatives. Br 
Med Bull 1983; 39: 210-213. 
Crews F. Rapid changes in phospholipid metabolism during secretion and receptor 
activation. Int Rev Neurobiol 1982; 10: 19-45. 
Cross AR, Jones OTG, Garcia R, Segal AW. The subcellular localization of ubiquinone in 
human neutrophils. Biochem J 1983; 216: 765-768. 
Cross AR, Parkinson JF, Jones OTG. Mechanism of the superoxide-producing oxidase of 
neutrophils - 02 is necessary for the fast reduction of cytochrome b_245 by NADPH. 
Biochem J 1985; 226: 881-884. 
Crow TJ. Constraints on concepts of pathogenesis - language and the speciation process as 
the key to the etiology of schizophrenia. Arch Gen Psychiat 1995; 52 (12): 1011-1014. 
Crow TJ. Sexual selection as the mechanism of evolution of Machiavellian intelligence: A 
Darwinian theory of the origins of psychosis. J Psychopharmacol 1996; 10 (1): 77-87. 
Cutler RG. Carotenoids and retinol - their possible importance in determining longevity of 
primate species. Proc Natl Acad Sci USA 1984; 81 (23): 7627-7631. 
Dalen P. Season of birth: A study of schizophrenia and other mental disorders. 
Amsterdam: North Holland, 1975. 
Daniele JJ, Fidelio GD, Bianco ID. Calcium dependency of arachidonic acid incorporation 
into cellular phospholipids of different cell types. Prost Other Lipid Mediat 1999; 57: 341-
350. 
306 
David AS, Malmberg A, Lewis G, Allebeck P. Psychiatric morbidity, social development 
and cognition, and later schizophrenia: Premorbid adjustment or prodrome? Schizophr Res 
1997; 24 (1-2): 249-249. 
Davidson BC, Kurstjens NP, Patton J, Cantrill RC. Essential fatty acids modulate 
apomorphine activity at dopamine receptors in rat caudate slices. Eur J Pharmacol 1998; 
149:317-322. 
Davies MJ, Fu S, Dean RT. Protein hydroperoxides can give rise to reactive free radicals. 
Biochem J 1995; 305: 643-649. 
Davies MJ. Protein and peptide alkoxyl radicals can give rise to C-terminal 
decarboxylation and backbone cleavage. Arch Biochem Biophys 1996; 336 (1): 163-172. 
de Carvalho MGS, McCormack AL, Olson E, Ghomashchi F, Gelb MH, Yates JR, Leslie 
CC. Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A2 
expressed in insect cells and present in human moriocytes. J Biol Chem 1996; 271: 6987-
6997. 
Dennis EA. Diversity of group types, regulation and function of phospholipase A2. J Biol 
Chem 1994; 269: 13057-13060. 
Dennis EA. Regulation of eicosanoid production - role of phospholipases and inhibitors. 
Bio/Technol 1987;5: 1294-1300. 
Department of Health and Human and Human Services, Food and Drug Administration. 
Substances affirmed as generally recognized as safe: Menhaden oil. Federal Register June 
5, 1997;62:30751-30757. 
de Rijk MC, Breteler MMB, den Breeijen JH, Launer U, Grobbee DE, vanderMeche FGA, 
Hofman A. Dietary antioxidants and Parkinson's disease - The Rotterdam study. Arch 
Neurol 1997; 54 (6): 762-765. 
Desjardins GC, Beaudet A, Schipper HM, Brawer JR. Vitamin E protects hypothalamic 
beta-endorphin neurons from estradiol neurotoxicity. Endocrinol 1992; 131: 2482-2484. 
Devaraj S, Li D, Jialal I. The effects of alpha tocopherol supplementation on monocyte 
function. J Clin Invest 1996; 98: 756-763. 
De Zwart LL, Meerman JHN, Commandeur JNM, Vermeulen NPE. Biomarkers of free 
radical damage applications in experimental animals and humans. Free Radie Biol Med 
1999; 26: 202-226. 
Diaz M, Frei B, Vita J, Keaney J. Antioxidants and atherosclerotic heart disease. New 
Engl J Med 1997; 337: 408-416. 
Diez E, Mong S. Purification of a phospholipase A2 from human monocytic leukemic 
U937 cells - calcium-dependent activation and membrane association. J Biol Chem 1990; 
265: 14654-14661. 
307 
Dillon DA, Chen XM, Zeimetz GM, Wu WI, Waggoner DW, Dewald J, Brindley DN, 
Carman GM. Mammalian Mg2+ -independent phosphatidate phosphatase (P AP2) displays 
diacylglycerol pyrophosphate phosphatase activity. J Biol Chem 1997; 272: 10361-10366. 
Diplock AT. Safety of antioxidant vitamins and~ - carotene. Am J Clin Nutr 1995; 62: 
1510S-1516S. 
Dorfman-Etrog P, Hermesh H, Prilipko L, Weizman A, Munitz H. The effect of vitamin E 
addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in 
schizophrenic patients: An open label study. Eur Neuropsychopharmacol 1999; 9: 475-
477. 
Douglas CE, Chan AC, Chroy PC. Vitamin E inhibits platelet phospholipase A2• Biochim 
Biophys Acta 1986; 876: 639-645. 
Dugas TR, Morel DW, Harrison EH. Impact of LJ?L carotenoid and a-tocopherol content 
on LDL oxidation by endothelial cells in culture. J Lipid Res 1998; 39: 999-1007. 
Dumuis A, Sebben M, Haynes L., Pin J-P, Bockaert J. NMDA receptors activate the 
arachidonic acid cascade system in striatal neurons. Nature 1988; 336: 68-70. 
Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in 
Parkinson's disease. Prog Neurobiol 1996; 48: 1-19. 
Edgar AD, Strosznajder J, Horrocks LA. Activation of ethanolamine phospholipase A2 in 
brain during ischaemia. J Neurochem 1982; 39: 1111-1116. 
Edge R, McGarvey DJ, Truscott TG. The carotenoids as anti-oxidants - a review. J 
Photochem Photobiol B 1997; 41: 189-200. 
Emilsson A, Sundler R. Differential activation of phosphatidylinositol deacylation and a 
pathway via diphosphoinositide in macrophages responding to zymosan and ionophore 
A23187. J Biol Chem 1984; 259: 3111-3116. 
Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled 
study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J 
Psychiat 2002; 159 (9): 1596-1598. 
Enright HU, Miller WJ, Hebbel RP. Nucleosomal histone proteins protects DNA from 
iron-mediated damage. Nucleic Acids Res. 1992; 20: 3341-3346. 
Ernster L. Lipid peroxidation in biological membranes: Mechanisms and implications. In: 
Yagi K ed. Active Oxygens, Lipid Peroxides and Antioxidants.· Japan: CRC Press, 1993: 
1-38. 
Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of 
phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition 
and removal by macrophages. J Immunol 1992; 148: 2207-2216. 
308 
Falkai P, Bogerts B. The neuropathology of schizophrenia. In: Hirsch SR, Weinberger 
DR, eds. Schizophrenia. Oxford: Blackwell, 1995: 275-292. 
Parde L. Brain imaging of schizophrenia - the dopamine hypothesis. Schizophrenia 
Research 1997; 28: 157.:.162 . 
. Farooqui AA, Hirashima Y, Horrocks LA. Brain phospholipases and their role in signal 
transduction. In: Bazan NG, Toffano G, Murphy M, eds. Neurobiology of essential fatty 
acids. Plenum Press, New York, 1992; 11-25. 
Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, 
incorporation into membranes, functions and involvement in neurological disorders. Chem 
Phys Lipids 2000; 106: 1-29. 
Farooqui AA, Horrocks LA. Excitatory amino acid receptors, neural membrane 
phospholipid metabolism and neurological disorders. Brain Res Rev 1991; 16: 171-191. 
Farooqui AA, Horrocks LA. Involvement of glutamate receptors, lipases and 
phospholipases in long-term potentiation and neurodegeneration. J Neurosci Res 1994; 38: 
6-11. 
Farooqui AA, Yang H-C, Horrocks LA. Involvement of phospholipase A2 in 
neurodegenration. Neurochem Int. 1997; 30 (6): 517-522. 
Farooqui AA, Yang HC, Rosenberger TA, Horrocks LA. Phospholipase A2 and its role in 
brain tissue. J Neurochem 1997a; 69 (3): 889-901. 
Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and 
the diagnosis and treatment of schizophrenia. Biol Psychiat 2000; 47: 8-21. 
Fernandez B, Solis-Herruzo JA, Balsinde J. Mouse peritoneal-macrophages contain an 
acylating system specific for 20-carbon polyunsaturated fatty acids. A study with intact 
cells. Eicosanoids 1992; 5: 115-120. 
Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol 1998; 10: 248-253. 
Finstad HS, Myhrstad MCW, Heimli H, Blomhoff HK, Kolset SO, Drevon CA. 
Multiplication and death-type of leukaemia cell lines exposed to very long-chain 
polyunsaturated fatty acids. Leukemia 1998; 12: 921-929. 
Fischer S, Werner K, Kub H-J. Schizophrenic patients treated with high dose 
phenothiazine or thioxanthene become deficient in polyunsaturated fatty acids in their 
thrombocytes. Biochem Pharmacol 1992; 44: 317-323. 
Fish B. Infant predictors of the longitudinal course of schizophrenic development. 
Schizophrenia Bull 1987; 13 (3): 395-409. 
309 
Fisher T, Zumbihl R, Armand J, Casellas P, Rouot B. Prolonged elevation of intracellular 
cyclic AMP levels in U937 cells increases the number of receptors for and the responses to 
forkyl-methionyl-leucylphenylalanine, independently of the differentiation process. 
Biochem J 1995; 311: 995-1000. 
Folch J, Lees M, Sloane-Stanley OH. A simple method for the isolation and purification of 
total lipld from animal tissues. J Biol Chem 1957; 226: 497-509. 
Foote CS, Chang YC, Denny RW. Chemistry of singlet oxygen. X. Carotenoid quenching 
parallels biological protection. J Am Chem Soc 1970; 92: 5216-5218. 
Foote CS, Denny RW. Chemistry of singlet oxygen. VIII. Quenching by (3-carotene. J Am 
Chem Soc 1968; 90: 6233-6235. 
Ford-Hutchinson AW. Regulation of the biosynthesis of the sulphido-leukotrienes. 
Adv Exp Med Biol, Part A&B 1997; 400: 841-847. 
Frank H, Hintze T, Bimboes D, Remmer H. Monitoring lipid peroxidation by breath 
analysis - endogenous hydrocarbons and their metabolic elimination. Toxicol Appl 
Pharmacol 1980; 56(3): 337-344. 
Franke AA, Harwood PJ, Shimamoto T, Lumeng S, Zhang LX, Bertram JS, Wilkens LR, 
Le-marchand L, Cooney RV. Effects of micronutrients and antioxidants on lipid 
peroxidation in human plasma and cell culture. Cancer Lett 1994; 79: 17-26. 
Freysz L, Dreyfus H, Vincendon G., Binaglia L, Roberti R, Porcellati G. Asymmetry of 
brain microsomal membranes: correlation between the asymmetric distribution of 
phospholipids and the enzymes involved in their synthesis. In: Horrocks LA, Ansell GB, 
Porcellati G, eds. Phospholipids in the nervous system. Raven Press, New York, 1982: 37-
47. 
Fridovich I. Superoxide radical and superoxide dismutases. Ann Rev Biochem 1995; 64: 
97-112. 
Fujimoto T, Nakano T, Takano T, Hokazono Y, Asakura T, Tsuji T. Study of chronic 
schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiat Scand 
1992; 86: 455-462. 
Gassen M, Y oudim MBH. The potential role of iron chelators in the treatment of 
Parkinson's disease and related neurological disorders. Pharmacol Toxicol 1997; 80: 159.-
166. 
Gattaz WF, Hubner CK, Nevalainen TJ, Thuren T, Kinnunen PKJ. Increased serum 
phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiat 1990; 28: 
495-501. 
Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PKJ. Increased plasma 
phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy. 
Biol Psychiat 1987; 22: 421-426. 
310 
Gattaz WF, Schmitt A, Maras A. Increased platelet phospholipase A2 activity in 
schizophrenia. Schizophr Res 1995; 16: 1-6. 
Gay C, Collins J, Gebicki JM. Determination of iron in solutions with the ferric-xylenol 
orange complex. Anal Biochem 1999; 273: 143-148. 
Gebicld S, Gebicki JM. Formation of peroxides in amino acids and proteins exposed to 
oxygen free radicals. Biochem J 1993; 289: 743-749. 
Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron 
as a cause of µeurodegenerative diseases. J Neurochem 1994; 63: 793-807. 
Gey KF. Prospects for the prevention of free radical disease, regarding cancer and 
cardiovascular disease. Brit Med Bull 1993; 49: 679-699. 
Gieseg S, Duggan S, Gebicki JM. Peroxidation of proteins before lipids in U937 cells 
exposed to peroxyl radicals. Biochem J 2000; 350: 215-218. 
Gijon MA, Leslie CC. Regulation of arachidonic acid release and cytosolic phospholipase 
A2 activation. J Leukocyte Biol. 1999; 65: 330-336. 
Gijon MA, Spencer DM, Kaiser AL, Leslie CC. Role of phosphorylation sites and the C2 
domain in regulation of cytosolic phospholipase A2• J Cell Biol 1999; 145: 1219-1232. 
Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002; 
56 (8): 388-396. 
Glatz JFC, van der Vusse OJ. Cellular fatty acid binding proteins: their function and 
physiological significance. Progr Lipid Res 1996; 35: 243-282. 
Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K, 
Skinner FS. A red cell membrane abnormality in a subgroup of schizophrenic patients: 
Evidence for two diseases. Schizophr Res 1994; 12: 53-61. 
Goeree R, O'Brien BJ, Goering P, Blackhouse G, Agro K, Rhodes A, Watson J. The 
economic burden of schizophrenia in Canada. Can J Psychiat 1999; 44: 564-572. 
Goetz! EJ, Pickett WC. Novel structural determinants of the human neutrophil chemotactic 
activity ofleukotriene-B. J Exp Med 1981; 153 (2): 482-487. 
Gomez-Fernandez JC, Villalain J, Aranda FJ, Ortiz A, Micol V, Coutinho A, Berberan-
Santos MN, Prieto MJE. Localization of alpha-tocopherol in membranes. Ann NY Acad 
Sci 1989;570: 109-120. 
Goto S, Kogure K, Abe K, Kimata Y, Kitahama K, Yamashita E, Terada H. Efficient 
radical trapping at the surface and inside the phospholipid membrane is responsible for 
highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys 
Acta 2001; 1512: 251-258. 
311 
Gottleib K, Zarling EJ, Mobarhan S, Bowen P, Sugerman S. .Beta-carotene decreases 
markers oflipid peroxidation in healthy volunteers. Nutr Cancer 1993; 19: 207-212. 
Greden JF, Tandon R. Long-term treatment for lifetime disorders? Arch Gen Psychiat 
1995; 52: 197-200. 
Gruszecki WI, Sielewiesiuk J. Orientation of xanthophylls in phosphatidylcholine 
multibilayers. Biochim Biophys Acta 1990; 1023 (3): 405-412. 
Guidarelli A, Brambilla L, Rota C, Tomas A, Cattabeni F, Cantoni 0. The respiratory-
chain poison ~timycin A promotes the formation of DNA single-strand breaks and reduces 
toxicity in U937 cells exposed to t-butylhydroperoxide. Biochem J 1996; 317: 371-375. 
Guidarelli A, De Sanctis R, Cellini B, Fiorani M, Dacha M, Cantoni 0. Intracellular 
ascorbic acid enhances the DNA single strand breakage and toxicity induced by 
peroxynitrite in U937 cells. Biochem J 2001; 356: 509-513. 
Gutteridge JMC. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin 
Chem 1995; 41: 1819-1828. 
Hajimohammadreza I, Brammer M. Brain membrane fluidity and lipid peroxidation in 
Alzheimer's disease. Neurosci Lett 1990; 112: 333-337. 
Halliwell B, Gutteridge JMC, eds. Free radicals in biology and medicine. Oxford 
University Press, 1999. 
Halliwell B, Gutteridge JMC. Antioxidant of human extra-cellular fluids. Arch Biochem 
Biophys 1990a; 280: 1-8. 
Halliwell B, Gutteridge JMC. Oxygen free radicals and iron in relation to biology and 
medicine: some problems and concepts. Arch Biochem Biophys 1986; 246: 501-514. 
Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human 
disease: an overview. Methods Enzymol 1990b; 186: 1-85. 
Halliwell B. Free radicals and antioxidants: A personal view. Nutr Rev 1994; 52: 253-265. 
Halliwell B. Oxidants and the central nervous system: some fundamental questions. Acta 
Neurol Scand 1989; 126: 23-33. 
Halliwell B. Oxygen radicals and metal ions: potential antioxidants intervention strategies. 
In: Cross CE, moderator. Oxygen radicals and human disease. Ann Intern Med 1987; 107: 
526-545. 
Halliwell B. Vitamin C: antioxidants or pro-oxidants in vivo? Free Radie Res 1996; 25: 
439-454. 
Hamelin SS, Chan AC. Modulation of platelet thromboxane and malonaldehyde by dietary 
vitamin E and linoleate. Lipids 1983; 18: 267-269. 
312 
Handelman OJ, van Kuijk FJGM, Chatterjee A, Krinsky NI. Characterization of products 
formed during the autoxidation of (3 - carotene. Free Radie Biol Med 1991; 10: 427-437. 
Hatanaka Y, Suzuki K, Kawasaki Y, Endo Y, Taniguchi N, Takei N. A role of peroxides in 
Ca2+ ionophore-induced apoptosis in cultured.rat cortical neurons. Biochem Biophys Res 
Comm~n 1996; 227 (2): 513-518. 
Heinle H, Brehme U, Friedemann G, Frey JC, Wolf AT, Kelber 0, Weiser D, Schmahl FW, 
Lang F, Schneider W. Intimal plaque development and oxidative stress in cholesterol-
induced atherosclerosis in New Zealand rabbits. Acta Physiol Scand 2002; 17 6: 101-107. 
Heliovaara M, Knekt P, Aho K, Aaran RK, Alfthan G, Aroma A. Serum antioxidants and 
risk of rheumatoid arthritis. Ann Rheumatoid Dis 1994; 53: 51-53. 
Hendriks T, Klompmakers AA, Daemen FJM, Bonting SL. Biochemical aspects of the 
visual process: XXXII. Movement of sodium ions through bilayers composed of retinal 
and rod outer segment lipids. Biochim Biophys Acta 1976; 433: 271-281. 
Hess D, Keller HE, Oberlin B, Bonfanti R, Schuep W. Simultaneous determination of 
retinol, tocopherols, carotenes and lycopene in plasma by means of high-performance 
liquid-chromatography on reversed phase. Int J Vitam Nutr Res 1991; 61: 232-238. 
Hill EE, Husbands DR, Lands WEM. The selective incorporation of 14C-glycerol into 
different species of phosphatidic acid, phosphatidylethanolamine, and phosphatidylcholine. 
J Biol Chem 1968; 243: 4440-4451. 
.Hinsberger A, Williamson PC, Carr, T. Stanley J, Drost D, Densmore M, MacFabe G, 
Montemurro D. MRI volumetric measures and 31P MRS in schizophrenia. Schizophr Res 
1995; 15: 83-84. 
Hirata F, Corcoran BA, Venkatasubramanian K, Schiffmann E, Axelrod J. 
Chemoattractants stimulate degradatio'n of methylated phospholipids and release of 
arachidonic acid in rabbit leukocytes. Proc Natl Acad Sci USA 1979; 76: 2640-2643. 
Holub BJ, Kuksis A. Resolution of intact phosphatidylinositols by argentation thin-layer 
chromatography. J Lipid Res 1971; 12: 510-512. 
Homayoun P, Stacey DW. Inhibitory effect of arachidonic acid on GTPase-activating 
protein is antagonized by 1-stearoyl, 2-arachidonoyl glycerol. Biochem Biophys Res 
Commun 1993; 194: 1413-1419. 
Horrobin DF, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. 
Schizophr Res 1994; 13 (3): 195-207. 
Horrobin DF, Jenkins K, Bennett CN, Christie WW. Eicosapentaenoic acid and 
arachidonic acid: collaboration and not antagonism is the key to biological understanding. 
Prost Leuk Ess 2002; 66 (1): 83-90. 
313 
Horrobin Df, Manku MS, Hillman H, Iain A, Glen AIM. Fatty acid levels in the brains of 
schizophrenics and normal controls. Biol Psychiat 1991; 30: 795-805. 
Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS, Courtney P, Glen AIM Glen E, 
Spellman M, Bates C. Essential fatty acids in plasma phospholipids in schizophrenia. Biol · 
Psychiat 1989; 25: 562-568. 
Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout 
the body. Prost Leuk Ess 1996; 55: 3-7. 
Horrobin DF~ The effect of antipsychotic drugs on membrane phospholipids: A possible 
novel mechanism of action of clozapine. In: Peet M, Glen I, Horrobin DF, eds. 
Phospholipid spectrum disorder in psychiatry. Marius Press, 1999a: 113-117. 
Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the 
neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30 (3): 193-208. 
Horrobin DF. The phospholipid concept of psychiatric disorders and its relationship to the 
neurodevelopmental concept of schizophrenia. In: . Peet M, Glen I, Horrobin DF, eds. 
Phospholipid spectrum disorder in psychiatry. Marius Press, 1999b: 3-20. 
Horrocks LA, Ansell GB. The incorporation of ethanolamine into ether-containing lipids in 
rat brain. Lipids 1967; 2: 329-333. 
Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 
1999; 40: 211-225. 
Hsu F-F, Ma Z,. Wohltmann M, Bohrer A, Nowatzke W, Ramanadham S, Turk J. 
Electrospray ionization/mass spectrometric analyses of human promonocytic U937 cell 
glycerolipids and evidence that differentiation is associated with membrane lipid 
composition changes that facilitate phospholipase A2 activation. J Biol Chem 2000; 275: 
16579-.16589. 
Hugli TE. Structure and function of the anaphylatoxins. Springer Semin Immunopathol 
1984; 7: 193-219. 
Humad S, Zarling E, Clapper M, Skosey JL. Breath pentane excretion as a marker of 
disease activity in rheumatoid arthritis. Free Radie Res Comm 1988; 5: 101-106. 
Hyman SE. Mental illness: genetically complex disorders of neural circuitry and neural 
communication. Neuron 2000; 28: 321-323. 
Iacano WG, Beiser M. Where are the women in first-episode studies of schizophrenia? 
Schizophr Bull 1992; 18: 471-480. 
Ingold KU, Webb AC, Witter D, Burton GW, Metcalfe TA, Muller DPR. Vitamin E 
remains the major lipid-soluble chain breaking antioxidant in human plasma even in 
individuals suffering severe vitamin E deficiency. Arch Biochem Biophys 1987; 259: 224-
225. 
314 
Irvine RF. How is the level of free arachidonic acid controlled in mammalian cells? 
Biochem J 1982; 204: 3-16. 
Jablensky A, Sartorius N, Emberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A. 
Schizophrenia: manifestations, incidence and course in different ·cultures: A World Health 
Organiz_ation ten-country study. Psychological Medicine Monograph 1992; 20 (Suppl). 
Jain MK, Gelb MH, Rogers J, Berg 0. Kinetic basis for interfacial catalysis by 
phospholipase A2. Meth Enzym 1995; 249: 567-614. 
Janero DR. Jvfalondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of 
lipid peroxidaton and peroxidative tissue injury. Free Radie Biol Med 1990; 9: 515-540. 
Jenski LJ, Zerouga M, Stillwell W. Omega-3 fatty acid - containing liposomes in cancer 
therapy. Proc Soc Exp Biol Med 1995; 210: 227-233. 
Jiang ZY, Woollard ACS, Wolf SP. Lipid hydroperoxide measurement by oxidation of 
Fe2+ in the presence of xylenol orange: Comparison with the TBA assay and an iodometric 
method. Lipids 1991; 26: 853-856. 
Jones NJ, Ellard S, Waters R, Parry EM. Cellular and chromosomal hypersentivity to DNA 
crosslinking agents and toposiomerase inhibitors in the radiosensitive Chinese hamster irs 
mutants: phenotypic similarities to ataxia teleangiectasia and Fanconi' s anaemia cells. 
Carcinogenesis 1993; 14: 2487-2494. 
Jones P, Rodgers B, Murray R, Marmot, M. Child developmental risk factors for adult 
schizophrenia in the British 1946 birth cohort. Lancet 1994; 344: 1398-1402. 
Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid for schizophrenia. Cochrane 
Database Review 2000; 2: 1257. 
Kaikaus RM, Bass, NM, Ockner RK. Functions of fatty acid binding proteins. Experientia 
1990; 46: 617-630. 
Kaiya H, Horrobin DF, Manku MS, Morse-Fisher N. Essential and other fatty acids in 
plasma from schizophrenics and normal individuals from Japan. Biol. Psychiat 1991; 30: 
357-362. 
Kaizer L, Boyd NF, Kriukov V, Tritchler D. Fish consumption and breast cancer risk: an 
ecological study. Nutr Cancer 1989; 12: 61-68. 
Kane JM Smith JM. Tardive dyskinesia: prevalence ·and risk factors. Arch Gen Psychiat 
1982; 39: 473-481. 
Kane JM. Efficacy, mechanisms, and side effects of typical and atypical neuroleptics. In: 
Andreason NC, ed. Schizophrenia from mind to molecule. American Psychiatric Press, 
Washington. DC, 1994; 173 - 188. 
315 
Kanofsky JD, Sandyk R. Antioxidants in the treatment of schizophrenia. Intl J Neurosci 
1992; 62: 97-100. 
Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the 
incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, 
and adipose tissue: an 18-month controlled study. J Lipid Res 1997; 38: 2012-2022. 
Katsuki H, Okuda S. Arachidonic acid as a neurotoxic and neutrotrophic substance. Progr 
Neurobiol 1995; 46: 607-636. 
Katsumata M, Gupta C, Goldman AS. A rapid assay for activity of phospholipase A2 using 
radioactive substrate. Anal Biochem 1986; 154: 676-681. 
Keaney JF, Frei B. Antioxidant protection of low-density lipoprotein and its role in the 
prevention of atherosclerotic vascular disease. In: Frei B, ed. Natural antioxidants in 
human health and disease. San Diego, CA: Academic Press; 1994: 303-351. 
Khachik F., Spangler CJ, Smith JC, Canfield LM, Steck A, Pfander H. Identification, 
quantification, and relative concentrations of carotenoids and their metabolites in human 
milk and serum. Anal Chem 1997; 69: 1873-1881. 
Kim D, Clapham DE. Potassium channels in cardiac-cells activated by arachidonic acid 
and phospholipids. Science 1989; 244: 1174-1176. 
Kivits GAA, Ganguli-Swarttouw MACR, Christ EJ. The compos1tlon of alkanes in 
exhaled air of rats as a result of lipid peroxidation in vivo. Effects of dietary fatty acids, 
vitamin E and selenium. Biochim Biophys Acta 1981; 665: 559-570. 
Knapp M. Costs of schizophrenia. Brit J Psychiat 1997; 171: 509-518. 
Koronkiewicz S, Kalinowski S, Bryl K. Changes of structural and dynamic properties of 
model lipid membranes induced by a-tocopherol: implication to the membrane stabilization 
under external electric field. Biochim Biophys Acta 2001; 1510: 300-306. 
Kovaleva ES, Orlov ON, Tsutsulkovskaia MIA, Vladimirova TV, Beliaev BS. Lipid 
peroxidation in patients with schizophrenia. Zh Nevropatol Psikhiatr Imeni S. S. 
Korsakova 1989; 89: 108-110. 
Kramer RM, Roberts EF, Manetta J, Putnam JE. The Ca2+-sensitive cytosolic 
· phospholipase A2 is a 100-kDa protein in human monoblast U937 cells. J Biol Chem 1991; 
266 (8): 5268-5272. 
Kramer RM, Roberts EF, Manetta N, Sportsman JR, Jakubowski JA. Ca2+-sensitive 
cytosolic·phospholipase A2 (cPLA2)} in human platelets. J Lipid Mediators 1993; 6 (1-3): 
209-216. 
Kramer RM. Structure and function of Ca2+-sensitive cytosolic phospholipase A2. In: 
Liscovitch M, ed. Signal-Activated Phospholipases. Landes RG Co., Austin, TX, USA, 
1994: 13-30. 
316 
Krinsky NI, Deneke SM. The interaction of oxygen and oxyradicals with carotenoids. J 
Natl Cancer Inst 1982; 69: 205-210. 
Krinsky NI, Wang XD, Tang G, Russell RM. Mechanism of carotenoid cleavage to 
retinoids. ·Ann NY Acad Sci 1993; 691: 167-176. 
Krinsky NL Antioxidant functions of carotenoids. Free Radie Biol Med 1989; 7: 617-635. 
Krinsky NL Membrane antioxidants. Ann NY Acad Sci 1988; 551:17-33. 
Krinsky NL , Plant carotenoids and related molecules: Important dietary antioxidants. 
Biochem Soc Symp 1995; 61: 117-126. 
Kudo I, Murakami M, Hara S, and Inoue K (1993) Mammalian non-pancreatic 
phospholipases A2. Biochim Biophys Acta 117: 217-231. 
Kulhara P, Wig NN. The chronicity of schizophrenia in North-West India. Results of a 
follow-up study. Brit J Psychiat 1978; 132: 186-190. 
Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid 
peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar 
disorder. Cell Biochemistry and Function 2002; 20: 171-175. 
Kunert KJ, Tappel AL. The effect of vitamin C on in vivo lipid peroxidation in guinea pigs. 
as measured by pentane and ethane production. Lipids 1983; 18: 271-274. 
Kuo CF, Cheng S, Burgess JR. Deficiency of vitamin E and selenium enhances calcium-
independent phospholipase A2 activity in rat lung and liver. J Nutr 1995; 125: 1419-1429. 
Kuperberg G, Heckers S. Schizophrenia and cognitive function. Current Opinion in 
Neurobiology 2000; 10: 205-210. 
Lambertsen CJ. Transport of oxygen, carbon dioxide, and inert gases by the blood. In: 
Mountcastle VB ed. Medical Physiology. 2. CV Mosby Co: St Louis, MO, 1980: 1722. 
Lands WEM, Crawford CG. Enzymes of membrane phospholipid metabolism. In: 
Martonosi A, ed. The enzymes of biological membranes. Volume 2. Biosynthesis of Cell 
Components. Plenum Publishing Corp, New York, 1976: 3-85. 
Lands WEM. Stories about acyl chains. Biochim Biophys Acta 2000; 1483:' 1-14. 
Lapetina EG, Billah MM, Cuatrecasas P. The phosphatidylinositol cycle and the regulation 
of arachidonic acid production. Nature 1981; 292: 367-369. 
Larsen GL, Henson PM. Mediators of inflammation. Annu Rev Immunol 1983; 1: 335-
339. 
317 
Latour I, Demoulin JB, Bue-Calderon P. Oxidative DNA damage by t-butyl hydroperoxide 
causes DNA single strand breaks which is not linked to cell lysis. A mechanistic study in 
freshly isolated rat hepatocytes. FEBS Lett 1995; 373: 299-302. 
Lee BR, Um HD. Hydrogen peroxide supresses U937 cell death by two different 
mechanisms depending on its concentration. Exp Cell Res 1999; 248: 430-438. 
Leslie_ CC, Voelker DR, Channon JY, Wall MM, Zalarney PT. Properties and purification 
of an arachidonoyl-hydrolyzing phospholipase A2 from a macrophage cell-line, RAW-
264.7. Biochim Biophys Acta 1988; 963: 476-492. 
Leung HW, Vang MJ, Mavis RD. The cooperative interaction between vitamin E and 
vitamin C in suppression of peroxidation of membrane phospholipids. Biochim Biophys 
Acta 1981; 664 (2): 266-272. 
Liebich HM, Wirth C, Jakober B. Analysis of polyunsaturated fatty acids in blood serum 
after fish oil administration. J Chromatogr - Biomed Appl 1991; 572: 1-9. 
Liebler D, Kaysen K, Burr J. Peroxyl radical trapping and autoxidation reactions of a-
tocopherol in lipid bilayers. Chem Res Toxicol 1991; 4: 89-93. 
Ligeti E, Pizon V, Wittinghofer A, Gierschik P, Jakobs KH. GTPase activity of small 
GTP-binding proteins in HL-60 membranes is stimulated by arachidonic · acid. Eur J 
Biochem 1993; 216: 813-820. 
Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and 
activated by MAP Kinase. Cell 1993; 72: 269-278. 
Linday LA, Pippenger CE, Howard A, Lieberman JA. Free radical scavenging enzyme 
activity and related trace metals in clozapine-induced agranulocytosis. A pilot study. J 
Clin Psychopharmacol 1995; 15: 353-360. 
Linn S. DNA damage by iron and hydrogen peroxide in vitro and in vivo. Drug Metab 
Rev 1998; 30: 313-326. 
Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen 
Psychiat 1991; 48: 1097-1106. 
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin 
phenol reagent. J Biol Chem 1951; 193: 265-275. 
Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol 2001; 
.. 280: C719-C741. 
Luquain C, Dolmazon R, Enderlin JM, Laugier C, Lagarde M, Pageaux JF. 
Bis(monoacylglycerol) phosphate in rat uterine stromal cells: structural characterization 
and specific esterification of docosahexaenoic acid. Biochem J 2000; 351: 795-804. 
318 
MacDonald DJ, Glen ACA, Boyle RM, Glen AIM, Ward P, Horrobin DF. Schizophrenia 
Research 2000; 41(1): 259. 
MacDonald JI, Sprecher H. Phospholipid fatty acid remodeling in mammalian cells. 
Biochim Biophys Acta 1989; 1084: 105-121. 
Machlin LJ, Bendich A. Free-radical tissue-damage - protective role of antioxidant 
nutrients. FASEB J., 1987; 1(6): 441-445. 
Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and ro-3 essential 
fatty acid supplementation in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiat 
2001; 25: 463-493. 
Mahadik SP, Evans DR. Essential fatty acids in the treatment of schizophrenia. Drugs 
Today 1997; 33 (1): 5-17. 
Mahadik SP, Mukherjee S, Correnti EE, Kelkar HS, Wakade CG, Costa RM, Scheffer R. 
Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-
naive patients at the onset of psychosis. Schizophr Res 1994; 13:239-247. 
Mahadik SP, Mukherjee S. Cultured skin fibroblasts as a cell model for investigating 
schizophrenia. J Psych Res 1996b; 30(6): 421-439. 
Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense m 
schizophrenia: a review. Schizophr Res 1996a; 19: 1-17. 
Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants m 
schizophrenia. Prost Leuk Ess 1996; 55: 45-54. 
Mahadik SP, Shendarkar NS, Scheffer RE, Mukherjee S, Correnti EE. Utilization of 
precursor essential fatty acids in culture by skin fibroblasts from schizophrenic p~tients and 
normal controls. Prost Leukotr Ess 1996; 55: 65-70. 
Majerus PW, Neufeld EJ, Wilson DB. Production of Phosphoinositide-derived 
Messengers. Cell 1984; 37: 701-703. 
Marcus J. Cerebral functioning in offspring of schizophrenics: a possible genetic factor. 
Int J Ment Health 1974; 3:57-73. 
Markesbury WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radie Biol 
Med 1997; 23: 124-147. 
Martin DSD, Spencer P, Horrobin DF, Lynch MA. Long-term potentiation in aged rats is 
restored when the age-related decrease in polyunsaturated fatty acid concentration is 
reversed. Prost leuk Ess 2002; 67 (2-3): 121-130. 
Matsuo M, Matsumoto S, Iitaka Y, Niki E. Radical-scavenging reactions of vitamin E and 
its model compound, 2, 2, 5, 7, 8-pentamethylchroman-6-ol, in a tert-butyl peroxyl radical 
generating system. J Am Chem Soc 1989; 111: 7179-7185. 
319 
Matsushita S, Terao J. In: Simic MG, Karel M, eds~ Autoxidation in Food and Biological 
systems. Plenum Press, New York, 1980: 27-44. 
Mauco G, Simon MF, Chap H, Douste-Blazy L. Phosphatidic and lysophosphatidic acid 
production in phospholipase C and thrombin-treated platelets. Possible involvement of a 
platelet lipase. Biochimie 1978; 60: 653-661. 
Mayne ST, Parker RS. Antioxidant activity of dietary canthaxanthin. Nutr Cancer 1989; 
12: 225-236. 
Maziere C, , Dantin F, Conte MA, Degonville J, Ali D, Dubois F, Maziere JC. 
Polyunsaturated fatty acid enrichment enhances endothelial cell-induced low-density.-
lipoprotein peroxidation. Biochem J 1998; 336: 57-62. 
McCord JM. Oxygen-derived radicals and reperfusion injury. Ann Intern Med 1987; 107: 
526-545. 
McCreadie RG. The Nithsdale schizophrenia surveys. 16. Breast-feeding and 
schizophrenia: Preliminary results and hypotheses. Brit J Psychiat 1997; 170: 334-337. 
McGrath J, Murray R. Risk factors for schizophrenia: from conception to birth. In: Hirsch 
SR, Weinberger DR, eds. Schizophrenia. Oxford: Blackwell, 1995: 187-205. 
McGuffin P, Asherton P, Owen M, Farmer A. The strength of the genetic effect. Is there 
room for an environmental influence in the aetiology of schizophrenia? Br J Psychiat 1995; 
164: 593-599. 
McLean LR, Hagaman KA, Davidson WS. Role of lipid structure in the activation of 
phospholipase A2 by peroxidized phospholipids. Lipids 1993; 28: 505-509. 
McNeil TF, Cantor-Graae E, Nordstrom LG, Rosenlund T. Head circumference in 
'preschizophrenic' and control neonates. Br J Psychiat 1993; 162: 517-523. 
McNeil TF, Kaij L. Obstetric factors in the development of schizophrenia: complications 
in the births of preschizophrenics and in reproduction by schizophrenic patients. In: Wynne 
LC, Cromwell RL, Matthysee S, eds. The nature of schizophrenia. Ne\Y York: John Wiley 
and sons, 1978: 401-429. 
Mellor JE, Laugharne JDE, Peet M. Schizophrenic symptoms and dietary intake of n-3 
fatty acids. Schizophr_ Res 1995; 18: 85-86. 
Miki W. Biological functions and actions of animal carotenoids. Pure Applied Chem 
1991; 63: 141-146. 
Miller DM, Buettner GR, Aust SD. Transition metals as catalysts of 'autoxidation' 
reactions. Free Rad Biol Med 1990; 8: 95-108. 
320 
Minetti M, Forte T, Soriani M, Quarisima V, Menditto A, Ferrari M. Iron-induced 
ascorbate oxidation in plasma as monitored by ascorbate free radical formation: no spin-:-
trapping evidence for the hydroxyl radical in iron-overload plasma. Biochem J 1992; 282: 
459-465. 
Mobarhan S, Bowen P, Anderson B, Evans M, Stacewicz-Sapuntzakis M, Sugerman S, 
Simms· P, Lucchesi D, Friedman H. Effects of f3-carotene repletion on f3-carotene 
absorption, lipid peroxidation and neutrophil superoxide formation in young men. Nutr 
Cancer 1990; 14: 195-206. 
Mochizuki-Oda N, Negishi M, Mori K, Ito S. Arachidonic acid activates cation channels in 
bovine adrenal chromaffin cells. J Neurochem 1993; 61: 1882-1890. 
Moolenaar WH. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol 
Chem 1995; 270 (22): 12949-12952. 
Moore T. Vitamin A. Amsterdam: Elsevier Publishing Company, 1957. 
Morrow JD, Awad JA, Oates JA, Roberts LJ. Identification of skin as a major site of 
prostaglandin D2 release following oral administration of niacin in humans. J Invest 
Dermatol 1992; 98: 813-815. 
Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of 
prostaglandin F2-like compounds are produced in vivo in humans by a noncyclooxygenase,_ 
free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387. 
Mosior M, Six DA, Dennis EA. Group IV cytosolic phospholipase A2 binds with high 
affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dqunatic 
increases in activity. J Biol Chem 1998; 273 (4): 2184-2191. 
Mukherjee AB, Miele L, Pattabiraman N. Phospholipase A2 enzymes: regulation and 
physiological role. Biochem Pharmac 1994; 48: 1-10. 
Murray HW, Rubin BY, Rothermel CD. Killing of intracellular leishmania-donovani by 
lymphokine-stimulated human mononuclear phagocytes - evidence that interferon-gamma 
is the activating lymphokine. J Clin Invest 1983; 72 (4): 1506-1510. 
Murray HW. How protozoa evade intracellular killing. Ann Intern Med 1983; 98: 1016-
1018. 
Murray RM, O'Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the 
classification of schizophrenia. Schizophr Bull 1992; 18: 319-332. 
Nardini M, Pisu P, Gentili V, Natella F, Di Felice M, Piccolella E, Scaccini C. Effect of 
caffeic acid on tert-butyl hydroperoxide-induced oxidative stress in U937. Free Radie Biol 
Med 1998; 25: 1098-1105. 
Nasrallah HA. Neurodevelopmental pathogenesis of schizophrenia. Psychiat Clin North 
Am 1993; 16: 269-280. 
321 
. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the 
lymphokine that activates human macrophage oxidative-metabolism and anti-microbial 
activity. J Exp Med 1983; 158 (3): 670-689. 
Niki E, Kawakami A, Satio M, Yamamoto Y, Tsuchiya·J, Kamiya Y. Effect of phytyl side 
chain of vitamin Eon its antioxidant activity. J Biol Chem 1995b; 260: 2191~2196. 
Niki E, Noguchi N,Tsuchihashi H, Gotoh N. Interaction among vitamin C, vitamin E, and 
{)-carotene. Am J Clin Nutr 1995a; 62: 1322S-1326S. 
Niki E, Saitq T, Kawakami A, Kamiya Y. Inhibition of oxidation of methyl linoleate in 
solution by vitamin E and vitamin C. J Biol Chem 1984; 259: 4177-4182. 
Niki E. Antioxidants in relation to lipid peroxidation. Chem Phys Letts 1987; 44: 227-253. 
Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E, 
Rotrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol 
Psychiat 1993; 34: 641-649. 
Nordoy A, Marchioli R, Arnesen H, Videbaek J. n-3 polyunsaturated fatty acids and 
cardiovascular diseases. Lipids 2001; 36: S127-S129 Suppl. S. 
North J, Spector AA, Buettner GR. Cell fatty acid composition affects free radical 
formation during lipid peroxidation. Am J Phys Soc 1994; 267: Cl 77-C188. 
Obermeier H, Hrboticky N, Sellmayer A. Differential effects of polyunsaturated fatty acids 
on cell growth and differentiation of premonocytic U937 cells. Biochim Biophys Acta 
1995; 1266: 179-185. . 
Obi FO, Nwanze EAC. Fatty acid profiles in mental disease. Part 1. Linoleate variations 
in schizophrenia. J Neurol Sci 1979; 43: 447-454. 
O'Brien JS, Sampson EL. Lipid composition of the normal human brain: Gray matter, 
white matter, and myelin. J Lipid Res 1965; 6: 537-544. 
O'Callaghan E, Gibson T, Colohan HA, Buckley P, Walshe DG, Larkin C, Waddington JL. 
Risk of schizophrenia in adults born after obstetric complications and their association with 
early onset of illness: a controlled study. Brit Med J 1992; 305: 1256-1259. 
O'Callaghan E, Sham P, Takei N, Glover G, Murray RM. Schizophrenia after prenatal 
exposure to 1957 A2 influenza epidemic. Lancet 1991; 337: 1248-1250. 
Odeleye OE, Watson RR, Eskelson CD, Mufti SI. Dietary polyunsaturated fatty acid 
promotes peroxidation and its possible role in the promotion of cancer. In: Witmer CM, 
Snyder RR, follow DJ, Kalf GF, Kocsis JJ, eds. Biological reactive intermediates IV. 
Kluwer Academic press, 1990: 789-791. 
322 
Ojima F, Sakamoto H, Ishiguro Y, Terao J. Consumption of carotenoids in photosensitized 
oxidation of human plasma and plasma low-density- lipoprotein. Free Radie Biol Med 
1993; 15: 377-384. 
Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin 
Neurol 1994; 7: 548-558. 
Oliveira MM, Weglicki WB, Nason A, Nair PP. Distribution of a-tocopherol in beef heart 
mitochondria. Biochim Biophys Acta 1969; 180: 98-113. 
Olney JW, 1;4'arber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen 
Pschiat 1995; 52: 998-1007. 
Olson JA. Provitamin A function of carotenoids: The conversion of J3 - carotene into 
vitamin A. J Nutr 1989; 119: 105-108. 
Packer L. Antioxidant action of carotenoids in vitro and in vivo and protection against 
oxidation of human low ... density lipoproteins. Ann NY Acad Sci 1993; 691: 48-60. 
Pai S, Kapur RL. Impact on treatment intervention on the relationship between the 
dimensions of clinical psychopathology, social dysfunction and burden on families of 
schizophrenic patients. Psychological Medicine 1982; 12: 651-658. 
Palace VP, Khaper N, Qin QI, Qin Q, Singal PK. Antioxidant potentials of vitamin A and 
carotenoids and their relevance to heart disease. Free Radie Biol Med 1999; 26(5-6): 746-
761. 
Palozza P, Krinsky NI. The inhibition of radical-initiated peroxidation of microsomal 
lipids by both a-tocopherol and J3-carotene. Free Radie Biol Med 1991; 11: 407-414 . 
. Palozza P, Krinsky NL J3-carotene and a-tocopherol are synergistic antioxidants. Arch 
Biochem Biophys 1992; 297: 184-187. 
Parker J, Daniel LW, Waite M. Evidence of protein kinase C involvement in phorbol 
di ester-stimulated arachidonic acid release and prostaglandin synthesis. J Biol Chem 1987; 
262: 5385-5393. 
Parker RS. Carotenoids in human blood and tissues. J Nutr 1989; 119: 101-104. 
Peden DB, Hohman R, Brown ME, Mason RT, Berkebile C, Fales HM, Kaliner MA. Uric 
acid is a major antioxidant in human nasal airway secretions. Proc Natl Acad Sci USA 
1990; 87: 7638-7642. 
Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-
controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. 
Schizophr Res 2001; 49: 243-251. 
323 
Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in psychiatry. Marius 
Press, 1999. 
Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G. Depleted red cell membrane 
essential fatty acids in drug treated schizophrenic patients. J Psychiat Res 1995; 29: 227-
232. 
Peet M, Laugharne JDE, Mellor J, Ramchand CN. Essential fatty acid deficiency in 
erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of 
dietary supplementation. Prost Leuk Ess 1996; 55: 71-75. 
Peet M, Poole J, Laugharne J. Infant feeding and the development of schizophrenia. 
Schizophr Res. 1997; 24 (1-2): 255-256. 
Pettegrew JW, Koshavan MS, Panchalingram K, Strychor S, Kaplan DB, Tretta MG, Allen 
M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in 
first episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in 
vivo phosphorus-31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiat 1991; 
48: 563-568. 
Pfander H, Britton G, Liaaen-Jensen S, eds. Carotenoids: Isolation and Analysis. Volume 
lA. Birkhauser Boston publishing, 1994. 
Phillips M, Sabas M, Greenberg J. Increased pentane and carbon disulphide in ,the. breath 
.of patients with schizophrenia. J Clin Pathol 1993; 46: 861-864 . 
. Piomelli D, Greengard P. Lipoxygenase metabolites of arachidonic acid in neuronal 
transmembrane signaling. Trends Pharmacol Sci 1990; 367-373. 
Piomelli D. Eicosanoids in synaptic transmission. Crit Rev Neurobiol 1994; 8 (1-2): 65-
83. 
Porcellati G. Phospholipid metabolism in neural membranes. In: Sun GY, Bazan N, Wu 
JY, Porcellati G, Sun A Y, ~ds. Neural Membranes. Humana Press, New York, 1983: 3-35. 
Potwarka JJ, Drost DJ, Williamson PC. AH-decoupled 31P chemical shift imaging study of 
medicated schizophrenic patients and healthy controls. Biol Psychiat 1999; 45:687-693. 
Prisco D, Filippini M, Francalanci I, Paniccia R, Gensini GF, Abbate R, Semeri GGN. 
Effect of n-3 polyunsaturated fatty acid intake on phospholipid fatty acid composition in 
plasma and erythrocytes. Am J Clin Nutr 1996; 63 (6): 925 - 932. 
Pryor WA, Strickland T, Church DF. Comparison of the efficiencies of several natural and 
synthetic antioxidants in aqueous sodium dodecyl sulfate micelle solutions. J Am Chem 
Soc 1988; 110: 2224-2229. 
324 
Pryor WA. Free radicals in autoxidation and in aging. Part 1. Kinetics of the autoxidation 
of linoleic acid in SDS micelles: calculations of radical concentrations, kinetic chain 
lengths, and the effects of vitamin E. Part 11. The role radicals in chronic human diseases 
and in aging. In: Armstrong D, Sohal RS, Cutler RG, Slater TF, eds. Free radicals in 
molecular biology, aging and disease. New York: Raven Press, 1984: 13-41. 
Pryor WA. Vitamin E and heart disease: Basic science to clinical intervention trials. Free 
Radie Biol Med 2000; 28: 141-164. 
Puri BK, Counsell SJ, Hamilton G, Richardson AJ, Horrobin DF. Eicosapentaenoic acid in 
treatment-resistant depression associated with symptom remission, structural brain changes 
and reduced neuronal phospholipid turnover. Int J Clin Pract 2001; 55 (8): 560-563. 
Puri BK, Richardson AJ, Horrobin DF, Easton T, Saeed N, Oatbridge A, Hajnal JV, Bydder 
GM. Eicosapentaeonoic acid treatment in schizophrenia associated with symptom 
remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid 
turnover and structural brain changes. In J Clin Pratt 2000; 54: 57-63. 
Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of 
schizophrenia after treatment with eicosapentaenoic acid (letter). Arch Gen Psychiat 1998; 
55: 188-189. 
Radin NS. Lipid extraction. In: Boulton AA, Baker GB, Horrocks LA, eds~ 
Neuromethods 7. Lipids and related compounds. Humana Press, Clifton, New Jersey, 
1988: 1-61. 
Rafferty TS, Norval M, El-Ghorr A, Beckett GJ, Arthur JR, Nicol F, Hunter JAA, 
McKenzie RC. Dietary selenium levels determine epidermal Langerhans cell numbers in 
mice. Biol Trace Elem Res 2003; 92 (2): 161-171. 
Ramanadham S, Hsu F-F, Bohrer A, Zhongmin M, Turk J. Studies of the role of group VI 
phospholipase A2 in fatty acid incorporation, phospholipid remodeling, 
lysophosphatidylcholine generation and secretagogue-induced arachidonic acid release in 
pancreatic islets and insulinoma cells. J Biol Chem 1999; 274: 13915-13927. 
Ramchand CN, Davies JI, Tresman RL, Griffiths ICD, Peet M. Reduced susceptibility to 
oxidative damage of erythrocyte membranes from medicated schizophrenic patients. Prost 
Leuk Ess 1996; 55: 27-31. 
Ramirez F, Jain MK. Phospholipase A2 at the bilayer interface. Prot. Structure Functiol) 
Genetics 1991; 9: 229-239. 
Rao GN, Runge MS, Alexander RW. Hydrogen-peroxide activation of cytosolic 
phospholipase A2 in vascular smooth-muscle cells. Biochim Biophys Acta 1995; 1265: 67-
72. 
Reaven P, Khouw A, Beltz W, Parthasarathy S, Witztum J. Effect of dietary antioxidant 
combinations in humans: protection of LDL by vitamin E but not by f3-carotene. 
Arterioscler Thromb 1993; 13: 590-600. 
325 
Reddy R, Mahadik SP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense 
system in chronic schizophrenic patients. Biol Psychiat 1991; 30: 409-412. 
Reddy R, Yao J. Free radical pathology in schizophrenia: A review. Prost Leuk Ess 1996; 
55: 33-43. 
Renetseder R, Brunie S, Dijkstra BW, Drenth J, and Sigler PB (1985). A comparison of the 
crystal structures of phospholipase A2 from bovine pancreas and Crotalus Atrox venom. J 
BiolChem 1985; 260: 11627-11636. 
Richardson AJ, Easton T, Gruzelier JH, Puri BK. Laterality changes accompanying 
symptom remission in schizophrenia following treatment with eicosapentaenoic acid. Int J 
Psychophysiol 1999; 34: 333-339. 
Richardson AJ,-Easton T, Puri BK. Red cell and plasma fatty acid changes accompanying 
symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid. Eur 
Neuropsychopharmacol 2000; 10: 189-193. 
Rieder RO, Nichols PL. The offspring of schizophrenics. 3. Hyperactivity and neurological 
soft signs. Arch Gen Psychiat 1979; 36: 665-674. 
Riely CK, Cohen G, Lieverman M. Ethane evolution: A new index of lipid peroxidation~. 
Science; 1974: 183: 208-212. 
Rittenhouse-Simmons S. Production of diglyceride from phosphatidylinositol in activated_ 
platelets. J Clin Invest 1979; 63: 580-587. 
Robinson BS, Hii CST, Ferrante A. Activation of phospholipase A2 in human neutrophils 
by polyunsaturated fatty acids and its role in stimulation of superoxide production. 
Biochem J 1998; 336: 611-617. 
Rordorf G, Uemura Y, Bonventre JV. Characterization of phospholipase A2 (PLA2) 
activity in gerbil brain: enhanced activities of cytosolic, mitochondrial and microsomal 
forms after ischemia and reperfusion. J Neurosci 1991; 11: 1829-1836. 
Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the 
growth of two human prostate cancer cell lines. Prostate 1991; 18: 243-254. 
Rosenthal MD, Garcia MC, Sprecher H. Substrate specificity of the agonist-stimulated 
release of polyunsaturated fatty acids from vascular endot~elial cells. Arch Biochem 
Biophys 1989; 274: 590-600. 
Rosenthal MD, Jones JE, Release of arachidonic acid from vascular endothelial cells: fatty 
acyl specificity is observed with receptor-mediated agonists and with the calcium 
ionophore A23187 but not with melittin. J Cell Physiol 1988; 136: 333-340. 
Rosenthal MD. Rzigalinski BA, Blackmore PF, Franson RC. Cellular regulation of 
arachidonate mobilization and metabolism. Prost Leuk Ess 1995; 52: 93-98. 
326 
Ross BM. Phospholipase A2 associated processes in the humaJ?. brain and their role in 
neuro and psychopathology. In: Peet M, Glen I, Horrobin DF, eds. Phospholipid spectrum 
disorder in psychiatry. IL In press. 
Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in 
schizophrenia: Evidence for the involvement of a calcium-independent phospholipase A2. 
Arch Gen Psychiat 1997; 54: 487-494. 
Ross BM, Kim DK, Bonventre JV, Kish SJ. Characterization of a novel phospholipase A2 
activity in human brain. J Neurochem 1995; 64: 2213-2221. 
Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. Differential alteration of 
phospholipase A2 activities in brain of patients with schizophrenia. Brain Res 1999; 821: 
407-413. 
Ross BM, Ward PE, McLean R, Glen I. Oral and topical niacin flush test. In: Peet M, 
Glen I, Horrobin DF, eds. Phospholipid spectrum disorder in psychiatry. IL In press 
Rudolf IL, Kelley DS, Klasing KC, Erickson KL. Regulation of cellular differentiation and 
apoptosis by fatty acids and their metabolites. Nutr Res 2001; 21: 381-393. 
Rzigalinski- BA, Blackmore PF, Rosenthal MD. Arachidonate mobilization is coupled to 
depletion of intracellular calcium stores and influx of extracellular calcium in differentiated 
U937 cells. Biochim Biophys Acta 1996; 1299: 342-352. 
Sakamoto W, Fujie K, Handa H, Nishihara J, Mino M. Vitamin E inhibits PGE2 and 0 2 
production in rat peritoneal-macrophages. Biochim Biophys Acta 1991; 1074: 251-255. 
Sakamoto W, Fujie K, Nishihara J, Handa H. Effect of vitamin E on arachidonic acid-
release in rat peritoneal-macrophages. Biochim Biophys Acta 1993; 1170: 296-300. 
Salem Jr, N, Kim H-Y, Yergey JA. Docosahexaenoic acid: membrane function and 
metabolism, In: Simpoulos AP, Kifer RR, Martin RE, eds. Health effects of 
polyunsaturated fatty acids in seafoods. Academic Press, Orlando, FL, 1986: 263-317. 
Samanta A, Das DK, Jones R, George A, Prasad MR. Free radical scavenging by 
myocardial fatty acid binding protein. Free Radie Res Commun 1989; 7: 73-82. 
Samanta S, Perkington MS, Morgan M, Williams RJ. Hydrogen peroxide enhances signal-
responsive arachidonic acid relea~e from neurons: Role of mitogen-activated protein 
kinase. J Neurochem 1998; 70: 2082-2090. 
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, 
· Growdon J, Cotman DW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of seligiline, 
alpha tocopherol, or both as treatment for Alzheimer's disease. New Engl J Med 1997; 
336: 1216-1222. 
Savolainen H. Superoxide dismutase and glutathione peroxidase activities in rat brain. Res 
Commun Chem Pathol Pharmacol 1978; 21: 1379-1387. 
327 
Sayre L, Perry G, Smith MA. Redox. metals and neurodegenerative disease. Curr Opin 
Chem Biol 1999; 3: 220-225. 
Scheffer RD, Bradley J, Mahadik SP. Elevated lipid peroxidation and phospholipase A2: 
Possible mechanism of the lower cell membrane essential polyunsaturated fatty acids in 
schizophrenia. Biol Psychiat 1999; 43: 101. 
Serhan CN, Hamberg M, Samuelsson B. Lipoxins - novel series of biologically-active 
compounds formed from arachidonic acid in human-leukocytes. Proc Natl Acad Sci USA 
1984; 81 (17): 5335-5339. 
Shah SH, Ramchand CN, Peet M. The niacin skin flush test: First-degree relatives show 
responses intermediate between patients and controls. Schizophr Res 1999; 36 (1-3): 314-
314. 
Sham PC, O'Callaghan E, Takei N, Murray GK, Hare EH, Murray RM. Schizophrenia 
following exposure to influenza epidemics between 1939 and 1960. Br J Psychiat 1992; 
160: 461-466. 
Sharp JD, White DL, Chiou XG, Goodson T, Gamboa GC, McClure D, Burgett S, Hoskins 
J, Skatrud PL, Sportsman JR, Becker GW, Kang LH, Roberts BF, Kramer RM. Molecular 
cloning and expression of human Ca2+ - sensitive cytosolic phospholipase A2• J Biol Chem 
· 1991; 266: 14850-14853. 
Shohami E, Shapira Y, Yadid G, Riesfeld N, Yedgar S. Brain phospholipase A2 is 
activated after experimental closed head injury in the rat. J Neurochem 1989; 53: 1541-. 
1546 .. 
Sinclair AJ, Barnett AH, Lunec J. Free-radicals and antioxidant systems in health and 
disease. Brit J Hosp Med 1990; 43(5): 334. 
Sindelar PL, Guan ZZ, Dallner G, .Ernster L. The protective role of plasmalogens in iron-
induced lipid peroxidation. Free Radie Biol Med 1999; 26: 318-324. 
Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: 
classification and characterization. Biochim Biophys Acta 2000; 1488: 1-19. 
Smith C, Mitchinson MJ, Aruoma 01, Halliwell B. Stimulation of lipid peroxidation and 
hydroxyl radical generation by the contents of human atherosclerotic lesions. Biochem J 
1992;28~:901-905. 
Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992; 263: 
F181-F191. 
Smith WL. The eicosanoids and their biochemical-mechanisms of action. Biochem J 
1989;259:315-324. 
Snyderman R, Pike MC. Chemoattractant receptors on phagocytic-cells. Annu Rev 
Immunol 1984; 2: 257-281. 
328 
Spickett CJ\1, Rennie N, Winter H, Zambonin L, Landi L, Jerlich A, Schaur RJ, Pitt AR. 
Detection of phospholipid oxidation in oxidatively stressed cells by reversed-phase HPLC 
coupled with positive-ionization electroscopy MS. Biochem J 2001; 355: 449-457. 
Springfield JR, Levitt MD. Pitfalls in the use of breath pentane measurements to assess· 
lipid-peroxidation. J Lipid Res 1994; 35 (8): 1497-1504. 
Srivastava S, Phadke R, Govil G, Rao CNR. Fluidity, permeability and antioxidant 
behavior of model membranes incorporated with alpha-tocopherol and vitamin E acetate 
Biochim Biophys Acta 1983; 734: 353-362. 
Stahl W, Nicolai S, Briviba K, Hanusch M, Broszeit G, Peters M, Martin HD, Sies H. 
Biological activities of natural and synthetic carotenoids: Induction of gap junctional 
communication and singlet oxygen quenching. Carcinogenesis 1997; 18: 89-92. 
Stahl W, Sies H. Lycopene: A biologically important carotenoid for humans?._ Arch. 
Biochem Biophys 1996; 336: 1-9. 
Stenson WF, Parker CW. Metabolism of arachidonic acid in ionophore-stimulated 
neutrophils. Esterification of a hydroxylated metabolite into phospholipids. J Clin Invest 
1979;64: 1457-1465. 
Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA. Cytosolic phospholipase A2 (cPLA2) 
immunoreactivity is elevated in Alzheimer's Disease brain. Neurobiol Dis 1996; 3: 51-63. 
Stephenson DT, Manetta JV, White DI, Chiou XG, Cox L, Gitter B, May PC, Sharp JP, 
Kramer RM, Clemens JA. Calcium-sensitive cytosolic phospholipase A2 (CPLA2) is 
expressed in human brain astrocytes. Brain Res 1994; 637 (1-2): 97-105. 
Stocker R, Bowry V, Frei B. Ubiquinol-10 protects human low-density lipoprotein more 
efficiently against lipid peroxidation than does a-tocopherol. Proc Natl Acad Sci USA 
1991;88: 1646-1650. 
Stoklasova A, Zapletalek M, Kudmova K, Randova Z. Glutathione peroxidase activity of 
blood in chronic schizophrenics. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 
1986; 29: 103-108. 
Strauss JS. Is biological psychiatry building on an adequate base? Clinical realities and 
underlying process in schizophrenic disorders. In: Andreason NC, ed. Schizophrenia from 
mind to molecule. American Psychiatric Press, Washington. DC, 1994; 31 - 46. 
Sugimoto H, Yamashita S. Characterization of the transacylase activity of rat liver 60-kDa 
lysophospholipase-transacylase. Acyl transfer from the sn-2 to the sn-1 position. Biochim 
Biophys Acta 1999; 1438: 264-272. 
Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, 
Lambeth JD. Cell transformation by the superoxide-generating oxidase Mox 1. Nature 
1999; 401: 79-82. 
329 
Susser ES, Lin SP. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 
1944-1945. Arch Gen Psychiat 1992; 49: 983-988. 
Suzuki T, Taki T, Hachimine K, Sadasivan R. Biochemical properties of biologically 
active Fe gamma receptors of human B lymphocytes. Mol Immun 1981; 18 (1): 55-65. 
SuzuhY, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L. Structural 
and dynamic membrane-properties of alpha-tocopherol and alpha-tocotrienol - implication 
to the molecular mechanism of their antioxidant potency. Biochemistry 1993; 32: 10692-
10699. 
Swann PG, 'Parent CA, Croset M, Fonlupt P, Lagarde M, Venton DL, Lebreton GC. 
Enrichment of .platelet phospholipids with eicosapentaenoic acid and docosahexaenoic acid 
inhibits thromboxane A2 prostaglandin H2 receptor-binding and function. J Biol ,Chem 
1990;265:21692-21697. 
Tappel AL. In: Lundberg WO, ed. Autoxidation· and antioxidants. Wiley, New York, 
1962: 506-526. 
Terao J, Boey Pl, Ojima F, Nagao A, Suzuki T, Takama K. Astaxanthin as a chain-
breaking antioxidant in phospholipid peroxidation. In: Yagi K, Kondo M, Niki E, 
Yoshikawa T, eds. Oxygen radicals. New York: Elsevier Publishers, 1992: 657-660. 
Terao J, Yamauchi R, Murakimi H,.Matsushita S. Inhibitory effects of tocopherols and (3-
carotene on singlet oxygen-initiated photoxidation of methyl linoleate and soybean oil. J 
Food Process Preserv 1980; 4: 79-83. 
Terao J. Antioxidant activity of (3-carotene-related carotenoids in solution. Lipids 1989; 
24: 659-661. 
Tesoriere L, Ciaccio M, Bongiorno A, Riccio A, Pintaudi AM, Livrea MA. Antioxidant . 
activity of all-trans-retinal in homogeneous solution and in phosphatidyl choline liposomes. 
Arch Biochem Biophys 1993; 307: 217-223. 
Thara R, Eaton WW. Outcome of schizophrenia: The Madras longitudinal study. 
Australian and New Zealand Journal of Psychiatry 1996; 30(4): 516-522. 
Tone 0, Miller JC, Bell JM, Rapoport SI. Regional cerebral palmitate incorporation 
following transient bilateral carotid occlusion in awake gerbils. Stroke 1987; 18: 1120-
1127. 
Tornquist K, Ekokoski E, Forss L, Matsson M. Importance of arachidonic acid metabolites 
in regulating ATP-induced calcium fluxes in thyroid FRTL-5 cells. Cell Calcium 1994; 15: 
153-161. 
Torrey EF. Are we overestimating the genetic contribution to schizophrenia? Schizophr 
Bull 1992; 18: 159-170. 
330 
Tran K, Chan AC. Effect of vitamin E enrichment on arachidonic acid release and cellular 
phospholipids in cultured human-endothelial cells. Bioc~im Biophys Acta 1988; 963: 468-
475. 
Tran K, Chan AC. R,R,R-alpha-tocopherol potentiates prostacyclin release in human 
endothelial-cells - evidence for structural specificity of the tocopherol molecule. Biochim 
Biophys Acta 1990; 1043: 189-197. 
Tran K, Wong JT, Lee E Chan AC, Choy PC. Vitamin E potentiates arachidonic acid 
release and phospholipase A2 activity in rat heart myoblastic cells. Biochem J 1996; 319: 
385-391. 
Treadwell FP,. Hall WT. Analytical Chemistry. John Wiley and Sons Inc. London: 
Chapman and Hall Ltd, 1924: 533-534. 
Trenam CW, Blake DR, Morris CJ. Skin inflammation: reactive oxygen species and the 
role of iron. J Invest Dermatol 1992; 99: 675-682. · 
Ullrich 0, Ciftci 0, Hass R. Proteasome activation by poly-ADP-ribose-polymerase in 
human myelomonocytic cells after oxidative stress. Free Radie Biol Med 2000; 29: 995-
1004. 
Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-bind trial of 
essential fatty acid supplementation in patients with tardive dyskinesia. Psychiat Res 1989; 
27: 313-323. 
Vaddadi KS, Gilleard CJ, Mindham RHS, Butler R. A controlled trial of prostaglaridin E1 
precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacol 1986; 
88: 362- 367. 
Vaddadi KS, Gilleard CJ, Soosai E, Polonowita AK, Gibson RA, Burrows G. 
Schizophrenia, tardive dyskinesia, and essential fatty acids. Schizophr Res 1996; 20: 287-
294. 
van Deenen LLM, de Haas GH. The substrate specificity of phospholipase A2• Biochim 
Biophys Acta 1963; 70: 538-553. 
Van den Bosch H. Intracellular phospholipases A. Biochim Biophys Acta 1980; 604: 191-
246. 
van Furth R, Fedorko ME, Hirsch JG. Morphology and · peroxidase cyto-chemistry of 
mouse promonocytes, monocytes and macrophages. J Exp Med 1970; 132. 
van Kuijk FJGM, Sevanian A, Handelman GJ, Dratz EA. A new role for phospholipase-A2 
- protection of membranes from lipid-peroxidation damage. Trends Biochem Sci 1987; 12: 
31-34. 
331 
Vassault A. Lactate dehydrogenase: UV-method with pyruvate and NADH. In: Bergmeyer 
HU, Bergmeyer J, Grassl M, eds. Methods of enzymatic analysis. III. Enymes 1: 
Oxidoreductases, transferases, Third edition. Verlag-Chemie, Weinheim, 1983: 118-126. 
Veerkamp JH, Peeters RA, Maatman RGHJ. Structural and functional features of different 
types of cytoplasmic fatty acid binding proteins. Biochim Biophys Acta 1991; 1081:J-24. 
Vial D, Piomelli D. Dopamine D2 receptors potentiate arachidonate release via activation 
of cytosolic, arachidonic-specific phospholipase A2. J Neurochem 1995; 64: 2765-2772. 
Vidgren HM, Agren JJ, Schwab U, Rissanen T, Hanninen 0, Uusitupa MI. Incorporation 
of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets 
during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among 
healthy young men. Lipids 1997; 32: 697-705. 
Vile GF, Winterbome CC. Inhibition of adriamycin-promoted microsomal. lipid 
peroxidation by f3-carotene, a-tocopherol and retinal at high and low oxygen partial 
pressures. FEBS Lett 1988; 238: 353-356. 
Visioli F, Colombo C, Galli C. Oxidation of individual fatty acids yields different profiles 
of oxidation markers. Biochem Biophys Res Commun 1998; 245: 487-489. 
Vitorica J, Machado A, Satrustegui J. Age-dependent variations in peroxide-utilizing 
enzymes from rat brain mitochondrial and cytoplasm. J Neurohem 1984; 42: 351-356~ 
Vork MM, Glatz JFC, Surtel DA, van der Vusse GJ. Release of fatty acid binding proteins 
and lactate dehydrogenase from isolated rat heart during normoxia, low-flow ischemia, and 
reperfusion. Can J Physiol Pharmacol 1993; 71: 952-958. 
Wade CR, Van Rij AM. In vivo lipid peroxidation in man as measured by the respiratory 
excretion of ethane, pentane other low-molecular-weight hydrocarbons. Anal Biochem 
1985; 150 (1): 1-7. 
Waite M, DeChatelet LR, King L, Shirley PS. Phagocytosis-induced release of arachidonic 
acid from human neutrophils. Biochem Biophys Res Commun 1979; 90: 984-992. 
Waite M. In: Hanahan DJ, ed. Phospholipases. Plenum Press, New York, 1987: 111-133. 
Waite M. The Phospholipases: Handbook of lipid research. New York: Plenum Press, 
1988. 
Wakabayashi S, Freed LM, Bell JM, Rapoport SI. In vivo cerbral incorporation of 
radiolabeled fatty acids after acute unilateral orbital enucleation in adult hooded Long-
Evans rats. J Cereb Blood_Flow Metab 1994; 14: 312-323. 
Walsh CE, Waite BM, Thomas MJ, DeChatelet LR. Release and metabolism of 
arachidonic acid in human neutrophils. J Biol Chem 1981; 256: 7228-7234. 
Wang XD. Reviews: Absorption and metabolism of f3-carotene. J Am Coll Nutr 1994; 13: 
314-325. 
332 
Ward PE, Sutherland J, Glen EMT, Glen AIM. Niacin skin flush in schizophrenia: A 
preliminary report. Schizophr Res 1998; 29: 269-274. 
Weber C, Aepfelbacher M, Lux I, Zimmer B, Weber PC. Docosahexaenoic acid inhibits 
PAF and LTD4 stimulated [Ca2+]i-increase in differentiated monocytic U937 cells. 
Biochim Biophys Acta 1991; 1133 (1): 38-45. 
Weinberger DR. Schizophrenia as a neurodevelopmetal disorder. In: Hirsch SR, 
Weinberger DR, eds. Schizophrenia. Oxford: Blackwell, 1995: 293-323. 
Weltzien H(-!, Cytosolic and membrane-perturbing properties of lysophosphatidylcholine. 
Biochim Biophys Acta 1979; 559: 259-287. 
Winterboum CC. Hydroxyl radical production in body fluids: roles of metal ions, 
ascorbate and superoxide. Biochem J 1981; 198: 125-131. 
Williams EE, Hazel JR. -The role of docosahexaerioic acid containing molecular species of 
phospholipid in the thermal adaptation of biological membranes. In: Sinclair A, Gordon R 
eds. Essential fatty acids and eicosanoids. American Oil Chemist's Society, Champaign; 
IL 1993: 128-133. 
Witt MR, Nielson M. Characterization of the influence of unsaturated free fatty acids on 
brain GABA/benzodiazepine receptor binding in vitro. J Neurochem 1994; 62: 1432-1439. 
Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795. 
World Health Organization Report. Mental health: New understanding, .new .hope. 
Geneva, 2001. 
World Health Organization. Schizophrenia: An international follow-up study. _New York: 
John Wiley and Sons, 1979. 
Wroblewski F, Ladue, JS. Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med 
1955; 90: 210-215. 
Wu L, Katz S, Brown GR. Inositol 1,4,5-trisphosphate-mediated, GTP-mediated, 
arachidonic acid-mediated and thapsigargin-mediated intracellular calcium movement in 
PANC-1 microsomes. Cell Calcium 1994; 15: 228-240. 
Yakley J, Murray RM. Genetic and environmental risk factors for schizophrenia. In: 
Brunello N, Racagni G, Langer SZ, Mendlewicz J, eds. Critical issues in the treatment of 
schizophrenia. Basel: Karger, 1995; 10: 9-34. 
Yamashita A, Sugiura T, Waku K. Acyltransferases and transacylases involved in fatty 
_ acid remodelling of phospholipids and metabolism of bioactive lipids in mammalian cells. 
J Biochem (Tokyo) 1997; 122: 1-16. 
333 
Yano M, Kishida E, Iwasaki M, Kojo S, Masuzawa Y. Docosahexaenoic acid ap.d vitamin 
E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. J 
Nutr 2000; 130: 1095-1101. 
Yao JK, Stanley JA, Reddy RD, Keshavan MS, Pettegrew JW. Correlations between 
peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid 
metabolites. Biol Psychiatr 2002; 52: 823-830. 
Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem 
brains from schizophrenic patients. Schizophr Res 2000; 42: 7-17. 
Yao JK, Van Kammen DP, Gurklis J. Red blood cell dynamics in schizophrenia Ill. 
Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994; 13: 
227-232. 
Yassa R, Nair NPV and Jeste DV eds. Neuroleptic-induced movement disorders. 
Cambridge University Press, New York, 1997. 
Zerangue N, Arriza JL, Amara SG, Kavanaugh MP. Differential modulation of human 
glutamate transporter subtypes by arachidonic acid. J Biol Chem 1995; 270 (12): 6433-
6435. 
Zhang J, Driscoll TA, Hannun YA, Obeid LM. Regulation of membrane release in 
apoptosis. Biochem J 1998; 334: 479-485. 
Zheng X, Avella M, Botham KM. Comparison of the effects of dietary ro-3 and ro-6 
polyunsaturated fatty acids on very-low-density lipoprotein secretion when delivered to 
hepatocytes in chylomicron remnants. Biochem J 2001; 357: 481-487. 
Zimmer L, Rembert S, Durand G Breton P, Guilloteau D, Besnard J-C, Chalon S. Chronic 
n-3 polyunsaturated fatty acid diet - deficiency acts on dopamine metabolism in rat frontal 
cortex: a microdialysis study. Neurosci Lett 1998; 240: 177-181. · 
Zimmerman AW, Veerkamp JH, Fatty acid - binding proteins do not protect against 
induced cytotoxicity in a kidney cell model. Biochem J 2001; 360: 159-165. 
334 
· APPENDIX: STATISTICAL ANALYSIS 
Data are presented as the means ± 95% confidence intervals (Cls). Comparisons among 
normal groups of data (Anderson-Darling's test) with homogeneity of variance (Bartlett's 
test) w-ere made by one-way analysis of variance (ANOV A) using MINIT AB statistical 
software, version 13.32. When a significant effect was observed, post hoc comparisons of 
means were !llade using Tukey' s pairwise comparisons. Differences were considered at P 
<0.05. 
In chapters 6 and 7 (radioactivity counts in dpm expressed as percentage values), when the 
evidence indicated normal groups of data but with heterogeneity of variance, thereby 
failing the tests for performing one-way ANOV A, square root transformations of 
percentage values were used. After these transformations, homogenous variances were 
obtained. 
In situations where groups of data were not normally distributed (Anderson-Darling's test), 
but with equal variances (Levene's Test), comparisons were made by Kruskal-Wallis test" 
using MINIT AB release 13.32. This was followed by the Dunnett' s test for multiple 
comparisons. P values less than 0.05 were considered significant. 
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